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Resumo 
O trabalho descrito nesta dissertação teve como principal objetivo a síntese de novos inibidores 
selectivos da ciclooxigenase-2 (COX-2) baseados no núcleo de benzimidazole. A biblioteca de 
compostos foi construída através de uma estratégia racional de design de fármacos, recorrendo a 
diferentes metodologias de avaliação: docking, avaliação biológica e estudos de STD-RMN. 
Após aprofundados estudos de docking que tiveram por base a avaliação de diversos núcleos 
heterocíclicos, foi escolhida uma biblioteca de compostos cujos resultados foram os mais 
promissores. Os compostos foram avaliados tendo por base a premissa de que compostos com uma 
distribuição espacial em y dos substituintes aromáticos, possuem elevada capacidade de inibição 
seletiva da COX-2. Assim, o padrão de substituição ideal do núcleo de benzimidazole incluiu a 
substituição das posições N-1 e C-2 com anéis aromáticos, sendo que em N-1 o anel se encontra 
substituído em meta, enquanto o anel em C-2 contém um grupo sulfonamida em posição para. Foi 
ainda verificado por docking, que a presença de uma cadeia alquilíca contendo um grupo 
carboxílico ou ester na posição 4 do anel de benzimidazole, serviria de “âncora” formando 
interações relevantes com resíduos específicos no centro activo da proteína. Assim, a biblioteca de 
compostos foi sintetizada com sucesso utilizando diferentes estratégias sintéticas, sendo que um 
dos passos chave para formar o núcleo benzimidazólico englobou o acoplamento cruzado C-N 
catalisado por paládio. Os compostos foram obtidos com rendimentos globais de 27 a 41% para os 
derivados éster e ácido, ao final de sete e oito passos de síntese, respetivamente.  
A biblioteca de compostos foi testada de modo a avaliar a atividade inibitória dos mesmos para 
a COX-1 e COX-2, bem como determinar a sua seletividade para a COX-2, em sangue humano 
total. Os resultados demonstram que os derivados ácido (II.78a-e) não foram ativos ou tiveram 
uma fraca atividade, quer para a COX-1 quer para a COX-2, e.g. o composto II.78d apresentou 
percentagens de inibição iguais a 23 ± 8% e 18 ± 2% (50 M), respetivamente. Ao invés, os 
derivados éster (II.77a-e) revelaram-se inibidores potentes da COX-2, alguns dos quais com 
percentagens de inibição semelhantes à do celecoxib (72 ± 10 %, a 5 M), usado como controlo. 
De facto, o composto II.77d foi aquele que demonstrou os melhores resultados, i.e. 60 ± 8%, para 
uma concentração igual a 0.5 M. No entanto, apesar da menor (mas significativa) percentagem de 
inibição, os compostos II.77a-e também inibiram a COX-1 demonstrando uma fraca seletividade 
para a COX-2, e.g. a percentagem de inibição obtida para II.77d foi de 41 ± 14% (0.625 M). 
Os estudos de RMN por diferença de transferência de saturação (STD) mostraram que ambos os 
derivados ácido e éster interagem com a COX-2. No entanto, através de estudos de competição 
com fármacos conhecidos (ibuprofeno, naproxeno e diclofenac), é sugerido que os derivados ácido 
(II.78a-e) interagem com a COX-2 num terceiro local de ligação. Ao invés, os estudos de 
competição efetuados com II.77a, sugerem que este tipo de compostos compete com o naproxeno 
pelo mesmo local, não competindo pelo local de ligação do diclofenac. Este resultado indica que os 
benzimidazoles II.77a-e se ligam no centro ativo da COX-2de forma similar ao naproxeno. 
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Os resultados obtidos com os estudos de STD-NMR corroboram os resultados da avaliação 
biológica, sendo que os ácidos não se ligam a qualquer centro de decisão na enzima, ao contrário 
dos ésteres que parecem inibir a COX-2 com igual potência e de forma similar ao naproxeno. 
Foram também parcialmente validados os resultados obtidos por docking, já que este conseguiu 
prever a elevada potência dos compostos, mas falhou na previsão da seletividade dos mesmos. 
Dada a relevância da ligação C-N em compostos heterocíclicos, tais como benzimidazoles, e a 
necessidade de desenvolver uma síntese mais sustentável para estes compostos, foi desenvolvida 
uma metodologia para as reações de acoplamento cruzado C-N em fase sólida. Assim foram 
efetuados estudos de arilaminação catalisada por paládio de halo-arenos covalentemente ligados a 
um suporte sólido solúvel – o polietilenoglicol (PEG) 2000, atuando este como suporte sólido e 
como solvente. O acoplamento C-N entre as diferentes anilinas e os (para- ou orto-) bromo ou 
(para- ou meta-) cloro arenos imobilizados em PEG, foi efetuado com sucesso na ausência de 
qualquer solvente orgânico, usando o sistema catalítico Pd2dba3/XPhos. Os rendimentos obtidos 
variaram entre os 40 a 100%. Tentou-se ainda o mesmo tipo de acoplamento com aminas alquilícas 
e hidrazinas, apesar da reação para este tipo de substratos não se mostrar adequada. 
 Nesta dissertação são também descritos os estudos efetuados para a síntese enantioselectiva de 
estruturas heterocíclicas, aplicando a metodologia desenvolvida no grupo do Prof. Dr. Nuno 
Maulide: a ativação electrofilica de amidas com concomitante rearranjo de Claisen. Deste modo 
foram feitos esforços para a síntese enantioselectiva de cromanonas e coumaranonas, bem como 
dos correspondentes derivados azotados, as indolinonas e dihidroquinolinonas. No entanto, 
verificou-se que apesar de a metodologia funcionar para alguns tipos de substratos, a hidrólise dos 
auxiliares quirais usados revelou-se uma tarefa difícil. 
Sendo o grupo sulfonamida um importante farmacóforo amplamente utilizado, foram realizados 
diversos ensaios com o objetivo de obter um reagente de sulfonilação versátil para a preparação de 
sulfonamidas. Os ensaios realizados consistiram em utilizar metabissulfito de potássio ou 
trimetilsilil clorosulfonato como fonte de SO2. Enquanto a utilização do metabisulfito de potássio 
se revelou infrutífera, no segundo caso foi obtido o correspondente cloreto de sulfonilo ainda que 
em quantidades vestigiais. 
Os resultados descritos nesta dissertação demonstram o sucesso na preparação de novos 
derivados heterocíclicos com relevante atividade anti-inflamatória. É também reportado o 
desenvolvimento de importantes metodologias para a síntese deste tipo de compostos. Este trabalho 
permitiu ainda elucidar alguns dos mecanismos envolvidos na atividade inibitória da COX, através 
de estudos de interação entre os compostos sintetizados e as proteínas estudadas. Desta forma este 
trabalho contribuiu para o design racional de novas entidades com elevado potencial como 
fármacos anti-inflamatórios. 
 
Termos chave: síntese, heterociclos, benzimidazole, química medicinal, inibidores da COX.
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Abstract 
 
The main objective of this dissertation was the synthesis of novel selective cycloxygenase-2 
(COX-2) inhibitors based on the benzimidazole scaffold. The generated library was constructed 
using a rational design strategy where several screening methodologies were used in a synergic 
effort: docking studies, biological evaluation and STD-NMR monitoring. 
Drawing from initial docking studies that evaluated several heterocyclic scaffolds, 
benzimidazole structures were chosen as the most promising inhibitors. The compounds were 
analysed based on the known correlation between the y shape drugs (possessing two aryl 
substituents in 1,2 relationship) and its high inhibitory activity and selectivity towards COX-2. 
Thus, the ideal substitution pattern of benzimidazole scaffold included the N-1 and C-2 substitution 
with aromatic rings: a meta substituted ring in N-1, whereas the C-2 aromatic ring contains a 
sulfonamide in para position. It was also verified by docking, that the presence of an alkylic chain 
possessing an acid or an ester group in position 4 could act as an anchor, forming relevant 
interactions with specific residues at the active site of the protein. Thus, the library was 
successfully synthesized employing several synthetic approaches, where the C-N cross-coupling 
reaction was one of the key steps to attain the benzimidazole ring. The compounds were achieved 
with overall yields of 27 to 41% for the ester and acid derivatives, after seven and eight synthetic 
steps, respectively. 
The library of compounds was biologically evaluated by a whole blood assay (WBA) in order to 
verify the inhibitory activity towards COX-1 and COX-2, as well as to determine its COX-2 
selectivity. The results show that the acid derivatives (II.78a-e) were not active or exhibit a poor 
inhibition either for COX-1 and COX-2, e.g. II.78d yielded inhibitory percentages of 23 ± 8% and 
18 ± 2% (at 50 M), respectively. In opposition, the ester derivatives (II.77a-e) were excellent 
inhibitors towards COX-2, some of which showing similar inhibition percentages to celecoxib (72 
± 10 %, 5 M), used as control. In fact, compound II.77d obtained the best results, i.e. 60 ± 8%, at 
0.5 M. However, although the lower (but significant) inhibitory percentage, compounds II.77a-e 
also inhibited COX-1 showing a poor selectivity towards COX-2, e.g. the inhibitory percentage 
obtained for II.77d was 41 ± 14% (0.625 M). 
The saturation transfer difference (STD) NMR experiments demonstrated that both ester and 
acid derivatives interact with COX-2. However, from the several competition studies conducted 
against known drugs (ibuprofen, naproxen and diclofenac), it is suggested that the acid compounds 
(II.78a-e) can potentially bind to a third binding site. On the other hand, the competitive studies 
performed with II.77a, indicate that the ester derivatives bind in naproxen site and that do not 
compete for diclofenac binding site. This result suggests that benzimidazoles II.77a-e have a 
similar binding behavior such as naproxen.  
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The STD-NMR studies corroborate the biological evaluation results, showing that the acids do 
not bind to any decision centre in the enzyme in opposition to the esters that seem to inhibit COX-2 
in a similar way as naproxen. The results obtained by docking were also partially validated, since 
the method established the high potency of the ester-based benzimidazoles, although failing to 
predict its unselective character. 
Due to the relevance of C-N bond formation in heterocyclic compounds, such as 
benzimidazoles, and the need of a more sustainable synthesis for these compounds, it was 
developed a C-N cross-coupling methodology in solid-phase. Thus, several studies were performed 
on Pd-catalyzed arylamination using several PEG bound aryl halides and aromatic amines, where 
PEG 2000 acted as solvent and solid-support. The C-N cross-coupling of several substituted 
anilines and the PEG bound (para- or ortho-) bromo or (para- or meta-) cloro arenes was 
successfully achieved under solventless conditions, using the Pd2dba3/XPhos catalytic system.  The 
obtained yields varied from 40 to 100%.  The same cross-coupling reaction was attempted using 
alkyl amines and hydrazines, however without successful results. 
In the present dissertation are also described the studies towards the enantioselective synthesis 
of heterocyclic structures, applying the methodology developed by Maulide’s group: the amide 
electrophilic activation with concomitant Claisen rearragement. Several efforts were conducted to 
enanteoselectively synthesize chromanones and coumaranones, as well as the nitrogenated 
counterparts, the indolinones and dihydroquinolinones. However, despite the success of the method 
for some derivatives, the hydrolysis of the chiral auxiliaries was a difficult endeavor. 
Since the sulfonamide group is an important and widely used pharmacophore, several 
experiments were conducted in order to obtain a versatile sulfonylation reagent to prepare 
sulfonamides. The experiments used potassium metabisulfite and trimethylsilylchlorosulfonate as 
SO2 surrogates. While the approach using potassium metabisulfite was unsuccessful, in the second 
case it was obtained trace amount of the corresponding sulfonyl chloride. 
 
The results described in this dissertation demonstrate the successful preparation of novel 
heterocyclic derivatives with relevant anti-inflammatory activity. It is also reported the 
development of important methodologies to synthesize these compounds. This work also allowed 
the elucidation some of the mechanisms involved in COX inhibitory activity, via interaction studies 
between the prepared compounds and the studied proteins. Thus, this work has contributed to the 
rational design of new entities with high potential as anti-inflammatory drugs. 
 
Keywords: synthesis, heterocycles, benzimidazole, medicinal chemistry, COX inhibitors. 
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I.1 Inflammation and COX role 
Inflammation is the immune system’s response to infection or injury and a body's attempt of 
self-protection, restoration of tissue structure and physiological function. Inflammation has also 
been implicated in several pathologies such as arthritis or cancer, as well as in neurodegenerative 
and cardiovascular diseases. 
The acute phase of inflammation is characterized by the rapid influx of several blood 
granulocytes to the affected tissues causing some external signs such as redness, heat, swelling and 
pain. In fact, what is happening in physiological terms is the fast overproduction of several 
inflammation mediators that contributes to the development of the inflammation signs. These 
mediators include the prostanoids – prostaglandins (PG), prostacyclins and thromboxanes (TX) – 
which are end products of arachidonic acid (AA) metabolism (Figure I.1).
1,2 
There are several enzymes involved in this metabolites biosynthetic pathway, including the 
prostaglandin G/H endoperoxide synthase, commonly known as cyclooxygenase (COX). 
 
 
Figure I.1. Arachidonic acid metabolic pathway (adapted from Fitzgerald and Patrono).2 
In 1971, COX was identified as the enzyme responsible for the formation of prostaglandins 
during AA metabolism, eliciting a variety of physiological effects such as gastric ephithelial 
cytoprotection or symptoms associated with the inflammatory response. 
3
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Only twenty years later, in 1991, it was discovered that COX exists as two distinct isoforms 
referred to as COX-1 and COX-2 that are bifunctional enzymes containing both cyclooxygenase 
and peroxidase (POX) activity.
4
 COX-1 is constitutively expressed in most cells, synthesising 
prostaglandins at low levels to maintain physiological functions, such as cytoprotection in the 
gastrointestinal tract. On the other hand, COX-2 is usually viewed (in a simplistic way) as the 
inducible isoform in response to inflammatory stimuli, resulting in a high production and release of 
prostanoids. However, COX-1 is also inducible under inflammatory conditions in the kidney, and 
COX-2 is constitutively expressed in several tissues, contributing to the generation of 
autoregulatory and homeostatic prostanoids.
5
 
 
I.2 COX structure and its isoforms 
In order to develop selective and effective anti-inflammatory drugs, it is important to understand 
the COX structure, the differences on the active site of the different isoenzymes, COX-1 and COX-
2 and consequently the binding mode of substrates and its ideal structural features. 
 
Figure I.2. Ovine COX-1 structure: a) COX-1 homodimer with bound flurbiprofen (yellow); b) COX-1 
monomer with bound AA (yellow). EGF (green), MBD (gold), catalytic domain (blue), heme groups (red) 
and N-linked sugars are shown in ball-and-stick rendering (adapted from Garavito et al.).6 
Both COX isoforms are structural homodimers that contains three distinct domains: an 
extracellular growth factor (EGF) domain, a membrane binding domain (MBD) and a catalytic 
domain (Figure I.2).
7
 The EGF domains occur in membrane proteins that are inserted into a single 
leaflet of the cytoplasmic membrane and may be involved in the transport and insertion of COX 
isoforms. The MBD consists of four amphipatic helices that are responsible for anchoring COX to 
the membrane. The catalytic domain of COX isoforms is divided into peroxidase and 
cyclooxygenase active sites, which are spatially separated (by the heme prosthetic group) but 
structurally and functionally interconnected. Thus, COX has altogether two cyclooxygenase and 
two peroxidase active sites.  
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The COX active site is the place where two oxygen molecules will oxidize the AA to form 
PGG2, beginning the set of reactions of the prostanoids biosynthetic pathway (Figure I.3.a). In the 
entirely separate peroxidase site, PGG2 is reduced to PGH2 by a two electron reduction (Figure 
I.3.b).
8
 The cyclooxygenase active site is buried deep within the protein, and contains a long 
hydrophobic tunnel that begins at the MBD. The MBD acts like a funnel, guiding the AA and O2 
directly from the membrane into the core of the globular domain for processing. 
 
a)  
 
b)  
Figure I.3. a) AA bound in the active site of ovine COX-1; b) Prostaglandin biosynthetic pathway (adapted 
from Marnett et al.).8 
The two COX isoforms – COX-1 and COX-2 – have high sequence identity (about 60% within 
species), very similar three-dimensional structures and nearly indistinguishable kinetic parameters 
with AA as substrate.
9
 The COX active site is composed of twenty-four residues, though COX-2 is 
about 20% larger and has a slightly different shape than that of COX-1. This extra size is the 
structural feature exploited to construct selective COX-2 inhibitors. 
The difference relies on the amino acids present three particular positions in COX-1 and COX-
2: substitution of Ile523 in COX-1 by a Val523 in COX-2 results in the presence of a small side 
pocket adjacent to the active site channel, appreciably increasing the volume of the COX-2 active 
site; the substitution of Ile434 in COX-1 with Val434 in COX-2 in the surrounding second shell 
further increases the effective size of the active site channel by enhancing the local mobility of side 
chains within the side pocket. Additionally the combination of these two differences at positions 
523 and 434 in COX-2 causes a movement of Phe518 that further increases the size of the side 
pocket (Figure I.4). 
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Finally, the substitution of His513 in COX-1 with Arg513 in COX-2 alters the chemical 
environment of the side pocket. This substitution results in a stable positive charge being placed at 
the center of this pocket, which can interact with polar moieties entering the pocket.  
For example, Arg513 appears to interact with the 4-methysulfonyl or 4-sulfonamoylphenyl 
substituents of diarylheterocyclic COX-2 inhibitors and give rise to the time-dependent inhibition 
displayed by this class of inhibitors.  
 
 
Figure I.4. Differences in the active sites of COX-1 and COX-2. 
Other crucial amino acids include Arg120, Tyr355 and Glu524, which together form a narrow 
constriction in the hydrophobic channel acting as a gate to the bottom of the COX active site. The 
residue of Tyr385 at the top of the channel is the radical donor for the cyclooxygenase reaction. 
The anti-inflammatory drugs binding site involves the upper half of this channel from Arg120 to 
near Tyr385. 
Only three of the channel residues are polar – Arg120, Ser353, and Ser530. Ser530 is the site of 
acetylation by aspirin, and Arg120 binds to the carboxylate groups of fatty acids and many COX 
inhibitors.  
 
Recently, it was proposed that COX-2 acts as a conformational heterodimer having a catalytic 
(Ecat) and an allosteric monomer (Eallo).
10
 It is suggested that heme binding – to the peroxidase site 
of a monomer – defines one monomer as Ecat (while the other is defined as Eallo). It is suggested that 
some substrates and certain inhibitors (e.g. celecoxib, diclofenac) bind the cyclooxygenase site 
of Ecat. The nonsubstrate fatty acids and some COX inhibitors (e.g. naproxen, flurbiprofen) 
preferentially bind to the COX site of Eallo. Moreover, Eallo allosterically influences the catalytic 
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efficiency of the partner Ecat subunit, i.e. Ecat is regulated by Eallo in a manner-related way the ligand 
is bound to Eallo. 
 
Figure I.5. Model for the folding and processing of native human COX-2 yielding two pre-existent 
conformational heterodimers that are allosterically regulated by fatty acids (adapted from Smith et al.).10f 
It is suggested that both native COX-2 subunits have identical primary structure folds, but are 
processed so as to form a pair of stable conformational heterodimers. Once a conformational 
heterodimer is formed, the monomers comprising the dimer do not flux between Eallo and Ecat forms 
(Figure I.5).  
 
 
I.3 COX inhibitors: is COX-2 selectivity worthy? 
Acetylsalicylic acid, mostly known as aspirin, was the first drug used for the treatment of 
inflammation and since 1899 is the world's most widely used pain reliever. However, the reason 
why it works was not fully understood until 1971.
11
 John Vane found that aspirin have influence on 
the production of certain prostaglandins that are associated with inflammation, elucidating the 
aspirin's medical efficacy. For this discovery, Vane was awarded the Nobel Prize for Medicine in 
1982. 
Since then, several Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) were developed and 
commercialized, such as paracetamol,
12
 ibuprofen,
13
 indomethacin,
14
 diclofenac,
15
 naproxen
16
 and 
nimesulide (Figure I.6).
17
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These NSAIDs were found to inhibit prostaglandin synthesis through COX inhibition. However, 
most of them act as nonselective inhibitors of COX, inhibiting both COX-1 and COX-2 
isoenzymes, which conducts to significant side effects specifically at gastrointestinal and renal 
levels.
18
 
 
Figure I.6. Examples of early developed NSAIDs and corresponding release date. 
In late 20th century, the unraveling of COX structure and the discovery of COX-2 isoform,
7a
  
aided researchers to understand the selectivity observed with certain compounds and conducted to 
the development of new potent and high selective inhibitors towards COX-2. In 1990, the 
compound DuP 697 was reported as the first selective COX-2 inhibitor,
19
 followed by the release 
of NS 398 a couple of years later (Figure I.7).
20
 It was rapidly perceived that the shape of DuP 697, 
composed of a 1,2-diaryl heterocycle template, was an important feature to accommodate the drug 
inside the COX active site. This observation formed the basis of the early work in the field of 
selective COX-2 inhibitors. 
 
Figure I.7. The first two selective COX-2 inhibitors: DuP 697 and NS 398. 
In the late 90s, several highly selective COX-2 inhibitors (usually known as coxibs) were 
released to the market: celecoxib (Celebrex®),
21
 rofecoxib (Vioxx®),
22
 valdecoxib (Bextra®)
23
 and 
etoricoxib (Arcoxia®).
24
 All these compounds possess the same key structural features: a central 5- 
or 6-membered heterocylic core with two aryl substituents in a 1,2 relationship. One of the aryl 
groups has a sulfonyl group in the 4-position whilst the other is either unsubstituted or carries a 
small hydrophobic group. The central heterocycle is either unsubstituted or bears a small lipophilic 
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group. Other coxibs possess different structures, such as lumiracoxib that resemble diclofenac 
structure (Figure I.8).
25
 
 
 
Figure I.8. Commercialized coxibs (and corresponding delivery dates on market) and SC-558 with the 
corresponding IC50 values for COX-1 and COX-2.
7b 
 
Besides the 1,2-diaryl feature, the coxibs selectivity has been attributed to the sulfonyl 
functionality placed in para position of one of the aromatic rings. It is generally accepted that the 
methylsulfonyl or sulfonamide groups of the inhibitor can interact with specific key residues within 
the side pocket of COX-2 (Arg513, His90, Phe518 and Gln192).
7b
 This is not allowed in COX-1 
due to the steric bulk of Ile-523. In fact, the crystal structure of COX-2 with SC-558 – one of the 
most selective COX-2 inhibitors – demonstrated how the sulfonamide group of the inhibitor binds 
to these side pocket residues, establishing the key structural features for the COX-2 selectivity 
(Figure I.9).  
It is verified that the para-bromophenyl ring of SC-558 is positioned toward the top of the 
COX-2 active site, making hydrophobic contacts with Phe381, Leu384, Tyr385, Phe513 and 
Trp387. The CF3 group at the position 3 of the pyrazole ring is oriented toward a hydrophobic 
pocket consisting of Met113, Val116, Val349, Tyr355, Leu359 and Leu531. However, other 
distinct anchoring sites contribute to the inhibitors binding in the COX-2 active site. A distinctive 
feature in COX-2 selective inhibitors is generally the lack of a free carboxylate group, which may 
be related to their low affinity toward COX-1.
26
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Figure I.9. Crystal structure of SC-558 with COX-2.7b 
For example, the crystal structure of COX-2 with indomethacin reveals that the carboxyl group 
can form an ionic interaction with Arg120 and Tyr355 at the constriction site at the base of the 
active site.
7b
 The same was verified for naproxen.
16
 Other carboxylic acid-containing inhibitors, 
such as diclofenac and lumiracoxib, bind to COX-2 in a different orientation, placing their 
carboxylates at the top of the active site, allowing them to form hydrogen bonds with Ser530 and 
Tyr385 (Figure I.10).
27
 
 
Figure I.10. Representation of several ligands inside COX-2 active site as inferred from X-ray data (adapted 
from Ermondi et al.).28 
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Coxibs were designed based on the hypothesis that selective inhibition of the COX-2 isoform 
should reduce pain and inflammation without compromising the integrity of the gastric mucosa.  
As expected, these inhibitors presented reduced side effects at gastrointestinal level. However, due 
to acute cardiovascular side effects, Merck withdrew rofecoxib from the market in September 
2004, while valdecoxib (Pfizer) was also removed (in 2005) from the United States and Europe.
29
  
Some groups support that selective COX-2 inhibition is associated to an increased incidence of 
thrombotic events that could be reduced by a balanced inhibition of both isoenzymes.
30
 In fact, it is 
proposed that COX-2 inhibitors do not block thromboxane A2 (TXA2), which causes platelet 
aggregation, and selectively inhibit the beneficial vascular effects of prostacyclin (PGI2).With loss 
of the antiplatelet and vasodilatory effects of prostacyclin, a relative excess of TXA2 would 
promote vasoconstriction, platelet aggregation and thrombosis.
31
 
However, these facts are not plain since the risks of myocardial infarction were verified both in 
coxibs and in certain non-selective NSAIDs. Thus, the selective inhibition of the COX-2 is not the 
only cause of adverse side effects, and other factors must be considered such as patient medical 
background, dose- and duration-regimens.
2,32
 
As a result, gastrointestinal and cardiovascular risks must be carefully assessed in order to tune 
the inhibitory activity of the anti-inflammatory drugs: while gastrointestinal effects were less 
frequently verified for coxibs than NSAIDs, serious cardiovascular events occur at approximately 
equal rates.
33
 
These facts have been encouraging the scientific community to pursue new pharmaceutical 
entities devoid of adverse side effects. 
 
Heterocyclic compounds play an exclusive role in drug discovery and benzimidazole structures 
were found to be trendy structures, having numerous biological applications,
34
 being also described 
as highly promising COX inhibitors (Figure I.11).
35
 
 
 
Figure I.11. IC50 (COX-2) for benzimidazole structures and comparison with some COX inhibitors (obtained 
using human monocytic cell lines).35a 
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According to the presented facts, it is envisaged that benzimidazoles are an excellent choice to 
attain new NSAIDs with a balanced COX inhibition, i.e. with less adverse side effects than the 
presently commercialized anti-inflammatory drugs. 
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I.4 Main objectives and Thesis structure 
The main objective of the work described in the present thesis was to develop highly potent 
COX inhibitors with a balanced COX-1/COX-2 inhibition, employing a rational drug design which 
takes advantage of several techniques such as docking, NMR and biological assays. Moreover, it 
was also proposed to develop a new synthetic methodology to assemble the benzimidazole-based 
inhibitors, which possess a specific substitution pattern relevant for the inhibitory activity. 
Additionally, it was planned to extend the amide electrophilic activation methodology – 
developed by Maulide’s group – to prepare relevant heterocyclic compounds, and to develop a SO2 
surrogate to construct sulfonamides in a broad and versatile way. 
 
This work is divided in four main chapters: 
 
Chapter II. Describes the several synthetic approaches used to assemble the benzimidazole-
based inhibitors. It also comprises the evaluation of their inhibitory activity towards COX-1 and 
COX-2 and the STD-NMR experiments performed with COX-2. 
The work described in this chapter is published in: 
"Developments towards regioselective synthesis of 1,2 disubstituted benzimidazoles”, Luísa C. 
R. Carvalho, Eduarda Fernandes, M. Manuel B. Marques, Chem. – Eur. J. 2011, 12544. 
"1,2-Diaryl benzimidazoles as potent COX inhibitors”, Luísa C. R. Carvalho, S. Erhardt, E. 
Cabrita, Daniela Ribeiro, Raquel S. G. R. Seixas, Artur M. S. Silva, Eduarda Fernandes, M. 
Manuel B. Marques, 2014. (Paper under preparation) 
 
Chapter III.  Describes a new methodology useful to assemble heterocyclic structures on solid 
phase: the Pd-catalyzed arylamination using several PEG bound aryl halides and aromatic amines, 
where PEG 2000 acted as solvent and solid-support. 
The work described in this chapter is published in: 
“Pd-catalyzed amination on soluble polymer support: arylation of anilines with PEG-supported 
aryl halides” Luísa C. R. Carvalho, Marina J. Pires, Eduarda Fernandes, M. Manuel B. Marques, 
RSC Advances 2013, 25711. 
 
Chapter IV. Describes the amide electrophilic activation/Claisen rearrangement methodology 
developed in Maulide’s group, applied to substrates incorporating a phenyl ring within the alkyl 
tether. Are also described the attempts to expand the procedure to its aza analogs. 
The work performed in this section took place in Maulide’s former lab at Max Planck Institute 
für Kohlenforshung from October 2012 until December 2012. 
 
Chapter V.  Involves the studies to develop a versatile SO2 surrogate to prepare sulfonamides. 
 
 
 
14 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. Novel Benzimidazole-based COX inhibitors 
 
 
 
My contribution to the work was the synthesis of all compounds, part to the biological 
evaluation and the STD-NMR studies. 
The biological evaluation was performed in collaboration with Prof. Dr. Eduarda Fernandes 
(FF-UP). 
The STD-NMR studies were performed in collaboration with Prof. Dr. Eurico Cabrita (FCT-
UNL).  
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II.1 Backgroud 
II.1.1 1,2-Disubstituted benzimidazole assembly 
Heterocycles have a very important role in drug discovery since the majority of therapeutic 
drugs, which includes the NSAIDs, contain a heterocyclic unit. Benzimidazoles are trendy 
heterocyclic structures employed in several areas such as materials science
36
 or in the 
pharmaceutical industry. A successful example is Nexium (esomeprazole), a proton pump inhibitor 
used to treat peptic ulcers and gastroesophageal reflux disease, that became one of the most widely 
prescribed drugs, with sales of about $5 billion in 2009 (Figure II.1). In 1872, when Hobrecker 
reported the first benzimidazole synthesis, of 2,5- and 2,6-dimethylbenzimidazole, he never 
suspected that benzimidazole scaffold would become such a preeminent structure.
37
 
 
 
Figure II.1. Examples of some commercially available benzimidazole-based drugs. 
1,2-Disubstituted benzimidazoles and their derivatives are a representative branch of this 
family. Reported as valuable bioactive structures, such as specific angiotensin II receptor type 1 
selective antagonists,
38
 or hepatitis C virus NS5B polymerase inhibitors,
39
 they exhibit several other 
pharmacological activities including antidiabetic,
40
 antihistamine,
41
 analgesic,
42
 antiviral,
43
 
chemotherapeutic,
44
 antifungal,
45
 and antiparasitic
46
 applications. The relevance of these 
compounds can be demonstrated by the profusion of pharmaceutical products in the market, for 
example, the antihypertensives Micardis® (telmisartan) and Atacand® (candesartan), or the 
Bilaxten® (bilastine), a histamine H1 receptor antagonist for the oral treatment of allergic rhinitis 
and chronic idiopathic urticaria. Moreover, 1,2-disubstituted benzimidazoles were also described as 
intermediates for dyes and polymers,
47
 and have frequently been used as ligands. 
48
 In addition, 
there have also been reports of their use as possible precursors for aminoboronic acids with an 
interest as bifunctional organic catalysts.
49
 
Undoubtedly, benzimidazoles are important scaffolds and significant efforts have been made to 
develop new synthetic strategies for their assembling, both in solution
50
 and in solid phase.
51
 Solid-
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phase synthesis (SPS) is extremely useful for combinatorial approaches towards benzimidazole 
libraries with increased structural complexity. 
While methods to prepare 1- or 2-substituted benzimidazoles have highly increased during the 
last years,
52
 the assembly of 1,2-disubstutitued benzimidazoles remains an intricate task.
53 
The classical and most common methods to assemble benzimidazoles involve the condensation 
of o-phenylenediamine with aldehydes, carboxylic acids or their derivatives (nitriles, amidates, 
orthoesters) (Figure II.2, route a).
54
 The N-alkylation of benzimidazole derivatives is also a 
common alternative (Figure II.2, route b).
40
 
 
Figure II.2. Available methods to assemble 1,2-disubstituted benzimidazoles. 
However, these methods are usually not regioselective for the synthesis of the 1,2-disubstitutued 
benzimidazoles and are limited to the available starting materials. Consequently, improvements 
were made towards the development of new strategies, such as the metal-catalyzed aryl-amination 
chemistry (Figure II.2, route d) 
50c
 and the cascade arylamination/condensation method (Figure II.2, 
route e).
50a,b
 The development of SPS (Figure II.2, route c),
51
 allied with the optimization of 
microwave conditions
 55
 allowed a more rapid, efficient and sustainable route to achieve this 
relevant class of benzimidazoles. 
II.1.1.1 The classical methods struggle 
The classical synthetic methods to assemble the benzimidazole moiety are still widely used due 
to its inherent simplicity. One of the most used traditional procedures rely on the condensation of 
aldehydes, carboxylic acids or its derivatives with 1,2-diaminoarenes followed by cyclization.
54
 
The lack of differentiation between the two nitrogen atoms that usually lead to a mixture of 
regioisomers, makes this procedure inappropriate to assemble 1,2-disubstituted benzimidazoles. 
Additionally, these methods are also restricted to the commercially available starting materials, fact 
that constitutes a main limitation to construct more complex molecules. An example is the 
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condensation of o-phenylenediamine with aldehydes, one of the most studied approach to prepare 
simple 1,2-disubstituted structures. The employment of several catalysts under mild conditions,
56, 
57,58
 usually provides the products in good yields. 
When the two nitrogen atoms need to be differentiated, the reduction and cyclization from o-
nitroanilines is commonly used. First the free amine is adequately reacted, followed by the nitro 
group reduction and subsequent reaction with a suitable substrate to give the benzimidazole 
scaffold.
39,59
 o-Halo nitrobenzene structures like o-bromonitrobenzene (II.1) can also be used in 
order to achieve the corresponding N-substituted o-nitroaniline II.2 (Scheme II.1), which after 
hydrogenation affords the corresponding amine II.3 that can undergo subsequent acylation and 
cyclization to II.4.
59
 
 
Scheme II.1. Reduction and cyclization from o-nitroanilines.59 
 
II.1.1.2 Functionalization of the benzimidazole ring 
Another current method to attain 1,2-disubstituted benzimidazoles is the N-alkylation of 2-
substituted benzimidazoles that is often achieved by reaction with either an alkyl halide or an acyl 
chloride. Although commonly used, this method is usually not regiospecific, tending to elicit 
substitution on the sterically less hindered nitrogen.  
In the first reported synthesis of Telmisartan (II.7), the alkylation of II.5 with the 4-
(bromomethyl)-2-biphenylcarboxylic acid tert-butyl ester (II.6) afforded a mixture of two bis-
benzimidazoles (Scheme II.2).
60 
 
Scheme II.2. First reported Telmisartan synthesis.60 
N-alkylation of benzimidazole moiety could also be achieved performing an alkylation via 
Mitsunobu reaction or with alkyl bromides as described by Erion and co-workers.
40 
The acylation of position 2 was described by Kayalgil and co-workers that reported the 
synthesis of 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives.
61
 The reaction of benzimidazole 
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moiety with acyl chlorides gave the corresponding 2-aryloylbenzimidazole derivatives which were 
reacted with 2-bromoacetophenones to give 1-(2-aryl-2-oxoethyl)-2-aryloylbenzimidazoles 
intermediates (Scheme II.3).
61
 Several other methods for the functionalization of C-2 position were 
developed to achieve 1,2-disubstituted benzimidazoles.
62 
 
Scheme II.3. Kayalgil and co-workers approach to 1-(2-aryl-2-oxoethyl)-2-aryloylbenzimidazoles 
synthesis.61 
Due to its limitations in scope, metal-catalyzed N-arylation of benzimidazoles has been scarcely 
used, and has only been applied to unsubstituted benzimidazoles (Scheme II.4, a-c).
63
 The recent 
advances on Pd-based catalytic systems for efficient C-N coupling reactions have been highly 
useful. Buchwald group has described the arylation of simple imidazole or benzimidazole rings 
with aryl halides (Scheme II.4, b).
64
 
 
Scheme II.4. Metal-catalyzed N-arylation of benzimidazoles. 
On the other hand, Bao group have developed a copper-catalyzed reaction using ethyl 2-
oxocyclohexanecarboxylate as ligand (Scheme II.4, c). The group has demonstrated that under 
these conditions benzimidazole was less reactive towards aryl halides than imidazole, requiring 
higher temperatures to give the product in moderate yields.
65
 
The N-arylation of several 2-substituted 1H-benzimidazoles in a one-pot manner was also 
reported by Zhao and co-workers (Scheme II.5).
66
 The method relied on the use of amidine 
hydrochloride to form the 2-substituted 1H-benzimidazoles in the presence of CuBr and Cs2CO3, 
and sequential addition of the aryl iodide and ligand (3,4,7,8-tetramethyl-1,10-phenantroline) to 
afford the desired products in moderate yields. When 2-bromo 4-methylacetaniline (II.8) was 
employed, a mixture of the two regioisomers (II.10 and II.11) was obtained. 
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Scheme II.5. N-arylation of several 2-substituted 1H-benzimidazoles via one-pot approach by Zhao and co-
workers.66 
2-Halo substituted benzimidazoles, such as 2-chloro or 2-bromobenzimidazoles, are also 
important intermediates for functionalization of the benzimidazole scaffold at the position 2 
(Scheme II.6). These compounds are versatile intermediates to prepare of 2-hetero-benzimidazoles 
(Scheme II.6, paths a, b and c) and 2-arylbenzimidazoles (Scheme II.6, path d). 
.  
Scheme II.6. Benzimidazole C-2 functionalization via 2-halobenzimidazoles.62b-e 
In order to improve the regioselectivity of the synthesis of N-substituted benzimidazoles, novel 
methods have been developed. 
 
II.1.1.3 Metal-catalyzed intramolecular amination/cyclization 
The development of a metal-catalyzed intramolecular aryl-amination/cyclization approach was 
an elegant way to circumvent the limitations of classical methods, allowing the construction of 
complex benzimidazoles in a regioselective way.  
Firstly reported by Brain and co-workers (Scheme II.7),
67
 this method was readily adopted with 
success by several groups that used several catalytic systems including for example, palladium-, 
copper- or cobalt-based salts. 
 
Scheme II.7. Brain’s approach rely on the arylation of amidines. 
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In fact, the recent advances on metal-mediated coupling chemistry stimulated the development 
of these new methodologies, allowing the easy assembling of heterocyclic compounds. Palladium 
catalyzed aryl-amination chemistry has been extensively improved, mainly due to the development 
of new ligand systems.
68
 Concerning copper catalysis, the development of N,N-, N,O- and O,O-
bidentate ligands enhanced Ullmann-type coupling reactions.
69
 
In 2008, Buchwald group developed a copper-catalyzed amination for the synthesis of 
substituted 2-arylbenzimidazoles in good yields from the corresponding amidines, also 
demonstrating that the procedure could be extended to the preparation of N-methylated 
benzimidazoles (Scheme II.8).
50c
 
 
Scheme II.8. Buchwald Cu-catalyzed amination.50c 
Mani and co-workers which previously reported the CuI-catalyzed amination reaction of 1,2-
dihaloarenes with guanidines and amidines, to achieve 1-H-2-substituted benzimidazoles,
70
 
developed a comprehensive study on the regioselectivity of the reaction of 1,2-dihaloarenes with N-
substituted amidines to obtain 1,2-disubstituted benzimidazoles (Scheme II.9).  
Several factors and its influence on the regioselectivity were investigated, such as the 
chemoselectivity of nitrogen atoms on the first amination step; the steric and electronic effect of the 
substituent on the arene ring; the reactivity control between differentiated halides or even the 
reaction with different amidines.
71
 
 
Scheme II.9. Comprehensive study of the regioselectivity described by Mani and Deng.71 
Other methods using heterogeneous systems were also described for the synthesis of 1,2-
disubstituted benzimidazoles. Punniyamurthy group reported the use of copper(II) oxide 
nanoparticles under ligand-free conditions. The reactions revealed to be efficient and general for 
the synthesis of 2-alkyl, 2-aryl and 2-amino benzimidazoles and the catalyst could be recovered 
and recycled without loss of activity and selectivity.
72
 The same group described a cobalt-catalyzed 
intramolecular C–N cross-coupling using Z-N-(2-halophenyl)-N-phenylamidines and N-(2-
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bromophenyl)benzamides as starting materials to obtain the corresponding substituted 
benzimidazoles in excellent yields.
73 
The synthesis of benzimidazoles using a copper-catalyzed intramolecular amination in water 
was also reported.
74
 Although successfully applied for the synthesis of 1H-2-substituted 
benzimidazoles with good yields, it presented a limited scope for 1,2-disubstituted benzimidazoles.
 
The intramolecular amination method was also successfully applied to the synthesis of N-
substituted 2-heterobenzimidazoles. Batey and co-workers reported a palladium or copper-
catalyzed intramolecular aryl guanidinylation for the formation of 2-aminobenzimidazoles in 
moderate to high yields (Scheme II.10).
75
 Other fused imidazole systems like purine or xanthine 
nucleus, could also be readily obtained by this method.
76
 
 
 
Scheme II.10. Synthesis of 2-aminobenzimidazoles by a Cu-catalyzed guanidinylation method.75 
While by the usual method the precursors o-haloguanidines needed to be previously 
synthesized, Bao and Lv demonstrated that 2-heterobenzimidazoles like 2-amino, 2-imidazyl and 
2-phenoxyl benzimidazoles could be easily prepared from o-haloarylcarbodiimides.
77
 Thus, the 
group developed a one-pot copper-catalyzed addition/C-N coupling method (Scheme II.11), similar 
to the previously described metal-catalyzed intramolecular amination. Since diaza compounds have 
been previously described as ligands in copper catalyzed coupling reactions, Bao group also 
investigated the same approach in the absence of ligand.
78
 
 
Scheme II.11. Employment of o-haloarylcarbodiimides developed by Bao and co-workers.77  
Bao group also reported the use of Cu(OAc)2/O2 system to prepare benzimidazole derivatives 
directly from the reaction of diphenylcarbodiimides with different nucleophiles, via addition/C-H 
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activation in a one-pot cascade procedure.
79
 The same approach was adopted by Cai and co-
workers that synthesized a variety of 2-aminobenzimidazoles from o-haloanilines and 
carbodiimides via copper-catalyzed reaction, in the presence of NaO
t
Bu using N-methyl-2-
pyrrolidinone (NMP) as solvent in a “ligand-free” manner.
80
 
Wang and co-workers, following a previous work from the group,
81
 developed a three-
component reaction of sulfonylazides, terminal alkynes and 2-bromoaniline to achieve 2-
substituted 1-sulfonylbenzimidazoles. The proposed mechanism involves the copper-catalyzed 
azide/alkyne addition to form a ketenimine intermediate that is attacked by the amine to generate 
the corresponding N-sulfonylamidine. The copper-catalyzed intramolecular C-N coupling afforded 
the products in moderate to good yields (Scheme II.12).
82
 
 
 
Scheme II.12. Wang’s three-component reaction. 82 
The intramolecular copper-catalyzed aryl amination can also be applied to the synthesis of N-
substituted 2-mercapto benzimidazoles. The preparation of these compounds was described by 
Muzart and co-workers who attained the desired products by the S-alkylation of thiourea 
derivatives, followed by the intramolecular C-N coupling (Scheme II.13).
83
 
 
Scheme II.13. Synthesis of N-substituted 2-mercapto benzimidazoles by Muzart and co-workers.83 
They also demonstrated that benzimidazole thiones could be obtained from 2-mercapto 
benzimidazoles substituted with a p-methoxybenzyl group. 
 
Despite of the advantages of the method, it commonly required a multi-step synthesis to prepare 
the o-halo-aryl or alkylamidine precursors. Thus, cascade arylamination method emerged as a 
suitable alternative. 
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II.1.1.4 Cascade arylamination/condensation method 
In 2007, Ma and co-workers developed a mild process to achieve 1,2-disubstituted 
benzimidazoles.
50b
 Encouraged by previous studies, the group investigated the o-NHCOR group 
effect on copper-catalyzed aryl-amination, producing the corresponding o-aminoanilides. The 1,2-
disubstituted benzimidazoles were achieved in a one-pot manner through an intramolecular 
condensation/cyclization route (Scheme II.14) in moderate to high yields. 
 
Scheme II.14. Intramolecular condensation/cyclization procedure developed by Ma and co-workers.50b 
 
In a related report, Buchwald and co-workers developed a palladium-catalyzed amination of o-
bromo or o-chloro acetanilide followed by cyclization to afford the corresponding N-
arylbenzimidazoles (Scheme II.15).
50a 
 
Scheme II.15. Palladium catalyzed arylamination/condensation method.50a 
 
When isomeric forms of aryl bromides were applied (II.13 and II.14, respectively), the method 
provided access to the regioselective synthesis of compounds II.15 and II.16 in high yields, 
proving the advantage of the method (Scheme II.16). 
 
 
Scheme II.16. Regioselective synthesis of compounds II.15 and II.16. 
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As alternative to amination approach, Buchwald and Zheng reported a copper-catalyzed 
amidation method for the preparation of N-alkylbenzimidazoles. The first amidation step was 
accomplished using CuI as catalyst and trans-N,N-dimethyl-1,2-cyclohexanediamine as ligand. 
Further dehydration conditions allowed the preparation of N-alkylbenzimidazoles in a 
regioselective form (Scheme II.17).
84 
 
Scheme II.17. Copper-catalyzed amidation by Buchwald and Zheng.84 
This method was also successfully applied by Legraverend and Ibrahim in the synthesis of 
substituted purines.
85
 
Lindenschimdt and co-workers developed a general palladium-catalyzed amidation of 2-
halonitroarenes with secondary amides using a Pd(TFA)2/(R)-BINAP system. After reductive 
aminocyclization with Fe/AcOH the desired 1,2-disubstituted benzimidazoles were achieved with 
moderate to high yields (Scheme II.18).
86
 
 
 
Scheme II.18. Amidation of 2-halonitroarenes described by Lindenschimdt.86 
Very recently, Buchwald reported a three component amination/amidation method for the 
regiocontrolled synthesis of N-arylbenzimidazoles (Scheme II.19).
87
 
 
Scheme II.19. Cascade Palladium catalysis.87 
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II.1.1.5 Other methods 
Fluorinated compounds constitute a significant part of the benzimidazole family. Resembling 
the metal-catalyzed intramolecular amination process, Wu and co-workers reported the synthesis of 
N-alkyl and N-aryl 2-fluoroalkylbenzimidazoles by intramolecular cyclization reaction of several 
amidines mediated by [bis(trifluoroacetoxy)-iodo]benzene (BTI) (Scheme II.20).
88 
 
Scheme II.20. Synthesis of N-substituted 2-fluoroalkylbenzimidazoles by Wu et al.88 
Wu
89
 and Zhang
90
 groups have independently developed similar procedures to assemble N-
substituted 2-fluoromethyl benzimidazoles. Both groups reported the double amination of 
fluorinated acetimidoyl halides with primary amines catalyzed by CuI. While Wu group applied a 
ligand free approach, Zhang group used a CuI/TMEDA system (Scheme II.21). Wu approach 
consisted on a Cu-catalyzed coupling of imidoyl chlorides and primary amines under mild 
conditions. 
 
Scheme II.21. N-substituted 2-fluoromethyl benzimidazoles assembly.89-90 
Zhang group enlarged the scope using different (2-haloaryl)-trifluoroacetimidoyl chlorides with 
Cl, Br or I in ortho position in the presence of a CuI/TMEDA system. It was demonstrated that the 
presence of trifluoromethyl group is essential for the amination reaction to proceed. 
Schmidt and co-workers
91
 described the preparation of substituted benzimidazoles from 1,1-
dibromoethenes and o-diaminobenzenes. The reaction proceeds in the presence of 1,4-
diazabiclyco[2.2.2]octane (DABCO), using NMP as solvent at 100ºC (Scheme II.22). The 
proposed mechanism, based on experimental observations, involves the generation of an alkynyl 
bromide intermediate upon treatment of dibromide with base. Reaction of the generated 
intermediate with a corresponding diamine provides an alkynylamine compound, that subsequently 
cyclises to give the desired substituted benzimidazoles.  
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Scheme II.22. Synthesis of substituted benzimidazoles from 1,2 dibromoarenes.91 
More recently Siddapa group
92
 used dibromomethylarenes to accesses substituted 
benzimidazoles in the presence of KO
t
Bu as base followed by the addition of iodine and catalytic 
amount of benzoylperoxide under reflux conditions. 
Cho and Kim reported the synthesis of 1,2-disubstituted benzimidazoles from N-alkyl-1,2-
diaminoarenes by means of alkyl group transfer, in the presence of a ruthenium catalyst and 
acetophenone as hydrogen acceptor (Scheme II.23).
93 
 
Scheme II.23. Ruthenium catalyzed alkyl group transfer to prepare benzimidazoles.93 
The development of the novel approaches for benzimidazole synthesis offer alternatives to the 
restricted classical methods, permitting the access to molecules with increased structural diversity 
in a straightforward way. However several challenges remain, in particular concerning 
regioselectivity particularly in solid-phase approaches, for which recently developed solution phase 
methods might be applied. Moreover, the new advances in metal-mediated C-N couplings could 
open new possibilities to the successful assembly of heterocyclic compounds. 
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II.1.2 Evaluation of the inhibitory activity of NSAIDs 
The methods applied to evaluate the inhibitory capacity of anti-inflammatory drugs towards 
COX were developed in the last decades, in an intimate effort to construct new COX inhibitors. 
Each of these assay systems comprises advantages and drawbacks, and the type of assay must be 
carefully selected based on the aim of the experiment. 
The first in vitro testing systems were described in the early 90s and were based on the use of 
cell lines cultured in the presence of the drugs.
94
 The progress made on these assays conducted to 
systems that use isolated enzymes, receiving exact information about the enzyme-drug interaction 
while avoiding other cellular influences.
95
 However, their major advantages also constitute a 
drawback since these assays do not mimic the patho-physiological conditions. In fact, several 
important parameters such as cell-cell interactions, plasma-protein binding of the drug and other 
blood compounds are neglected. 
The use of isolated cell assays has the advantage of being derived from fresh whole blood. 
However, all these assays are vulnerable to artifacts that take place during cell separation steps, 
also sharing the disadvantages of isolated enzyme assays since several interactions – besides the 
drug-cell interplay – are being ignored. Additionally they are time-consuming and therefore 
inappropriate for routine testing. 
Nevertheless, enzyme and cell based assays are useful and powerful tools to determine 
preliminary drug kinetics and dose-response relationships. Some examples of in vitro COX 
inhibition assay systems use purified/recombinant enzymes, or cell lines obtained from either 
human or animal sources. 
96,97
 
 
Whole blood assays (WBAs) were developed in order to overcome the main drawbacks of 
isolated enzyme-based or isolated cell assays.
96,98
 Unlike in vitro assays, WBAs are carried out in 
the presence of all blood components, and the compounds activity can be examined in a semi-
physiological environment similar to in vivo conditions, i.e. 37 °C, homeostasis and cell-cell 
interactions remain intact.  
The WBA for COX inhibition determination has been ameliorated, and recently an improved 
method was reported by Laufer.
97,99
 This WBA is more rapid (stimulation takes only 3-5 h 
compared to other existing protocols) allowing routine testing. 
Thus, human WBA is a simple, fast and reliable method to examine the capacity of NSAIDs at 
inhibiting COX activity and can be applied for rapid and routine screening purposes. This method 
can be roughly divided in 3 phases (Figure II.3): 
1) Sample preparation (or stimulation of blood); 
2) ELISA (enzyme-linked immunosorbent assay) test; 
3) Detection and evaluation of results. 
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In this assay the variability of different donors has to be considered because of metabolism and 
different enzyme expression. The sample preparation consists on the amplification of PGE2 content 
and the stimulation of COX in the presence of the drug (in a fixed concentration) for a 
predetermined incubation time.  
 
Figure II.3. Whole blood assay stages. 
 
The ELISA test employed in these studies is a commercially available, colorimetric competitive 
enzyme immunoassay (EIA) kit – the PGE2 EIA kit. This assay monitors the activity of COX-1 or 
COX-2 inhibitors by measuring the levels of downstream PGE2. These levels are inversely related 
with the added colorimetric reagent which absorvance is read at 405 nm, i.e. the lower the 
production of PGE2 (which indicates a higher inhibitory activity), the higher the absorvance. 
 
The in vitro evaluation of NSAIDs and selective COX-2 inhibitors can provide the IC50 values 
for both the COX-1 and COX-2 isoforms. This information allows to calculate COX-2 selectivity 
(ratio of COX-1 IC50/COX-2 IC50), which can be used to compare the different COX inhibitors 
(Table II.1).  
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Table II.1 Classification of NSAIDs according to their COX-1/2 inhibitory activities. 
Class Properties Examples 
Group 1 
NSAIDs that inhibit both COX-1 and 
COX-2 completely with little selectivity 
Aspirin, ibuprofen, diclofenac, 
indomethacin, naproxen, piroxicam 
Group 2 
NSAIDs that inhibit COX-2 with a 5-50 
fold 
Celecoxib, etodolac, meloxicam, 
selectivity nimesulide 
Group 3 
NSAIDs that inhibit COX-2 with a > 50 
fold selectivity 
Rofecoxib, NS-398 
Group 4 
NSAIDs that are weak inhibitors of both 
isoforms 
5-Aminosalicylic acid, sodium 
salicylate, nabumetone, sulfasalazine 
 
Interestingly, Vane and coworkers classified NSAIDs and COX-2-selective compounds based 
on a careful in vitro analysis of COX-1 and 2 inhibition and selectivity data obtained using a 
human WBA, as shown in Table II.2.
96
 
 
Table II.2. NSAIDs COX-1 and 2 inhibitory activities and COX-2 selectivity index determined using WBAs 
by Vane et al.96 
Drug 
Whole Blood Assay 
IC50 ( M) Selectivity index 
COX-1 COX-2 
Indomethacin 0.013 1.0 0.013 
Fluorbiprofen 0.075 5.5 0.013 
Ketoprofen 0.047 2.9 0.016 
Aspirin 1.7 > 100 0.017 
Naproxen 9.3 28 0.33 
Ibuprofen 7.6 7.2 1.05 
Diclofenac 0.075 0.038 1.97 
Paracetamol > 100 49 > 2.04 
Meloxicam 5.7 2.1 2.7 
Nimesulide 10 1.9 5.26 
Celecoxib 6.7 0.87 7.7 
Valdecoxib 26 0.87 29.8 
Rofecoxib 19 0.53 35.8 
Etoricoxib 116 1.1 105.4 
Lumiracoxib 67 0.13 515 
 
The aim of the study was to present a simple, fast and reliable method to examine the capacity 
of the studied compounds to inhibit COX-1 and COX-2 and to evaluate their selectivity. 
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II.1.3 Saturation Transfer Difference (STD) NMR experiments 
Reported fifteen years ago by Meyer and Mayer,
100
 saturation transfer difference (STD) NMR 
turned to be a popular ligand-based NMR technique to study molecular interactions of small 
ligands with biologically relevant macromolecules, such as proteins or nucleic acids.
101,102
 It allows 
the identification of the ligand moieties important for binding, which are important tools for 
identification of lead structures in the rational drug-discovery process. 
The success of this technique is a consequence of its robustness and the fact that it is focused on 
the signals of the ligand, without any need of processing NMR information about the receptor and 
only using small quantities of the nonlabeled macromolecule. In fact, this technique, developed 
over the last decade, offers several advantages over the usual methods to study the binding 
activities. 
The STD-NMR experiment is based on the Nuclear Overhauser Effect (NOE). It starts by 
irradiating the spectral region containing resonances of the receptor and where no resonances of 
free ligands are located (such as 0 ppm to -1 ppm), so the protons of the macromolecular receptor 
are selectively saturated. Due to effective spin diffusion, saturation quickly propagates across the 
entire receptor. If the ligand contains any residues that bind the receptor, saturation will also spread 
onto these residues. By chemical exchange, that saturation is carried into solution where is 
detected. The result will be that intensity of the ligand signals will be attenuated (Figure II.4). 
 
 
Figure II.4. The STD experiment. 
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By subtraction of a spectrum, with Isat (on-resonance spectrum), from a spectrum without 
protein irradiation, with I0 (off-resonance spectrum), the STD-NMR spectrum is obtained, 
possessing only signals from the ligand residues that bind to the protein. Other compounds that 
may be present but do not bind to the receptor will not receive any saturation transfer. Thus, their 
signals will be of equal intensity on the on-resonance and the off-resonance spectra and, as a 
consequence, after subtraction no signals will appear in the difference spectrum from the 
nonbinding small molecule(s) (Figure II.4).  
Thus, the STD spectrum (ISTD = I0-ISAT) contains only the signals of the residues that received 
saturation transfer from the protein (via spin diffusion, through the nuclear Overhauser effect). The 
moieties of the ligand having the closest contact to the protein shows the most intense NMR 
signals, enabling the mapping of the ligand’s binding epitope. The term binding epitope is 
frequently used in the STD-NMR literature to characterize the hydrogens of the ligand that are 
closer to the protein upon binding.  
STD-NMR is a very sensitivity method allowing using as little as 1 nmol of protein with a 
molecular weight >10 kDa. Moreover, the ligand is normally used in an approximately 50 to 100-
fold molar excess over the protein, allowing one to work with low protein and ligand 
concentrations. 
However, the STD-NMR experiment relies on the residence time of the ligand in the protein 
binding site. The degree of ligand saturation obviously depends on this binding time and on the 
exchange between the bound and the free ligand state, that allows the screening of binding ligands 
(with dissociation constants, KD, ranging from 10
-3
 molL
-1
 to 10
-8
  molL
-1
).
103
 The dissociation of 
the weak binding ligand will transfer this saturation into solution where the free ligand is detected 
possessing narrow line widths. For those ligands that have strong affinity with protein, a decrease 
in intensity is observed. In fact, the STD-NMR main drawback is the incapacity to detect the high-
affinity ligands which possess a slow chemical exchange on the NMR time-scale. Thus, the 
detection of these ligands can be made by the competition STD-NMR binding experiments. This 
approach can be used for screening of ligands over a wider affinity range including high-affinity 
ligands that would be missed by the STD-NMR method.
103b 
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Figure II.5 Competitive experiments between ibuprofen and a) ketorolac, b) diclofenac. 104 
STD-NMR was already used in our group to characterize the binding mode of some anti-
inflammatory drugs such as ibuprofen, diclofenac, and ketorolac to COX-1 and COX-2.
104
 Based 
on these studies and in crystallographic structures, the authors proposed that ketorolac should bind 
to the COX-2 active site in an orientation similar to the already reported for diclofenac. Moreover, 
the combination of STD-NMR with competition experiments constitutes a valuable tool to address 
the proposed behavior of COX-2 as functional heterodimer and complements enzyme activity 
studies in the effort to rationalize COX inhibition mechanisms (Figure II.5). 
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II.2 Research Objectives 
The main objective of this chapter was the development of new benzimidazole-based structures 
that could act as powerful and selective COX-2 inhibitors. Consequently, it was adopted a rational 
design strategy comprising docking studies, an original synthetic plan, STD-NMR studies and the 
biological evaluation of the synthesized compounds. This iterative approach, combining different 
and complementary tasks allowed an efficient and sustainable construction and monitoring of the 
new anti-inflammatory candidates (Figure II.6). 
 
 
Figure II.6. Rational drug design approach used for the development of novel NSAIDs. 
The first step consisted on the screening of all the literature background in order to direct the 
docking studies and to perceive which structures would have the optimum substitution pattern as 
potential COX inhibitors. The docking studies narrowed the heterocyclic possibilities to a small 
group of molecules based on the benzimidazole scaffold. Thus, it was proposed to synthesise this 
library employing an optimized and straightforward synthetic methodology. 
In order to validate the anti-inflammatory activity, the generated benzimidazole library was 
further evaluated using two different screening methodologies; the biological assays in order to 
confirm the inhibitory activity towards COX, and the STD-NMR experiments which can unravel 
the binding mechanism (whitin COX-2) of the studied compounds. 
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II.3 Results and Discussion 
II.3.1 Docking studies and proposed structures 
The docking studies performed by Dr. Stefan Erhardt (Edinburgh University) involved the 
evaluation of several heterocyclic scaffolds with different substitution patterns. The best results 
were verified for benzimidazole structure (Figure II.7) which conducted to a restricted group of 
compounds that were selected to be synthesized.  
 
Figure II.7. Proposed docking structure. 
The substitution pattern that gave the most promising results was, as expected, the one that 
contains benzimidazole as the heterocylic core, possessing two aryl substituents at the adjacent N-1 
and C-2 positions. The aromatic ring in position C-2 should contain a sulfonyl group (sulfonamide 
or methylsulfone group) in the para position, an important feature for activity and selectivity, as 
already described in Chapter I. 
 
Figure II.8. Docking results based on meta substitution (for acid derivatives). 
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Moreover, it was also proposed that the aromatic ring at N-1 must be substituted in meta 
position with a halogen, trifluoromethyl, hydroxyl or nitro group (Figure II.8). 
It was also established by the docking studies, that the central benzimidazole core should 
contain a carboxylic acid, an ester or an amide group in position 4. In fact, it was reported that an 
additional acetic acid chain, analogous to indomethacin, can lead to an increased inhibitory activity 
(Figure II.9).
105
 
 
Figure II.9. Pyrrole based structures containing an acetic acid chain and corresponding IC50 (COX-2).
105a,b
 
Therefore, the proposed general structure for the NSAIDs library is described in Figure II.10. 
 
 
Figure II.10. Proposed benzimidazole structures. 
 
Having in mind the substitution pattern of our goal structures, all the reported synthetic 
approaches were carefully analysed, as well as the available starting materials, in order to devise an 
efficient and short-step synthetic plan. Despite the not so evident application in our approach, it 
was chosen as starting material, the commercially available 7-bromo isatin (II.22), which after few 
synthetic manipulations possesses the key structural features to construct the benzimidazole ring 
with the desired functionalization. In fact, the manipulation of already existent heretocycles in 
order to attain new heterocyclic entities with increased structural complexity is a commonly used 
synthetic approach.  
 
 
 
 
II.Results and Discussion 
38 
 
II.3.2 Synthesis of 1,2-Disubstituted benzimidazole library 
II.3.2.1 Preliminary experiments 
In the preliminary retrosynthetic plan to generate the 1,2-disubstituted benzimidazoles library it 
was envisaged that compounds of general structure II.19 could be obtained by condensation with 
concomitant ring opening of II.20, which could be prepared by arylamination of II.21 via a metal-
catalyzed C-N cross coupling. The retrosynthetic plan included the preparation of II.21 by N-
benzoylation of oxindole which in turn, was obtained from the reduction of 7-bromo isatin (II.22) 
(Scheme II.24). 
 
 
Scheme II.24. Preliminary retrosynthetic plan. 
Despite its low nucleophilicity, the N-benzoylation of oxindole (II.24) was performed using 
benzoic anhydride in order to obtain compound II.25 (Scheme II.25). Moreover, the benzoylation 
on position C-3 (to give II.23) was not observed. In fact, the formation of II.23 could be favoured 
using benzoyl chloride as acylation agent, in the presence of triethylamine, which can elicit the 
corresponding O-benzoylated enol intermediate that rearranges to form II.23. 
 
 
Scheme II.25. N-Benzoylation of oxindole II.24. 
As a result, it was attempted to synthesize the desired anhydride substituted in the para position 
with the sulfonamide group (II.28). 
Thus, the corresponding acyl chloride (II.27) was synthesized from the commercially available 
4-sulfamoyl benzoic acid (II.26) (Scheme II.26). After a brief optimization step, it was observed 
that thionyl chloride needed to be previously placed in an ice bath and vigorously stirred before the 
slow addition of II.26, otherwise side products were obtained. After heating for 1 h at 60ºC, SOCl2 
was co-evaporated with dried toluene, to afford II.27 as a white solid further characterized by IR. 
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Scheme II.26. Synthesis of acyl chloride II.27 and attempt to prepare the anhydride II.28. 
The preparation of the corresponding sulfamoyl benzoic anhydride was then tried reacting the 
benzoyl chloride II.27 with the corresponding sodium salt of the acid II.26, in DMF. However, 
product II.28 was not attained, fact that can be explained by the low solubility of both II.26 and 
II.27, allied to benzoyl chloride instability. Consequently, this preliminary approach was 
abandoned.  
Since the Pd-catalyzed arylamination of heterocycles was already described with good 
results,
106
 this methodology was also tested for 7-bromo isatin as well as 7-bromo oxindole (Table 
II.3). A preliminar test was made between II.22 and aniline in the absence of any Pd salt, and no 
reaction ocurred. 
The BrettPhos system,
107
 initially described by Buchwald et al. as an excellent ligand to couple 
anilines with aryl chlorides at low catalyst loadings (e.g. 0.01 mol%), was chosen due to its good 
results in the cross-coupling of aromatic amines with heterocyclic structures.
106
  
 
Table II.3. Conditions and observations of arylamination of 7-Br isatin (II.22) and 7-Br oxindole (II.29).a 
 
Entry Compound System Solvent Temperature TLC 
1 II.22 
BrettPhosPd/BrettPhos 
precatalyst;  
LiHMDS (5 equiv) 
THF 65ºC 
Complex 
mixture 
2 II.22 
BrettPhosPd/BrettPhos 
precatalyst;  
LiHMDS (3.4 equiv) 
THF 65ºC 
Complex 
mixture 
3 II.22 
BrettPhosPd/BrettPhos 
precatalyst;  
LiHMDS (2.2 equiv) 
THF 65ºC No reaction 
4 II.29 
BrettPhosPd/BrettPhos 
precatalyst;  
LiHMDS (5equiv) 
THF 65ºC No reaction 
5b II.29 
Pd2dba3/BINAP; 
Cs2CO3
b dioxane 90ºC 
Complex 
mixture 
a
 BrettPhos Pd (1 mol %), BrettPhos precatalyst (1 mol %), aniline (1.2 equiv);
 b
 Pd2dba3 (5mol%), BINAP (7.5 mol%); Cs2CO3 (3 
equiv). 
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However, employing the same procedure for II.22 resulted in a complex mixture that was 
insoluble during the work up procedure (entries 1 and 2). This could be attributed to the 
intermolecular arylamination to form a polymeric structure. Decreasing the amount of base to 2.2 
equivalents prevented the reaction to occur. 
BrettPhos system was also employed to II.29 without obtaining the expected results (entry 4). 
Using Pd2dba3/BINAP in the presence of Cs2CO3 resulted in a complex TLC (entry 5). The reaction 
was not further explored for II.29 due to the possible intermolecular C-arylation in position 3, since 
this type of oxindole arylations was already reported by Buchwald group.
108
 
Since the preliminary approach failed, an improved retrosynthetic plan was proposed. 
 
 
II.3.2.2 First retrosynthetic approach 
As in the preliminary experiments, 7-bromo isatin (II.22) was chosen as starting material. The 
retrosynthetic analysis is depicted in Scheme II.27.  
It was anticipated that compounds of general structure II.19 could be obtained from II.30 by an 
acid catalyzed cyclization and carboxylic acid deprotection. Derivative II.30 could be conceivably 
produced by Pd-catalyzed arylamination of II.31 with several meta-substituted anilines.  
The synthetic intermediate II.31 could be prepared from 7-bromo oxindole (II.29) by basic 
hydrolysis, carboxylic acid protection and benzoylation with sulfamoyl benzoyl chloride (II.27). 7-
Bromo oxindole (II.29) can be readily attained by reduction of II.22. 
 
Scheme II.27. First retrosynthetic plan to prepare benzimidazole of general structure II.19. 
The first synthetic step involved the reduction of the 7-bromo isatin (II.22) to compound II.29, 
which can be performed using different procedures.
109
 Hence, it was adopted the method described 
by Saladino et al. 
110
 In this method, that describes a mild Wolff-Kishner reduction of isatins, it was 
expected to obtain the desired product in a very fast manner and in good yields without isolation of 
the corresponding hydrazone. It was proposed that the reduction is more efficient than the usual 
Wolff-Kishner procedure since -ketoamide can form an intramolecular hydrogen bonding with 
the hydrazine proton, creating a six member ring intermediate (II.32). Proton tranfer can proceed 
through the enol form to product II.33, that after a second similar process with subsequent loss of a 
nitrogen molecule yields the final product II.35 (Scheme I.28). 
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Scheme II.28. Proposed mechanism for reduction of isatins by Crestini and Saladino.110 
However, the 
1
H NMR of the crude mixture showed a complex mixture of the hydrazone 
(II.36), the product II.29 and other uncharacterized products (Table II.4, entries 1 and 2). 
 
Table II.4. Conditions used for Wolff-Kishner reduction and corresponding observations. 
 
Entry Conditions Solvent Temperature/Time 
Observation/ 
Yield (%) 
1 Hydrazine hydrate 65% --- Reflux (30 min). Mixture 
2 Hydrazine hydrate 99-100% --- Reflux (30 min). Mixture 
3 
1) Hydrazine hydrate 99-100% 
2) KOH (5 equiv) 
DEG 
1) 80 ºC (1h) 
(hydrazone isolation) 
2) 80 ºC (1h) 
II.29 + II.36 
4 
1)  Hydrazine hydrate 99-100% 
2) KOH (5 equiv) 
DEG 
1) 80 ºC (1h) 
2) 80 ºC (1h) 
Product not 
characterized 
5 
1)  Hydrazine hydrate 99-100% 
2) KOH (5 equiv) 
DEG 
1) 80 ºC (1h) 
2) 80 ºC (overnight) 
Product not 
characterized 
6 
1) Hydrazine hydrate 99-100% 
2) NaOEt (3 equiv)/ethanol 
EtOH 
1) 80 ºC (1h) 
(hydrazone isolation) 
2) 120 ºC (2h) 
II.22 + Product 
not characterized 
7 
1)  Hydrazine hydrate 99-100% 
2) KOH (5 equiv) 
DEG 
1) 80 ºC (1h) 
2) 120 ºC (2h) 
II.29 (82%) 
8 
1)  Hydrazine hydrate 99-100% 
2) KOH (17 equiv) 
DEG 
1) 80 ºC (1h) 
2) 120 ºC (2h) 
II.37 (90%) 
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In this way it was adopted the classical Wolff-Kishner conditions; in a first step the formation of 
II.36 using hydrazine hydrate in diethyleneglycol (DEG), followed by a basic hydrolysis with 
KOH (entries 3-5). Thus, compound II.36 was formed by heating the isatin solution in DEG with 
hydrazine hydrate at 80ºC. The formation of II.36 could be visually monitored: the translucid red 
solution corresponding to II.22 progressed towards a strong yellow precipitate (hydrazone). It can 
be also pointed out that the water content of hydrazine highly influenced the reaction outcome. The 
hydrazone was then isolated and further hydrolysed under basic conditions, at 80ºC, to yield a 
mixture of II.36 and II.29 (entry 3). When hydrazone was not isolated an uncharacterized product 
was obtained (entry 4 and 5). 
Facing these problems it was then explored a similar procedure where the hydrolysis step was 
performed at 120ºC for 2 h using sodium ethoxide (NaOEt) in ethanol (entry 6).
111
 However, it was 
obtained a mixture of starting material and an uncharacterized product. Gladly, applying these 
same temperature and time conditions to the previous method (KOH/DEG) the product II.29 was 
isolated in good yield (entry 7).  
The next step consisted on the amide bond hydrolysis of II.29 that could be made after the 
purification of this compound. Given that the Wolff-Kishner reaction evolves under harsh basic 
conditions, it was verified that using an excess of KOH (17 equiv), the ring opening product (II.37) 
could be easily obtained (Table II.4, entry 8, and Scheme II.29). 
 
Scheme II.29. Cascade reaction to obtain compound II.37. 
In fact this compound was easily purified in the work-up procedure; performing several 
extractions with ethyl acetate before neutralization of the reaction mixture, allowed the removal of 
all undesired organic compounds. A careful neutralization using a 1M HCl solution (performed in 
an ice bath), allowed the product to precipitate. Filtration and washing with cold water afforded 
II.37 in almost quantitative yield. 
 
II.3.2.3 Arylamination experiments 
Encouraged by the early studies, developed by Ma and Buchwald that reported the o-acetanilide 
group effect on arylamination, we devised that similar molecules could aid the construction of the 
benzimidazole library.
50a,b
 Thus, in order to perform preliminary studies on the arylamination 
reaction, two N-benzoylated model structures II.39 and II.40 were synthesized from 2-bromo 
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aniline (II.38). Thus, II.38 was reacted with benzoyl and the 4-sulfamoylbenzoyl chlorides, to 
obtain the compounds II.39 and II.40, respectively (Scheme II.30). 
 
 
Scheme II.30. Benzoylation of II.38 with the corresponding acid chlorides to yield II.39 and II.40. 
Both copper and the palladium salts were already described as efficient catalysts in C-N cross-
coupling reactions. Moreover, both were described for the amination of 2-haloacetanilides (see 
Schemes II.14 and II.15). However, copper salts as well as their ligands are readily available and 
much cheaper than the palladium counterparts that require particular ligands in order to attain 
enhanced yields. 
Thus, the first approach to the arylamination reaction involved a copper catalysis previously 
described by Ma et al.
50b
 In this work, it was demonstrated that NHCOR groups provide an ortho-
substituent effect in the amination of 2-haloacetanilides, allowing the reaction to proceed under 
very mild conditions. This amination reaction was catalyzed by CuI/L-proline under K2CO3 
conditions in DMSO (see Scheme II.14).  
The reaction was then tested using the model structure II.39 and aniline under the conditions 
reported by Ma et al. (Table II.5).  
Table II.5. Conditions and observations to the copper catalyzed arylamination of compound II.39.a 
 
Entry  Base Solvent Temperature Yield (%) 
1 K2CO3 DMSO rt  40ºC  60ºC 
b 23 
2 K
2
CO
3
 DMSO 70ºC 22 
3 K
3
PO
4
 DMSO 65ºC 59 
4 K2CO3 toluene reflux 61 
5 K
3
PO
4
 toluene reflux 94 
a CuI (10 mol %), L-proline (20 mol %), K
2
CO
3
 (2 equiv), aniline (1.5 equiv),  overnight; b 3 days. 
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However, using the reported conditions (at 40ºC) the reaction did not proceed towards the 
desired product (monitored by TLC). When the temperature was further raised to 60ºC, a small 
amount of benzoxazole (II.41) was isolated (entry 1). 
The same result was obtained when the reaction was carried at 70ºC (entry 2). Using K
3
PO
4
 as 
base, a slightly increase of benzoxazole quantity was observed but without any product formation 
(entry 3). Changing the solvent to toluene, increased the benzoxazole amount either using K
2
CO
3
 or 
K
3
PO
4
 (entries 4 and 5). Moreover, K
3
PO
4
 seems to potentiate II.41 formation. 
It was assumed that copper-catalyzed amination reaction only works for alkyl amines, requiring 
moderate temperatures for these derivatives. The less nucleophilic aniline hinders the reaction, and 
an increase in temperature gives the corresponding benzoxazole despite the several reaction 
conditions used. Moreover, Ma et al. employed the more reactive aryl iodides instead of aryl 
bromides, which requires higher temperatures and longer times, promoting the benzoxazole 
formation. The observed results establish that the conditions used by Ma et al. cannot be employed 
for these substrates, which tend to form the corresponding benzoxazoles by cyclization of the 
corresponding amides under copper conditions.
112
  
 
Since catalysis using the system CuI/L-proline did not give the expected results, it was adopted 
a Pd-catalyzed arylamination method reported by Buchwald using the BrettPhos precatalyst with 
the corresponding phosphine ligand.
5
 These new palladium based systems, mostly developed on the 
last decade, allowed to extend the C-N cross coupling to a wide scope of reactants (Figure II.11).
113
  
 
 
Figure II.11. Some of the most widely used Buchwald ligands. 
The Buchwald-Hartwig amination (independently reported by Buchwald and Hartwig),
114
 is a 
cross-coupling reaction of an aryl halide with an amine using a palladium salt as catalyst in the 
presence of a strong base.  
The active catalyst is commonly achieved using a Pd(0) source, such as Pd2dba3 or by reducing 
a Pd(II) salt in situ [e.g. Pd(OAc)2]. The mechanism starts with the oxidative addition of the aryl 
halide to Pd(0) which is followed by coordination of the amine to the palladium (Scheme II.31). A 
strong base then abstracts a proton from the amine, which in turn attacks the palladium expelling 
the halide as a leaving group. Finally, reductive elimination yields the aryl amine product and 
regenerates the catalyst.  
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Scheme II.31. Catalytic cyclic for Pd-catalyzed amination reaction. 
Indeed, the first experiment using BrettPhos catalytic system was very encouraging since the C-
N cross coupling reaction involving the model compound II.39 yielded the derivative II.42 in 
quantitative yield (after chromatographic isolation). After cyclization under acidic conditions 
(acetic acid under reflux), it was obtained the corresponding 1,2-disubstituted benzimidazole II.43 
(Scheme II.32.a). 
The same procedure was also employed for sulfonamide derivative II.40 though without 
success, maybe due to the poor solubility of compound II.40 in THF (Scheme II.32.b). 
 
 
Scheme II.32. Arylamination experiments using BrettPhos system to achieve the benzimidazole core. 
Having the preliminary information about the BrettPhos catalyzed cross-coupling reaction, the 
key intermediate II.37 was further modified in order to proceed with the synthesis.  
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The first step consisted on carboxylic acid moiety modification to the corresponding benzyl 
ester, which was expected to survive under the amination conditions while increasing the 
compound solubility. Thus, compound II.37 was reacted with benzyl bromide in DMF in the 
presence of Cs2CO3 at room temperature to give II.44 in 74% yield. Compound II.44 was further 
N-benzoylated to obtain II.45 quantitatively. Moreover, the sulfonamide group was protected using 
the tert-butyloxycarbonyl (Boc) group expecting to reduce the solubility issue. Thus product II.46 
was obtained with a global yield of 56% (Scheme II.33). 
 
 
Scheme II.33. Synthesis of derivative II.46. 
The arylamination of derivative II.46 with aniline was firstly attempted using the BrettPhos 
system conditions. After four hours of reaction at 65ºC, it was verified the total consumption of 
starting material, although compound II.48 was formed with 84% yield instead of the desired II.47 
(Scheme II.34). This fact was confirmed by mass analysis and by 
1
H RMN that clearly showed the 
absence of the signal corresponding to the benzylic CH2 (5.1 ppm). Moreover, the aromatic signals 
corresponding to aniline were identified, along with the observation of the signal corresponding to 
the formed amide NH at 10.1 ppm (acetone-d6). 
 
Scheme II.34. BrettPhos catalyzed arylamination of derivative II.46. 
It was further made an exhaustive study in order to establish the optimal conditions for the 
arylamination reaction without the loss of the benzyl group (see Table II.6). 
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Decreasing the reaction temperature from 65 ºC to 40 ºC did not change the reaction outcome, 
since after 4 h it was observed the formation of compound II.48, although with low conversion 
(entry 2). Changing the solvent to toluene and using the same catalytic system, it was verified that 
after 2 h at 65 ºC there was no product formation. Increasing the temperature to 100 ºC gave II.48 
in 71 % yield (entry 3).  
Table II.6. Reaction conditions and observations of Pd-catalyzed arylamination of II.46 with aniline.a 
a aniline (1.5 equiv); b starting material recovery; c 2 h; d 18 h. 
 
Changing the base to Cs2CO3, a base not as strong as LiHDMS, the starting material was 
recovered without formation of any product (entry 4). The same was verified when NaO
t
Bu was 
employed despite the high temperature used overnight (entry 5). Increasing the mol% of BrettPhos 
Pd and ligand from 1 mol% to 10 mol% while using NaO
t
Bu, it was verified that after 20 h the 
debenzylated product II.49 was obtained without arylamination reaction (entry 6). These results 
indicate that the BrettPhos system is not promoting the arylamination reaction, while other side 
reactions are taking place such as ester hydrolysis or amidation. Other catalytic systems were used, 
such as Pd2dba3 (2 mol%) and BrettPhos (8 mol%) in the presence of K3PO4 in 
t
BuOH, which 
conducted to a mixture of product II.49 and starting material (entry 7), or Pd2dba3 (8 
mol%)/BINAP (12 mol%), although a complex mixture was obtained in this case (entry8). 
 
Entry Catalyst (mol %) Base Solvent Temperature Yield (%) 
1 
BrettPhos Pd (1 mol%) +  
BrettPhos ligand (1 mol%) 
LiHMDS 
(3.4 equiv) 
THF 65 ºC 84 (II.48) 
2 
BrettPhos Pd (1 mol%) +  
BrettPhos ligand (1 mol%) 
LiHMDS 
(3.4 equiv) 
THF 40 ºC 58 (II.48) 
3 
BrettPhos Pd (1 mol%) +  
BrettPhos ligand (1 mol%) 
LiHMDS 
(3.4 equiv) 
Toluene 
1) 65 ºC c 
2) 100 ºC c 
71 (II.48) 
4 
BrettPhos Pd (1 mol%) +  
BrettPhos ligand (1 mol%) 
Cs2CO3 
(2.5 equiv) 
Toluene 
1) 65 ºC c 
2) 100 ºC c 
0 b 
5 
BrettPhos Pd (1 mol%) +  
BrettPhos ligand (1 mol%) 
NaOtBu 
(3.2 equiv) 
Toluene 
1) 80 ºC c 
2) 100 ºC c 
0 b 
6 
BrettPhos Pd (10 mol%) +  
BrettPhos ligand (10 mol%) 
NaOtBu 
(3.2 equiv) 
Toluene 
1) 80 ºC c 
2) 100 ºC d 
62 (II.49) 
7 
Pd2(dba)3 (2 mol%) +  
BrettPhos ligand (8 mol%) 
K3PO4 
(2.5 equiv) 
tBuOH 110ºC 66 (II.49) 
8 
Pd2(dba)3 (8 mol%) +  
BINAP (12 mol%) 
Cs2CO3 
(1.4 equiv) 
dioxane 100ºC 
Complex 
mixture 
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II.3.2.4  Protection of carboxylic acid 
In order to solve the debenzylation problem verified in the arylamination reaction, some 
attempts were made to protect the carboxylic acid with different protecting groups. Despite its 
known lability, groups like the tert-butyl dimethylsilane (TBDMS) or the trimethylsilane ether 
(TMSE) were tested. However, the conditions used for the insertion of these groups promoted the 
ring closing to obtain mainly the oxindole II.29. It was also attempted the protection of II.37 with 
trytil group, however with poor yields. 
Since the first attempts to protect II.37 failed, it was tried to mask the carboxylic acid moiety 
forming the corresponding Weinreb amide (II.50). Weinreb amides are important intermediates in 
organic chemistry,
115
 and usually cleaved under basic conditions.
116
 Although in less extension, it 
was also expected the intramolecular attack of amine to the activated acid specie. Thus, some 
efforts were made to avoid this lateral reaction and to enhance the product formation (Table II.7).  
Thus, II.37 was activated with DCC in DCM (at -10ºC) followed by the addition of the free 
N,O-dimethylhydroxylamine. However, it was observed by 1H NMR that besides the desired 
product II.50 it was also formed the corresponding oxindole that unhappily possessed the same 
retardation factor (Rf) of II.50 (entry 1). This fact made the reaction monitoring and the product 
purification difficult tasks.  
Table II.7. Conditions and observations of Weinreb amide formation (II.50). 
a verified by 1H RMN. 
 
When the amount of hydroxylamine was increased, a small increase of II.50 was achieved 
(entries 2 and 3). In THF, the yield was very poor since the N,O-dimethylhydroxylamine 
hydrochloride was very insoluble (entry 4). Since the ring closing is promoted by the initial acid 
 
Entry Conditions Solvent Temperature Ratio a 
1 
1) II.37 + DCC (10 min.) 
2) hydroxylamine (1.1 equiv) + TEA (10 min.) DCM 
1) – 10 ºC 
2) rt 
1:1 
2 
1) II.37 + DCC (10 min.) 
2) hydroxylamine (2 equiv) + TEA (30 min.) DCM 
1) – 25 ºC 
2) rt 
1.5:1 
3 
1) II.37 + DCC (5 min.) 
2) hydroxylamine (5 equiv) + TEA (20 min.) DCM 
1) 0ºC 
2) rt 
1.6:1 
4 
1)  II.37 + DCC (15 min.) 
2) hydroxylamine (1.1 equiv) + TEA (10 min.) THF 
1) -10ºC 
2) rt 
0.4:1 
5 
1) II.37  +  hydroxylamine  (1.1 equiv) + TEA 
2) DCC DCM 
1) 0 ºC 
2) rt 
1.4:1 
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activation, the addition order was inverted. Thus, a solution of DCC in DCM was added to a 
mixture of starting material, hydroxylamine and triethylamine in DCM, however without 
improvement (entry 5). 
 
II.3.2.5 Trifluoroacetyl group in ortho- position 
Due to the failure of the previous attempts, it was envisioned that trifluoroacetyl group could be 
a valuable ortho-auxiliary group in arylamination.50b,117 Thus, compound II.51 was prepared 
reacting II.44 with the corresponding trifluoroacetic anhydride in quantitative yield (Scheme II.35). 
 
 
Scheme II.35. Trifluoroacetylation of derivative II.44. 
 
Several arylamination experiments were made using compound II.51 as described in Table II.8. 
Despite using the reported conditions for these type of compounds (Pd2(dba)3/RuPhos/K3PO4), the 
reaction did not proceed (entry 1).
50a
  
Table II.8. Arylamination attempts using derivative II.51.a 
 
 
 
Entry Conditions Base Solvent Temperature Observations 
1 
Pd2(dba)3 (2 mol%), 
RuPhos (8 mol%) 
K3PO4  
(2.5 equiv) 
tBuOH 110 ºC (18h) 
Complex 
mixture 
2 
Pd2(dba)3 (2 mol%), 
RuPhos (8 mol%) 
LiHMDS 
(2.5 equiv) 
THF 80 ºC (18h) 
Complex 
mixture 
3 
Pd2(dba)3 (8 mol%),  
BINAP (12 mol%) 
Cs2CO3  
(1.4 equiv) 
Toluene 
60ºC (3.5h) - 
b 
4 
Pd2(dba)3 (8 mol%),  
BINAP (12 mol%) 
Cs2CO3 (1.4 equiv), 
TEA (0.5 equiv) 
Toluene 
90 ºC (18h) -
 b
 
5 
Pd2(dba)3 (10 mol%), 
BINAP (15 mol%) 
NaOtBu  
(2.1 equiv) 
dioxane 
1) 65 ºC (2h) 
2) 100 ºC (18h) 
- b 
a aniline (1.2 – 1.4 equiv);  b starting material recovery. 
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Employing a stronger base such as LiHMDS, a complex mixture was verified by TLC (entry 2). 
It was then envisaged the use of the Pd2(dba)3/BINAP system, but once more complex mixtures 
were obtained (entries 3-5).  
The obtained results can be attributed to the substitution pattern of this molecule. It can be 
suggested that the presence of the benzyl ester moiety is impeding the arylamination reaction.  
 
 
II.3.2.6 Second retrosynthetic approach 
As discussed in the previous sections, there were several handicaps that hampered the first 
strategies to assemble the desired benzimidazole structures. A new plan was formulated as depicted 
in Scheme II.36. In this new retrosynthetic plan, it was envisaged that amine group should be 
masked in order to affect neither the acid protection nor the arylamination step. Moreover, the 
introduction of an adequate group at this position can highly favor the arylamination reaction. 
Thus, benzimidazoles II.19 could be obtained by benzoylation of derivative II.53 followed by 
an acid catalyzed condensation. Synthon II.53 could be attained by arylamination of II.54 with 
different meta substituted anilines. Additionally, an extra synthetic (reductive) step is needed to 
recover the amine moiety. Derivative II.54 can be prepared by amine oxidation followed by 
esterification of intermediate II.37. 
 
 
Scheme II.36. Second retrosynthetic plan to assemble benzimidazoles of general structure II.19. 
It is noteworthy that compound II.37 [obtained from the reduction 7-bromo isatin (II.22) with 
concomitant amide bond hydrolysis] is the key molecule to construct the desired benzimidazole 
core. This structure contains the key elements to assemble the benzimidazole core with the acetic 
acid moiety in position 4.  
 
II.3.2.7 Benzimidazole library synthesis through the nitro intermediate 
Due to the observed difficulties to accomplish the arylamination reaction using the above 
mentioned methods, it was devised the amine modification to a nitro group. In fact, it seems that 
the introduction of a nitro group can favor the arylamination reaction, as previously reported for o-
halo nitro arenes (Scheme II.37).
118
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Scheme II.37. Previous reported strategies of arylamination using anilines.
118 
Thus, it was envisaged that the amine moiety of derivative II.37 could be readily oxidized to 
nitro group in order to obtain derivative II.56. 
Direct oxidation of aromatic amines to nitro compounds can be achieved using several 
reagents.
119
 However, some of these procedures usually lead to the formation of side products 
formed mainly from the partial oxidation of the amines. 
In this work, it was adopted a method previously described in the literature for anilines,
120
 that 
uses Oxone® as the oxidizing agent – a triple salt of  2KHSO5·KHSO4·K2SO4 – where the active 
component is the potassium peroxymonosulfate. This salt, when placed in a buffered aqueous 
acetone medium, forms the active and unstable intermediate dimethyldioxirane II.55 that will act 
as the oxidant specie of amine group (Scheme II.38). 
 
 
Scheme II.38. Formation of the intermediate dimethyldioxirane (II.55) and proposed oxidation mechanism. 
Compound II.37 was firstly stirred in a basic solution of NaOH and NaHCO3 placed in an ice 
bath protected from light. Then, Oxone® was added to the solution followed by the slow addition 
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of a water/acetone mixture. After quenching with an acidic solution and extraction with ethyl 
acetate, the product was afforded in 93% yield (Scheme II.39). Since the chromatographic isolation 
of compound II.56 was problematic (due to the strong affinity to silica-gel), it was chosen to use it 
directly in the next reaction step, without any purification.  
 
 
Scheme II.39. Preparation of nitro derivative II.56. 
Due to the preliminary problems faced with the choice of the carboxylic acid protecting group, 
it was prepared the methyl ester derivative (II.57) in order to be further used in the arylamination 
reaction. To prepare the compound II.57, several standard methods were examined: 1) formation of 
the corresponding acyl chloride by using SOCl2 in MeOH; 2) acid activation with DCC followed 
by methanol addition; 3) methylation using MeI or diazomethane, or 4) esterification in 
MeOH/HCl. In Table II.9 are resumed the results for the different methods. 
 
Table II.9. Conditions for esterification of compound II.56. 
 
It was verified that the yields were globally not high, which can be explained by the use of the 
crude mixture of II.56. Other explanation could be attributed to the presence of the nitro group 
since it could form intramolecular hydrogen bonds with the hydroxyl group of carboxlic acid, 
decreasing its reactivity on the reaction. 
 
Entry Conditions Solvent Temperature/Reaction time Yield (%) 
1 SOCl2 MeOH rt/overnight 19
 
2 1) DCC; 2) MeOH DCM rt/3h 48 
3 MeI, K2CO3 DMF rt/overnight Mixture 
4 1) NaH; 2) MeI DMF rt/overnight Mixture 
5 Diazomethane DCM rt/1h 58 
6 MeOH/HCl MeOH reflux/3h 67 
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Esterification methods like SOCl2/MeOH or the DCC activation followed by the addition of 
MeOH, presented poor yields (entries 1 and 2). It was also verified on TLC – by comparison with 
the isolated product, that methylation with MeI did not form II.57, yielding a mixture of products 
(entries 3 and 4). Reaction with the freshly prepared diazomethane yielded the product in 58% 
yield (entry 5) while the esterification with MeOH in aqueous HCl afforded the product in 67% 
yield (entry 6, Table II.9). Thus, this last method was further used to prepare II.57. 
 
The synthesis of compound II.57 was also attempted through oxidation of compound II.58 with 
Oxone® (Schemes II.40). However, in these conditions it was obtained the 7-bromo oxindole and a 
compound that could be the nitroso derivative II.59 (as suggested by IR).  
 
 
Scheme II.40. Oxidation of derivative II.58.121 
Consequently, an alternative oxidation methodology was employed (Schemes II.41); a solution 
of trifluoroacetic peracid in DCM was prepared by the addition of 50% hydrogen peroxide to a 
solution of trifluoroacetic anhydride in DCM, followed by the addition of compound II.58. 
However, it was verified the formation of the same compound II.59.
121
 
 
 
Scheme II.41. Oxidation of derivative II.58. 
 
II.3.2.8 Preliminar synthesis – synthesis of meta-substituted anilines with NHBoc, OAc 
and OMe groups and arylamination optimization 
In order to obtain the final benzimidazole structures where the phenyl ring in position N-1 
possesses a hydroxyl or nitro group in meta position (Figure II.12), it would be necessary to 
perform the arylamination of II.57 with the corresponding meta-substituted anilines. However, due 
to the incompatibility of these groups (-OH and -NO2) with the subsequent synthetic steps, it was 
necessary to prepare the corresponding anilines where these groups were masked. 
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Figure II.12. Benzimidazole structures where N-phenyl ring is meta-substituted with the hydroxyl or nitro 
groups. 
Therefore, 3-nitro aniline (II.62) was protected with Boc group followed by the nitro reduction 
with 10% Pd/C under H2 atmosphere in methanol, to form the aniline II.64 in quantitative yield 
over two steps (Scheme II.42).
122
 
 
 
Scheme II.42. Synthesis of meta-substituted anilines with NHBoc (II.64) and OAc (II.68) groups. 
Using 3-amino phenol (II.65) directly for the arylamination of II.60 (used as a model structure) 
(see Table II.10), afforded the arylation product in 28% yield. It was then chosen to protect the 
hydroxyl group of II.65 with the acetyl group, which could easily removed in a later stage. Thus, 
hydroxyl group was protected in a sequential protection/deprotection strategy: the amine group was 
Boc protected followed by acetylation of hydroxyl group to afford II.67. The last step consisted on 
the Boc removal in water to form II.68 (Scheme II.42). It was verified that this aniline was very 
unstable even when stored for short periods of time, hence being prepared just before used. 
The preliminary arylamination trials were performed using II.60, aniline and the prepared 
anilines, tert-butyl 3-aminophenyl carbamate (II.64), the amino-phenol (II.65) and the O-
acetylated compound (II.68), to attain the compounds II.69a-d, according to the Table II.10.  
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Table II.10 Cross-coupling of II.60 with the desired anilines.a 
 
    
a reaction conditions: Pd2dba3 (5 mol%), BINAP (7.5 mol%), Cs2CO3 (2 equiv), aniline (2 equiv), 
toluene (0.25 M) in a sealed tube under an argon atmosphere, 90 ºC, 3 – 6 h. 
 
As expected, the arylamination of II.60 with aniline yielded II.69a quantitatively. The reaction 
with II.64 afforded compound II.69b in good yield, without cleavage of the Boc group (that could 
occur due to the high temperature employed).  
Since, arylamination of II.60 with II.65 rendered compound II.69c in a poor yield, along high 
amounts of unreacted starting material, it was stipulated that hydroxyl protection was needed. It is 
worth mentioning that O-arylation product was not expected, since chemoselectivity of Pd-
catalyzed cross-coupling procedure involving aminophenols was already described, yielding the N-
arylated derivative.
123
  
In the arylamination with II.68, it was verified the total consumption of starting material. 
However, it was observed on TLC the partial hydrolysis of acetyl group, to form a mixture of 
acetylated (II.69d) and the free hydroxyl product (II.69c). This mixture could be fully acetylated 
with Ac2O in the presence of Cs2CO3 in toluene to attain II.69d in quantitative yield.  
Since II.69d was unstable, it was further proposed to transform the hydroxyl in a methoxyl 
group.  
 
Scheme II.43. Preparation of methoxylated product II.70. 
Thus, compound II.69c was placed in acetone and reacted with MeI in the presence of K2CO3 at 
room temperature, to yield the methoxylated compound (II.70) in 82% yield (Scheme II.43).  
In order to test the viability of these groups, compounds II.69a, II.69b and II.70 were reduced 
under standard conditions (10% Pd/C, H2 atmosphere) and benzoylated with sulfamoyl benzoyl 
chloride (II.27) with concomitant cyclization to afford benzimidazoles II.71a-c (Table II.11). 
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Table II.11. Reduction and benzoylation/cyclization of II.69a-b and II.70 to afford benzimidazoles II.71a-c. 
 
   
 
 
All the benzimidazole structures were achieved in good to excellent yields (although trace 
amounts of the corresponding ring opening products were observed). Moreover it was verified that 
benzimidazole II.71b can be attained without cleavage of Boc group. Compound II.71c was also 
achieved in good yield. 
It was further investigated the cleavage of Boc group. Despite the good results observed for 
compound II.67 (see Scheme II.42), the Boc cleavage under water reflux conditions did not occur 
for benzimidazole structure II.71b. This compound was also subjected to acidic conditions (acetic 
acid in acetonitrile) under reflux for 5 h, however without good results. When stronger acidic 
conditions were used (refluxing II.71b in a 3M HCl solution) Boc was successfully removed, 
yielding the corresponding product (II.72) along with (uncharacterized) side products (Scheme 
II.44). 
 
Scheme II.44. Deprotection of Boc group for compound II.71b. 
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II.3.2.9 Arylamination reaction 
The optimization of arylamination reaction was performed using the intermediate II.57 and 
aniline. Several palladium based catalytic systems were tested, and the results are presented in 
Table II.12. 
Table II.12. Optimization of arylamination of II.57 with aniline. 
 
As previously mentioned, derivatives containing a nitro group in an adjacent position to the 
halide were successfully submitted to arylamination using Pd2(dba)3 (5 mol%) and BINAP (7.5 
mol%) in toluene.
118a,b
 These conditions were tested for derivative II.57, yielding the product 
II.73a in excellent yields (entries 1 and 2, Table II.12). It was also verified that a slight decrease in 
temperature improved the yield, maybe due to less decomposition. 
The system that comprises a Pd(II) salt, such as Pd(OAc)2/BINAP in the presence of Cs2CO3, 
yielded the product in 66% (entry 3).
118c
 The BrettPhos system
107
 was also examined, proving its 
inadequacy for these type of derivatives, either with LiHMDS or with a milder base such as 
Cs2CO3 (entries 4 and 5, Table II.12).  
Therefore, the Pd2(dba)3/BINAP system was chosen for the arylamination of II.57 with the 
required anilines, to obtain the corresponding products II.73a-g in excellent yields (Table II.13). 
However, derivative II.73f was obtained in moderate yield (52%) due to the Boc deprotection that 
occurred during the reaction. The corresponding Boc free derivative was recovered in 27% along 
with a minor portion of unreacted aniline. 
 
Entry Conditions Base Solvent Temperature/time Yield (%) 
1a 
Pd2(dba)3 (5 mol%) + 
BINAP (7.5 mol%) 
Cs2CO3 
(2 equiv) 
Toluene 110 ºC (4.5 h) 73 
2a 
Pd2(dba)3 (5 mol%) + 
BINAP (7.5 mol%) 
Cs2CO3 
(2 equiv) 
Toluene 
1) 70ºC (2 h) 
2) 90ºC (3 h) 
83 
3b 
Pd(OAc)2 (2 mol%) + 
BINAP (3 mol%) 
Cs2CO3 
(3 equiv) 
Toluene 65 ºC (overnight) 66 
4c 
BrettPhos (1 mol%) + 
BrettPhos precatalyst (1 mol%) 
LiHMDS 
(3.4 equiv) 
THF 65ºC (4 h) 47 
5d 
BrettPhos (1 mol%) + 
BrettPhos precatalyst (1 mol%) 
Cs2CO3 
(2 equiv) 
Toluene 
1) 65ºC (5 h) 
2) 90ºC (overnight) 
45 
a aniline (3 equiv), toluene (0.25 M); b aniline (2 equiv), toluene (0.25 M); c aniline (1.2 equiv); d aniline (2 equiv), 
solvent (0.25 M); 
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Table II.13. Cross-coupling of II.57 with the several anilines to obtain the derivatives II.73a-g. 
 
    
   
a
 recovered with the Boc free derivative (27%) and unreacted aniline. 
 
Having the arylamination products (II.73a-g) in hands, the next step involved the reduction of 
nitro group of to obtain the derivatives II.74a-g. However, several concerns were raised due to the 
deliverance of a free amine that could be prone to an unsought cyclization.  
The reduction of nitro derivatives was firstly performed using the usual hydrogenation 
conditions with 10% Pd/C in methanol under H2 atmosphere (1 h). To our distress, these conditions 
promoted the ring closing reaction to afford the 7-substituted oxindole structures II.75. Gladly, 
when the reaction was performed in toluene, the desired products II.74 were obtained as the major 
compounds, although with a small amount of the corresponding oxindole structures (Scheme II.45). 
These compounds were simply filtered and used in the following step without further purification. 
 
 
Scheme II.45. Nitro group reduction of compounds II.73a-g. 
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The next step involved the N-benzoylation of derivatives II.74a-f with the previously 
synthesized sulfamoyl benzoyl chloride (II.27). As a result, it was envisaged that the final 
compounds could be easily attained after this step, through an acid promoted cyclization using 
acetic acid, as described by Ma et al. (Scheme II.46).
50b
 
 
Scheme II.46. Preparation of the final products using Ma et al. procedure. 
The reaction was initially performed by adding derivative II.74a to a cold solution of II.27 
(freshly prepared) in THF in the presence of K2CO3. The reaction was then stirred at room 
temperature overnight. However, under these conditions it was observed (by TLC) the formation of 
II.76a as the major product along with the corresponding benzimidazole II.77a and oxindole 
II.75a (amounts not quantified) (Scheme II.47). 
 
Scheme II.47. N-Benzoylation of derivative II.74a under basic conditions. 
These two products – II.76a and II.77a – despite their easy isolation from other side-products, 
such as the corresponding oxindole, were very difficult to isolate from each other, since they are 
strongly retained in silica-gel and overlap. 
The observation of the benzimidazole structure II.77a and the need of an acidic medium to 
achieve the cyclization, gave us the input to the next experiment. 
 
Scheme II.48. Consecutive N-benzoylation and cyclization steps to prepare II.77a. 
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In the second attempt, it was added II.74a to a solution of II.27 in THF without the addition of 
K2CO3, and the mixture was stirred at 50ºC. This reaction evolved in a fast way, with total 
consumption of starting material after 3 h (monitored by TLC). As expected, this trial led to the N-
benzoylation of II.74a with a concomitant cyclization to directly attain the benzimidazole II.77a as 
the major product (Scheme II.48). 
 
Table II.14. Sequential N-benzoylation and condensation/cyclization steps to prepare derivatives II.77a-f. 
 
   
   
 
 
Under these conditions, the ring open product II.76a as well as the oxindole II.75a were also 
formed and isolated in 7% and 13 % yield, respectively. In order to maximize the amount of 
benzimidazole II.77a, the crude mixture was subjected to a further step of cyclization in AcOH in 
order to fully convert derivative II.76a into benzimidazole II.77a. The process was repeated for 
derivatives II.74a-f (Table II.14). 
 
The acid derivatives were obtained by hydrolysis of the methyl ester group with LiOH.H2O, a 
fast (1 h) and smooth process that yielded the target benzimidazoles (II.78a-f) quantitatively (Table 
II.15). 
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Table II.15. Ester hydrolysis to prepare derivatives II.78a-f. 
 
   
   
a hydrolysis performed with 3M HCl aqueous solution at 80ºC, 4h. 
 
It is noteworthy that the acetyl protection of derivative II.77e was also cleaved under the 
hydrolysis step, affording the corresponding hydroxylated derivative II.78e. In order to cleave the 
Boc group, derivative II.77f was placed in a 3M HCl aqueous solution at 80ºC for 4 h, yielding 
compound II.78f quantitatively.  
 
In order to perform the biological evaluation, is required a high degree of purity of the 
synthesized compounds. Thus, all the ester derivatives II.77a-e as well as the acid compounds 
II.78a-e were analyzed by HPLC. Despite their high levels of purity – above 96% – it was verified 
that the ester compounds had small amounts of the corresponding acid derivatives (<3%). 
Having in hands the purified benzimidazole compounds, the next step consisted on the 
biological evaluation in order to verify their potential as efficient COX inhibitors, and the STD-
NMR experiments to study their binding mechanism within COX. 
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II.3.3 Evaluation of the synthesized library 
The inhibitory activity of the synthesized compounds was tested against COX-1 and COX-2 
isoenzymes in order to verify their selectivity. The chosen method to evaluate this activity was the 
human WBA. 
 As above mentioned the WBA involves three tasks. However, the sample preparation 
procedure is slightly different for the different COX isoforms, affecting the time spent in the two 
assays (excluding the ELISA test). While for COX-1 assay, the incubation takes place within less 
than 3 h (incubation times excluding in-between operational tasks), for COX-2 assay is required a 
longer period of incubation to attain the desired plasma, which takes approximately 6 h. 
The inhibitory activity studies were performed for the ester and acid compounds (II.77a-e and 
78a-e, respectively) at different concentrations, starting at 100 M, and gradually decreasing until 
the compounds showed inexpressive inhibitory activity. Desirably, each study must correspond to 
at least three (reproducible) experiments for each concentration. Due to solubility issues and 
experimental strategy, the compounds were not tested within the same range of concentrations. 
 
II.3.3.1 Evaluation of inhibitory activity towards COX-1 
In the COX-1 assay, the blood stimulation was achieved by COX stimulation using a calcium 
ionophore (II.80) following to the exposure to the analyzed compound at a specific concentration, 
in the presence a thromboxane synthetase inhibitor (TXBSI) (II.79) (see Experimental for details). 
As the name suggests, the TXBSI is used to inhibit the thromboxane synthase, an enzyme that 
converts the AA derivative – PGH2 – to TXA2, which in turn degrades into the stable TXB2. Since 
PGE2 is produced in substantially lower amounts compared to TXB2 (only 1–2 %), the introduction 
of TXBSI will amplify the PGE2 content. The TXBSI used in this work is the (E)-7-phenyl-7-(3-
pyridyl)-6-heptenoic acid (II.79) also known by CV-4151, a selective TXA2 synthase inhibitor with 
an IC50 of 0.026 μ M (Figure II.13).
99,124
 
Calcium ionophore A23187 (II.80), also known as Calcimycin, is an antibiotic and a mobile 
ion-carrier that forms stable complexes with divalent cations (such as, Mn
2+
, Ca
2+
 and Mg
2+
), 
allowing these ions to cross cell membranes, which are usually impermeable to them.
125
 It is also 
used to stimulate prostanoids formation through a COX-1 and COX-2 pathway, as previously 
reported.
126
 
 
Figure II.13. TXBSI (II.79) and calcium ionophore (II.80). 
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For each compound, solutions of desired concentrations were freshly prepared in a buffer from 
the compound stock solution (4 mM) which was prepared in DMSO. Although its unfavorable 
interferences with blood, DMSO can be used in low concentrations (< 1%) being used as vehicle in 
most WBAs.
99
  
The solubility of the studied compounds was analyzed for the tested concentrations, and the 
insolubility of some compounds was observed at higher concentrations. After a period of 
incubation in the presence of all assay components, the blood samples were centrifuged and the 
plasma was taken for the ELISA test. 
The employed PGE2 EIA kit is a colorimetric competitive enzyme immunoassay kit that 
measures the levels of downstream PGE2 of an assay exposed to the different concentrations of 
COX inhibitors. A low PGE2 content conducts to a higher absorbance read for the sample (at a 
given concentration), which means a high inhibitory activity (and vise-versa). The percentage of 
inhibition is obtained from standard equations described on literature.
97
 
 
The majority of the tested compounds were found to inhibit COX-1 as observed in Table II.16. 
Inhibition of COX-1 by the synthesized compounds is expressed as the percent inhibition of COX-
1 activity and the known COX inhibitor indomethacin was used as positive control. 
It was neatly observed that the ester derivatives (II.77a-e) showed higher inhibition values 
when compared to acid related structures (II.78a-e), inhibiting COX-1 in a concentration-
dependent manner. In fact, only the acid derivatives II.78a, II.78b and II.78d showed inhibitory 
activities, e.g. 52 ± 9 %, 25 ± 2 % and 23 ± 8 %, respectively, for 50 μM. Moreover, these 
compounds showed high values of SEM making difficult to achieve a concentration-dependent 
effect.  
Indomethacin inhibitory percentages were 88 ± 8 % (1 M) and 55 ± 12 % at 0.625 M, thus 
having higher potency towards COX-1 than the studied compounds. 
The inhibition percentages that displayed high values of SEM were considered inconclusive. 
 
As observed in Table II.16 and Figure II.14, all the ester derivatives (II.77a-e) presented high 
inhibitory values (e.g. 74 ± 5 % to 99.85 ± 0.05 % at 50 M) while the acids where poor inhibitors 
or fail to inhibit COX-1. The inhibition differences between acids and esters derivatives can be 
attributed to the high affinity of acids to a different region in the protein which does not influence 
its activity. 
In fact, it was already described that some acid containing inhibitors possess a time-dependent 
effect that can be attributed to an allosteric effect or due to chemical modification of the active 
site.
127
 However, transforming the carboxylic acid moiety in a methyl ester group modifies its 
character, conferring to these compounds the reversible ability to inhibit the protein.
127
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More recently, it was also described that pyrrole based structures containing an acetic ester 
chain at C-3 possess an increased activity toward COX-2 than the corresponding acids.
105c
 
Table II.16. Percent inhibition of COX-1 activity of synthesized compounds determined by human WBA. 
 
Compound 
Conc (%) 
100 M 50 M 25 M 12.5 M 5 M 2.5 M 1 M 0.625 M 
II.77a 
a 
99.25 
±0.35 
a 
93 
±2 
80 
±3 
60 
±4 
a 
15.20 
±0.42 
II.77b 
92 
±2 
77 
±6 
b 61 
±3 
2.50 
±2.50 
a a a 
II.77c 
a 
97 
±1 
92 
±2 
81 
±6 
68 
±6 
42 
±11 
b 
32 
±5 
II.77d 
a 
99.85 
±0.05 
a 
94 
±2 
86 
±5 
64±8 b 
41 
±14 
II.77e 
94.77 
±0.47 
74 
±5 
59 
±9 
24 
±2 
0.50 
±0.50 
a a a 
II.78a 
68 
±16 
52 
±9 
a a b a a a 
II.78b 
b 
25 
±2 
a a b a a a 
II.78c 
b b a a b a a a 
II.78d 
50 
±15 
23 
±8 
a a b a a a 
II.78e 
b b a a b a a a 
II.71a 
b 
32 
±14 
a a b a a a 
Indomethacin 
a
 
a
 
a
 
a
 
a
 
a
 
88 
±8 
55 
±12 
a
 not performed; 
b
 inconclusive
 
 
Within the ester compounds, it can be observed a clear distinction for compounds II.77a, II.77c 
and II.77d when compared to II.77b (R = CF3) and II.77e (R = OH). While the first three 
compounds presented 99.25 ± 0.35 %, 97 ± 1 % and 99.85 ± 0.05 %, at 50 M, compounds II.77b 
and II.77e presented 77 ± 6 % and 74 ± 5 %, respectively. The same trend was verified for lower 
concentrations and below 5 M, II.77b and II.77e displayed inhibition values less than 10%, 
which were considered not significant. These facts, allows one to consider II.77a, II.77c and II.77d 
the most active compounds towards COX-1. 
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Figure II.14. COX-1 inhibitory activity. 
It is interesting to observe that small structural differences confer discrepant inhibitory activities 
against COX-1. Compound II.77a – which does not have any substituent in aromatic ring – has 
similar values to compounds II.77c and II.77d that possess a halogen atom in meta position, F and 
Cl, respectively. For compounds II.77b and II.77e, the presence of a m-CF3 or a m-OAc seems to 
have an unfavorable effect. 
It appears that the halogen atom has an important role in the inhibitory activity, being verified a 
correlation in the activities and the halogen present in the molecule, e.g. F < Cl. Unfortunately m-
bromine compound was not possible to achieve, but it was expected that this structure could 
possess the higher inhibition percentages toward COX, as confirmed by docking studies. 
 
Compound II.71a was also evaluated in order to understand the impact of the acetic acid anchor 
on the inhibitory activity. This compound presented poor inhibition values towards COX-1, similar 
to the obtained for the acid derivatives. This result suggests that none of these compounds bind 
COX catalytic site, and that the acetic acid side chain do not contribute to improve compounds 
activity. However, one cannot say that the free acetic acid chain moiety is dispensable, since the 
acid moiety can interact differently with protein leading to the similar (poor) results observed for 
II.71a. 
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Unfortunately, despite the several inhibition percentages taken for all the compounds, there 
weren’t enough data to calculate the corresponding IC50 values for each compound. Nevertheless, a 
dose-response curve was constructed for all the ester derivatives, showing the unfeasibility of IC50 
assignment (Figure II.15).  
 
Figure II.15. Dose-response curve for COX-1 (fitting performed in GraphPad Prism 6). 
As can be seen, the curves did not show the desired top and bottom plateaus, corresponding to 
the maximum and minimum inhibition concentrations achieved, respectively. Evidently, more 
points would be needed in order to obtain a correct fitting and to determine the IC50 values, 
however due to time and costs limitations it couldn´t be taken. 
 
 
II.3.3.2 Evaluation of inhibitory activity towards COX-2 
For the evaluation of inhibitory activity towards COX-2, the blood stimulation included a 
selective inhibition of COX-1 activity using acetylsalicylic acid, the use of TXBSI as described 
above and the COX-2 induction via lipopolysachacaride (LPS) stimuli.
128
  
The majority of the tested compounds were found to inhibit COX-2 as observed in Table II.17.  
As observed for COX-1 assay, while the acid derivatives (II.78a-e) showed poor inhibitory 
activities, the ester derivatives (II.77a-e) inhibit COX-2 in a same level as Celecoxib, the selective 
COX-2 inhibitor used as control. 
Within the acids group, II.78a and II.78d exhibited the higher inhibitory activities, 30 ± 3 % 
and 18 ± 2 %, respectively, at 50 μM, following the previous trend. The other acid compounds 
displayed inhibition values less than 10%, which conducted to high values of SEM thus not being 
considered. 
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Table II.17. Percent inhibition of COX-2 activity of synthesized compounds, determined by human WBA. 
 
Compound 
Conc (%)  
100 M 50 M 25 M 12.5 M  M 1.25 M 0.5 M 0.125 M 
II.77a 
b 88 
±3 
--  
81 
±5 
59 
±4 
30 
±2 
a 
II.77b 
b 78.94 
±0.13 
a a 
65 
±7 
31 
±3 
7 
±2 
a 
II.77c 
b 88 
±2 
a a 
81 
±2 
82 
±3 
42 
±8 
a 
II.77d 
b 84 
±3 
a a 
81 
±2 
83 
±3 
60 
±8 
21±2 
II.77e 
88 
±3 
83 
±5 
80 
±6 
40 
±4 
5 
±2 
a a a 
II.78a 
b 30 
±3 
a 
4 
±4 
a a a a 
II.78b 
b b a b a a a a 
II.78c 
b 7 
±7 
a 
0.33 
±0.33 
a a a a 
II.78d 
b 18 
±2 
a 
0.85 
±0.85 
a a a a 
II.78e 
b 7 
±7 
a 
1 
±1 
a a a a 
II.71a 
a 46 
±1 
 3 
±3 
 
 
4 
±4 
a a a 
Celecoxib 
a a a a 
72 
±10 
a a a 
a
 not performed; 
b
 inconclusive
 
 
Compound II.71a was also evaluated for COX-2, but besides its lower inhibition, no selectivity 
was found for this compound, that presented 46 ± 1 % at 50 M (32 ± 14 % at the same 
concentration for COX-1). It is interesting to compare II.71a with the already reported 
benzimidazoles structures, I.1 and I.2, both highly potent and selective towards COX-2 (Figure 
II.16). None of these compounds possess the acid or ester anchor in position 4, while the 
substituents in aromatic ring in position 1, appear as an important feature for the inhibitory activity. 
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Figure II.16. Benzimidazoles showing inhibitory activity towards COX-2. 35a 
The ester compounds II.77a-e presented high inhibitory values towards COX-2 (Figure II.17). 
As already verified, compounds II.77a, II.77c and II.77d were the most potent, showing a similar 
pattern and inhibiting COX-2 by 88 ± 3 %, 88 ± 2 % and 84 ± 3 (50 M), respectively. At the same 
concentration, compound II.77b and II.77e exhibit 78.94 ± 0.13% and 83 ± 5 %, respectively. 
However, below 5 M, II.77e displayed inhibition values less than 10%, while for II.77b the same 
was verified below 0.5 M. Thus, the less potent compound was II.77e possessing an acetyl group 
at the meta position. 
 
 
Figure II.17. COX-2 inhibitory activity. 
Once more, compound II.77d – which have a chlorine atom at meta position, showed the higher 
potency, inhibiting 21 ± 2 % in 0.125 M. Remarkably, this compound seems to be even more 
active than Celecoxib which inhibitory percentage was 72 ± 10 % at 5 M. As described before, it 
was expected that m-bromine compound presented the higher inhibitions toward COX-2, as 
predicted by the preliminary docking studies (Figure II.18). 
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Figure II.18. Docking structure of compound II.77d (using AutoDock 4.2.5.1). 
This difference between acid and esters derivatives was previously observed for pyrrole based 
structures. As reported by Biava et al., pyrroles containing an acetic ester chain at C-3 possess an 
increased activity toward COX-2 than the corresponding acids.
105
 Moreover, it is proved that the 
type of ester, e.g. insertion of isopropyl or butyl moiety, have high influence in the inhibitory 
activity (Figure II.19). 
105c
  
 
Figure II.19. Pyrrole structures and corresponding IC50 obtained by WBA for COX-2 (Biava et al.).
105c
 
Biava also proposed that the ester anchor creates very important hydrophobic interactions with 
specific residues such as Leu93, Val116, Tyr355, and Leu359 contributing to the observed 
enhanced COX-2 inhibition (Figure II.20). 
105c
 
 
Figure II.20. Representation of the binding mode of II.81 within the COX-2 binding site (adapted from 
Biava et al.). 105c 
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These results are according to the inhibitory activities observed for the ester compounds. 
Moreover our docking studies also predict that ester anchor can perform important interactions 
with the same Leu93, Val116, Tyr355, and Leu359 residues. 
 
As discussed for COX-1 evaluation, despite the several inhibition percentages taken for all the 
compounds, there weren’t enough data to calculate the corresponding IC50 values for each 
compound. Once more, a dose-response curve was constructed for all the ester derivatives, to 
demonstrate the unfeasibility of this assignment (Figure II.21).  
 
Figure II.21. Dose-response curve for COX-2 (fitting performed in GraphPad Prism 6). 
 
It can be said that both esters and acid derivatives presented a similar inhibition pattern for 
COX-1 and COX-2 isoforms: while the acid derivatives did not show or presented low inhibitory 
activities, the ester compounds were able to inhibit both COX isoforms in a high and concentration-
dependent way. Within the esters group, the chlorine derivative II.77d showed the best results, 
having a comparable inhibitory activity to Celecoxib. 
The results obtained for acid derivatives (II.78a-e) are against the preliminary docking studies 
that predicted an elevated potency and selectivity toward COX-2 for this benzimidazole library. 
Moreover, despite their low selectivity it was simply expected that the acid derivatives should be 
good inhibitors toward COXs. An explanation can reside in different binding locations in protein 
that docking studies cannot predict. These higher affinity sites for the acid derivatives can prevent 
their function as inhibitors. 
For ester derivatives, despite their high inhibitory activity, it was demonstrated a moderate 
COX-2 selectivity. It is known that the residues drive the affinity of inhibitors affecting their 
orientation inside the catalytic active site. Thus, it is suggested that the orientation adopted inside 
the active site places the sulfonamide pointed towards the side pocket, as predicted. However, the 
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aromatic ring in N-1 is pointed upwards to the top of the active site while the ester anchor forms 
interactions with the residues at the entrance of the active site, i.e. Leu93, Arg 120, Val116, 
Tyr355, and Leu359. This observation is consistent for the general non-selective NSAIDs. 
Diclofenac and lumiracoxib have their carboxylates pointed at the top of the active site, which may 
be a required position to be a COX-2 selective inhibitor.  
In order to clarify the binding mode of these compounds within protein, several STD-NMR 
studies were undertaken. 
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II.3.4 STD-NMR studies 
To investigate the relationship between the inhibitory activities found for benzimidazoles 
(against COX-2) and their binding mode to protein, the epitope mapping of different compounds 
was examined by STD-NMR. Moreover, STD-NMR competitive experiments were also conducted 
in the presence of known drugs in order to understand if the designed ester and acid compounds 
bind on the same location or have different binding sites. 
Unfortunately, it was verified that the ester derivatives had a poor solubility in the buffer 
solution used in the NMR studies. Consequently, the STD-NMR studies were performed for 
compounds II.78a-e and for the ester II.77a (soluble on the studied conditions) (Figure II.22). 
 
 
Figure II.22. Compounds examined by STD-NMR. 
The STD-NMR experiments were acquired at 37 °C using commercial ovine (oCOX-2) and 
human (hCOX-2) COX-2 buffered solutions. It can be referred that the majority of studies were 
performed with oCOX-2 due to the expensive costs associated to hCOX-2. This enzyme was only 
used for one of the most promising ester derivatives, II.77a, in order to validate the preliminary 
STD-NMR studies and the biological experiments. 
In the previous STD-NMR studies, it was observed that the spectra were dominated by strong 
signals in the aliphatic zone from the Tris buffer and the additives (Tween 20 and DDC), showing 
that the surfactant also interacts with the protein.
104
 These results were not unexpected, since the 
surfactant is added to stabilize and solubilize the protein and some degree of association between 
the enzyme and the surfactant is expected to occur. The same was observed in the present work, 
where the additives signals overlap with some ligand resonance peaks making the complete epitope 
mapping not possible. Earlier attempts to resuspend the protein in different buffers resulted in 
precipitation. Thus the studies were conducted with the proteins as supplied. 
 
 
II.3.4.1 Epitope mapping of ligands 
Initially, the compounds were examined individually in order to establish their binding 
interaction with COX-2. The region of the ligand having the closest/strongest contact to the protein 
would show the most intense NMR signals allowing the epitope mapping of the ligand. 
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The experiments were performed using a protein:ligand ratio of 1:100. All the acid based 
compounds were soluble in the buffer solution used, while the ester derivatives showed a low 
solubility within the used range of concentrations. Thus, only compound II.77a was tested. The 
corresponding STD-NMR spectra (expanded aromatic region) are depicted in Figure II.23. 
 
 
 
 
 
 
Figure II.23. Expansion of the aromatic region of the reference and 1H STD-NMR spectra of II.78a-e 
(300 M) in the presence of oCOX-2 (3 M) and II.77a (115 M) in the presence of hCOX-2 (1.15 M), at 
600 MHz and 37 °C. 
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For all the analyzed acid compounds (II.78a-e), the aromatic protons showed strong STD 
responses, indicating reversible binding to the enzyme. It reveals that in all cases the drug is in 
close contact with the protein. In the aromatic region it is possible to integrate the resonances of the 
resolved proton signals and determine the relative STD intensities (Figure II.23). Due to the strong 
signals in the aliphatic zone from the buffer and the additives that overlaps with the ligand 
resonance peaks, it is not possible to verify the interaction between the acetic acid anchor and 
protein, e.g. CH2 STD percentages. 
The related STD percentages are similar for all studied compounds. This is not unexpected, 
since the studied compounds belong to the same family having structural similarities. The STD 
percentages observed for the aromatic protons of the heterocyclic core are above 86 % for all the 
studied compounds. It is also seen that the aromatic ring containing the sulfonamide group has 
lower STD interaction when compared with the other aromatic protons. This can indicate that the 
molecules possess an orientation in protein binding site where this ring is pointed outwards the 
protein or is inserted in a hollow place. 
 
 
Figure II.24. A. Orientation of SC-558 inside COX-2 active site; B – D. Possible orientations for the studied 
compounds inside COX-2 active site. 
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According to the previous STD-NMR studies performed for diclofenac and ibuprofen, it was 
suggested that the ligand moieties with higher STD response were directed to Arg120 and Tyr355 
residues, while the moieties receiving less saturation transfer were pointed towards Ser530 and 
Tyr385.
104
 Based on these observations, the sulfonamide group would be directed to the top of 
COX-2 active site, i.e. towards Ser530 and Tyr385 (Figure II.24, c). However, it was anticipated 
that the compounds should have an orientation similar to the already reported coxibs (Figure II.24, 
a), result that was also predicted by the docking studies (Figure II.24, b). Moreover, it was also 
expected that the carboxylate group could particularly interact with Arg120 and Tyr355 residues, as 
verified for naproxen or indomethacin (see Figure I.10). Other possible orientation places the 
carboxylic acid moiety at the top of the active site, forming hydrogen bonds with Ser530 and 
Tyr385, similarly to lumiracoxib and diclofenac (see Figure I.10). Unfortunately, it was not 
possible to verify the STD response for the acetic acid chain, which could confirm the orientation 
of the studied molecules within the COX-2 binding site. 
It can be inferred that the results obtained for the previously studied NSAIDs cannot be 
extrapolated for the presently studied compounds, which share the y shape structure of coxibs. 
Thus, one can say that these were the first STD-NMR studies performed for coxib-like molecules, 
and that further studies are still required (using a well-known coxib) in order to confirm the 
obtained results. 
 
It can be said that the strong STD signals observed for all the compounds reflects a reversible 
binding to enzyme sites and a fast exchange on the NMR time scale. However one cannot conclude 
about their binding site on protein without additional STD-NMR studies. 
 
 
II.3.4.2 Competitive STD-NMR Studies 
In order to have a deeper insight of the mechanisms of action for the designed compounds, 
competitive STD-NMR experiments were carried using ibuprofen, diclofenac and naproxen as spy 
molecules. 
The choice of these drugs is related to the way these drugs bind the protein. The time-
independent inhibitor ibuprofen binds to both COX active sites, Ecat and Eallo, while time-dependent 
inhibitors such as naproxen and diclofenac bind preferentially to a single monomer.  
Diclofenac binds Ecat and compete with AA for the catalytic site which conducts to the complete 
COX inhibition, while naproxen is an allosteric regulator that binds to Eallo, causing an incomplete 
inhibition (Figure II.25). 
10
 According to the reported IC50 values, diclofenac (IC50 of 38 nM) is a 
more potent inhibitor of COX-2 than ibuprofen (IC50 = 7.2 μM) and naproxen (IC50 = 28 μM). 
96
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Figure II.25. Competitive experiments to understand the binding mechanism of the synthesized compounds. 
The first experiment consisted on the competition between the known drugs: ibuprofen, 
naproxen and diclofenac (Figure II.26). The first two superimposed spectra corresponds to the 
reference and STD-NMR of ibuprofen (7.20-7.35 ppm) (Figure II.26, a). 
To the sample containing ibuprofen (1:100, protein:ligand ratio) an excess of naproxen was 
added (2 equiv. relatively to ibuprofen). Both drugs displayed STD interactions; however naproxen 
signals overlapped with those belonging to ibuprofen making the analysis a difficult task (Figure 
II.26, b). Nevertheless, it can be seen a decrease of naproxen STD response of approximately 1/2. 
This corroborates the fact that while naproxen binds to one of the monomers, ibuprofen can bind to 
both. This result can also indicate that both ibuprofen and naproxen possess similar binding 
patterns, allowing ibuprofen to compete for Eallo. Ibuprofen binds both monomers possessing a 
reversible, poor binding behavior, which can conduct to a high STD response. 
The next step consisted on the addition of two equivalents (relatively to ibuprofen) of diclofenac 
to the previous mixture (Figure II.26, c). It is worth to notice that a competitive experiment was 
already conducted between diclofenac and ibuprofen, where the STD response of ibuprofen was 
about 1/2 of diclofenac.
104
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Figure II.26 Expansion of the aromatic region of the reference (black) and 1H STD-NMR spectra (green) of 
a) ibuprofen (326 M) and competition experiments with b) naproxen (652 M) and c) naproxen and 
diclofenac (652 M) in the presence of oCOX-2 (3.26 M), at 600 MHz and 37 °C. 
In our experiment it was expected that the presence of both naproxen and diclofenac would 
suppress almost completely the STD response from ibuprofen because of its lower IC50 compared 
to those drugs. This would prove its binding character to both Ecat and Eallo. Unfortunately, due to 
spectral overlap in the ibuprofen region (7.20-7.35 ppm), it is difficult to separate the STD 
responses from ibuprofen, naproxen and diclofenac in order to compare with the individual 
experiments. It seems that ibuprofen signals are attenuated, however one cannot confirm the 
disappearance of ibuprofen signals. Thus only the latter drugs were compared.  
In this case, a clear alteration in STD spectrum is observed. Both diclofenac and naproxen 
possess STD interactions; however naproxen signals are significantly attenuated. This can indicate 
three different binding mechanisms; a) diclofenac (which is a strong time-dependent inhibitor) 
binds preferentially to Ecat and ibuprofen will in turn compete with naproxen by Eallo, leading to the 
observed results; b) diclofenac binds to Ecat and its presence can modulate Eallo, impeding naproxen 
to bind its site; or c) diclofenac also competes for Eallo. These two last proposals would be in 
opposition to the previously reported results.
10
 Moreover, it seems that the presence of naproxen 
(which binds to Eallo) does not have influence in the binding mode of diclofenac. 
 
II.Results and Discussion 
78 
 
II.3.4.3 Compound II.78a vs ibuprofen, diclofenac and naproxen 
The existence of STD signals for compounds II.78a-e – although the poor results for biological 
evaluation – suggests that these derivatives might bind to a third location which do not influence 
the COX activity. In order to elucidate this hypothesis, competitive STD experiments were carried. 
The initial competition experiments with the acid derivative II.78a were performed using 
ibuprofen as spy molecule. The experiment depicted in Figure II.28 consisted on titration of 
ibuprofen in the presence of II.78a (protein:ligand, 1:25).  
In case of ligand competition for the same binding site, it was expected that ibuprofen would 
suppress almost completely the STD response from II.78a due to this compound poor inhibitory 
activity (see Chapter II.2, page 65) when compared to ibuprofen. What can be observed in Figure 
II.27 is a similar STD response for both ibuprofen and II.78a when the compounds are in 1:1 ratio 
(Figure II.27, c). When ibuprofen is in 4-fold excess to II.78a, the acid derivative still maintains 
similar STD intensities, showing that the increase of ibuprofen does not affect the binding of II.78a 
to the protein (Figure II.27, d). This could indicate that both compounds bind to Eallo and Ecat; while 
ibuprofen was binding to one monomer, II.78a could bind to the other and vise-versa. However, 
due to the poor inhibitory activity presented by II.78a it is not possible to exclude a third binding 
site that does not take part in the mechanism of inhibition. 
 
Figure II.27 Expansion of the aromatic region of the reference (black) and 1H STD-NMR spectra (red) of:  
a) II.78a (81.5 M), and with different ibuprofen concentrations: b) 32.6 M; c) 81.5 M; d) 326 M, in the 
presence of oCOX-2 (3.26 M), at 600 MHz and 37 °C. 
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The same trend was verified for all the acid compounds II78b-e (see Appendix, page 255). 
The competition studies between II78a and naproxen are represented in Figure II.28. 
Unfortunately, because of spectral overlap in the aromatic region, it is difficult to separate the STD 
responses from II.78a and naproxen in order to individually compare both compounds. Thus, only 
the signals corresponding to H2’ and H3’ from II.78a, and H5 from naproxen were evaluated and 
compared. Taking the II.78a signal – corresponding to H2’/3’ – as reference it is observed that 
despite the successive increasing of naproxen concentration, the STD response of II.78a is 
maintained. This can indicate that naproxen is not competing for the same binding site of II.78a. 
However, for 1:1 ratio, naproxen STD response seems to be ½ the II.78a response (Figure II.28, d), 
indicating that while naproxen is only binding one monomer (Eallo), II.78a could bind both Eallo and 
Ecat. Other possibility is that the binding of II.78a to Ecat or to a third site, can influence the 
naproxen binding to Eallo. 
 
Figure II.28 Expansion of the aromatic region of the reference (black) and 1H STD-NMR spectra (red) of: a) 
II.78a (163 M) and with different naproxen concentrations: b) 32.6 M; c) 81.5 M; d) 163 M; e) 326 
M); f) 652 M, in the presence of oCOX-2 (3.26 M), at 600 MHz and 37 °C. 
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The competitive STD-NMR experiment between II.78a (protein:ligand, 1:400) and diclofenac, 
shows that the increase of diclofenac amount decreases the II.78a STD response (Figure II.29). In 
fact, comparing the signal corresponding to H2’,3’ (II.78a) with the signal of H3/5 (diclofenac), 
allows one to approximately quantify the STD response of II.78a as 1/2 of that corresponding to 
diclofenac. 
This result is similar to the previously reported competitive studies between diclofenac and 
ibuprofen, where was concluded that the existence of STD response for ibuprofen in the presence 
of diclofenac could indicate that the inhibitors were not competing for the same binding site. 
 
Figure II.29 Expansion of the aromatic region of the reference (black) 1H STD-NMR spectra (red) of: a) 
II.78a (1.304 mM) and with different diclofenac concentrations: b) 326 M, c) 652 M and d) 1.304 mM, 
and e) with naproxen (1304 M) in the presence of oCOX-2 (3.26 M), at 600 MHz and 37 °C . 
Thus, the results suggest that II.78a is not competing neither for the naproxen binding site, Eallo, 
nor for Ecat, but that diclofenac attachment to Ecat affects the way that II.78a binds COX-2. The 
STD-NMR studies indicate that the acids II.78a-e might have higher affinity to a third binding site, 
that is influenced by the way diclofenac binds to Ecat. 
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II.3.4.4 Compound II.77a vs naproxen and diclofenac 
Similarly to the studies undertaken for the acid derivatives, competitive STD experiments were 
carried for esters. Due to the higher inhibitory activity detected by biological assays, our interest 
was to verify whether these compounds bind Ecat and/or Eallo. 
The competitive STD-NMR studies were conducted using II.77a, soluble on the experimental 
conditions. Nevertheless, II.77a yielded poor resolution STD-NMR spectra, which can be due to its 
high affinity towards COX-2, i.e. high Ki. 
 
 
Figure II.30 Expansion of the aromatic region of the reference (left) and 1H STD-NMR (right) spectra of: a) 
naproxen (163 M) and with different II.77a concentrations: b) 81.5 M; c) 163 M; d) 245 M and e) 
addition of naproxen (326 M), in the presence of oCOX-2 (3.26 M), at 600 MHz and 37 °C. 
In Figure II.30 are represented the spectra of naproxen (protein:ligand, 1:50) and the 
competitive experiments with II.77a (at different concentrations – Figure II.29, b-d). Initially, for a 
naproxen:II.77a ratio of 1:0.5 (Figure II.30, b), it was observed that the STD response of II.77a 
was higher than the response of naproxen (Figure II.30, c). When both drugs were in 1:1 ratio, 
II.77a also demonstrated higher STD signals compared to naproxen. Unfortunately the signals 
overlap and do not allow the determination of STD percentages. 
 
This result suggests two different mechanisms. The first mechanism would indicate the 
existence of a competition of II.77a for the same binding site of naproxen (which preferentially 
binds to Eallo) (Figure II.31-A). In addition, the result can suggest that compound II.77a has a 
stronger affinity than naproxen, corroborating the results obtained by the biological evaluation. 
However, naproxen signals never disappeared suggesting that the inhibitor is being pushed to Ecat 
or that it can still bind to Eallo thus presenting a moderate STD response. 
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Figure II.31. Competitive experiments between II.77a (blue) and naproxen (red) and proposed binding 
mechanisms.  
The second mechanism could indicate that II.77a can bind both Ecat and Eallo having a time-
independent, ibuprofen-like behavior, while naproxen still binds to Eallo (Figure II.31-B). 
When the order of addition is reversed, i.e. naproxen concentration is twice the II.77a (Figure 
II.30, e), is clear the reduction of II.77a STD response, suggesting that naproxen is expelling this 
compound from its binding site (Figure II.31-C). 
These competitive STD-NMR experiments were also made with hCOX-2 (protein:ligand, 
1:100). In this case, STD-NMR spectra of II.77a had enhanced resolution compared to oCOX-2 
counterpart, despite the small protein concentration used (Figure II.32). 
When one equivalent of diclofenac was added to II.77a both compounds showed STD response 
with similar intensities, demonstrating that the compounds do not compete for the same binding 
place (Figure II.32, b). Moreover, if II.77a is binding Eallo, that is not influencing the binding mode 
of diclofenac to Ecat.  
 
Figure II.32 Expansion of the aromatic region of the reference (left) and 1H STD-NMR (right) spectra of: a) 
II.77a (115 M) with b) diclofenac (115 M) and c) naproxen (115 M), d) naproxen (345 M) in the 
presence of hCOX-2 (1,15 M), at 600 MHz and 37 °C. 
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Then, one equivalent of naproxen was added to the previous mixture. It can be observed on 
STD spectrum a slight decrease of naproxen STD response compared to II.77a, while diclofenac 
intensities were maintained (Figure II.32, c). This result suggests the competition of II.77a for the 
binding site of naproxen.  
It was then expected from the reverse order addition experiment (in opposition to experiment 
depicted on Figure II.30), i.e. when three equivalents of naproxen were added – that the STD 
response of II.77a would disappear. However that was not observed (Figure II.32, d). Since 
diclofenac has a tight, slow binding mode (and IC50 higher than naproxen and II.77a), the result 
suggests that II.77a still binds to Eallo having a binding behavior compared to naproxen. However 
one cannot rule out the existence of a third binding location for II.77a only by these experiments. 
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II.4 Conclusions 
Taking advantage of a rational drug design approach which included the insights obtained from 
the previously synthesized indole based library,
129
 the herein reported second generation of 
heterocyclic structures was successfully synthesized and evaluated, confirming the improvement 
achieved on the development of novel highly potent COX inhibitors. It was also established that the 
iterative and cooperative strategy between the several groups, was a fast and effective methodology 
to construct biologically relevant targets. 
Despite the initial drawbacks, a synthetic route was successfully conceived, allowing a direct 
access to the benzimidazole structures with the desired substitution pattern. Taking 7-bromo isatin 
as starting material, twelve new benzimidazole based compounds were synthesized in good yields.  
From these compounds, ten were biologically evaluated against COX-1 and COX-2. It was 
verified that the acid derivatives were very poor COX inhibitors, while the ester compounds 
inhibited both COX isoforms in a high and concentration-dependent way. Compound II.77d 
(Figure II.33) was the most promising inhibitor, showing a COX-2 inhibitory activity of 81 ± 2%, 
at 5 M, comparable to Celecoxib which showed 72 ± 10% of inhibition, at the same concen-
tration. As anticipated by the docking studies, the compounds having a halogen at meta position 
displayed a superior inhibitory activity. It was expected that bromine derivative would be the most 
potent of the esters group. Unfortunately, it was not possible to attain this compound. 
 
Figure II.33. Docking and chemical structure of compound II.77d. 
It was concluded that the biological results do not corroborate the docking predictions that 
envisaged high inhibitory activities and COX-2 selectivity for all the studied compounds. Only the 
ester derivatives showed a poor COX-2 selectivity at lower concentrations: 41 ± 14 % (at 0.625 
M) for COX-1 and 60 ± 8 % (at 0.5 M) for COX-2.  
The performed STD-NMR studies support that the acid derivatives (II.78a-e) most likely 
possess a third binding site on COX-2 which do not contribute for its activity. Although the poor 
inhibitory activity obtained on the biological assays, it was verified that all the acid compounds 
possessed good STD response that proves its interaction with the protein. The competitive STD-
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NMR studies carried between II.78a and ibuprofen, naproxen and/or diclofenac also support that 
the compound do not compete for the same binding sites of the NSAIDs. It is concluded that there 
is different binding locations in protein that docking studies cannot predict. These higher affinity 
sites for the acid derivatives can prevent their function as inhibitors. 
The ester II.77a, which possesses excellent inhibitory percentages towards COX-2, also 
presented good STD response. In this case, the performed competitive experiments suggest that 
II.77a compete with naproxen for Eallo. 
It can be said that small substituent changes – even within the same scaffold – can produce 
significant differences on the inhibition or selectivity results mainly due to different molecular 
interactions within the protein. Although the moderate COX-2 selectivity achieved, the present 
compounds possess enhanced inhibitory activities compared to the first generation of indolic 
structures.
129
  
Despite the lack of data to determine the IC50 for our compounds, it can be inferred by the 
results obtained for COX-1 and COX-2, that the compounds showing the best inhibitory activities 
(II.77a, II.77c and II.77d) can be placed in the blue zone of the graphical representation (Figure 
II.34). 
 
Figure II.34. IC50 of several drugs determined by WBA. Drugs below the diagonal line are more potent 
inhibitors of COX-2 than drugs on or above the line.2 Our best candidates are within the blue zone. 
In conclusion, the ester derivatives show higher potencies and almost similar selectivity to a 
vast range of commercially available NSAIDs, conferring some commercial viability. It can be said 
that due to the ester moiety, these drugs could not be used in an oral regimen, but could be 
administrated for example, in an intravenous way.  
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II.5 Experimental 
II.5.1 Benzimidazole Library Synthesis 
II.5.1.1 General information 
All commercially obtained reagents were used without further purification unless specified. All 
the mentioned solvents used in the reactions were dried by usual methods.
130
 Molecular sieves 4Å 
were activated by heating at 300 ºC for 3 h. 
Column chromatography was carried out with silica gel 60 Å (220-440 mesh) using the 
described eluent for each case. Preparative and analytical TLC was performed with silica gel 60 
plates of 1 mm, 0.5 mm and 0.25 mm, respectively.  
IR spectra were recorded using a Perkin‐Elmer Spectrum 1000 FT‐IR. The IR bands are 
classified as strong (s), medium (m), or weak (w). NMR spectra were recorded with a Brucker 
ARX 400, Brucker Avance 400 and Brucker Avance 600 spectrometers using CDCl3, DMSO-d6, 
acetone-d6 and D2O as solvents using their corresponding CHCl3, DMSO, acetone and water 
signals as reference, respectively. Melting points were determined using melting point apparatus 
Reichert Thermovar equipped with a Kofler plate and uncorrected. Mass spectra were obtained on 
a Micromass AutoSpecQ and a Micromass GTC (MALDI-TOF-MS, Matrix: -Cyano-4-hydroxy-
cinnamic acid).  
HPLC was performed using a Merck HITACHI La Chrom chromatograph equipped with a 
DAD detector L-7450A and a LiChrospher 100 RP-18 (10 µm) LiChroCART® 250-4 column; 
injection volume: 20 L; A: water (pH 2.5), B: methanol; gradient elution (time, %A, %B):  0 min., 
50:50; 5 min., 30:70; 20min. 10:90; 30min. 0:100; 35min, 0:100; 38 min. 50:50. Measured at 270 
nm. 
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II.5.1.2 3-Benzoyl oxindole (II.23)131 
 
To an oxindole solution (100 mg, 0.751 mmol) in toluene (3 mL, 0.25 M) was added benzoyl 
chloride (87 L, 0.751 mmol). The mixture was placed in an oil bath and heated to 70 ºC. Then, a 
triethylamine (0.105 mL, 0.751 mmol) solution in toluene (1 mL) was added dropwise. The 
mixture was allowed to stir overnight at 70 ºC. The reaction was quenched with saturated aqueous 
NaHCO3 (15 mL), extracted with EtOAc and washed with brine. The combined organic layer was 
dried over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography using 
a gradient system from hexane to hexane:EtOAc (9:1), afforded II.23 as a white solid (110 mg, 62 
%). Rf = 0.7, hexane:EtOAc (4:1). 
MP: 162-165 ºC; 
IR (KBr) νmax (cm
‐1
): 3364 (s, N-H), 1732 (s, C=O), 1450 (w), 1263 (s), 1066 (m), 702 (m); 
1
H NMR (400 MHz, acetone-d6) : 10.58 (s, NH, 1H), 8.21 (d, J = 8.0 Hz, ArH, 2H), 7.76 (t, J 
= 7.4 Hz, ArH, 1H), 7.63 (dd, J = 7.6 Hz, ArH, 2H), 7.54 (d, J = 7.7 Hz, ArH, 1H), 7.38 (d, J = 7.9 
Hz, ArH, 1H), 7.09 (m, ArH, 2H), 6.36 (s, H3, 1H); 
13
C NMR (100 MHz, acetone-d6) : 163.9 (CO), 144.0 (CAr), 135.0 (CAr), 132.6 (CAr), 130.9 
(CAr), 129.8 (CAr), 129.6 (CAr), 128.1 (CAr), 122.0 (CAr), 120.9 (CAr), 120.6 (CAr), 111.7 
(CAr), 88.8 (CH). 
 
 
II.5.1.3 N-Benzoyl oxindole (II.25)132 
 
To a round bottom flask were added benzoic anhydride (255 mg, 1.13 mmol) and oxindole (100 
mg, 0.75 mmol). The mixture was placed in an oil bath and was allowed to stir overnight at 120 ºC. 
After cooling, the residue was purified by flash column chromatography to give II.25 as a white 
solid (100 g, 56 %). Rf = 0.6, hexane:ether (3:2). 
MP: 135-138ºC; 
IR (KBr) νmax (cm
‐1
): 1755 (s, C=O), 1682 (s), 1350 (m), 1297 (s) 756 (w); 
1
H NMR (400 MHz, CDCl3) : 7.81 – 7.75 (m, ArH, 3H), 7.60 (t, J = 7.4 Hz, ArH, 1H), 7.47 
(t, J = 7.6 Hz, ArH, 2H), 7.37 – 7.32 (m, ArH, 2H), 7.20 (t, J = 7.5 Hz, ArH, 1H), 3.76 (s, CH2, 
2H). 
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13
C NMR (400 MHz, CDCl3) : 174.4 (CO), 169.6 (CO), 133.1 (CAr), 130.3 (CAr), 129.5 
(CAr), 128.4 (CAr), 124.9 (CAr), 124.5 (CAr), 115.1 (CAr), 36.7 (CH2). 
 
 
II.5.1.4 4-Sulfamoylbenzoyl chloride (II.27)133 
 
A sealed tube containing SOCl2 (2.2 mL, 29.8 mmol) was placed in an ice bath. The SOCl2 was 
stirred while the oven dried potassium salt of 4-sulfamoylbenzoyl acid (500 mg, 2.49 mmol) was 
added portion wise. The mixture was refluxed for 1 h. It was then was allowed to cool to room 
temperature and transferred to a round bottom flask, where SOCl2 was evaporated until dryness. 
The obtained crude was recrystallized from benzene, to give II.27 as a white solid (400 mg, 73%). 
MP: 138-140 ºC; 
IR (KBr) νmax (cm
‐1
): 3332 (s, N-H), 3251 (s, N-H), 1723 (s, C=O), 1349 (s, S-O), 1161 (s, S-
O), 879 (m), 741 (m); 
1
H NMR (400 MHz, CDCl3 + 2% DMSO-d6) : 8.10 (d, J = 7.5 Hz, 2H), 7.90 (d, J = 7.5 Hz, 
2H), 7,28 (bs, NH2, 2H).  
 
 
II.5.1.5 7-Bromo oxindole (II.29)134 
 
To a 7-bromo isatin solution (50 mg, 0.221 mmol) in DEG (0.5 mL) was added hydrazine 
hydrate 99-100% (0.103 mL, 3.32 mmol). The mixture was heated at 80 ºC for 1 h until it turned 
strong yellow. The mixture was allowed to cool down and a KOH aqueous solution (1.11 mmol, 5 
equiv) was added. The mixture was heated at 80 ºC for an additional hour. The aqueous layer was 
neutralized with 1M HCl solution and extracted several times with EtOAc. The combined organic 
layer was washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4 and concentrated 
in vacuo. The residue was purified by preparative thin layer chromatography to give II.29 as a 
white solid (38 g, 81%). Rf = 0.5, hexane:EtOAc (3:2). 
MP: 201ºC (decomp.); 
IR (KBr) νmax (cm
‐1
): 3209 (w), 1700 (s, C=O), 1617 (m), 1322 (w), 1123 (w), 705 (w); 
1
H NMR (400 MHz, CDCl3) : 8.48 (s, NH, 1H), 7.34 (d, J = 8.2 Hz, ArH6, 1H), 7.15 (d, J = 
7.2 Hz, ArH4, 1H), 6.90 (t, J = 7.8 Hz, ArH5, 1H), 3.65 (s, CH2, 2H); 
13
C NMR (100 MHz, CDCl3) : 176.0 (CO), 142.0 (Cq), 130.8 (CAr), 126.5 (Cq), 123.7 (CAr), 
123.6 (CAr), 102.8 (Cq), 37.4 (CH2). 
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II.5.1.6 2-(2-Amino-3-bromophenyl)acetic acid (II.37) 
 
To a 7-bromo-isatin solution (250 mg, 1.11 mmol) in DEG (2.5 mL) was added hydrazine 
hydrate 99-100% (0.81 mL, 17 mmol). The mixture was heated at 80 ºC for 1 h until it turned 
strong yellow. The mixture was allowed to cool down and a KOH solution (1 g, 18.8 mmol, 17 
equiv) was added. The mixture was heated at 120 ºC for additional 2 h. The reaction was diluted 
with water and washed with EtOAc to remove any unreacted oxindole. The aqueous layer was 
carefully neutralized with 1M HCl solution (in an ice bath), and the product precipitated as a light 
brown solid. The residue was filtrated and washed with cold water to give II.37 as a light brown 
solid (230 mg, 90%). Rf = 0.2, hexane:EtOAc (3:2). 
MP: 206 ºC (decomp.); 
IR (KBr) νmax (cm
‐1
): 3366 (s, N-H), 3301 (s, N-H), 1695 (s), 1458 (s), 1251 (s), 1229 (s), 743 
(w); 
1
H NMR (400 MHz, acetone-d6) : 7.34 (d, J = 8.0 Hz, ArH, 1H), 7.10 (d, J = 7.4 Hz, ArH, 
1H), 6.58 (t, J = 7.7 Hz, ArH, 1H), 4.90 (bs, NH2, 1H), 3.63 (s, CH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 172.6 (CO), 132.2 (CAr), 131.3 (CAr), 131.0 (CAr), 124.8 
(CAr), 119.2 (CAr), 38.8 (CH2). 
 
 
II.5.1.7 N-(2-Bromophenyl)benzamide (II.39)135  
 
To a 2-bromo aniline solution (100 mg, 0.580 mmol) in THF (1.7 mL, 0.35 M) was added 
triethylamine (0.126 mL, 0.640 mmol). The mixture was placed on an ice bath and benzoyl 
chloride (74 L, 0.640 mmol) was added dropwise. The mixture was filtrated through a celite pad 
and the residue was purified by silica preparative to give II.39 as a white solid (150 mg, 93%). Rf = 
0.6, hexane:ether (2:1). 
MP: 99-101ºC; 
IR (KBr) νmax (cm
‐1
): 3276 (m, N-H), 1651 (s), 1533 (s), 1436 (m), 1310 (m), 1027 (w), 750 
(m); 
1
H NMR (400 MHz, CDCl3) : 8.56 (dd, J = 8.2 Hz, ArH, 1H), 8.47 (bs, NH 1H), 7.94 (d, J = 
7.4 Hz, ArH, 2H), 7.61 – 7.51 (m, ArH, 4H), 7.38 (t, J = 7.8 Hz, ArH, 1H), 7.03 (t, J = 7.7 Hz, 
ArH, 1H); 
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13
C NMR (400 MHz, CDCl3) : 165.4 (CO), 136.0 (Cq), 134.8 (Cq), 132.4 (CAr), 132.3 (CAr), 
129.1 (2xCAr), 128.7 (CAr), 127.2 (2xCAr), 125.4 (CAr), 120.0 (CAr), 113.9 (Cq). 
 
 
II.5.1.8 N-(2-Bromophenyl)-4-sulfamoylbenzamide (II.40) 
 
To a 2-bromo aniline solution (50 mg, 0.29 mmol) in THF (0.8 mL) was added triethylamine 
(61 L, 0.44 mmol). The mixture was placed in an ice bath and a 4-sulfamoylbenzoyl chloride (96 
mg, 0.44 mmol) solution in THF (0.3 mL) was added dropwise. The mixture was stirred overnight 
at room temperature. The reaction was quenched with saturated aqueous NaHCO3, extracted with 
EtOAc and washed with brine. The combined organic layer was dried over Na2SO4 and 
concentrated in vacuo. The residue was recrystallized to give II.40 as a white solid (36 mg, 70% 
based on starting material recovered). Rf = 0.2, hexane:EtOAc (3:2). 
MP: 248-253 ºC; 
IR (KBr) νmax (cm
‐1
): 3362 (s, N-H), 3332 (s, N-H), 3066 (m), 2925 (m), 1658 (s), 1524 (s), 
1335 (s, S-O), 1164 (s, S-O), 758 (m), 614 (m); 
1
H NMR (400 MHz, DMSO-d6) : 10.28 (bs, NH), 8.15 (d, J = 8.2 Hz, ArH, 2H), 7.98 (d, J = 
8.3 Hz, ArH, 2H), 7.75 (d, J = 8.0 Hz, ArH, 1H), 7.58 – 7.44 (m, ArH, NH2, 4H), 7.27 (t, J = 7.7 
Hz, ArH, 1H); 
13
C NMR (100 MHz, DMSO-d6) :  164.4 (CO), 146.7 (Cq), 136.8 (Cq), 136.1 (Cq), 132.7 
(CAr), 128.9 (CAr), 128.2 (2xCAr), 128.2 (CAr), 128.1 (CAr), 125.7 (2xCAr), 120.6 (Cq). 
 
 
II.5.1.9 tert-Butyl 4-(2-bromophenylcarbamoyl)phenylsulfonylcarbamate 
 
In a two neck flask equipped with a magnetic stir bar, was placed N-(2-bromophenyl)-4-
sulfamoylbenzamide (10 mg, 0.028 mmol), triethylamine (4.6 L, 0.033 mmol), DMAP (1.7 mg, 
0.014 mmol) and DCM (0.5 mL). The vial was suba-sealed, evacuated and backfilled with argon. 
(Boc)2O (18 L, 0.084 mmol) was added via syringe. The reaction mixture was stirred at room 
temperature for 4 h. The reaction was diluted with water, extracted with DCM and washed with 
brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by silica flash chromatography (hexane:EtOAc 4:1) to give the product as a white solid (12 
mg, quant.). Rf = 0.5, hexane:EtOAc (4:1). 
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MP: 118-120 ºC; 
IR (KBr) νmax (cm
‐1
): 3234 (m), 2982 (m), 1746 (s, C=O carbamate), 1667 (s, C=O amide), 
1520 (s), 1436 (s, S-O), 1148 (s, S-O); 
1
H NMR (400 MHz, CH3OD) : 8.16 (d, J = 8.6 Hz, ArH, 2H), 8.12 (d, J = 8.7 Hz, ArH, 2H), 
7.71 (dd, J = 8.0, 1.3 Hz, ArH, 2H), 7.43 (td, J = 7.9, 1.3 Hz, ArH, 1H), 7.22 (td, J = 8.0, 1.5 Hz, 
ArH, 1H), 1.38 (s, C(CH3)3, 9H); 
13
C NMR (100 MHz, CH3OD) : 167.3 (CO), 151.6 (COC(CH3)3), 144.1 (Cq), 140.1 (Cq), 
137.0 (Cq), 134.1 (CAr), 129.3 (2xCAr), 129.3 (2xCAr), 129.3 (2xCAr), 129.0 (CAr), 121.0 (Cq), 
84.3 (C(CH3)3), 28.1 (C(CH3)3). 
 
 
II.5.1.10 2-Phenyl-benzoxazole (II.41)135  
 
 A screw-cap test-tube, equipped with a magnetic stir bar, was charged with N-(2-
bromofenil)benzamide (0.1 mmol), CuI (10 mol %), L-proline (20 mol%) and the desired base (0.2 
mmol). The vial was sealed with a teflon screw-cap, evacuated and backfilled with argon. The 
solvent (0.1 mL) was added via syringe, followed by aniline (0.12 mmol). The reaction mixture 
was heated (see Table II.5 for temperature and reaction time). The solution was allowed to cool to 
room temperature, quenched by the addition of NH4Cl solution, diluted with EtOAc and poured 
into sat. NaHCO3. After extracting 3 times with EtOAc, the combined organic layers were washed 
with brine, dried over MgSO4, and then concentrated. The crude product was purified by silica 
flash chromatography to give II.41 as a white solid. Rf = 0.8, hexane:ether (2:1). 
MP: 100-103ºC; 
IR (KBr) νmax (cm
‐1
): 1552 (m), 1447 (m), 1242 (m), 1053 (m), 745 (s); 
1
H NMR (400 MHz, CDCl3) : 8.28 – 8.26 (m, ArH, 2H), 7,79 – 7.77 (m, ArH, 1H), 7,60 – 
7.52 (m, ArH, 4H), 7,36 – 7.34 (m, ArH, 2H); 
13
C NMR (100 MHz, CDCl3) : 163.1 (Cq), 150.9 (Cq), 142.2 (Cq), 131.6 (CAr), 129.0 (CAr), 
127.7 (CAr), 127.3 (Cq), 125.2 (CAr), 124.7 (CAr), 120.1 (CAr), 110.7 (CAr). 
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II.5.1.11 N-(2-(Phenylamino)phenyl)benzamide (II.42) 
 
A screw-cap test-tube, equipped with a magnetic stir bar, was charged with BrettPhos ligand 
(2.8 mg, 1 mol %), BrettPhos precatalyst (4.0 mg, 1 mol %) and N-(2-bromophenyl)benzamide (70 
mg, 0.253 mmol). The vial was sealed with a teflon screw-cap, evacuated and backfilled with 
argon. LiHMDS (1M in THF) (0.9 mL, 0.86 mmol, 3.4 equiv) was added via syringe, followed by 
aniline (29 μL, 0.304 mmol, 1.2 equiv). The reaction mixture was heated at 65 °C for 4 h. The 
solution was allowed to cool to room temperature, quenched by the addition of 1M HCl solution (1 
mL), diluted with EtOAc and poured into sat. NaHCO3. After extracting with 3 portions of EtOAc, 
the combined organic layers were washed with brine, dried over MgSO4, and then concentrated. 
The crude product was purified by pTLC, eluting with ether:hexane (1:4), to provide II.42 as a 
light brown solid (70 mg, quant.). Rf = 0.2, hexane:Et2O (4:1). 
MP: 134-136ºC; 
IR (KBr) νmax (cm
‐1
): 3371 (m, N-H), 3326 (m, N-H), 1644 (s), 1600 (s), 1520 (s), 1453 (s), 
1312 (s), 741 (m), 689 (m); 
1
H NMR (400 MHz, CDCl3) : 8.49 (bs, NH, 1H), 8.21 (d, J = 7.5 Hz, ArH, 1H), 7.68 (d, J = 
7.3 Hz, ArH, 2H), 7.51 – 7.17 (m, ArH, 8H), 6.94 – 6.84 (m, ArH, 3H), 5.77 (bs, NH, 1H); 
13
C NMR (100 MHz, CDCl3) : 165.9 (CO), 144.9 (CAr), 134.7 (CAr), 133.5 (CAr), 132.7 
(CAr), 131.9 (CAr), 129.6 (2xCAr), 128.8 (2xCAr), 127.1 (2xCAr), 125.5 (CAr), 125.3 (CAr), 
124.4 (CAr), 122.3 (CAr), 120.5 (CAr), 116.3 (CAr). 
 
 
II.5.1.12 1,2-Diphenyl-1H-benzimidazole (II.43)74 
 
To a N-(2-(phenylamino)phenyl)benzamide (II.42) solution (10 mg, 0.035 mmol) in dry DMSO 
(0.1 mL, 0.35 M) was added AcOH (0.4 mL, 6.94 mmol). The mixture was stirred overnight at 
85ºC. The mixture was co-evaporated with toluene, diluted with EtOAc and washed with water and 
brine. The combined organic layer was dried over Na2SO4 and concentrated in vacuo. The brown 
residue was recrystallized to give II.43 as a white solid (9 mg, quant.). Rf = 0.3, hexane:Et2O (4:1). 
MP:110-113ºC; 
IR (KBr) νmax (cm
‐1
): 3433 (w), 3049 (w), 1594 (w), 1492 (s), 1476 (s), 1455 (m), 1382 (s), 764 
(S), 750 (s), 704 (s); 
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1
H NMR (400 MHz, CDCl3) : 7.92 (d, J = 7.5 Hz, ArH, 1H), 7.61 – 7.51 (m, ArH, 5H), 7.35 
– 7.29 (m, ArH, 8H); 
13
C NMR (100 MHz, CDCl3) δ: 152.3 (CAr), 143.0 (CAr), 137.1 (CAr), 136.8 (CAr), 129.9 
(CAr), 129.8 (CAr), 129.4 (CAr), 129.4 (CAr), 128.5 (CAr), 128.2 (CAr), 127.4 (CAr), 123.3 
(CAr), 122.9 (CAr), 119.8 (CAr), 110.4 (CAr). 
 
 
II.5.1.13 Benzyl 2-(2-amino-3-bromophenyl)acetate (II.44) 
 
To a 2-(2-amino-3-bromophenyl)acetic acid solution (II.37) (15 mg, 0.065 mmol) in DMF (0.4 
mL, 0.2 M) was added benzyl bromide (8 L, 0.065 mmol) and Cs2CO3 (21 mg, 0.065 mmol). The 
mixture was stirred overnight at room temperature. The reaction was quenched with water (10 mL), 
extracted with EtOAc (20 mL) and washed with brine. The combined organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by silica flash chromatography to give 
II.44 as a yellow solid (15 mg, 72%). Rf = 0.8, hexane:Et2O (4:1). 
MP: 70-75ºC; 
IR (KBr) νmax (cm
‐1
): 3443 (s, NH2), 3363 (s, NH2), 3026 (w), 2926 (w), 1721 (s, C=O ester), 
1629 (s), 1457 (m), 1330 (m), 1161 (s), 969 (w), 737 (w), 696 (w); 
1
H NMR (400 MHz, CDCl3) : 7.39 – 7.29 (m, ArH, 6H), 7.04 (dd, J = 10.4, 3.8 Hz, ArH, 
1H), 6.61 (t, J = 7.8 Hz, ArH, 1H), 5.13 (s, CH2Ph, 1H), 3.65 (s, CH2, 1H); 
13
C NMR (100 MHz, CDCl3) : 171.3 (CO2Bn), 135.5 (Cq), 132.1 (CAr), 130.5 (CAr), 128.8 
(2xCAr), 128.5 (CAr), 128.3 (2xCAr), 127.1 (Cq), 119.5 (Cq), 67.2 (CH2Ph,), 39.3 (CH2,). 
 
 
II.5.1.14 Benzyl 2-(3-bromo-2-(4-sulfamoylbenzamido)phenyl)acetate (II.45) 
 
To an ice cold suspension of sulfamoylbenzyl chloride (485 mg, 2.2 mmol, 1.5 equiv) and 
K2CO3 (203mg, 1.47 mmol) in THF (3 mL) was added dropwise a benzyl 2-(2-amino-3-
bromophenyl)acetate solution (II.44) (470 mg, 1.47 mmol) in THF (2 mL). The mixture was stirred 
overnight at room temperature. The reaction was quenched with water (15 mL), extracted with 
EtOAc and washed with brine. The combined organic layer was dried over Na2SO4 and 
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concentrated in vacuo. The residue was purified by silica flash chromatography (EtOAc:hexane 
2:3)  to give II.45 as a white solid (690 mg, 93%). Rf = 0.2, hexane:EtOAc (1:1). 
IR (KBr) νmax (cm
‐1
): 3393 (s, N-H), 3278 (s, N-H), 3200 (m), 1730 (s, C=O ester), 1640 (s), 
1535 (m), 1328 (s, S-O), 1159 (s, S-O), 745 (w); 
1
H NMR (400 MHz, DMSO-d6) : 10.34 (bs, NH, 1H), 8.09 (d, J = 8.4 Hz, ArH, 2H), 7.94 (d, 
J = 8.4 Hz, ArH, 2H), 7.68 (d, J = 7.6 Hz, ArH, 1H), 7.53 (s, ArH, 2H), 7.43 (d, J = 7.6 Hz, ArH, 
1H), 7.30 – 7.26 (m, ArH, 4H), 7,19 – 7.18 (m, ArH, 2H), 5.01 (s, CH2Ph, 2H), 3.74 (s, CH2, 2H); 
13
C NMR (100 MHz, DMSO-d6) : 170.6 (CO2Bn), 164.8 (CONHR), 147.2 (Cq), 137.1 (Cq), 
136.2, 135.9 (Cq), 132.1 (CAr), 131.1 (CAr), 129.4 (Cq), 128.8 (4xCAr), 128.5 (CAr), 128.4 
(2xCAr), 126.2 (2xCAr), 123.9 (Cq), 66.4 (CH2Ph), 38.2 (CH2). 
 
 
II.5.1.15 Benzyl 2-(3-bromo-2-(4-(N-(tert-butoxycarbonyl)sulfamoyl)benzamido) 
phenyl)acetate (II.46) 
 
To a two neck flask equipped with a magnetic stir bar, was added benzyl 2-(3-bromo-2-(4-
sulfamoylbenzamido)phenyl)acetate (II.45) (100 mg, 0.199 mmol), triethylamine (56 L, 0.398 
mmol, 2 equiv), DMAP (12 mg, 0.10 mmol, 0.5 equiv) and DCM (2 mL, 0.1 M). The vial was 
suba-sealed, evacuated and backfilled with argon. (Boc)2O (85 L, 0.398 mmol, 2 equiv) was 
added via syringe. The reaction mixture was stirred at room temperature for 1 h. The reaction was 
quenched with water, extracted with DCM and washed brine. The combined organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica flash 
chromatography (EtOAc:hexane 1:1 gradient to EtOAc:acetone 1%)  to give II.46 as a white solid 
(91 mg, 76%). Rf = 0.6, 2x hexane:EtOAc (1:1). 
MP: 154-157ºC; 
IR (KBr) νmax (cm
‐1
): 3211 (s), 1755 (s, C=O carbamate), 1733 (s, C=O ester), 1653 (s), 1522 
(m), 1432 (m), 1342 (m), 1163 (s), 1140 (s), 733 (m), 607 (m); 
1
H NMR (400 MHz, CDCl3) : 8.28 (bs, NH, 1H), 8.07 – 7.94 (m, ArH, 4H), 7.64 (s, ArH, 
1H), 7.34 – 7.20 (m, ArH, 8H), 5.11 (s, CH2Ph, 2H), 3.77 (s, CH2, 2H), 1.41 (s, C(CH3)3, 9H); 
13
C NMR (100 MHz, CDCl3) : 171.2 (CO2Bn), 164.0 (CONHR), 148.9 (COC(CH3)3), 141.9 
(Cq), 138.3 (Cq), 135.2 (Cq), 134.6 (Cq), 134.0 (CAr), 132.7 (CAr), 130.3 (CAr), 129.1 (CAr), 128.7 
(2xCAr), 128.6 (2xCAr), 128.3 (2xCAr), 128.0 (2xCAr), 123.4 (Cq), 84.5 (C(CH3)3), 67.2 (CH2Ph), 
39.3 (CH2), 27.9 (C(CH3)3). 
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II.5.1.16 t-Butyl 4-(2-bromo-6-(2-oxo-2-(phenylamino)ethyl)phenylcarbamoyl) phenyl 
sulfonylcarbamate (II.48) 
 
Following the general arylamination procedure used for II.42, were used II.46 (50 mg, 0.083 
mmol), aniline (10 μL, 0.12 mmol) and LiHMDS (0.28 mL, 0.28 mmol). The crude product was 
purified via chromatography on silica, eluting with a gradient from EtOAc:hexane 1:1 to 
EtOAc:MeOH 5%, to provide II.48 as a white solid (see Table II.7 for yields). Rf = 0.2, 
2x(hexane:EtOAc, 3:2). 
MP: > 200ºC (decomposition); 
IV (KBr) νmax (cm
‐1
): 3301 (m), 3262 (m), 1746 (s, C=O carbamate), 1664 (s), 1444 (m), 1148 
(m); 
1
H NMR (400 MHz, acetone-d6) δ: 10.1 (bs, NH, 1H), 9.49 (bs, NH, 1H), 8.35 (d, J = 7.9 Hz, 
ArH, 2H), 8.18 (d, J = 7.9 Hz, ArH, 2H), 7.73 – 7.54 (m, ArH, 4H), 7.34 – 7.33 (m, ArH, 3H), 7.11 
(m, ArH, 1H), 3.91 (s, CH2, 2H), 1.37 (s, C(CH3)3, 9H); 
13
C NMR (100 MHz, acetone-d6) δ: 169.7 (CO), 165.5 (CONHR), 150.5 (COC(CH3)3), 143.7 
(Cq), 140.1 (Cq), 139.5 (Cq), 137.6 (Cq), 136.4 (Cq), 132.7 (CAr), 130.9 (CAr), 129.8 (CAr), 129.5 
(2xCAr), 129.3 (2xCAr), 129.0 (2xCAr), 124.4 (CAr), 120.2 (CAr), 83.6 (C(CH3)3), 41.9 (CH2), 
28.0 (C(CH3)3); 
HRMS: calcd for C26H27BrN3O6S [M + Na]
+
: 588.0798, found 588.0795. 
 
 
II.5.1.17 2-(3-Bromo-2-(4-(N-(tert-butoxycarbonyl)sulfamoyl)benzamido) phenyl)acetic 
acid (II.49) 
 
Following general arylamination procedure used for II.42, were used II.46 (25 mg, 0.041 
mmol), aniline (6 μL, 0.061 mmol), NaO
t
Bu (13 mg, 0.131 mmol), BrettPhos precatalyst (3 mg, 10 
mol%) and BrettPhos ligand (2 mg, 10 mol%). The crude product was purified via chromatography 
on silica, eluting with a gradient from EtOAc:hexane 2:1 to EtOAc:MeOH 5%, to provide the II.49 
as a white solid (13 mg, 62%). Rf = 0, hexane:EtOAc (3:2). 
MP: 198-202ºC; 
IR (KBr) νmax (cm
‐1
): 3358 (m), 3260 (m), 1731 (s), 1646 (m), 1515 (m), 1319 (m), 1163 (s); 
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1
H NMR (400 MHz, acetone-d6) : 9.65 (bs, NH, 1H), 8.28 (d, J = 8.2 Hz, ArH, 2H), 8.15 (d, J 
= 8.2 Hz, ArH, 2H), 7.67 (d, J = 7.7 Hz, ArH, 1H), 7.46 (d, J = 7.2 Hz, ArH, 1H), 7.30 (m, ArH, 
1H), 3.77 (s, CH2, 2H), 1.38 (s, C(CH3)3, 9H); 
13
C NMR (100 MHz, acetone-d6) : 172.3 (CO2H), 165.3 (CONHR), 150.4 (COC(CH3)3), 
143.6 (Cq), 139.7 (Cq), 137.2 (Cq), 136.4 (Cq), 132.6 (CAr), 131.3 (CAr), 129.8 (CAr), 129.2 
(2xCAr), 128.9 (2xCAr), 124.3 (Cq), 83.6 (C(CH3)3), 38.8 (CH2), 28.0 (C(CH3)3). 
 
 
II.5.1.18 2-(2-amino-3-bromophenyl)-N-methoxy-N-methylacetamide (II.50) 
 
To a hydroxylamine hydrochloride (21 mg, 0.215 mmol) solution in DCM (0.5 mL), was added 
triethylamine (30 L, 0.215 mmol) and the mixture was allowed to stir for 30 min. In a separate 
flask placed in an ice bath, was added II.37 (45mg, 0.195 mmol), DCM (0.5 mL) and DCC (44 mg, 
0.215 mmol). To this last mixture was added the hydroxylamine solution and the mixture was 
stirred for 4h at room temperature. The reaction was quenched with water (15 mL), extracted with 
DCM and washed with brine. The combined organic layer was dried over Na2SO4 and concentrated 
in vacuo. The residue was purified by silica flash chromatography to give a mixture of product and 
oxindole, 1:1 (40 mg). 
1
H NMR (400 MHz, CDCl3) : 7.31 (dd, J = 8.0, 1.2 Hz, 1H), 7.09 (d, J = 7.3 Hz, 1H), 6.54 (t, 
J = 7.7 Hz, 1H), 5.14 (bs, 2H), 3.76 (s, 3H), 3.73 (s, 2H), 3.14 (s, 3H). 
 
 
II.5.1.19 Benzyl 2-(3-bromo-2-(2,2,2-trifluoroacetamido)phenyl)acetate (II.51) 
 
To a II.44 (25 mg, 0.078 mmol) and triethylamine (15 L, 0.109 mmol) solution in DCM (0.5 
mL, 0.15 M) in a ice bath, was added dropwise trifluoroacetic anhydride (14 L, 0.094 mmol). The 
reaction mixture was stirred at room temperature for 3 h. The mixture was evaporated and the 
crude was purified, to give II.51 (32 mg, quant.) as a white solid. Rf = 0.2, hexane:EtOAc (8:1). 
MP: 23-28ºC; 
IR (KBr) νmax (cm
‐1
): 3272 (m, N-H), 1728 (s, C=O, amide and ester), 1532 (m), 1343 (m), 
1236 (s), 1199 (s), 1165 (s), 736 (m); 
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1
H NMR (400 MHz, CDCl3) : 8.51 (bs, 1H, NH), 7.65 (dd, J = 7.9, 1.3 Hz, 1H, ArH), 7.43 – 
7.22 (m, 7H, ArH), 5.18 (s, 2H, CH2), 3.73 (s, 2H, CH2); 
13
C NMR (100 MHz, CDCl3) : 171.1 (COOBn), 155.2 (q, J = 37.8 Hz, COCF3), 135.0 (CqAr), 
133.5 (CqAr), 133.0 (CAr), 132.2 (CqAr), 130.3 (CAr), 129.9 (CAr), 128.7 (2xCAr), 128.6 (CAr), 
128.4 (2xCAr), 123.0 (CqAr), 115.83 (q, J = 288.6 Hz, CF3), 67.5 (CH2), 38.8 (CH2). 
 
 
II.5.1.20 2-(3-Bromo-2-nitrophenyl)acetic acid (II.56)134 
 
To a NaOH (24 mg, 0.62 mmol) solution at 0ºC were added II.37 (200 mg, 0.87 mmol) and 
NaHCO3 (730 mg, 8.7 mmol). The mixture was protected from light and allowed to stir for 10 min. 
A solution of Oxone (1.34 g, 2.18 mmol) in EDTA solution (4x10
-4 
M, 8 mL) was then added 
followed by a solution of H2O:acetone 1:1 (8 mL). The mixture was stirred for 4 h in an ice/water 
bath. The mixture was quenched by a saturated NaHSO4 solution until a suspension was formed. 
Then, was extracted three times with EtOAc (25 mL), washed with water and brine, dried over 
Na2SO4 and evaporated. The yellow residue was used in the next step without further purification 
(210 mg, 93%). Rf = 0.2, 2x(hexane:EtOAc, 3:2). 
MP: 144-147ºC; 
IR (KBr) νmax (cm
‐1
): 3075 (b, w), 2929 (w), 1719 (s, C=O), 1534 (m), 1277 (m), 1229 (m), 
942 (w); 
1
H NMR (400 MHz, acetone-d6) : 7,78 (d, J = 7.9 Hz, ArH, 1H), 7,61 (d, J = 7.5 Hz, ArH, 
1H), 7,53 (t, J = 7.8 Hz, ArH, 1H), 3,77 (s, CH2, 2H); 
13
C NMR (100 MHz, acetone d6) : 172.3 (CO), 152.7 (CqNO2), 133.9 (CAr), 133.3 (CAr), 
133.1 (CAr), 131.3 (CqAr), 113.5 (CqAr), 38.4 (CH2). 
 
 
II.5.1.21 Methyl 2-(3-bromo-2-nitrophenyl)acetate (II.57) 
 
To a II.56 (30 mg, 0.078 mmol) solution in DCM (1 mL) in a ice bath, was added dropwise 
diazomethane (0.25 mL, 0.2 mmol). The reaction mixture was stirred at room temperature for 1 h. 
The mixture was evaporated and the crude was purified, to give II.57 (18 mg, 60%) as a light 
yellow solid. Rf = 0.7, hexane:EtOAc (3:2). 
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Mp: 53-56ºC; 
IR (KBr) νmax (cm
‐1
): 3075 (w), 2954 (w), 2888 (w), 1737 (s, C=O ester), 1529 (s), 1438 (m), 
1368 (m), 1338 (m), 1218 (m), 1162 (m), 1000 (w), 764 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.81 (d, J = 7.0 Hz, ArH, 1H), 7.63–7.54 (m, ArH, 2H), 
3.80 (s, CH2, 2H), 3.67 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 170.6 (CO), 152.7 (CqNO2), 134.3 (CAr), 133.2 (2xCAr), 
130.3 (CqAr), 113.8 (CqAr), 53.0 (CH3), 37.8 (CH2); 
HRMS: calcd for C9H8BrNO4 [M + Na]
+
: 295.9529, found 295.9527. 
 
 
II.5.1.22 Methyl 2-(2-amino-3-bromophenyl)acetate (II.58) 
 
To a II.56 (100 mg, 0.43 mmol) solution in DMF (2 mL, 0.2 M) placed in a ice bath, was added 
dropwise MeI (33 L, 0.52 mmol) and K2CO3 (33 L, 0.52 mmol). The reaction mixture was 
stirred at room temperature for 2 h. The mixture was evaporated and the crude was purified by 
flash column chromatography (EtOAc:hexane, 1:5) to give II.58 (92 mg, 87 %) as a light yellow 
solid. Rf = 0.7, hexane:EtOAc (3:2). 
MP: 62-64ºC; 
IR (KBr) νmax (cm
‐1
): 3450 (w), 3376 (w), 2851 (w), 1728 (s, C=O ester), 1624 (m), 1460 (m), 
1250 (m), 1159 (m), 751 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.35 (d, J = 7.7 Hz, ArH, 1H), 7.08 (d, J = 7.1 Hz, ArH, 
1H), 6.57 (t, J = 7.6 Hz, ArH, 1H), 4.87 (bs, NH2, 2H), 3.65 (s, CH2, 5H). 
 
 
II.5.1.23 tert-Butyl 3-aminophenylcarbamate (II.64)122 
 
Compound II.64 was prepared according to the literature and obtained as a white solid (quant). 
Rf = 0.2, EtOAc:hexane (2:3). 
MP: 106-109ºC; 
IR (KBr) νmax (cm
‐1
): 3487 (m, N-H), 3385 (m, N-H), 3328 (s, N-H), 2981, 1690 (s, C=O), 
1533 (m), 1247 (m), 1158 (s); 
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1
H NMR (400 MHz, CDCl3) : 7.04 (dd, J = 8.0 Hz, ArH, 1H), 6.98 (bs, NH, 1H), 6.57 (dd, J 
= 8.0, 1.3 Hz, ArH, 1H), 6.43 (s, ArH, 1H), 6.38 (dd, J = 7.9, 1.7 Hz, ArH, 1H), 3.66 (bs, NH2, 
2H), 1.51 (s, C(CH3)3, 9H). 
 
 
II.5.1.24 tert-Butyl 3-hydroxyphenylcarbamate (II.66)136 
 
To a 3-aminophenol (400 mg, 3.67 mmol) solution in THF (4 mL) was added Boc2O (880 mg, 
4.03 mmol). The mixture was stirred overnight at room temperature. The mixture was diluted with 
EtOAc and washed with water and brine. The combined organic fractions were combined and 
evaporated. The crude product was purified by flash column chromatography using a gradient 
(EtOAc:hexane, 1:7 to 1:3 ) to give II.66 (765 mg, quant.) as a white solid. Rf = 0.5, EtOAc:hexane 
(2:3). 
MP: 135º-137ºC; 
IR (KBr) νmax (cm
‐1
): 3382 (m), 3314 (m), 1694 (s, C=O), 1598 (m), 1525 (m), 1443 (s), 1150 
(m); 
1
H NMR (400 MHz, CDCl3) : 7.12 – 7.06 (m, ArH, 2H), 6.75 (dd, J = 8.0 Hz, ArH, 1H), 6.67 
(s, NH, 1H), 6.54 (dd, J = 8.1, 1.8 Hz, ArH, 1H), 1.50 (s, C(CH3)3, 9H). 
 
 
II.5.1.25 3-(tert-Butoxycarbonylamino)phenyl acetate (II.67) 
 
To a tert-butyl 3-hydroxyphenylcarbamate (II.66) (300 mg, 1.43 mmol) solution in THF (14 
mL, 0.1 M) was added Cs2CO3 (932 mg, 2.86 mmol). Then, Ac2O (0.15 mL, 1.58 mmol) was 
added. The mixture was allowed to stir for 2 h at room temperature. The mixture was quenched 
with water and washed with water and brine. The combined organic fractions were combined and 
evaporated. The crude product was purified by flash column chromatography (EtOAc:hexane, 1:5) 
to give II.67 (360 mg, quant) as a light brown oil. Rf = 0.3, 2x(ether:hexane, 1:4). 
IR (KBr) νmax (cm
‐1
): 3349 (m, N-H), 2925 (s, C-H), 1767 (s, C=O), 1729 (s, C=O), 1538 (m), 
1151 (s); 
1
H NMR (400 MHz, CDCl3) : 7.34 (bs, NH, 1H), 7.21 (dd, J = 8.1 Hz, ArH, 1H), 7.03 (dd, J 
= 8.1, 1.1 Hz, ArH, 1H), 6.82 (s, ArH, 1H), 6.73 (dd, J = 8.0, 1.5 Hz, ArH, 1H), 2.24 (s, COCH3, 
3H), 1.49 (s, C(CH3)3, 9H); 
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13
C NMR (100 MHz, CDCl3) : 169.5 (COCH3), 152.6 (COC(CH3)3), 151.2 (CAr), 139.7 
(CAr), 129.5 (CAr), 115.9 (CAr), 115.7 (CqAr), 111.9 (CqAr), 28.3 (C(CH3)3) , 21.1 (COCH3). 
 
 
II.5.1.26 3-Aminophenyl acetate (II.68)137 
 
A 3-(tert-butoxycarbonylamino)phenyl acetate (II.67) (170 mg, 0.68 mmol) solution in water 
(14 mL) was refluxed for 3 h. The mixture was extracted with EtOAc and washed with brine. The 
combined organic fractions were combined, dried over Na2SO4 and evaporated. The crude was 
purified by flash column chromatography (EtOAc:hexane, 1:4  1:2) to give II.68 (42 mg, 41%) 
as light orange solid. Rf = 0.6, EtOAc:hexane (2:3). 
MP: 52-55ºC; 
IR (KBr) νmax (cm
‐1
): 3437 (m, N-H), 3354 (m, N-H), 1734 (s, C=O), 1625 (m), 1223 (s), 1143 
(m); 
1
H NMR (400 MHz, CDCl3) : 7.13 (dd, J = 8.0 Hz, ArH, 1H), 6.52 (dd, J = 8.0, 1.4 Hz, ArH, 
1H), 6.46 (dd, J = 8.0, 1.4 Hz, ArH, 1H), 6.40 (dd, J = 2.1 Hz, ArH, 1H), 3.72 (bs, NH2, 2H), 2.27 
(s, COCH3, 3H); 
13
C NMR (100 MHz, CDCl3) : 169.7 (COCH3), 151.7 (CqAr), 147.8 (CqAr), 130.1 (CAr), 
112.7 (CAr), 111.3 (CAr), 108.3 (CAr), 21.2 (COCH3). 
 
 
General procedure for arylation: 
To a screw-cap test-tube equipped with a magnetic stir bar, was added Pd2dba3 (5 mol%), 
BINAP (7.5 mol%) and Cs2CO3 (2 equiv). The vial was sealed with a suba-seal, evacuated and 
backfilled with argon. A solution of 1-bromo 2-nitro benzene (1 equiv) in dry toluene (0.25 M) was 
then added via syringe, and several cycles vacuum/argon were performed. Then was added the 
aniline (3 equiv) and the suba-seal was replaced by the teflon screw-cap. The reaction mixture was 
heated at 90 °C for 3 to 6 h. The solution was allowed to cool to room temperature, quenched by 
the addition of 1 mL HCl (1M) and diluted with EtOAc and water. The mixture was extracted with 
EtOAc and washed with water and brine. The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. 
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II.5.1.27 2-Nitro-N-phenylaniline (II.69a)118a 
 
The crude product was purified by flash column chromatography (Et2O:hexane, 1:6) to give 
II.69a (84 mg, quantitative yield) as red oil. Rf = 0.7, Et2O:hexane (1:4). 
IR (KBr) νmax (cm
‐1
): 3355 (m, N-H), 3063 (w), 1618 (m), 1595 (m), 1573 (m), 1504 (s, N=O), 
1351 (m, N=O), 1263 (s). 
1
H NMR (400 MHz, acetone-d6) : 9.44 (bs, NH, 1H), 8.17 (dd, J = 8.4, 0.9 Hz, ArH, 1H), 
7.50 – 7.24 (m, ArH, 7H), 6.86 (t, J = 7.4 Hz, ArH, 1H). 
13
C NMR (100 MHz, acetone-d6) : 143.6 (CqAr), 140.0 (CqAr), 136.6 (CAr), 134.4 (CqAr), 
130.4 (CAr), 127.1 (CAr), 126.1 (CAr), 125.0 (CAr), 118.4 (CAr), 117.1 (CAr). 
 
 
II.5.1.28 tert-Butyl (3-((2-nitrophenyl)amino)phenyl)carbamate (II.69b) 
 
The crude product was purified by flash column chromatography (Et2O:hexane, 1:7) to give 
II.69b (70 mg, 86%) as yellow solid. Rf = 0.6, Et2O:hexane (1:4). 
MP: 171-173ºC; 
IR (KBr) νmax (cm
‐1
): 3340 (m, N-H), 2974 (w), 1742 (s, C=O), 1505 (s), 1256 (s), 1145 (s); 
1
H NMR (400 MHz, acetone-d6) : 9.44 (s, NH, 1H), 8.18 (d, J = 8.5 Hz, ArH, 1H), 7.50 (t, J 
= 7.7 Hz, ArH, 2H), 7.38 – 7.20 (m, ArH, 4H), 6.90 (t, J = 7.7 Hz, ArH, 1H), 1.47 (s, C(CH3)3, 
9H). 
 
 
II.5.1.29 3-(2-Nitrophenylamino)phenol (II.69c)138 
 
The crude product was purified by flash column chromatography (Et2O:hexane, 1:4 to 1:1) to 
give II.69c (16 mg, 28%) as red solid. Rf = 0.3, Et2O:hexane (1:4).  
Mp: 137-140ºC (lit. 139-141ºC); 
IR (KBr) νmax (cm
‐1
): 3352 (m), 1598 (m), 1573 (m), 1505 (s), 1259 (m), 1155 (m); 
II. Novel Benzimidazole-based COX inhibitors 
 
103 
 
1
H NMR (400 MHz, acetone-d6) : 9.35 (bs, NH, 1H), 8.64 (s, ArH, 1H), 8.15 (dd, J = 8.5, 1.2 
Hz, ArH, 1H), 7.50 (t, J = 7.1 Hz, ArH, 1H), 7.33 – 7.23 (m, ArH, 2H), 6.87 – 6.72 (m, ArH, 4H); 
13
C NMR (100 MHz, acetone-d6) : 159.4 (CqAr), 143.6 (CqAr), 141.2 (CqAr), 136.6 (CAr), 
134.4 (CqAr), 131.2 (CAr), 127.1 (CAr), 118.5 (CAr), 117.5 (CAr), 115.9 (CAr), 113.3 (CAr), 
111.8 (CAr). 
 
 
II.5.1.30 3-(2-Nitrophenylamino)phenyl acetate (II.69d) 
 
The crude product was purified by flash column chromatography (Et2O:hexane, 1:7 to 1:1) to 
give II.69d (21 mg, 31%) as red oil. Rf = 0.6, 2x(Et2O:hexane, 1:4). 
IR (KBr) νmax (cm
‐1
): 3350 (w, N-H), 2924 (w), 1765 (s, C=O), 1602 (s), 1501 (s), 1205 (s); 
1
H NMR (400 MHz, acetone-d6) : 9.41 (bs, NH, 1H), 8.17 (dd, J = 8.5, 1.4 Hz, ArH, 1H), 
7.56 – 7.49 (m, ArH, 1H), 7.48 – 7.42 (m, ArH, 1H), 7.34 (dd, J = 7.6 Hz, ArH, 1H), 7.27 (dd, J = 
10.0, 8.8 Hz, ArH, 1H), 7.16 (t, J = 2.0 Hz, ArH, 1H), 6.98 (dd, J = 8.1, 1.5 Hz, ArH, 1H), 6.95 – 
6.89 (m, ArH, 1H), 2.26 (s, COCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 169.6 (COCH3)), 152.8 (CqAr), 143.4 (CqAr), 142.9 
(CqAr), 141.3 (CqAr), 136.6 (CAr), 131.17, 131.0 (CAr), 129.8 (CqAr), 129.2 (CqAr), 127.1 (CAr), 
126.5 (CAr), 121.7 (CAr), 119.2 (CAr), 119.1 (CAr), 118.1 (CAr), 117.5 (CAr), 20.9 (COCH3). 
 
 
II.5.1.31 N-(3-methoxyphenyl)-2-nitroaniline (II.70)118a 
 
In a two neck flask was added II.69c (75 mg, 0.325 mmol), K2CO3 (68 mg, 0.487 mmol, 1.5 
equiv) and acetone (1.1 mL, 0.3 M). The flask was placed in an ice bath and MeI (28 L, 0.456 
mmol, 1.4 equiv) was added dropwise via syringe. The reaction mixture was stirred at room 
temperature overnight. Then it was evaporated to dryness and dissolved in EtOAc. The organic 
layer was washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (Et2O:hexane, 1:8) to give II.70 (65 
mg, 82%) as red oil. Rf = 0.6, Et2O:hexane (1:4). 
IR (KBr) νmax (cm
‐1
): 3351 (m, N-H), 2940 (w), 1617 (m), 1600 (s), 1504 (s), 1259 (s); 
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1
H NMR (400 MHz, acetone-d6) : 9.39 (s, NH, 1H), 8.16 (dd, J = 8.1 Hz, ArH, 1H), 7.51 (t, J 
= 7.3 Hz, ArH, 1H), 7.34 (m, ArH, 2H), 6.96 – 6.80 (m, ArH, 4H), 3.82 (s, OCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 161.8 (CqAr), 143.3 (CqAr), 141.3 (CqAr), 136.6 (CAr), 
134.5 (CqAr), 131.1 (CAr), 127.1 (CAr), 118.7 (CAr), 117.5 (CAr), 116.8 (CAr), 111.8 (CAr), 
110.4 (CAr), 55.7 (OCH3). 
 
 
General procedure for the nitro group reduction: 
To compounds II.69a, II.69b, II.69d and II.70 (1 equiv) in EtOAc:ethanol (1:1, 0.2 M), was 
added 10 mol% Pd/C (1 mol%) and the mixture was allowed to stir at room temperature over an H2 
atmosphere for 2 to 4 h (until total consumption of starting material, monitored by TLC). The 
mixture was filtered and concentrated in vacuo. The reduced compounds were immediately used 
without further purification. 
 
II.5.1.32 N-phenylbenzene-1,2-diamine 139 
 
The residue was purified by flash column chromatography (hexane/ethyl acetate, 8:1) to give 
the compound as a light orange solid (133 mg, 97%). Rf = 0.4 EtOAc:hexane (1:6). 
Mp: 77-79 ºC; 
IR (KBr) νmax (cm
‐1
): 3448 (m), 3387 (m), 3363 (m), 3014 (w), 1615 (s), 1597 (s), 1504 (s), 
1316 (m); 
1
H NMR (400 MHz, acetone-d6) : 7,17 – 7,08 (m, ArH, 3H), 6,96 – 6,61 (m, ArH, 6H), 6,42 
(bs, NH, 1H), 4,43 (bs, NH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 147.3 (CqAr), 144.1 (CqAr), 129.7 (2xCAr), 128.9 (CqAr), 
125.9 (CAr), 125.5 (CAr), 118.9 (CAr), 118.2 (CAr), 116.3 (CAr), 115.5 (2xCAr). 
 
 
General procedure for the benzoylation/cyclization: 
To a sulfamoylbenzyl chloride (2.5 equiv) suspension in dry THF (0.5 M) placed in an ice bath, 
was added the corresponding amine solution (1equiv) drop wise. The mixture was stirred for 1 h at 
room temperature and then heated at 50ºC until total consumption of starting material 
(benzimidazole products show a distinctive blue spot visible in UV light). The reaction was 
quenched with water, extracted with EtOAc and washed with brine. The combined organic layer 
was dried over Na2SO4 and concentrated in vacuo.  
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II.5.1.33 4-(1-Phenyl-1H-benzo[d]imidazol-2-yl)benzenesulfonamide (II.71a)133 
 
The crude was isolated by pTLC (eluted twice with EtOAc:hexane 2:3 and EtOAc:hexane 1:1) 
to give II.71a as a white solid (150 mg, 93%). Rf = 0.2, ether:hexane (1:4). 
MP: 262-265 ºC; 
IR (KBr) νmax (cm
‐1
): 3281 (b, m), 3034 (b, m), 2924 (w), 1597 (w), 1500 (m), 1456 (m), 1409 
(m), 1336 (s, S=O), 1164 (s, S=O); 
1
H NMR (400 MHz, acetone-d6) : 7.87 – 7.55 (m, ArH, 5H), 7.66 – 7.58 (m, ArH, 3H), 7.49 
– 7.47 (m, ArH, 2H), 7.35-7.24 (m, ArH, 3H), 6.73 (bs, -SO2NH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 151.5 (CqAr), 145.5 (CqAr), 144.0 (CqAr), 138.5 (CqAr), 
137.7 (CqAr), 134.5 (CqAr), 131.0 (2xCAr), 130.5 (2xCAr), 128.8 (CAr), 128.5 (2xCAr), 126.7 
(2xCAr), 124.5 (CAr), 123.8 (CAr), 120.7 (CAr), 111.4 (CAr). 
HPLC: RT = 12, 88 min. Purity 98 %. 
 
 
II.5.1.34 N-(2-(Phenylamino)phenyl)-4-sulfamoylbenzamide140 
 
The compound was isolated as a white solid (4 mg, 2 %). Rf = 0.3, ether:hexane (1:4). 
MP: 197-200 ºC; 
IR (KBr) νmax (cm
‐1
): 3436 (b, s), 3363 (s), 2925 (w), 1640 (m), 1599 (m), 1326 (s, S=O), 1160 
(S=O); 
1
H NMR (400 MHz, acetone-d6) : 9.33 (bs, NH, 1H), 8.02 – 7.89 (m, ArH, 5H), 7.37 (dd, J = 
7.5 Hz, ArH, 1H), 7.21 – 7.07 (m, ArH, 4H), 6.92 – 6.81 (m, ArH, 3H), 6.72 (bs, -SO2NH2, 1H). 
 
 
II.5.1.35 tert-Butyl 3-(2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-1-yl)phenylcarba 
mate (II.71b) 
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The crude was isolated by pTLC (eluted twice with EtOAc:hexane 1:1) to give II.71b as a light 
brown solid (89 mg, 82 %). Rf = 0.3, EtOAc:hexane (3:2). 
IR (KBr) νmax (cm
‐1
): 3337 (b, w), 2978 (w), 1725 (m), 1705 (m), 1603 (m), 1335 (m, S=O), 
1162 (s, S=O); 
1
H NMR (400 MHz, acetone-d6) : 8.78 (bs, NH, 1H), 7.87 (d, J = 8.7 Hz, ArH, 2H), 7.83 – 
7.73 (m, ArH, 5H), 7.49 (t, J = 8.3 Hz, ArH, 1H), 7.34 – 7.31 (m, ArH, 3H), 7.04 – 7.00 (m, ArH, 
1H), 6.76 (bs, -SO2NH2, 2H), 1.46 (s, 9H). 
 
 
II.5.1.36 tert-Butyl 3-(2-(4-sulfamoylbenzamido)phenylamino)phenylcarbamate 
 
The compound was isolated as a white solid (4 mg, 4 %). Rf = 0.4, EtOAc:hexane (3:2). 
IR (KBr) νmax (cm
‐1
): 3340 (b, w), 1735 (m), 1336 (m, S=O), 1160 (s, S=O); 
1
H NMR (400 MHz, acetone-d6) : 9.34 (s, NH, 1H), 8.32 (s, NH, 1H), 8.04 (d, J = 8.4 Hz, 
ArH, 2H), 7.97 (d, J = 8.7 Hz, ArH, 2H), 7.88 (d, ArH, 1H), 7.39 (dd, J = 7.5 Hz, ArH, 1H), 7.24 – 
7.17 (m, ArH, 2H), 7.12 – 7.06 (m, ArH, 2H), 6.98 (dd, J = 8.8 Hz, ArH, 1H), 6.75 (bs, -SO2NH2, 
2H), 6.53 (dd, J = 6.9 Hz, ArH, 1H), 1.45 (s, 9H). 
 
 
II.5.1.37 4-(1-(3-Methoxyphenyl)-1H-benzo[d]imidazol-2-yl)benzenesulfonamide 
(II.71c) 
 
The crude was isolated by pTLC (eluted twice 3 x EtOAc:hexane 1:1) to give II.71c as a light 
pink solid (60 mg, 68 %). Rf = 0.3, EtOAc:hexane (3:2).  
MP: 261-264ºC; 
IR (KBr) νmax (cm
‐1
): 3271 (b, m), 3006 (b, m), 1602 (m), 1493 (m), 1336 (s, S=O), 1163 (s, 
S=O), 747 (m); 
1
H NMR (400 MHz, acetone-d6) : 7.87 (d, J = 8.7 Hz, ArH, 2H), 7.80 (d, J = 8.7 Hz, ArH, 
2H), 7.52 (t, J = 8.1 Hz, ArH, 1H), 7.33 – 7.29 (m, ArH, 3H), 7.15 (ddd, J = 8.4, 2.5, 0.8 Hz, ArH, 
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1H), 7.09 (t, J = 2.2 Hz, ArH, 1H), 7.01 (ddd, J = 7.8, 1.9, 0.9 Hz, ArH, 1H), 6.71 (bs, -SO2NH2, 
2H), 3.83 (s, OCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 161.8 (CqAr), 151.5 (CqAr), 145.8 (CqAr), 144.0 (CqAr), 
138.7 (CqAr), 138.5 (CqAr), 134.4 (CqAr), 131.7 (CAr), 130.4 (2xCAr), 126.7 (2xCAr), 124.5 
(CAr), 123.7 (CAr), 120.6 (CAr), 120.5 (CAr), 115.6 (CAr), 114.0 (CAr), 111.5 (CAr), 56.0 
(OCH3). 
 
 
II.5.1.38 N-(2-(3-Methoxyphenylamino)phenyl)-4-sulfamoylbenzamide 
 
The compound was isolated as a white solid (6 mg, 7 %). Rf = 0.4, EtOAc:hexane (3:2). 
IR (KBr) νmax (cm
‐1
): 3344 (b, m), 3250 (m), 1646 (m), 1597 (s), 1522 (s), 1456 (m), 1337 (m, 
S=O), 1158 (s, S=O), 756 (w); 
1
H NMR (400 MHz, acetone-d6) : 9.35 (bs, NH, 1H), 8.03 – 7.87 (m, ArH, 5H), 7.39 (dd, J = 
7.5 Hz, ArH, 1H), 7.22 – 7.08 (m, ArH, 3H), 6.76 (bs, -SO2NH2, 1H), 6.49 – 6.39 (m, ArH, 3H), 
3.70 (s, OCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 165.3 (CO), 161.8 (CqAr), 147.7 (CqAr), 147.0 (CqAr), 
138.8 (CqAr), 136.6 (CqAr), 131.8 (CqAr), 130.8 (CAr), 128.9 (CAr), 127.0 (CAr), 126.7 (CAr), 
125.3 (CAr), 124.0 (CAr), 123.3 (CAr), 109.7 (CAr), 106.1 (CAr), 102.9 (CAr), 55.3 (OCH3). 
 
 
General procedure for arylamination: 
To a screw-cap test-tube equipped with a magnetic stir bar, was added Pd2dba3 (5 mol %), 
BINAP (7.5 mol %) and Cs2CO3 (2 equiv). The tube was sealed with a suba-seal, evacuated and 
backfilled with argon. A solution of the aryl halide (1 equiv) in dry toluene (0.25 M) was then 
added via syringe, and several cycles vacuum/argon were performed. Then was added the aniline (3 
equiv) and the suba-seal was replaced by the teflon screw-cap. The reaction mixture was heated at 
90 °C for 4 h. The solution was allowed to cool to room temperature, quenched by the addition of 
HCl solution (1M) and diluted with EtOAc and water. After extracting with 3 portions of EtOAc, 
the combined organic layers were washed with water, brine, dried over Na2SO4, filtered and 
concentrated in vacuo. 
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II.5.1.39 Methyl 2-(2-nitro-3-(phenylamino)phenyl)acetate (II.73a) 
 
The crude product was purified by pTLC (Et2O:hexane, 1:4) to give II.73a (86 mg, 83 %) as red 
oil; Rf = 0.5, EtOAc:hexane (1:4). 
IR (NaCl) νmax (cm
‐1
): 3381 (m, N-H), 2952 (w), 1738 (s, C=O ester), 1592 (s), 1504 (s), 1280 
(s), 1175 (s), 1065 (w), 752 (w); 
1
H NMR (400 MHz, acetone-d6) : 8.15 (bs, NH, 1H), 7.41 – 7.27 (m, ArH, 6H), 7.12 (t, J = 
7.1 Hz, ArH, 1H), 6.91 (d, J = 7.1 Hz, ArH, 1H), 3.93 (s, CH2, 2H), 3.67 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 171.0 (CO), 141.8 (CqAr), 141.0 (CqAr), 133.5 (CAr), 
131.7 (CqAr), 130.4 (2xCAr), 124.6 (CAr), 124.2 (CAr), 122.7 (2xCAr), 118.3 (CAr), 52.2 
(CO2CH3), 39.6 (CH2); 
HRMS: calcd for C15H14N2O4 [M + Na]
+
 309.0846, found 309.0842. 
 
 
II.5.1.40 Methyl 2-(2-nitro-3-(phenylamino)phenyl)acetate (II.73b) 
 
The crude product was purified by pTLC (Et2O:hexane, 1:6) to give II.73b (80 mg, 95%) as a 
red solid. Rf = 0.5, 2x(Et2O:hexane, 1:4).  
MP: 69-73ºC; 
IR (NaCl) νmax (cm
‐1
): 3379 (w, N-H), 2957 (w), 1739 (s, C=O ester), 1593 (s), 1503 (s), 1330 
(s), 1166 (m), 1123 (m), 782 (w); 
1
H NMR (400 MHz, acetone-d6) : 8,15 (s, NH, 1H), 7,55 – 7,33 (m, ArH, 6H), 7,07 (d, J = 
6.9 Hz, ArH, 1H), 3,92 (s, CH2, 2H), 3,67 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 170.9 (CO), 143.9 (CqAr), 138.9 (CqAr), 133.4 (CAr), 
131.3 (CAr), 126.1 (CAr), 124.2 (CAr), 120.3 (CAr), 119.7 (CAr), 117.4 (CAr), 52.3 (CO2CH3), 
39.1 (CH2); 
HRMS: calcd for C16H13F3N2O4 [M + Na]
+
: 377.0720, found 377.0725. 
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II.5.1.41 Methyl 2-(3-(3-fluorophenylamino)-2-nitrophenyl)acetate (II.73c) 
 
The crude product was purified by silica flash chromatography using a gradient from 
Et2O:hexane, 1:6 to 1:5 to give II.73c (79 mg, 89%) as red solid. Rf = 0.5, 2x(Et2O:hexane, 1:4). 
MP: 88-91ºC; 
IR (NaCl) νmax (cm
‐1
): 3379 (s, N-H), 2949 (w), 1742 (s, C=O ester), 1600 (s), 1505 (s), 1357 
(m), 1168 (m), 784 (w); 
1
H NMR (400 MHz, acetone-d6) : 8,03 (1H, bs, NH), 7,48 – 7,32 (3H, ArH, m), 7,03 – 6,99 
(3H, ArH, m), 6,78 (1H, ArH, m), 3,91 (2H, CH2, s), 3,66 (3H, CO2CH3, s); 
13
C NMR (100 MHz, acetone-d6) : 170.9 (CO), 164.52 (d, J = 243.1 Hz, CF), 144.8 
(CqAr), 142.0 (CqAr), 139.2 (CqAr), 133.4 (CqAr, J = 113.0 Hz), 133.4 (CAr), 131.8 (d, J = 9.7 Hz, 
CAr), 131.3 (CqAr), 125.8 (CAr), 120.3 (CAr), 116.8 (CAr), 110.0 (d, J = 21.4 Hz, CAr), 107.9 (d, 
J = 24.7 Hz, CAr), 52.3 (CO2CH3), 39.1 (CH2); 
HRMS: calcd for C15H13FN2O4 [M + Na]
+
: 327.0752, found 327.0748. 
 
 
II.5.1.42 Methyl 2-(3-(3-chlorophenylamino)-2-nitrophenyl)acetate (II.73d) 
 
The crude product was purified by pTLC (CH2Cl2:hexane:MeOH = 1:5:0.1) to give II.73d (75 
mg, 80%) as red oil. Rf = 0.5, 2x(EtOAc:hexane, 1:4). 
IR (NaCl) νmax (cm
‐1
): 3383 (w, N-H), 2949 (w), 1739 (s, C=O ester), 1587 (s), 1494 (s), 1352 
(s), 1284 (s), 1176 (m), 774 (w); 
1
H NMR (400 MHz, acetone-d6) : 8,03 (s, NH, 1H), 7,48 – 7,02 (m, ArH, 7H), 3,91 (s, CH2, 
2H), 3,66 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 171.0 (CO), 144.3 (CqAr), 141.8 (CqAr), 139.2 (CqAr), 
135.4 (CqAr), 133.4 (CAr), 131.7 (CAr), 131.4 (CqAr), 125.8 (CAr), 123.4 (CAr), 121.0 (CAr), 
120.2 (CAr), 119.5 (CAr), 52.3 (CO2CH3), 39.2 (CH2); 
HRMS: calcd for C15H13ClN2O4 [M + Na]
+
: 343.0456, found 343.0453. 
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II.5.1.43 Methyl 2-(3-(3-acetoxyphenylamino)-2-nitrophenyl)acetate (II.73e) 
 
The crude product was purified by pTLC (Et2O:hexane, 1:3 to 1:2) to give II.73e (105 mg, 66% 
yield) as red oil. Rf = 0.5, EtOAc:hexane (2:3). 
IR (NaCl) νmax (cm
‐1
): 2954 (w), 1745 (b, s, C=O ester), 1538 (s), 1368 (m), 1239 (m), 1173 
(m), 849 (w); 
1
H NMR (400 MHz, acetone-d6) : 8.08 (bs, 1H), 7.45 – 7.33 (m, ArH, 3H), 7.12 (dd, J = 7.9, 
1.7 Hz, ArH, 1H), 7.02 – 6.99 (m, ArH, 2H), 6.82 (dd, J = 8.1, 1.5 Hz, ArH, 1H), 3.91 (s, CH2, 
2H), 3.66 (s, CO2CH3, 3H), 2.24 (s, OCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 171.0 (CO), 169.7 (COCH3), 153.0 (CqAr), 143.4 (CqAr), 
140.0 (CqAr), 133.5 (CAr), 131.6 (CqAr), 131.0 (CAr), 125.2 (CAr), 119.4 (CAr), 119.0 (CAr), 
117.4 (CAr), 115.3 (CAr), 52.3 (CO2CH3), 39.4 (CH2), 21.1 (COCH3). 
 
 
II.5.1.44 Methyl 2-(3-(3-(tert-butoxycarbonylamino)phenylamino)-2-nitrophenyl) 
acetate (II.73f) 
 
The crude product was purified by silica flash chromatography using a gradient of Et2O:hexane 
from 1:4 to 1:1, to give II.73f (100 mg, 52% yield) as red solid. Rf = 0.5, EtOAc:hexane (2:3). 
MP: 43-45ºC; 
IR (KBr) νmax (cm
‐1
): 3391 (b, m, N-H), 2978 (w), 1728 (b, s, C=O ester, carbamate), 1596 (s), 
1159 (s), 772 (w); 
1
H NMR (400 MHz, acetone-d6) : 8.45 (bs, NH, 1H), 8.12 (bs, NH, 1H), 7.55 (s, ArH, 1H), 
7.43 – 7.33 (m, ArH, 2H), 7.26 – 7.25 (m, ArH, 2H), 6.93 – 6.88 (m, ArH, 2H), 3.91 (s, CH2, 2H), 
3.66 (s, CO2CH3, 3H), 1.47 (s, C(CH3)3, 9H); 
13
C NMR (100 MHz, acetone-d6) : 171.1 (CO), 153.7 (COC(CH3)3), 142.3 (CqAr), 141.9 
(CqAr), 140.9 (CqAr), 133.5 (CAr), 131.7 (CqAr), 130.6 (CAr), 124.3 (CAr), 118.9 (CAr), 116.4 
(CAr), 114.5 (CAr), 112.2 (CAr), 80.2 (C(CH3)3), 52.2 (CO2CH3), 39.6 (CH2), 28.6 (C(CH3)3). 
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General procedure for the nitro group reduction: 
To compounds II.73a-f (1 equiv) in toluene (0.2 M), was added 10% Pd/C (1 mol%) and the 
mixture was allowed to stir at room temperature over an H2 atmosphere overnight (until total 
consumption of starting material, monitored by TLC). The mixture was filtered and concentrated in 
vacuo. The reduced compounds were immediately used without further purification. 
 
II.5.1.45 Methyl 2-(2-amino-3-bromophenyl)acetate (II.73a) 
 
The residue was purified by silica flash chromatography (eluted with hexane to EtOAc:hexane 
1:2) to give II.73a as yellow oil (20 mg, 74%). Rf = 0.3, EtOAc:hexane (1:4). 
IR (KBr) νmax (cm
‐1
): 3436 (b, w, N-H), 3363 (m, N-H), 3038 (w), 1727 (s, C=O ester), 1591 
(s), 1496 (s), 1310 (m), 1243 (m), 1154 (m), 750 (m); 
1
H NMR (400 MHz, acetone-d6) : 7.13 – 6.92 (m, ArH, 4H), 6.74 – 6.49 (m, ArH, NH, 5H), 
4.47 (bs, NH2, 2H), 3.65 – 3.63 (m, CH2, CO2CH3, 5H); 
13
C NMR (100 MHz, acetone-d6) : 172.6 (CO), 147.5 (CqAr), 143.1 (CqAr), 130.0 (CqAr), 
129.8 (2xCAr), 128.2 (CAr), 125.1 (CAr), 121.1 (CqAr), 119.1 (CAr), 118.3 (CAr), 115.7 (2xCAr), 
52.2 (CO2CH3), 38.4 (CH2). 
 
 
II.5.1.46 7-(phenylamino)indolin-2-one (II.75a)141 
 
The compound was isolated (as side product) as a white solid (4 mg, 13 %). Rf = 0.3, 2x 
(EtOAc:hexane, 2:3). 
MP: 158-161ºC; 
IR (KBr) νmax (cm
‐1
): 3395 (w, N-H), 3054 (w), 1698 (s, C=O), 1593 (w), 1498 (w), 1330 (w), 
751 (m); 
1
H NMR (400 MHz, acetone-d6) : 9,09 (bs, NH, 1H), 7,21-7,12 (m, ArH, 3H), 6,96-6,77 (m, 
ArH, 5H), 3,50 (s, CH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 176.3 (CO), 145.6 (CqAr), 137.2 (CqAr), 130.0 (2xCAr), 
127.8 (CqAr), 126.4 (CqAr), 122.8 (CAr), 121.2 (CAr), 120.1 (CAr), 119.8 (CAr), 116.4 (2xCAr), 
36.8 (CH2). 
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II.5.1.47 7-(3-Chlorophenylamino)indolin-2-one (II.75d) 
 
The compound was isolated (as side product) as a white solid. Rf = 0.5, 2x(EtOAc:hexane, 2:3). 
MP: 147-151 ºC; 
IR (KBr) νmax (cm
‐1
): 3344 (m), 1690 (s, C=O), 1593 (s), 1331 (m), 758 (m); 
1
H NMR (400 MHz, acetone-d6) : 9.27 (bs, NH, 1H), 7.20 – 6.71 (m, ArH, 7H), 3.50 – 3.49 
(s, 2H); 
13
C NMR (100 MHz, acetone-d6) : 176.4 (CO), 147.8 (CAr), 135.1 (CAr), 131.3 (CAr), 129.9 
(CAr), 123.3 (CAr), 122.8 (CAr), 121.2 (CAr), 120.0 (CAr), 119.0 (CAr), 116.3 (CAr), 114.9 
(CAr), 113.8 (CAr), 36.8 (CH2). 
 
 
II.5.1.48 3-(2-oxoindolin-7-ylamino)phenyl acetate (II.75e) 
 
The compound was isolated (as side product) as a white solid. Rf = 0.4, EtOAc:hexane, (3:2). 
MP: 62-65ºC; 
IR (KBr) νmax (cm
‐1
): 3350 (b, m, N-H), 2924 (w), 1764 (m), 1698 (s, C=O), 1598 (m), 1491 
(m), 1204 (s), 759 (w); 
1
H NMR (400 MHz, acetone-d6) : 9.26 (bs, NH, 1H), 7.19 – 7.12 (m, ArH, 2H), 7.02 – 6.93 
(m, ArH, 2H), 6.70 (dd, J = 8.2, 1.2 Hz, ArH, 1H), 6.57 (m, ArH, 1H), 6.50 (dd, J = 7.8, 1.7 Hz, 
ArH, 1H), 3.50 (s, CH2, 2H), 2.20 (s, COCH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 176.5 (CO), 169.7 (COCH3), 153.1 (CqAr), 147.4 (CqAr), 
138.2 (CqAr), 130.6 (CAr), 128.0 (CqAr), 125.7 (CqAr), 122.9 (CAr), 122.5 (CAr), 120.7 (CAr), 
113.2 (CAr), 112.9 (CAr), 109.2 (CAr), 36.9 (CH2), 21.1 (COCH3). 
 
 
 
 
 
II. Novel Benzimidazole-based COX inhibitors 
 
113 
 
II.5.1.49 tert-Butyl 3-(2-oxoindolin-7-ylamino)phenylcarbamate (II.75f) 
 
The compound was isolated (as side product) as a light brown solid. Rf = 0.5, EtOAc:hexane, 
(3:2). 
IR (KBr) νmax (cm
‐1
): 3344 (b, m, N-H), 2976 (w), 1698 (s, C=O), 1598 (m), 1160 (s), 767 (w); 
1
H NMR (400 MHz, acetone-d6) : 9.11 (bs, NH, 1H), 8.28 (bs, NH, 1H), 7.21 – 7.14 (m, ArH, 
2H), 7.07 (t, J = 8.0 Hz, ArH, 1H), 6.95 – 6.91 (m, ArH, 3H), 6.81 (bs, NH, 1H), 6.51 (d, J = 7.9 
Hz, ArH, 1H), 3.49 (s, CH2, 2H), 1.46 (s, C(CH2)3, 9H); 
13
C NMR (100 MHz, acetone-d6) : 176.4 (CO), 153.7 (COC(CH3)3), 146.2 (CqAr), 141.6 
(CqAr), 130.2 (CAr), 127.8 (CqAr), 126.5 (CqAr), 122.8 (CAr), 121.4 (CqAr), 119.8 (CAr), 110.3 
(CAr), 106.5 (CAr), 79.8 (C(CH3)3), 36.9 (CH2), 28.6 (C(CH3)3). 
 
 
General procedure for the benzoylation/cyclization: 
To a sulfamoylbenzyl chloride (2.5 equiv) suspension in dry THF (0.5 M) placed in an ice bath, 
was added the corresponding II.73a-e (1 equiv) solution in THF (0.5M), dropwise. The mixture 
was stirred for 1h at 0 ºC and then at 50 ºC overnight. The reaction was quenched with water (15 
mL), extracted with EtOAc and washed with brine. The combined organic layer was dried over 
Na2SO4 and concentrated in vacuo to obtain the below mentioned products II.77a-e. 
 
II.5.1.50 Methyl 2-(1-phenyl-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetate 
(II.77a) 
 
The residue was purified by pTLC [EtOAc:hexane (2:3)] to give II.77a as a light pink solid (51 
mg, 89%). Rf = 0.2, 2x(EtOAc:hexane 2:3). 
MP: 199-200ºC; 
IR (KBr) νmax (cm
‐1
): 3383 (w, N-H), 3270 (w, N-H), 1724 (s, C=O ester), 1500 (w), 1329 (s, 
S-O), 1170 (s, S-O), 767 (w); 
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1
H NMR (400 MHz, acetone-d6) : 7.87 (d, J = 8.0 Hz, H2’’, 2H), 7.76 (d, J = 8.0 Hz, H3’’, 2H), 
7.64 – 7.61 (m, H3’, H4’, 3H), 7.52 – 7.49 (m, H2’, 2H), 7.29 – 7.27 (m, H4, H5, 2H), 7.16 (dd, H6, 
1H), 6.69 (bs, NH2, 2H), 4.18 (s, CH2, 2H), 3.70 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 172.3 (COCH3), 151.3 (C1’’), 145.3 (C1), 143.2 (C2), 138.4 
(C1’), 137.8 (C7), 134.4 (C4’’), 131.1 (C3’), 130.7 (C3’’), 130.0 (C4’), 128.6 (C2’), 127.3 (C3), 126.9 
(C2’’), 124.6 (C5), 124.5 (C4), 110.3 (C6), 52.1 (CO2CH3), 36.2 (CH2); 
HRMS m/z calcd for C22H20N3O4S [M+H]
+
: 422.1169, found 422.1162; 
HPLC Purity: RT = 12,8 min., Purity 98%. 
 
 
II.5.1.51 Methyl-2-(2-(4-sulfamoylphenyl)-1-(3-(trifluoromethyl)phenyl)-1H-
benzo[d]imidazol-4-yl) acetate (II.77b) 
 
The residue was purified by pTLC (2x EtOAc:hexane 1:2) and recrystallized from ethanol to 
give II.77b as a white solid (65 mg, 62 %); Rf = 0.2, EtOAc:hexane (1:1). 
MP: 259-261ºC; 
IR (KBr) νmax (cm
‐1
): 3310 (m, N-H), 1716 (s, C=O ester), 1345 (s), 1317 (m), 1172 (s), 1130 
(m), 845 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.98 (s, H6’,1H), 7.95 (dd, J = 7.9 Hz, H4’,1H), 7.89 – 7.87 
(m, H3’, H2’’, 3H), 7.82 (dd, J = 8.0 Hz, H2’, 1H), 7.77 (d, J = 8.5 Hz, H3´´, 2H), 7.31 – 7.30 (m, H4, 
H6, 2H), 7.20 – 7.18 (m, H5, 1H), 6.72 (bs, NH2, 2H), 4.17 (s, CH2, 2H), 3.70 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 172.2 (CO2CH3), 151.3 (C1’’), 145.8 (C1), 143.2 (C2), 
138.5 (C1’), 138.0 (C7), 134.2 (C4’), 132.7 (C2’), 132.6 (q, J = 32.9 Hz, C5’), 132.2 (C3’), 130.8 
(C3’’), 127.4 (C3), 126.9 (C2’’), 126.6 (d, J = 3.8 Hz, C4’), 125.5 (d, J = 3.9 Hz, C6’), 124.8 (C5) 
124.7 (C4), 124.6 (q, J = 270.7 Hz, CF3), 110.1 (C6), 52.1 (CO2CH3), 36.1 (CH2); 
HRMS: m/z calcd for C23H19 F3N3O4S [M+Na
+
]
+
: 490.1043, found 490.1051; 
HPLC Purity: 97% (RT = 15,3 min.). 
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II.5.1.52 Methyl 2-(1-(3-fluorophenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-
yl)acetate (II.77c) 
 
The residue was purified by pTLC [EtOAc:hexane (2:3)] to give II.77c as a white solid (36 mg, 
59%); Rf = 0.4, hexane:EtOAc (2:3). 
MP: 179-181ºC; 
IR (KBr) νmax (cm
‐1
): 3368 (b, m, N-H), 1732 (s, C=O ester), 1596 (m), 1492 (m), 1338 (s, 
S=O), 1166 (s, S=O); 
1
H NMR (400 MHz, acetone-d6) : 7.89 (d, J = 8.6 Hz, H2’’, 2H), 7.78 (d, J = 8.6 Hz, H3´´, 2H), 
7.67 (dd, J = 14.5, 8.1 Hz, H3’, 1H), 7.43 – 7.29 (m, H2’, H4’, H6’, 3H), 7.30 – 7.29 (m, H4, H5, 2H), 
7.22 – 7.20 (m, H6, 1H), 6.72 (bs, NH2, 2H), 4.17 (s, CH2, 2H), 3.70 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 172.2 (CO2CH3), 164.0 (d, J = 247.3 Hz, C5’), 151.2 (C1’’), 
145.8 (C1), 143.1 (C2), 139.2 (d, J = 10.1 Hz, C1’), 138.1 (C7), 134.3 (C4’’), 132.7 (d, J = 9.3 Hz 
C3’), 130.7 (C3’’), 127.4 (C3), 126.9 (C2’’), 124.8 (d, J = 3.3 Hz, C2’), 124.8 (C5), 124.7 (C4), 116.91 
(d, J = 21.1 Hz, C6’), 116.01 (d, J = 23.7 Hz, C4’), 110.2 (C6), 52.1 (CO2CH3), 36.1 (CH2); 
HPLC Purity: 96% (RT =12,9 min.); 
HRMS: m/z Calculated for C22H18N3O4FS [M+Na]
+
: 439.1002, found: 439.1004. 
 
 
II.5.1.53 Methyl 2-(1-(3-chlorophenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-
yl)acetate (II.77d) 
 
The residue was purified by pTLC [2x EtOAc:hexane (2:3)] to give II.77d as a white solid (85 
mg, 84%). Rf = 0.2, hexane:EtOAc (3:2). 
MP: 197-199ºC; 
IR (KBr) νmax (cm
‐1
): 3368 (w, N-H), 2949 (w), 1734 (s, C=O ester), 1590 (w), 1339 (s, S-O), 
1165 (s, S-O), 757 (w); 
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1
H NMR (400 MHz, acetone-d6) : 7.90 (d, J = 8.7 Hz, H2’’, 2H), 7.80 (d, J = 8.7 Hz, H3´´, 2H), 
7.66 – 7.64 (m, H2’, H3’, H6’, 3H), 7.49 – 7.47 (m, H4’, 1H), 7.30 – 7.28 (m, H4, H5, 2H), 7.20 – 7.18 
(m, H6, 1H), 6.73 (bs, NH2, 2H), 4.17 (s, CH2, 2H), 3.69 (s, CO2CH3, 3H); 
13
C NMR (100 MHz, acetone-d6) : 172.2 (CO2CH3), 151.2 (C1’’), 145.8 (C1), 143.2 (C2), 
139.1 (C1’), 138.1 (C7), 135.8 (C5’), 134.3 (C4’’), 132.4 (C3’), 130.7 (C3’’), 130.1 (C6’), 128.6 (C2’), 
127.4 (C4’, C3), 126.9 (C2’’), 124.8 (C5), 124.7 (C4), 110.2 (C6), 52.0 (CO2CH3), 36.1 (CH2); 
HPLC Purity: 96% (RT =14,5 min.); 
HRMS: m/z Calculated for C22H18N3O4ClS [M+Na]
+
: 455.0707, found: 455.0717. 
 
 
II.5.1.54 Methyl 2-(1-(3-acetoxyphenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-
yl)acetate (II.77e) 
 
The residue was purified by pTLC [(2x EtOAc:hexane (2:3)] to give II.77e as a white solid (95 
mg, 73%). Rf = 0.25, hexane:EtOAc (3:2). 
MP: 167-169ºC; 
IR (KBr) νmax (cm
‐1
): 3317 (m, N-H), 2956 (w), 1768 (s, C=O acetyl), 1718 (s, C=O ester), 
1596 (m), 1342 (s, S-O), 1165 (s, S-O), 758 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.88 (d, J = 8.4 Hz, H2’’, 2H), 7.80 (d, J = 8.5 Hz, H3´´, 1H), 
7.64 (t, J = 8.1 Hz, H3’, 1H), 7.41 – 7.33 (m, H2’, H4’, H6’, 3H), 7.30 – 7.27 (m, H4, H5, 2H), 7.20 – 
7.18 (m, H6, 1H), 6.72 (bs, NH2, 1H), 4.17 (s, CH2, 2H), 3.69 (s, CO2CH3, 3H), 2.28 (s, COCH3, 
3H); 
13
C NMR (151 MHz, acetone-d6) : 172.2 (CO2CH3), 169.5 (COCH3), 152.8 (C5’), 151.1 (C1’’), 
145.6 (C1), 143.1 (C2), 138.4 (C1’), 138.2 (C7), 134.3 (C4’’), 131.7 (C3’), 130.6 (C3’’), 127.3 (C3), 
126.8 (C2’’), 125.8 (C5), 124.7 (C4), 124.6 (C4’), 123.4 (C2’), 122.4 (C6’), 110.2 (C6), 52.0 
(CO2CH3), 36.1 (CH2), 20.9 (COCH3); 
HRMS: m/z Calculated for C24H21N3O6S [M+Na]
+
: 479.1151, found: 479.1154. 
HPLC Purity: 94%, (RT = 11,1 min.). 
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II.5.1.55 Methyl 2-(1-(3-(tert-butoxycarbonylamino)phenyl)-2-(4-sulfamoylphenyl)-1H-
benzo[d]imida- zol-4-yl)acetate (II.77f) 
 
The residue was purified by pTLC [2x hexane:EtOAc (3:2)] to give II.77f as a light pink solid 
(44 mg, 85%); Rf = 0.3, hexane:EtOAc (3:2). 
MP: 116-118º C; 
IR (KBr) νmax (cm
‐1
): 3400 (b), 2926 (w), 1725 (s, C=O ester), 1602 (m), 1340 (m), 1162 (s, S-
O); 
1
H NMR (400 MHz, acetone-d6) : 8.76 (s, NH, 1H), 7.88 (d, J = 8.6 Hz, H2’’, 2H), 7.83 (d, J = 
8.6 Hz, H3´´, 2H), 7.78 – 7.73 (m, H2’, H6’, 2H), 7.50 (t, J = 8.1 Hz, H3’, 1H), 7.29 – 7.28 (m, H4, H5, 
2H), 7.23 – 7.21 (m, H6, 1H), 7.05 (dd, J = 7.8, 1.1 Hz, H4’, 1H), 6.69 (bs, NH2, 2H), 4.17 (s, CH2, 
2H), 3.69 (s, CO2CH3, 3H), 1.47 (s, C(CH3)3, 9H); 
13
C NMR (151 MHz, acetone-d6) : 172.2 (CO2CH3), 153.6, 151.1 (C1’’), 145.6 (C1), 143.2 
(C2), 142.4 (C5’), 138.3 (C1’), 138.1(C7), 134.6 (C4’’), 131.3 (C3’), 130.6 (C3’’), 127.3 (C3), 126.9 
(C2’’), 124.6 (C5), 124.5 (C4), 122.0 (C4’), 119.2 (C6’), 117.7 (C2’), 110.4 (C6), 80.6 (C(CH3)3), 52.0 
(CO2CH3), 36.1 (CH2), 28.5 (C(CH3)3). 
 
 
General procedure for hydrolysis: 
To the II.77a-e (1 equiv) solution in a dioxane:THF:water mixture (1:1:1, 0.5 M), was added 
LiOH.H2O (5 equiv). The mixture was stirred at room temperature until total conversion verified 
by TLC (about 1h). The mixture was diluted with EtOAc and washed with water and brine. The 
combined organic layer was dried over Na2SO4 and concentrated in vacuo to give the below 
described products II.78a-e that were not further purified. 
 
II.5.1.56 2-(1-phenyl-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetic acid 
(II.78a) 
 
The compound was obtained as a light pink solid (quant.), Rf = 0.1, EtOAc: hexane (3:2). 
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MP: 275-278ºC; 
IR (KBr) νmax (cm
‐1
): 3418 (b, s), 3331 (s), 1668 (s), 1338 (m), 1160 (s); 
1
H NMR (400 MHz, acetone-d6) : 7.87 (d, J = 8.3 Hz, H2’’, 2H), 7.75 (d, J = 8.3 Hz, H3´´, 2H), 
7.63 – 7.48 (m, H1’, H2’, H3’, 5H), 7.28 – 7.12 (m, H4, H5, H6, 3H), 7.03 (bs, NH2, 2H), 4.11 (s, CH2, 
2H); 
1
H NMR (600 MHz, D2O) δ: 7.99 (d, J = 8.3 Hz, H2´´, 2H), 7.86 (d, J = 8.4 Hz, H3´´, 2H), 7.70 
– 7.79 (m, H3’, H4’, H5’, 3H), 7.53 – 7.35 (m, H1’, H6’, H4, H5, H6, 5H), 4.06 (s, CH2, 2H). 
13
C NMR (100 MHz, acetone-d6) : 173.1 (CO2H), 151.1 (C1’’), 145.9 (C1), 143.1 (C2), 138.2 
(C1’), 137.7 (C7), 134.2 (C4’’), 130.9 (C3’), 130.4 (C3’’), 129.8 (C4’), 128.4 (C2’), 127.8 (C3), 126.7 
(C2’’), 124.4 (C4, C5), 109.9 (C6), 36.5 (CH2); 
HPLC Purity: 97% (RT = 9,60 min.). 
HRMS: m/z Calculated for C21H17N3O4S [M+Na]
+
: 407.0940, found: 407.0922. 
 
 
II.5.1.57 2-(1-phenyl-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetic acid 
(II.78b) 
 
The compound was obtained as a white solid (quant.). Rf = 0.1, EtOAc: hexane (3:2). 
MP: 265-268ºC; 
IV (KBr) νmax (cm
‐1
): 3416 (b, m), 3343 (m), 3078 (m), 1671 (m), 1458 (m), 1338 (s), 1162 (s), 
1128 (s), 756 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.99 (s, H6’,1H), 7.95 – 7.85 (m, H2’’, H3’, H4’, 4H), 7.82 – 
7.75 (m, H3’’, H2’, 3H), 7.33 – 7.28 (m, H4, H5, 2H), 7.17 (dd, J = 7.3, 1.8 Hz, H6, 1H), 7.11 (bs, 
NH2, 2H), 4.11 (s, CH2, 2H); 
1
H NMR (600 MHz, D2O) δ: 8.08 – 7.95 (m, H2’’, H6’, 3H), 7.92 – 7.81 (m, H3’’, H3’, H4’, H2’, 
5H), 7.50 – 7.35 (m, H4, H5, H6, 3H), 4.06 (s, CH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 173.1 (CO2H), 151.2 (C1’’), 146.1 (C1), 143.1 (C2), 138.4 
(C1’), 137.9 (C7), 133.9 (C4’), 132.7 (C2’), 132.5 (q, J = 32.8 Hz, C5’), 132.2 (C3’), 130.6 (C3’’), 
128.0 (C3), 126.8 (C2’’), 126.5 (d, J = 3.8 Hz, C4’), 125.4 (d, J = 3.8 Hz, C6’), 124.8 (C5), 124.7 (C4), 
109.8 (C6), 36.4 (CH2); 
HPLC Purity: 98 % (RT = 13,25 min.). 
HRMS: m/z Calculated for C22H17N3F3O4S [M+Na]
+
: 476.0888, found: 476.0886. 
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II.5.1.58 2-(1-(3-fluorophenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetic 
acid (II.78c) 
 
The compound was obtained as a white solid (quant.). Rf = 0.1, EtOAc: hexane (3:2). 
MP: 256-258ºC; 
IV (KBr) νmax (cm
‐1
): 3420 (b, m), 3337 (m), 3084 (m), 1676 (m), 1594 (m), 1341 (m), 1162 
(s), 754 (w); 
1
H RMN (400 MHz, acetone-d6) : 7.90 (d, J = 8.5 Hz, H2’’, 2H), 7.79 (d, J = 8.5 Hz, H3’’, 2H), 
7.68 (dd, J = 14.5, 8.1 Hz, H3’, 1H), 7.45 – 7.29 (m, H2’, H4’, H6’, H4, H5, 5H), 7.22 (dd, J = 7.3, 1.8 
Hz, H6, 1H), 6.70 (bs, NH2, 2H), 4.16 (s, CH2, 2H); 
1
H NMR (600 MHz, D2O) δ: 8.01 (d, J = 8.4 Hz, H2’’, 2H), 7.87 (d, J = 8.4 Hz, H3’’, 2H), 7.71 
(dd, J = 15.0, 8.4 Hz, H3’, 1H), 7.52 – 7.37 (m, H2’, H4’, H6’, H4, H5, H6, 6H), 4.06 (s, CH2, 2H); 
13
C RMN (100 MHz, acetone-d6) : 172.4 (CO2H), 164.0 (d, J = 247.3 Hz, C5’), 151.1 (C1’’), 
145.8 (C1), 143.0 (C2), 139.2 (d, J = 10.2 Hz C1’), 138.0 (C7), 134.2 (C4’’), 132.6 (d, J = 9.4 Hz, 
C3’), 130.7 (C3’’), 127.5 (C3), 126.9 (C2’’), 124.8 (d, J = 3.2 Hz, C2’), 116.90 (d, J = 21.1 Hz, C6’), 
116.0 (d, J = 23.7 Hz, C4’), 110.2 (C6), 36.5 (CH2). 
HPLC Purity: 96% (RT = 9,95 min.). 
HRMS: m/z Calculated for C21H16N3O4FS [M+Na]
+
: 425.0846, found: 425.0843. 
 
 
II.5.1.59 2-(1-(3-chlorophenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetic 
acid (II.78d) 
 
The compound was obtained as a white solid (quant). Rf = 0.1, EtOAc: hexane (3:2). 
MP: 269-270 ºC; 
IV (KBr) νmax (cm
‐1
): 3338 (m), 3068 (m), 1671 (m), 1591 (m), 1338 (m), 1160 (s); 
1
H RMN (400 MHz, acetone-d6) : 7.90 (d, J = 8.4 Hz, H2’’, 2H), 7.80 (d, J = 8.4 Hz, H3´´, 2H), 
7.68 – 7.63 (m, H2’, H3’, H6’, 3H), 7.51 – 7.48 (m, H4’, 1H), 7.34 – 7.28 (m, H4, H5, 2H), 7.20 (dd, J 
= 7.3, 1.5 Hz, H6, 1H), 6.71 (bs, NH2, 2H), 4.16 (s, CH2, 2H); 
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1
H NMR (600 MHz, D2O) δ: 8.01 (d, J = 5.9 Hz, H2’’, 2H), 7.87 (d, J = 8.3 Hz, H3´´, 2H), 7.73 
– 7.67 (m, H2’, H3’, 2H), 7.62 (s, H6’, 1H), 7.51 – 7.49 (m, H4’, H5, 2H), 7.44 (d, J = 7.2 Hz, H4, 
1H), 7.37 (d, J = 8.2 Hz, H6, 1H), 4.06 (s, CH2, 2H); 
13
C RMN (100 MHz, acetone-d6) : 172.5 (CO2H), 151.1 (C1’’), 145.8 (C1), 143.0 (C2), 139.0 
(C1’), 138.0 (C7), 135.8 (C5’), 134.2 (C4’’), 132.4 (C3’), 130.7 (C3’’), 130.1 (C6’), 128.6 (C2’), 127.6 
(C4’), 127.4 (C3), 126.9 (C2’’), 124.8 (C5), 124.8 (C4), 110.1 (C6), 36.5 (CH2); 
HPLC Purity: 92% (RT = 12,11 min.). 
HRMS: m/z Calculated for C21H16N3O4ClS [M+H]
+
:
 
441.0550, found: 441.0564. 
 
 
II.5.1.60 2-(1-(3-hydroxyphenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-
yl)acetic acid (II.78e) 
 
The compound was obtained as a white solid (8 mg, quant.); Rf = 0, EtOAc: hexane (3:2). 
MP: 245-247 ºC; 
IR (KBr) νmax (cm
‐1
): 3368 (b), 1596 (m), 1338 (s), 1161 (s), 757 (w); 
1
H NMR (400 MHz, acetone-d6) : 7.89 (d, J = 8.5 Hz, H2’’, 2H), 7.82 (d, J = 8.5 Hz, H3´´, 2H), 
7.44 (t, J = 8.3 Hz, H3´, 1H), 7.30 – 7.29 (m, H4, H5, 2H), 7.20 (dd, J = 6.8, 2.3 Hz, H6, 1H), 7.06 
(dd, J = 7.9 Hz, H2´, 1H), 6.96 – 6.94 (m, H4´, H6´, 2H), 6.71 (bs, NH2, 1H), 4.16 (s, CH2, 2H); 
1
H NMR (600 MHz, D2O) δ: 7.98 (d, J = 8.2 Hz, H2’’, 2H), 7.88 (d, J = 8.3 Hz, H3´´, 2H), 7.45 
– 7.36 (m, H3´, H4, H5, H6, 4H), 6.93 (d, J = 9.4 Hz, H2´, 1H), 6.78 (s, H6´, 1H), 6.73 (d, J = 8.2 Hz, 
H4´, 1H), 4.04 (s, CH2, 2H); 
13
C NMR (100 MHz, acetone-d6) : 172.4 (CO2H), 159.7 (C5’), 151.0 (C1’’), 145.6 (C1), 142.9 
(C2), 138.6 (C1’), 138.2 (C7), 134.4 (C4’’), 131.8 (C3’), 130.5 (C3’’), 127.3 (C3), 126.8 (C2’’), 124.6 
(C5), 124.5 (C4), 119.3 (C4’), 117.1 (C2’), 115.3 (C6’), 110.4 (C6), 36.7 (CH2); 
HPLC Purity: 95% (RT = 7,5 min.). 
HRMS: m/z Calculated for C21H17N3O5S [M+H
+
]
+
: 423.0889, found: 423.0887. 
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II.5.1.61 2-(1-(3-aminophenyl)-2-(4-sulfamoylphenyl)-1H-benzo[d]imidazol-4-yl)acetic 
acid (II.78f) 
 
The compound was obtained as a white solid (quant.). Rf = 0, EtOAc: hexane (3:2). 
MP: 168-171ºC; 
IR (KBr) νmax (cm
‐1
): 3141 (b, m), 1557 (m), 1384 (m), 1063 (m), 758 (w); 
1
H NMR (400 MHz, D2O) : 8.01 (d, J = 8.4 Hz, H2’’, 2H), 7.81 (d, J = 8.5 Hz, H3’’, 2H), 7.75 
(t, J = 8.1 Hz, H3’, 1H), 7.64 – 7.60 (m, H5, H4, H2’, H4’ , 4H), 7.53 – 7.51 (m, H6, H6’, 2H), 4.25 (s, 
CH2, 2H); 
13
C NMR (100 MHz, D2O) : 174.8 (CO2H), 148.6 (C1’’), 145.1 (C1), 134.0 (C5’), 133.6 (C1’), 
132.3 (C3’), 131.4 (C3’’), 131.0 (C2), 128.8 (C4), 127.5 (C5), 127.2 (C2’), 126.7 (C2’’), 126.2 (C5’), 
125.0 (C4’), 121.9 (C7), 121.5 (C6’), 112.1 (C6), 36.3 (CH2). 
HPLC Purity: < 90% (RT = 8 min.). 
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II.5.2 Evaluation of the inhibitory activity of NSAIDs 
Cremophor-EL®, gentamicinin sulfate, calcium ionophore, acetylsalicylic acid and 
lipopolysaccharides from E. Coli 026:B6 were obtained from Sigma Aldrich. PGE2 ELISA Kit was 
purchased in Enzo Life Sciences (all components for the PGE2 ELISA are stable at 4°C until the 
expiration date; the conjugate and standard must be stored frozen at −20°C. The components have 
to be prepared as described by the company’s manual and must be brought to room temperature for 
at least 30 min prior to opening). TXBSI was kindly provided by Prof. Dr. Artur Silva 
(Universidade de Aveiro). 
The protocol used in this thesis for whole blood assay was adopted from Laufer and Luik.
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II.5.2.1 Samples and Solutions Preparation 
II.5.2.1.1 COX-1 Whole Blood Assay 
1. Calcium ionophore: 2.5 mg Calcium ionophore is diluted in 1 mL ethanol and stored in single-
use aliquots at −20°C. 
2. DPBS Buffer: 4.0 g NaCl, 0.1 g KCl, 0.1 g KH2PO4, 0.575 g Na2HPO4, and 0.5 g glucose are 
diluted in water (500 ml) and stored at 4°C for a maximum of 7 days. 
3. Cremophor-EL/ethanol: 116.9 g Cremophor-EL is mixed with 50.0 g ethanol 99% (250 mL) and 
stored limitless under cover of darkness. 
4. Thromboxane Synthetase Inhibitor (TXBSI) stock solution: 1 mM TXBSI (previously 
synthesized) in Cremophor-EL/ethanol and stored in single-use aliquots at −20°C. 
5. Thromboxane Synthetase Inhibitor (TXBSI) working solution: 81 L DPBS buffer is added to an 
eppendorf and 9 L of the TXBSI stock solution is added. 
6. Test compounds are dissolved preferentially in 10 mM in Cremophor-EL/ethanol. As 
compounds sometimes are difficult to be dissolved, stock solutions can be prepared in DMSO that 
does not interfere with the methodology. Working solutions must be freshly prepared by diluting 
the stock solution accordingly. Diluted standards should be used within 60 min. of preparation. 
7. Dilution of the test compounds, e.g.: 
1000 μM 
→ 90 L DPBS buffer + 10 μL of 10 mM Stock test compound 
solution 
100 M → 90 L DPBS buffer + 10 μL of 1000 M Test compound 
10 M → 90 L DPBS buffer + 10 μL of 100 M Test compound 
1 μM → 90 L DPBS-buffer + 10 μL of 10 M Test compound 
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Test compounds are further diluted when added to blood to give final working concentrations of 10–
0.01 μM. 
8. Accordant amount of heparinized blood of different donors. 
 
II.5.2.1.2 COX-2 Whole Blood Assay 
1. DPBS Buffer: (see COX-1). 
2. Cremophor-EL/ethanol: (see COX-1). 
3. Thromboxane Synthetase Inhibitor (TXBSI) stock solution: (see COX-1). 
6. DPBS–Gentamicin buffer: 12.5 mg Gentamicin is diluted in 50 mL DPBS buffer. 
5. Thromboxane Synthetase Inhibitor (TXBSI) working solution: (see COX-1). 
6. Acetylsalicylic Acid Solution: 2.0 mg Acetylsalicylic acid is diluted in 10.0 mL DPBS–
Gentamicin. Working concentration is defined as 10 mg/mL. 
7. LPS-Solution: 1.0 mg LPS is diluted in 5 mL DPBS–Gentamicin. Working concentration is 
defined as 10 mg/mL. 
8. Samples: Initial drug concentration range from 10 mM to 10 pM and is prepared by diluting the 
stock solution in DPBS–Gentamicin. Starting from 10 mM, 1:1000-fold dilution is required to 
obtain 10 μM. 
9. Accordant amount of heparinized blood of different donors. 
 
II.5.2.1.3 PGE2-ELISA 
PGE2 was measured using a commercial ELISA kit from Enzo Life Sciences. Below is a list of the 
kit’s components with a description. 
1. This assay is based on the use of a 96-wells plate coated with goat anti-Mouse IgG antibody. The 
plates are made from break-apart strips coated with goat antibody specific to mouse IgG. 
2. Alkaline Phosphatase PGE2 Conjugate: A blue solution of alkaline phosphatase conjugated with 
PGE2. Ready to use. 
3. PGE2, EIA antibody: A yellow solution of a monoclonal antibody to PGE2. Ready to use. 
4. Assay Buffer Concentrate: Tris buffered saline containing proteins and sodium azide as 
preservative. The Assay buffer is prepared by diluting 10 mL of the concentrate with 90 mL of 
bidistillated water.  
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5. Wash Buffer Concentrate: tris buffer saline containing detergents. The wash buffer is prepared 
by diluting 5 mL of the supplied concentrate with 95 mL of bidistillated water. This is stored at 
room temperature until the kit expiration date, or for 3 months, whichever is earlier. 
6. Prostaglandin E2 standard: A solution of 50.000 pg/mL PGE2. 
7. pNpp Substrate: a solution of p-nitrophenyl phosphate in buffer. Ready to use. 
8. Stop Solution: a solution of trisodium phosphate in water. Keep tightly capped. 
9. PGE2 Assay Layout Sheet and Plate Sealers. 
 
II.5.2.2 Methods 
II.5.2.2.1 COX-1 Whole Blood Assay 
1. Before starting the assay, the centrifuge was cooled to 4°C and the water bath brought to 37°C; 
2. The eppendorf tubes were labeled from 1 to 6 (or 8), and placed in the water bath at 37°C; 
3. Six to eight samples can be incubated at the same time. The tip was always washed out three 
times in the blood suspension. The tip was changed after each step. 
4. 500 L of the heparinized blood of donor was placed into each tube. The remaining blood was 
stored on the titramax at a low rpm to avoid accumulation of the blood cells. 
5. Addition of 5 L of the TXBSI into each tube. Keep a 15 s rhythm. 
6. Addition of 5 L of the sample dilutions into the corresponding tube. Keep a 15 s rhythm. 
7. The blood was carefully mixed with the 1 mL pippet. Start counting exact 15 min. of incubation 
from the first tube. 
8. After 15 min incubation time, 2.5 L of the calcium ionophor dilution was added to all tubes for 
starting the reaction. Keep the 15 s rhythm. 
9. The blood was carefully mixed with the 1 mL pippet. Start counting exact 15 min. of incubation 
from the first tube. 
10. The tubes were taken out of the water bath and stored on iced water for 5 min. to stop the 
reaction. 
11. The tubes were centrifuged at 1000 × g and 4°C for 20 min. 
12. The plasma was taken out and put into a fresh tube and stored at −20°C. 
13. If the PGE2-ELISA of the compounds cannot be tested within 1 day, the samples were stored at 
−10°C. 
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14. Repeat steps 4 to 6 for the remaining tubes. 
15. In the tubes for basal level and for the maximal stimulation data was added 2.5 L of the DPBS 
buffer. 
16. The blood was carefully mixed with the 1 mL pippet. Start counting exact 15 min. of incubation 
from the first tube. 
17. After 15 min. incubation time, 2.5 L of the calcium ionophor dilution was added to all tubes 
for starting the reaction (except the tube for the basal level). Keep the 15 s rhythm. 
18. Mix the blood with the 1mL pippet. Start counting exact 15 min. of incubation from the first 
tube. 
19. Handle remaining blood in the exact same manner. 
Table II.18. Brief overview of the individual pipetting steps for COX-1 determination. 
Basal level 
500 μL Blood 
5 μL TXBSI 
5 μL DPBS-buffer 
2.5 μL DPBS-buffer 
Maximal stimulation (Control) 
500 μL Blood 
5 μL TXBSI 
5 μL DPBS-buffer 
2.5 μL Calciumionophor-dilution 
Samples 
 
500 μL Blood 
5 μL TXBSI 
5 μL Accordant inhibitor-dilution 
2.5 μL Calciumionophor-dilution 
 
 
II.5.2.2.2 COX-1 PGE2-ELISA 
1. The number of wells to be used was previously determined. Usually were used three to four 
individual strips corresponding to 24 or 32 wells (Figure II.35). The remaining wells (strips) were 
stored at 4°C. (Note: all the twelve strips can be individually separated from the microplate) 
2. The Assay Buffer solution was prepared mixing 1 mL of Assay Buffer concentrate in 9 mL of 
deionized water. The solution was kept in a dark flask. 
2. Preparation of PGE2 standards: 
450 L of Assay buffer solution was added to the first tube (S1) and 250 L in the 
remaining seven (S2-S3). Then, 50 L of PGE2 stock solution was placed in S1 and the 
tube was stirred in the vortex. 250 L of S1 solution were taken to S2 and the tube was 
stirred. The same procedure was made until S8. 
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3. Preparation of the samples:  
190 L Assay Buffer was mixed with 10 L of the corresponding samples. Remaining 
sample volume was stored at −20°C.  
4. 100 μL of PGE2 standards S1 through S8 were added into the appropriate wells (Figure II.35). 
5. 100 μL of Assay Buffer solution were added into the B0 (0 pg/mL Standard) well (Figure II.35). 
6. 100 L of the samples were added into the corresponding wells (Figure II.35). 
 
a)         b)  
 
5000 pg/mL (S8) Bo 8 
2500 pg/mL (S7) 1 9 
1250 pg/mL (S6) 2 10 
625 pg/mL (S5) 3 11 
312.5 pg/mL (S4) 4 12 
156.25 pg/mL (S3) 5 Basa1 level 
78.125 pg/mL (S2) 6 Control 
39.1 pg/mL (S1) 7 Blank (B0) 
 
Figure II.35. a) 96-Well microplate (with 8 rows x 12 strips) used for ELISA test and b) schematic 
representation of the adopted strategy. 
7. Using the multipipet, 50 L of conjugate was added into each well, except the Blank well. 
8. In the same way, 50 L of the antibody solution were added into each well, except the Blank 
well. Every well should be green in colour except the Blank well that is empty at this point. 
9. The plate was incubated at room temperature on a plate shaker for 120 min at ~500 rpm. The 
plate was covered with the plate sealer and aluminum foil. 
10. The contents of the wells were discarded and the wells were washed by adding 200 L of wash 
solution to every well. After each wash, the wells were emptied and the plate tapped on a lint free 
paper towel. The washing procedure was repeated five more times for a total of six washes. 
11. 200 L of the pNpp substrate solution were added to every well. The plate was incubated in the 
dark at room temperature for 45 min, without shaking. 
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12. 50 L of Stop solution was added to every well, to stop the reaction. The plate should was read 
immediately. 
13. Blank the plate reader against the Blank wells and read the optical density at 405 nm, 
preferably with correction between 570 and 590 nm. If the plate reader is not able to be blanked 
against the Blank wells, manually subtract the mean optical density of the Blank wells from all 
readings. 
 
II.5.2.2.3 COX-1 Calculation of PGE2 Concentration 
1. The average of the PGE2 concentration of stimulation data must be calculated first (B). 
2. The average of PGE2 concentration of basal data (Blk) has to be subtracted from the average of 
each sample (including the values for maximal stimulation – B0). 
3. To generate the percentage inhibition, use the following formula  
Inhibition [%] = 100 – [Csample(Bcorr)/Cstim(B0corr)] x 100, 
where C = PGE2 concentration. 
4. Using GraphPad Prism software, plot percent inhibition versus concentration of PGE2 for the 
standards. Approximate a straight line through the points. The concentration of PGE2 in the 
unknowns can be determined by interpolation. 
 
 
II.5.2.2.4 COX-2 Whole Blood Assay 
1. 800 L/well of heparinized blood was placed into a six well plate, and mixed with 10 L TXBSI 
per well. 
2. 50 L of acetylsalicylic acid was added at time zero to exclude any contribution of COX-1 to 
metabolite formation. 
3. 100 L of the sample dilutions were added into the corresponding wells. 
4. 100 L of the DPBS were added into the wells corresponding to maximal stimulation and basal 
data. 
5. The blood was carefully mixed with the 1 mL pippet and incubated in a humidified incubator 
(37°C, 5% CO2) for 15 min. 
6. 50 L of LPS was added to sample and maximum stimulation wells to induce COX-2 
expression. 
7. 50 μL of DPBS–Gentamicin buffer was added into the well for basal data (instead of LPS). 
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Table II.19. Brief overview of the individual pipetting steps for COX-2 determination. 
Basal level 
800 μL Blood 
10 μL TXBSI 
50 μL Acetylsalicylic acid 
100 μL DPBS-Gentamicin-buffer 
Control (Maximal stimulation) 
800 μL Blood 
10 μL TXBSI 
50 μL Acetylsalicylic acid 
100 μL DPBS-Gentamicin-buffer 
50 μL LPS-Dilution 
Samples 
800 μL Blood 
10 μL TXBSI 
50 μL Acetylsalicylic acid 
100 μL Accordant inhibitor dilution 
50 μL LPS-Dilution 
 
8. Blood samples were carefully mixed with the 1mL pippet. Samples were incubated in a 
humidified incubator (37°C, 5% CO2) for 5 h. 
9. Handle remaining blood in the exact same manner. 
10. The reaction was stopped by adding iced DPBS buffer (1 mL) into the aliquots and further 
cooling on ice for 10 min. 
11. The blood mixture was placed in Falkon tubes that were centrifuged (1000 × g, 4°C, 15 min). 
Plasma was removed and stored at −20°C. 
12. PGE2 concentration in thawed plasma supernatants is determined by correlate enzyme 
immunoassay as an indicator of COX-2 activity according to the manufacturers’ instructions. 
 
II.5.2.2.5 COX-2 PGE2-ELISA 
Same procedure used for COX-1. 
 
II.5.2.2.6 COX-2 Calculation of PGE2 Concentration 
Same procedure used for COX-1. 
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II.5.3 STD-NMR studies 
II.5.3.1 Materials 
COX-2 isolated from sheep placenta was purchased from Cayman Chemical (Item number 
60120). The protein was supplied in 80 mM Tris-HCl, pH 8.0, 0.1% Tween 20, and 300 μM 
diethyldithiocarbamate and was used as such.  
COX-2 human was purchased from Cayman Chemical (Item number 60120). The protein was 
supplied in 80 mM Tris-HCl, pH 8.0, 0.1% Tween 20, and 300 μM diethyldithiocarbamate and 
10% glycerol and was used as such. 
Ibuprofen and diclofenac were purchased from Sigma and Merck, respectively and were used as 
such. Naproxen was purchased from Sigma. 
All STD-NMR experiments were acquired at 37 °C in a Bruker Avance III spectrometer 
operating at 600 MHz, with a 5 mm triple resonance cryogenic probe head. The STD-NMR spectra 
were acquired with 1024 transients in a matrix with 32K data points in t2 in a spectral window of 
12019.23 Hz centered at 2814.60 Hz. Excitation sculpting with gradients was employed to suppress 
the water proton signals. A spin lock filter (T1ρ) with a 2 kHz field and a length of 20 ms was 
applied to suppress protein background. Selective saturation of protein resonances (on resonance 
spectrum) was performed by irradiating at −300 Hz using a series of 40 Eburp2.1000 shaped 90° 
pulses (50 ms, 1 ms delay between pulses) for a total saturation time of 2.0 s. For the reference 
spectrum (off resonance) the samples were irradiated at 20 000 Hz. Proper control experiments 
were performed with the reference samples in order to optimize the frequency for protein saturation 
(−0.5 ppm) and off resonance irradiation, to ensure that the ligand signals were not affected.  
 
II.5.3.2 Sample Preparation 
For the STD-NMR experiments, the synthesized compounds, ibuprofen, diclofenac, and 
naproxen stock solutions (4 mM) were prepared in DMSO-d6.  
From these, an exact amount to attain the desired concentration was added to the COX solution 
directly in the NMR tube. Then 80 mM Tris-HCl buffer at pH 8.0 was used to adjust the volume to 
200 L. For the binding experiments, the ratio of inhibitors/protein was kept to 100:1. 
 
1. Tris-HCl buffer 80 mM preparation: 80 L of Tris-HCl 1M buffer solution in 920 L D2O. 
2. 4 mM ligand stock solutions were prepared dissolving the corresponding amount ligand in 500 
L of DMSO-d6. 
3. Example for one sample for the STD-NMR ligand-based screening experiment: 15 μL of 
compound stock solution (final concentration: 0.3 mM) and 6 μL COX solution (final 
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concentration: 3 M) were added to 180 μL of buffer solution, mixed and transferred to a 3 mm 
NMR tube. The excess concentration of ligand to protein was 100. 
 
II.5.3.3 STD-NMR Processing 
The spectra processing was made according to the procedure described by Viegas et al.
101
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My contribution to the work was the methodology optimization and the synthesis of the 
majority of the compounds. 
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III.1 Backgroud 
III.1.1 Pegylation 
PEGylation has been one of the most flourishing strategies employed to the delivery of 
therapeutic agents in body, such as oligonucleotides, small drugs, proteins and other biomolecules 
(Figure III.1).
1
 It simply involves the covalent attachment of polyethylene glycol (PEG) polymer 
chains to the target molecules, producing beneficial alterations in the physico-
chemical properties of the medicinal agent while maintaining its pharmacological properties.
  
 
 
Figure III.1. PEG as vehicle for drug delivery. 
Since PEG is a biocompatible, non-toxic and hydrophilic polymer, the modification of a 
biopharmaceutical compound with PEG provides several advantages. The most relevant one is the 
increased water solubility afforded to hydrophobic drugs and proteins allowing its easier 
distribution in the body. Moreover, the increase in the hydrodynamic size of the molecule extends 
its life cycle by reducing the renal excretion. Pegylation can also influence the binding affinity of 
the therapeutic moiety to the cell receptors and can alter the absorption and distribution patterns, 
while protects the agent from the host's immune system contributing for a reduced enzymatic 
degradation, immunogenicity and antigenic reactions.
2
 
All these factors contribute to improve the pharmacokinetics and pharmacodynamic properties 
of many therapeutic agents, fact that leads to a reduced dosage frequency, increased drug stability 
maintaining its efficacy and safety.
2-3
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Several aspects, such as molecular weight, shape, reactivity or type of bond established between 
the therapeutic agent and the PEG moiety are crucial in determining the effect on PEGylated 
molecules. Consequently a wide number of PEG derivatives and PEG conjugation technologies 
were developed, in order to design the best PEGylation strategy for each particular application.
4
 
Pegylation process usually begins by a proper hydroxyl group modification at one or both PEG 
terminals in order to attach the desired target molecule. The choice of the functional group for the 
PEG polymer is based on the type of reactive group on the molecule that will be coupled to the 
PEG. PEGs that are activated at each terminus with the same reactive moiety are usually known as 
“homobifunctional”, whereas if the functional groups present are different, the PEG derivative is 
referred as “heterobifunctional” or “heterofunctional”. 
In contrast with other water soluble biocompatible polymers, the functionality of PEG is usually 
limited to its two chain termini regardless the molecular weight. However, an increased loading 
value is usually needed in order to improve the pharmacokinetic and pharmacodynamic effects of 
therapeutic agents. To this purpose, the preparation of new multifunctional branched PEGs and 
PEG dendrimers of increased molecular masses have been proposed for small drug delivery.
5
 These 
derivatives have enhanced characteristics, reaching higher drug to polymer ratios, shielding the 
bioactive molecule better than a linear PEG of the same size, affording a better protection from 
degradation.
6
  
 
This technology dramatically influences the clinical application of therapeutic biomolecules. 
Consequently, there is a continuously growing number of PEG conjugated drugs on the market 
involving new delivery formats and dosing regimens.
4
  
 
III.1.2 PEG as solid support in heterocyclic compounds synthesis 
Heterocyclic systems represent an important class of compounds in biologically active 
pharmaceuticals, natural products, and materials, and therefore the construction and selective 
functionalization of these molecules is of great interest.
7
 
Due to the imperative urgency to prepare new heterocyclic structures with increased structural 
diversity, solid-phase organic synthesis (SPOS) appeared as a valuable alternative over the 
synthesis in solution.
8
 This methodology simultaneously allows the rapid construction of small 
libraries of complex derivatives and a high-throughput screening. Although the considerable work 
that has been performed optimizing not only the SPOS reaction conditions but also the polymeric 
supports and linkers, it still reveals limitations mainly due to the heterogeneous character of the 
reactions.  
The use of a soluble polymer support in a combinatorial approach tremendously improved 
heterocyclic compounds preparation, overcoming the difficulty of solid-phase synthesis, while 
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maintaining its advantages. Moreover, the use of a soluble polymer support allows the reaction 
monitoring by a simple 
1
H NMR without cleaving the substrate from the resin while avoiding 
special NMR techniques used in SPOS, such as high resolution magic angle spinning NMR 
(HRMAS-NMR).
9 
During the last few years, polyethylene glycol (PEG) was largely used as soluble polymer 
support in several reactions.
10
 Available in a broad range of average molecular weights (the usually 
used vary from 200 to 4000), PEG is a non-toxic, inexpensive, thermally stable and recoverable 
polymer that can be used as a reaction medium or solid-liquid phase transfer catalyst.
10
 Based on 
these properties, it appeared as an environmental friendly alternative to the use of volatile, toxic 
and hazardous organic solvents. In solid phase synthesis, PEG has been described as versatile 
soluble solid support
11
 to assemble oligosaccharides,
12
 nucleotides,
2
 peptides
13
 and heterocycles.
14
 
PEG was initially reported as solid support in peptide synthesis.
15
 It is soluble in water and in 
most organic solvents and can be precipitated with solvents such as hexane or diethyl ether. 
However, due to its water soluble character, inorganic material and organometallic reagents can be 
difficult to remove. In order to improve its robustness while maintaining its properties, some 
grafted copolymers were developed.
 16 
 
 
Scheme III.1. PEG based resins. 
For example, grafting of PEG to divinylbenzene cross-linked polystyrene improves the 
handling, isolation, and purification of PEG. Other examples include TentaGel,
17
 HypoGel or 
ArgoGel resins (Scheme III.1).
18
 These PEG-based resins exhibit good swelling in polar solvents 
also allowing good diffusion of the reagents. Their main disadvantages are the loading capacity and 
the tendency to become sticky and difficult to handle as the synthesis progress. 
In heterocyclic chemistry, PEG-based resins play an important role.
19
 Additionally, the simple 
and cheaper PEG polymer (with different MWs) has been also used to assemble a large variety of 
heterocyclic structures, such as 1,2,4-triazoles,
20
 2,3-dihydro-4-pyridones,
21
 tetrahydro- -
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carbolines,
22
 benzoindolizines,
23
 oxadiazoles,
24
 hydantoin analogs
25
 or benzoimidazoylquinaxoli-
nones (Scheme III.2).
26
 
 
 
Scheme III.2. Heterocyclic structures synthesized on PEG. 
An example of benzimidazoles assembly on PEG was the reported by Sun et al.
27
 In this work 
the benzimidazole moiety is assembled by the classical methods using PEG 6000 as the soluble 
solid support. The process involves the attachment of 4-fluoro-3-nitrobenzoic acid to the solid 
support and subsequent coupling of a primary amine, by nucleophilic aromatic substitution, to 
provide the corresponding nitroarene. Subsequent reduction of nitro group to a primary amine 
followed by cyclization yields the benzimidazole ring. Moreover, microwave-assisted acceleration 
can be utilized in the synthesis process without prejudice for PEG backbone. In fact, Sun and co-
workers adopted a multidisciplinary approach in which a clear comparison between regular and 
microwave conditions was undertaken (Scheme III.3). It was demonstrated that microwave-assisted 
synthesis is very effective on speeding up the reaction, and that the reaction monitoring can be 
easily performed by 
1
H NMR spectroscopy without cleaving the PEG-bound products.
28
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Scheme III.3. Synthesis of benzimidazole library on PEG by Sun et al.27 
The construction of synthetic complex drugs on PEG would be a huge step forward, taking 
advantage of PEG as soluble support (in solid phase synthesis) and as polymeric support for 
pegylated structures. However, until nowadays, and as far is known, there is no reported procedure 
where a small heterocyclic structure is totally assembled in PEG followed by its application as a 
pegylated target. 
 
 
III.1.3 Pd-catalyzed C-N coupling on solid supports 
The aryl amine moiety can be found in a wide variety of heterocyclic compounds, and metal 
catalyzed cross-coupling reactions of anilines with aryl halides constitute the main methods for 
assembling this type of substructure.
29
 In fact, during the last years, there has been a great progress 
in the development of Pd-catalyzed C-N coupling of aryl halides and amines, leading to the 
generation of new ligands and catalytic systems.
30
 Despite using metal amounts below 1 mol %, 
these methods are highly dependent on the substrates and reaction conditions. These facts make the 
cross coupling reactions especially unpredictable, leading in some cases to several side products, 
laborious purifications and poor yields. Thus, a combinatorial approach would be of tremendous 
value, in developing and optimizing these reactions. 
Since a few years ago, PEG has been successfully employed as solvent or integrated in catalytic 
systems for some metal catalyzed reactions, such as olefin metathesis,
31
 hydroxylation,
32
 Suzuki 
and Sonogashira coupling,
33
 Mizoroki–Heck reaction,
34
 hydrogenation 
35
 or oxidations.
36
 PEG was 
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also described as an efficient and reusable soluble support for SPhos, a Buchwald type ligand used 
for Pd-catalyzed cross-couplings.
37
 
The first examples of the Pd-catalyzed amination of aryl halides using solid supports were 
described in the advent of Buchwald-Hartwig amination developments (Scheme III.4). 
 
 
 
Scheme III.4. Previously described arylation on PEG. 38 
In 1996, the procedure was independently described by Ward
38c
 and Willoughby
38b
 who 
immobilized the aryl bromides in different types of resins. Few years later, Weigand performed the 
Pd-mediated amination in an inverted way, immobilizing the amine onto a Rink-resin (Scheme 
III.4).
38a
 
It is noteworthy that a supported copper C-N cross-coupling reaction was also described using 
arylboronic acids in the presence of Cu(OAc)2 using the Wang resin.
39
 
 
Despite the early described Pd-mediated cross-coupling procedures,
38 
it was decided to 
investigate the possibility of using PEG 2000 as a soluble polymeric support for the preparation of 
arylated heteroarenes. To the best of our knowledge, so far, PEG has not been employed in this 
cross-coupling reactions acting as solvent and polymeric support for the halide substrate. 
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III.2 Results and discussion 
By considering the solubility profile and loading capacity of several polymer derivatives, PEG 
of average molecular weight 2000 was chosen as the polymer support for the synthetic protocol. 
Moreover, this PEG derivative was also previously reported as ideal solid support for the 
assembling of heterocyclic structures.
40 
 
III.2.1 Optimization studies 
The preparation of the PEG bound aryl halides (III.5-III.8), was performed by a standard 
esterification, activating the corresponding benzoic acid halide (2 equiv/PEGterminal) with DIC in 
DMF followed by addition of PEG 2000 and DMAP (Scheme III.5). Completeness of the coupling 
was monitored by the conventional 
1
H NMR. 
 
 
Scheme III.5. Preparation of PEG bound aryl halides (III.5-III.8). 
The reaction work-up involved a simple filtration over a celite pad in order to remove the 
formed diisopropylurea. The product was easily obtained by precipitation with cold diethyl ether 
followed by filtration and washing with an additional amount of cold diethyl ether to remove the 
remaining DMF. The compounds (III.5-III.8) were obtained in quantitative yield as white solids, 
and characterized by IR and NMR techniques. 
 
In order to optimize the reaction conditions, the p-chloro arylated PEG derivative (III.6) was 
reacted with aniline, employing different ligands and solvents as well as using solvent-free 
conditions, under a range of temperatures and reaction times (Table III.1). 
In 2005, Buchwald et al. reported the coupling of several anilines to 4,5-dichlorophthalimide 
derivatives using XPhos/Pd2dba3 in the presence of Cs2CO3.
41
 Interestingly, the amination reaction 
employing 4-nitroaniline as the nucleophile did not proceeded using Cs2CO3 or K3PO4 requiring the 
use of a weaker base such as K2CO3. The group also reported similar procedures. 
Inspired by this work, the ligand optimization was performed using Pd2dba3 as the palladium 
source, using 
t
BuOH as solvent. Consequently, several ligands (Figure III.2) were tested while 
maintaining the catalyst loading (1 mol% Pd and 3 mol% of ligand) (Table III.1 – entries 1 to 5).  
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Figure III.2. Ligands used in the optimization of Pd-catalyzed amination on PEG. 
 
Gladly, the use of Pd2dba3 and Buchwald ligands,
30c
 RuPhos, XPhos and BrettPhos, afforded the 
product (III.9) in good to excellent yields (Table III.1 – entries 3 to 5). It was observed that BINAP 
and XantPhos were unsuccessful for this type of reaction, as the reaction did not occur.  
Since XPhos gave the best results, this ligand was further used to investigate the adequate 
solvent. In this case, it was verified that 
t
BuOH, dioxane or toluene, were sufficient to lead the 
reaction to completion (Table III.1 – entries 5 to 7). 
 
Table III.1 Influence of the reaction conditions for palladium catalyzed direct coupling of PEG bound aryl 
chloride III.6 with aniline.a 
 
 
 
Entry Ligand Solvent Reaction time (h) Temp. (ºC) III.9 (%) b 
1 BINAP tBuOH 18 110 0 
2 Xantphos tBuOH 18 110 0 
3 BrettPhos tBuOH 18 110 83 
4 RuPhos tBuOH 18 110 66 
5 XPhos tBuOH 18 110 Quant. 
6 XPhos dioxane 18 110 Quant. 
7 XPhos toluene 18 110 Quant. 
8 XPhos --- 18 110 Quant. 
9 XPhos tBuOH 4 110 Quant. 
10 XPhos tBuOH 18 65 0 
11 XPhos --- 8 110 94 
12 XPhos --- 4 110 90 
a reaction conditions: Pd2dba3 (1 mol%), ligand (3 mol%), K2CO3 (1.4 equiv), aniline (1.4 equiv), solvent (0.25 M) in a 
sealed tube under an argon atmosphere. b Verified by 1H NMR. 
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PEG was already described as an alternative medium in several reactions,10  thus a solvent-free 
trial was also performed. Fortunately, the reaction proceeded to completion in the absence of 
solvent (Table III.1 - entry 8).  
The temperature and reaction time were also investigated. It was verified that after 20 h the 
product was obtained in quantitative yield. The decrease of the reaction time to 8 h or 4 h did not 
have a strong impact in the yield, since III.9 was obtained in 94 % and 90 % yield, respectively 
(Table III.1 - entries 11 and 12). 
 
The reaction could be easily monitored by IR, 
1
H or 
13
C NMR, as demonstrated in Figure III.3. 
In the IR spectrum it was observed a band shift of the corresponding carbonyl group of III.6 that 
shifted from 1718 cm
-1
 to 1702 cm
-1
, matching the carbonyl group of III.9.  
This product could also be identified by 
1
H NMR since the CH2 signals corresponding to the 
inner chain of PEG resin appeared as a multiplet at 3.63 ppm, and the CH2 signals corresponding to 
the ethylene chain direct linked to the benzyl moiety appear respectively at 4.43 and 3.80 ppm. The 
coupling product appears very clearly in the aromatic region (Figure III.4). 
 
 
Figure III.3. IR spectra of a) PEG bound aryl chloride (III.6) and b) amination product (III.9). 
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Figure III.4. 
1H NMR of III.9 (Table III.1, entry 5). 
 
 
III.2.2 Pd-catalyzed amination of arylated PEG substrates with substituted anilines 
Following the optimization condition study, we further investigated the solvent-free Pd-
catalyzed amination using different chloro and bromo arylated PEG substrates with several 
substituted anilines (Table III.2). 
Amination of p-chloro arylated PEG substrate with several anilines, led to the corresponding 
products (III.10-III.13) with good to excellent yields under the studied conditions (Table III.2 – 
entries 1 to 4). As expected, the same behavior was observed for the p-bromo arylated PEG 
compound, either with aniline or with the deactivated p-nitro aniline (Table III.2 – entries 5 and 6). 
However, o-bromo substrates revealed to be more difficult to react than the previous substrates, 
fact that can be explained by steric hindrance (Table III.2 – entries 7 to 10). The amination reaction 
with aniline performed in 8 h, rendered 50% conversion that was increased up to 66% when the 
reaction was performed in 20 h (Table III.2 – entry 7). Moreover, the PEG-bounded m-haloarenes 
were also screened and afforded the corresponding products in high yield (Table III.2 – entries 11 
and 12).  
In the experiments in which quantitative yields were not achieved, the unreacted starting 
material was recovered along with the reaction product. 
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Table III.2. Scope of palladium catalyzed direct coupling of PEG bound aryl halides with several anilines.a 
 
 
Entry Ar-X ArNH2 Compound (%)
b Entry Ar-X ArNH2 Compound (%)
b 
1 p-Cl 
 
III.10 (100) 7 o-Br 
 
III.15  
(50, 66c) 
2 p-Cl 
 
III.11 (89) 8 o-Br 
 
III.16 (40) 
3 p-Cl 
 
III.12 (100) 9 o-Br 
 
III.17 (50) 
4 p-Cl 
 
III.13 (100) 10 o-Br 
 
III.18 (80c) 
5 p-Br 
 
III.9 (100) 11 m-Cl 
 
III.19 (100) 
6 p-Br 
 
III.14 (90) 12 m-Cl 
 
III.20 (70) 
a reaction conditions: Pd2dba3 (1 mol%), XPhos (3 mol%), K2CO3 (1.4 equiv), aniline (1.4 equiv), in a sealed 
tube under an N2 atmosphere, 110ºC, 8 h. 
b Verified by 1H NMR. c Reaction performed in 20 h. 
 
It is also important to refer the work-up procedure of this cross-coupling reaction on a soluble 
solid support. The recovery of the PEG-bound structures consisted on the filtration of the reaction 
mixture to remove the inorganic salts followed by product precipitation with cold diethyl ether. The 
product was then thoroughly washed with diethyl ether to remove the amine excess, the catalyst 
and the ligand. Some structures were difficult to precipitate, forming a viscous slurry that, in these 
particular cases, made the work-up a delicate and time consuming task. 
 
 
 
Scheme III.6. Cleavage of PEG-bound compounds from the polymer. 
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Detachment of the compounds from the solid support could be easily handled by treatment with 
potassium cyanide in methanol, according to the reported procedure.
17
 This trans-esterification 
method is proved to be simple and efficient, affording the products in high yields and purity. Thus, 
in order to test the cleavage conditions in our system, some compounds (III.9, III.10 and III.12) 
were subjected to the reported conditions (KCN, MeOH, room temperature, overnight)
17a
 and, as 
expected, the corresponding methyl esters (III.21-III.23) were obtained in quantitative yields 
(Scheme III.6). 
 
 
III.2.3 Pd-catalyzed amination of arylated PEG substrates with alkyl amines 
The Pd-catalyzed amination on PEG using alkyl amines was also investigated, as described in 
Tables III.3 and III.4. 
Initial trials using benzylamine and piperidine showed that the general conditions applied to 
anilines could not be employed for aliphatic amines (Table III.3). 
 
Table III.3. Optimization of reaction conditions of palladium catalyzed direct coupling of PEG bound 
aryl halides with benzylamine and piperidine.a 
 
 
 
Entry X Amine Ligand Base Reaction time (h) Yield (%) b 
1 p-Cl benzylamine XPhos K2CO3 20 0 
2 p-Cl piperidine XPhos Cs2CO3 20 0 
3 p-Cl benzylamine BrettPhos c Cs2CO3 20 0 
4 p-Cl piperidine BINAP Cs2CO3 20 0 
5 p-Br piperidine XPhos Cs2CO3 20 0 
6 p-Br piperidine BINAP Cs2CO3 20 100 
7 p-Br benzylamine BINAP Cs2CO3 20 100 
8 p-Br benzylamine BINAP Cs2CO3 8 100 
a reaction conditions: Pd2dba3 (1 mol%), ligand (3 mol%), base (1.4 equiv), amine (1.4 equiv) in a sealed tube 
under an N2 atmosphere at 110ºC. 
b Verified by 1H NMR. c BrettPhos precatalyst as Pd source. 
 
It was observed that the chlorinated derivatives did not undergo the desired amination reaction, 
although several catalytic systems already described for amination of halo-arenes with aliphatic 
amines (in solution) were employed (Table III.3, entries 1 – 4). Systems like Pd2dba3/Xphos/K2CO3 
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(entry 1), Pd2dba3/Xphos/Cs2CO3 (entry 2), Brettphos system/Cs2CO3 (entry 3) or 
Pd2dba3/BINAP/Cs2CO3 (entry 4), were unsuccessful.
42
 
However, for bromine derivatives, while XPhos was ineffective as ligand (Table III.3 – entry 5), 
the system that used BINAP was successful (Table III.3 – entries 6 and 7).
42a
 The reaction 
proceeded in high yield using pegylated bromine arenes, BINAP as ligand and Cs2CO3 as base. 
Moreover, it was verified that for benzylamine the reaction occurred in 8 h in quantitative yield 
(Table III.3 – entry 8). 
After the initial screening, the reaction scope was extended to other amines and PEG bound 
halides. It was verified that the reaction worked nicely with some primary and secondary amines, 
such as benzylamine, piperidine, and pyrrolidine. However, the experiments performed proved the 
failure of this reaction for the studied amines (Table III.4). For pyrrolidine, it was also observed 
full conversion after 8 h of reaction. Attempts using aromatic amines, such as imidazole or pyrrole 
were unsuccessful.  
 
Table III.4. Scope of palladium catalyzed direct coupling of PEG bound aryl halides with several aminesa 
 
 
 
 
Entry Ar-X R2NH Compound (%)
b Entry Ar-X R2NH Compound (%)
b 
1 p-Br 
 
III.24 (100) 5 o-Br 
 
-- 
2 p-Br 
 
III.25 (100) 6 o-Br 
 
f 
3 p-Br 
 
III.26 (50, 100c) 7 o-Br 
 
e 
4 p-Br 
 
-- 8 m-Br 
 
e 
a reaction conditions: Pd2dba3 (1 mol%), ligand (3 mol%), Cs2CO3 (1.4 equiv), aniline (1.4 equiv), in a sealed 
tube under an N2 atmosphere, 110ºC, 8 h. 
b Verified by 1H NMR. c Reaction performed in 20 h. d Starting 
material. e NMR spectra inconclusive. f Hydrolysis. 
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III.2.4 Pd-catalyzed amination of arylated PEG substrates with hydrazines 
The Pd-catalyzed amination on PEG was also explored with arylhydrazines, since these 
molecules can produce valuable intermediates in heterocyclic synthesis. Several reports describe 
the Pd-catalyzed aminations of haloarenes with N,N-disubstituted hydrazines using different 
catalytic systems (Scheme III.7). 
 
 
Scheme III.7. Reported studies on coupling of hydrazines with aryl halides.43 
Since the first report by Koie and co-workers of Pd(OAc)2/P(
t
Bu)3 system in Pd-catalyzed 
amination of aryl chlorides,
44
 its use have been commonly reported for arylamination reactions 
involving hydrazines (Scheme III.7 – a, b).
43a,b
  
Liu et al. described the amination of bromo arenes with N,N-dialkylhydrazines using 
Pd2(dba)3/P(
t
Bu)3 as the catalyst system (Scheme III.7 – c).
43c
 The base optimization revealed that 
strong bases such as KOtBu were effective, although functional groups were less tolerated. Both 
K2CO3 and K3PO4 demonstrated to be suitable bases. However, Cs2CO3 provided the best yield. 
Other studies include the use of Pd2dba3/XPhos in the presence of NaO
t
Bu and despite K3PO4 could 
be used without big loss of activity, the use of Cs2CO3 proved to be unsuccessful (Scheme III.7 – 
d).
43d
 
 
In our study, the amination of PEG bound bromo arenes with arylhydrazines was attempted 
using the Pd2dba3/XPhos system and K3PO4 as base. However, the system proved to be inadequate 
to the studied arylhydrazines (Table III.5). In some cases, it was possible to recover the starting 
material (entries 1 and 4), whereas in other experiments the NMR spectra revealed complex 
reaction mixtures (entries 2 and 3). 
Once more, the precipitation of these derivatives with cold diethyl ether was very difficult, 
yielding gummy (and certainly impure) products. This fact led to a difficult interpretation of the 
NMR spectra. 
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Table III.5. Scope of Pd-catalyzed direct coupling of PEG bound aryl halides with some hydrazines.a 
 
 
 
Entry Ar-X ArNH2 Yield (%)
b Entry Ar-X ArNH2 Yield (%)
b 
1 p-Cl 
Phenyl 
hydrazine 
--c 4 p-Br 
N, N-methyl 
hydrazine 
--c 
2 p-Br 
Phenyl 
hydrazine 
--d 5 p-Br Hydrazine --c  
3 p-Br 
4-nitophenyl 
hydrazine  
--d 6 p-Br 
Benzophenone 
hydrazone 
100 
a Reaction conditions: Pd2dba3 (2 mol%), XPhos (3 mol%), K3PO4 (1.4 equiv.), amine  (1.2 equiv.), in a sealed 
tube under an N2 atmosphere, 80ºC, 20 h. 
b Verified by 1H NMR. c Starting material. d NMR spectra 
inconclusive. 
 
The amination of PEG bound bromo arene using hydrazine and benzophenone hydrazone was 
also explored (Table III.5 – entries 5 and 6). 
In 2010, Lundgren and Stradiotto reported a palladium based catalytic system and reaction 
conditions that allowed, for the first time, the cross-coupling of aryl chlorides and tosylates with 
hydrazine.
45
  More recently, Stradioto group also reported the monoarylation of hydrazine using a 
new BippyPhos/[Pd(cinnamyl)Cl]2 system.
46
 However, the reported conditions are highly 
dependent of the catalytic system, fact that could hamper the reaction scope broadening. Very 
recently, Buchwald describes the coupling of hydrazine with chloro derivatives using several 
ligands, in which BrettPhos precatalyst proved to be the best catalytic system.
47
 
Unfortunately, the cross-coupling with hydrazine was only attempted using the PEG bound 
bromo derivative, expecting a higher reactivity (entry 5). However, from the reported literature, it 
seems that the reaction is only efficient for chlorine derivatives. Moreover, the use of BrettPhos 
system can be the best choice for this reaction on PEG. 
 
The Pd-catalyzed arylation of benzophenone hydrazone can furnish arylhydrazines that are 
valuable synthetic intermediates, e.g. Fisher indolization. In the last years, several groups reported 
cross-coupling procedures involving benzophenone hydrazone.
48
 
Thus, it was examined the cross-coupling reaction of PEG p-Br arene with benzophenone 
hydrazone using the Pd2dba3/XPhos/K3PO4 system. As expected, using phenylhydrazone the 
reaction was effective yielding the product in quantitative yield.  
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III.2.5 Preliminary studies to assemble benzimidazoles on PEG using the Pd catalyzed 
strategy 
In order to assemble the benzimidazole structure on PEG taking advantage of the above 
described procedure and using the key intermediate (II.56) synthesized in Chapter II, some 
preliminary tests were made. 
In a first approach it was envisioned that the reaction of the corresponding PEG alkoxide 
(formed with NaH in DMF) with the oxindole under refluxing conditions, would give the PEG 
bound intermediate to further functionalization (Scheme III.8). However this approach was 
unsuccessful. 
 
Scheme III.8. Preliminary attempts to construct benzimidazoles on PEG. 
Due to the failure of these preliminary studies, further experiments were performed to attach the 
key intermediate II.56 (see Chapter II) to PEG. 
Thus, the tosylated PEG derivative (III.28) was synthesized in order to directly bind the acid 
II.56. Compound III.28 was easily synthesized in DCM with tosyl chloride in the presence of TEA 
and DMAP (Scheme III.9). 
 
 
Scheme III.9. Synthesis of tosylated derivative III.28. 
Hence, it was attempted to achieve compound III.29 by nucleophilic attack of the carboxylate 
of compound II.56 to III.28, in the presence of Cs2CO3. However, the 
1
H NMR of the crude 
mixture revealed that the major compound was the unreacted PEG polymer, only containing a trace 
amount of PEG-bound product (Scheme III.10). This observation could be attributed to the 
presence of hydrogen bridges between the acid and the nitro group, which makes the carboxylate 
less reactive, thus hindering the reaction. 
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Scheme III.10. Coupling failure using intermediate II.56. 
Thus, it was used the amine derivative II.37 (see Chapter II), that was reacted with PEG in the 
presence of Cs2CO3 to afford compound III.30 (Scheme III.11). However, this product was very 
difficult to precipitate (even using other solvents such as pentane or hexane) being obtained a 
brown slurry. This fact could be attributed to the increase of the organic character of the molecule 
or due to some impurities retained in the polymeric structure that prevents the polymer to 
precipitate. After several washing steps with cold diethyl ether, a small portion of a light brown 
solid was attained to further characterization of compound III.30. 
 
  
 
Scheme III.11. Envisioned strategy to prepare compound III.32. 
Due to the difficult product precipitation, it was envisioned the synthetic progress to N-
benzoylated compound III.31 with the compound mixture. Thus, the reaction was repeated and the 
compound III.30 slurry was dissolved in THF and reacted with benzoyl chloride in the presence of 
TEA. Even though the 
1
H NMR of the crude mixture revealed the N-benzoylation product (along 
other side products) once more the product could not be precipitated as a solid. 
Despite the mixture obtained, the next step was attempted. The slurry corresponding to 
compound III.31 was further subjected to cross coupling conditions, but in this case the 
1
H NMR 
showed a complex mixture of compounds along with free PEG since the intensity of the aromatic 
signals decreased. 
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III.3 Conclusions 
In order to construct the benzimidazole structures on PEG and obtain a pegylated library, it is 
necessary to overcome the precipitation issues observed in the preliminary experiments. The use of 
a PEG polymer with an increased molecular weight, such as PEG 6000, can surpass the lower 
MWs PEG derivatives while maintaining the same synthetic properties. 
 
 
 
Scheme III.12. Proposed retrosynthetic approach to attain the desired PEG bound benzimidazoles. 
On the other hand, it would be highly valuable the use of the key intermediate II.56 containing 
the nitro group, due to its enhanced properties towards the Pd-catalyzed cross-coupling reaction. 
Despite the demonstrated issues related to its coupling to PEG, an optimization stage can have a 
successful outcome. An alternative strategy to attain pegylated benzimidazoles is depicted in 
Scheme III.12. 
Having the compound III.29 in hands, the Pd-catalyzed amination would be a successful task to 
attain compound III.37. A critical step could be the reduction of nitro group to amine (to obtain 
III.36) and an exhaustive screening of reaction conditions could be necessary in this synthetic 
stage. The next step involves the benzoylation of III.36 that can be performed under basic 
conditions to obtain III.35. It is noteworthy, that the absence of base will promote both ring closing 
and the detachment of the benzimidazole from the polymer. However in this last case the 
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corresponding ester derivatives would not be achieved. Thus, in order to attain the benzimidazole 
bound to PEG (III.33) a careful analysis of reaction conditions need to be studied. The synthesized 
benzimidazoles (III.34) could be further detached from PEG using the transesterification procedure 
under MeOH/KCN conditions.  
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III.4 Experimental 
III.4.1 General Information: 
All commercially obtained reagents were used without further purification unless specified. 
PEG 2000 was purchased from Fluka as white flakes. Pyrrolidine, aniline, 2,5-dimethylaniline were 
previously distilled. Isopropanol was dried by usual methods. 
NMR spectra (400 MHz for 
1
H and 100 MHz for 
13
C) were recorded with a Brucker ARX 400 
spectrometer using CDCl3 as solvent using the corresponding CHCl3 signal as reference. IR spectra 
were recorded using a Perkin‐Elmer Spectrum 1000 FT‐IR. The IR bands are classified as strong 
(s), medium (m), or weak (w). 
 
 
 
III.4.2 General procedure for the preparation of PEG supported aryl halides: 
To the corresponding benzoic acid halide (4 equiv) in DMF (0.25 M) was added DIC (4 equiv) 
and the solution was stirred for 30 min. at room temperature. Then it was added PEG 2000 (1 
equiv) and DMAP (0.4 equiv). The mixture was stirred at 50ºC overnight. The mixture was filtered 
over a celite pad in order to remove the formed urea and the solution was placed in an ice bath. The 
product was precipitated by the addition of cold diethyl ether. The product was filtered and washed 
several times with cold diethyl ether in order to remove the DMF. The products were obtained as 
white solids and were vacuum dried and stored in a desiccator. The products were obtained in 
quantitative yield, and characterized by IR and NMR spectra. 
 
 
III.4.2.1 PEG-bis(4-bromobenzoate) (III.5) 
 
IR (KBr) νmax (cm
‐1
): 2872 (m), 1720 (s, C=O), 1105 (m); 
1
H NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 8.5 Hz, ArH, 4H), 7.57 (d, J = 8.5 Hz, ArH, 4H), 
4.47 – 4.44 (m, CH2 PEG, 4H), 3.83 – 3.63 (m, CH2 PEG, 192H); 
13
C NMR (100 MHz, CDCl3) : 165.9 (C=O), 131.8 (CAr), 131.4 (CAr), 129.1 (C-q), 128.2 
(C-q), 70.8 (CH2 PEG), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 69.2 (CH2 PEG), 64.5 (CH2 PEG). 
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III.4.2.2 PEG-bis(4-chlorobenzoate) (III.6) 
 
IR (KBr) νmax (cm
‐1
): 2875 (m), 1718 (s, C=O), 1638 (m), 1104 (m); 
1
H NMR (400 MHz, CDCl3) : 7.98 (d, J = 8.5 Hz, ArH, 4H), 7.41 (d, J = 8.5 Hz, ArH, 4H), 
4.47 – 4.44 (m, CH2 PEG, 4H), 3.83 – 3.45 (m, CH2 PEG, 216H); 
13
C NMR (100 MHz, CDCl3) :
 
165.8 (C=O), 139.5 (C-q), 131.2 (C-Ar), 128.8 (C-Ar), 128.7 
(C-q), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 70.7 (CH2 PEG), 69.3 (CH2 PEG), 64.4 (CH2 PEG). 
 
 
III.4.2.3 PEG-bis(4-chlorobenzoate) (III.7) 
 
IR (KBr) νmax (cm
‐1
): 2836 (m), 1730 (s, C=O), 1655 (m), 1114 (m); 
1
H NMR (400 MHz, CDCl3)  7.79 (dd, J = 7.5, 1.9 Hz, ArH, 2H), 7.63 (dd, J = 7.7, 1.4 Hz, 
ArH, 2H), 7.36 – 7.28 (m, ArH, 4H), 4.47 – 4.44 (m, PEG, 4H), 3.81 – 3.43 (m, PEG, 190H); 
13
C NMR (100 MHz, CDCl3) : 166.1 (C=O), 134.3 (CAr), 132.6 (CAr), 132.1 (CAr), 131.5 
(CAr), 127.2 (CAr), 121.7 (CAr), 70.7 (CH2 PEG), 70.6 (CH2 PEG), 70.6 (CH2 PEG), 69.0 (CH2 
PEG), 64.6 (CH2 PEG). 
 
 
III.4.2.4 PEG-bis(3-chlorobenzoate) (III.8) 
 
IR (KBr) νmax (cm
‐1
): 2882 (m), 1723 (s, C=O), 1467 (m), 1115 (m); 
1
H NMR (400 MHz, CDCl3) δ: 7.90 (m, ArH, 2H), 7.88 (d, J = 7.8 Hz, ArH, 2H), 7.49 – 7.47 
(m, ArH, 2H), 7.34 (t, J = 7.9 Hz, ArH, 2H), 4.48 – 4.46 (m, CH2 PEG, 4H), 3.78 – 3.59 (m, PEG, 
208H). 
13
C NMR (100 MHz, CDCl3) δ: 165.3 (C=O), 134.4 (C-q), 133.0 (CAr), 131.8 (C-q), 129.7 
(CAr), 129.7 (CAr), 127.8 (CAr), 70.6 (CH2 PEG), 70.6 (CH2 PEG), 70.5 (CH2 PEG), 69.0 (CH2 
PEG), 64.4 (CH2 PEG). 
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III.4.3 General procedure for Pd-catalyzed amination on PEG 
To a screw-cap test-tube equipped with a magnetic stir bar, was added the PEG supported aryl 
halide (0,1 mmol), Pd2dba3 (1 mol %), ligand (3 mol %) and base (1.4 equiv). The vial was sealed 
with a suba-seal, evacuated and backfilled with argon. Then was added the amine (1.4 equiv) and 
the suba-seal was replaced by the teflon screw-cap. The reaction mixture was heated at the desired 
temperature for 8 h (aryl amines) or 20 h (alkyl amines) (see tables). The solution was allowed to 
cool to room temperature, dissolved with dried isopropanol and filtered over a celite pad. The 
solution was placed in an ice bath and the product was precipitated by the addition of cold diethyl 
ether. The product was washed several times with cold diethyl ether. The obtained product was 
dried over vacuum and stored in a desiccator. 
 
III.4.3.1 PEG-bis(4-(phenylamino)benzoate) (III.9) 
 
IR (KBr) νmax (cm
‐1
): 2873 (m), 1705 (s, C=O), 1591 (m), 1104 (m); 
1
H NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 8.8 Hz, ArH, 4H), 7.31 (t, J = 7.9 Hz, ArH, 4H), 
7.17 (d, J = 7.6 Hz, ArH, 4H), 7.03-7.00 (m, ArH, 6H), 4.43 – 4.41 (m, CH2 PEG, 4H), 3.82 – 3.63 
(m, CH2 PEG, 218H); 
13
C NMR (100 MHz, CDCl3) δ: 166.5 (C=O), 148.2 (C-q), 141.1 (C-q), 131.7 (CAr), 129.5 
(CAr), 123.1 (CAr), 120.9 (CAr), 120.4 (CAr), 114.8 (CAr), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 
70.6 (CH2 PEG), 69.5 (CH2 PEG), 63.8 (CH2 PEG). 
 
III.4.3.2 PEG-bis(4-(3-(trifluoromethyl)phenylamino)benzoate) (III.10) 
 
IR (KBr) νmax (cm
‐1
): 2873 (m), 1706 (s, C=O), 1596 (m); 
1
H NMR (400 MHz, CDCl3) : 7.96 (d, J = 8.6 Hz, ArH, 4H), 7.40 – 7.39 (m, ArH, 6H), 7.23 
(d, J = 7.5 Hz, ArH, 2H), 7.07 (d, J = 8.7 Hz, ArH, 4H), 4.45 – 4.42 (m, CH2 PEG, 4H), 3.82 – 3.60 
(m, CH2 PEG, 215H); 
13
C NMR (100 MHz, CDCl3) : 166.3 (C=O), 147.2 (C-q), 142.2 (C-q), 131.8 (CAr), 130.1 
(CAr), 122.3 (CAr), 122.1 (C-q), 118.8 (CAr), 115.8 (CAr), 115.6 (CAr), 70.9 (CH2 PEG), 70.8 
(CH2 PEG), 70.7 (CH2 PEG), 69.5 (CH2 PEG), 63.9 (CH2 PEG). 
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III.4.3.3 PEG-bis(4-(3-nitrophenylamino)benzoate) (III.11) 
 
1
H NMR (400 MHz, CDCl3) : 8.00 – 7.97 (m, ArH, 6H), 7.79 (d, J = 7.8 Hz, ArH, 2H), 7.49 
– 7.39 (m, ArH, 4H), 7.13 (d, J = 8.7 Hz, ArH, 4H), 4.46 – 4.43 (m, CH2 PEG, 4H), 3.83 – 3.59 (m, 
CH2 PEG, 192H). 
13
C NMR (100 MHz, CDCl3) : 166.2 (C=O), 149.4 (CAr), 146.5 (CAr), 143.2 (CAr), 131.8 
(CAr), 130.3 (CAr), 124.2 (CAr), 122.8 (CAr), 116.3 (CAr), 116.2 (CAr), 112.8 (CAr), 70.9 (CH2 
PEG), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 69.4 (CH2 PEG), 64.0 (CH2 PEG). 
 
 
III.4.3.4 PEG-bis(4-(3-fluorophenylamino)benzoate) (III.12) 
 
IR (KBr) νmax (cm
‐1
): 2871 (m), 1705 (s, C=O), 1597 (m), 1106 (m); 
1
H NMR (400 MHz, CDCl3) : 7.94 (d, J = 8.7 Hz, ArH, 4H), 7.26 – 7.21 (m, ArH, 2H), 7.06 
(d, J = 8.7 Hz, ArH, 4H), 6.93 – 6.87 (m, ArH, 4H), 6.68 (td, J = 8.5, 2.1 Hz, ArH, 2H), 4.44 – 4.42 
(m, CH2 PEG, 4H), 3.82 – 3.60 (m, CH2 PEG, 210H); 
13
C NMR (100 MHz, CDCl3) : 166.4 (C=O), 163.7 (d, J = 245.0 Hz, C-q), 147.3 (C-q), 143.2 
(d, J = 10.3 Hz, C-q), 131.7 (2x CAr), 130.6 (d, J = 9.8 Hz, CAr), 121.8 (C-q), 115.6 (2x CAr), 
114.8 (d, J = 2.7 Hz, CAr), 109.0 (d, J = 21.3 Hz, CAr), 106.2 (d, J = 24.5 Hz, CAr), 70.9 (CH2 
PEG), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 69.5 (CH2 PEG), 63.9 (CH2 PEG).  
 
 
III.4.3.5 PEG-bis(4-(3-hydroxyphenylamino)benzoate) (III.13) 
 
IR (KBr) νmax (cm
‐1
): 2873 (m), 1702 (s, C=O), 1596 (m), 1105 (m). 
1
H NMR (400 MHz, CDCl3) : 7.89 (d, J = 8.7 Hz, ArH, 4H), 7.11 (t, J = 8.0 Hz, ArH, 2H), 
7.03 (d, J = 8.7 Hz, ArH, 4H), 6.73 – 6.68 (m, ArH, 4H), 6.52 (dd, J = 8.1, 1.7 Hz, ArH, 2H), 4.43 
– 4.41 (m, CH2 PEG, 4H), 3.81 – 3.58 (m, CH2 PEG, 220H); 
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13
C NMR (100 MHz, CDCl3) : 166.6 (C=O), 158.0 (C-q), 148.5 (C-q), 142.4 (C-q), 131.6 (2x 
CAr), 130.2 (CAr), 120.5 (C-q), 114.9 (CAr), 111.4 (CAr), 110.2 (CAr), 107.4 (CAr), 71.0 (CH2 
PEG), 70.8 (CH2 PEG), 70.6 (CH2 PEG), 69.5 (CH2 PEG), 63.8 (CH2 PEG). 
 
III.4.3.6 PEG-bis(4-chlorobenzoate) (III.14) 
 
Obs. Product did not precipitate with diethyl ether. It was only observed by 
1
H NMR along with 
the p-nitro aniline and unreacted starting material. 
1
H NMR (400 MHz, CDCl3) : 8.06 (d, J = 9.1 Hz, ArH, 4H), 7.93 (d, J = 8.6 Hz, ArH, 4H), 
7.31 (d, J = 8.7 Hz, ArH, 4H), 7.27 (m, ArH, 4H), 4.42 – 4.40 (m, CH2 PEG, 4H), 3.80 – 3.57 (m, 
CH2 PEG, 218H); 
13
C NMR (100 MHz, CDCl3) : 166.2 (C=O), 131.3 (CAr), 131.2 (CAr), 125.8 (CAr), 125.8 
(CAr), 118.2 (CAr), 115.7 (CAr), 70.6 (CH2 PEG), 70.3 (CH2 PEG), 69.3 (CH2 PEG), 63.8 (CH2 
PEG). 
 
III.4.3.7 PEG-bis(2-(phenylamino)benzoate) (III.15) 
 
Obs. It was observed by 
1
H NMR along with the unreacted starting material. 
1
H NMR (400 MHz, CDCl3) : 9.40 (s, NH, 2H), 7.99 (d, J = 8.1 Hz, ArH, 2H), 7.34 –7.26 (m, 
ArH, 12H), 7.08 (t, J = 7.4 Hz, 2H), 6.72 (t, J = 7.4 Hz, 2H), 4.46 (m, CH2 PEG, 4H), 3.84 – 3.45 (m, 
CH2 PEG, 300 H). 
 
III.4.3.8 PEG-bis(2-((3-hydroxyphenyl)amino)benzoate) (III.17) 
 
Obs. It was observed by 
1
H NMR along with the unreacted starting material. 
1
H NMR (400 MHz, CDCl3) : 9.19 (s, NH, 2H), 7.93 (t, J = 6.6 Hz, ArH, 2H), 7.36-7.21 (m, 
6H), 7.10 – 7.03 (m, 2H), 6.76 (s, ArH, 2H), 6.65 – 6.53 (m, 4H), 4.53 – 4.41 (m, CH2 PEG, 4H), 
3.88 – 3.48 (m, CH2 PEG, 254 H). 
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III.4.3.9 PEG-bis(2-((3-fluorophenyl)amino)benzoate) (III.18) 
 
Obs. It was observed by 
1
H NMR along with the unreacted starting material. 
1
H NMR (400 MHz, CDCl3) : 9.45 (s, NH, 2H), 8.00 (d, J = 8.0 Hz, ArH, 2H), 7.34 –7.26 (m, 
ArH, 6H), 6.99–6.76 (m, ArH, 4H), 6.81–6.72 (m, ArH, 4H), 4.46 (t, J = 11.0, 6.4 Hz, CH2 PEG, 
4H), 3.84 – 3.45 (m, CH2 PEG, 246 H); 
13
C NMR (100 MHz, CDCl3) : 168.3 (C=O), 163.6 (d, J = 245.3 Hz, CAr), 146.9 (CAr), 
142.9 (d, J = 10.2 Hz, CAr), 134.3 (CAr), 132.0 (CAr), 130.6 (d, J = 9.8 Hz, CAr), 118.2 (CAr), 
117.2 (d, J = 2.7 Hz, CAr), 114.7 (CAr), 113.0 (CAr), 109.8 (d, J = 21.3 Hz, CAr), 108.3 (d, J = 
23.9 Hz, CAr), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 70.7 (CH2 PEG), 69.3 (CH2 PEG), 64.0 (CH2 
PEG). 
 
 
III.4.3.10 PEG-bis(3-(2,5-dimethylphenylamino)benzoate) (III.19) 
 
1
H NMR (400 MHz, CDCl3) : 7.56 – 7.52 (m, ArH, 4H), 7.26 (m, ArH, 2H), 7.10 – 7.03 (m, 
ArH, 6H), 6.80 (d, J = 7.5 Hz, ArH, 2H), 4.46 – 4.43 (m, CH2 PEG, 4H), 3.82 – 3.64 (m, CH2 PEG, 
250H), 2.27 (s, CH3, 6H), 2.19 (s, CH3, 6H); 
13
C NMR (100 MHz, CDCl3) : 166.8 (C=O), 144.8 (CAr), 140.3 (CAr), 136.7 (CAr), 131.3 
(CAr), 131.0 (CAr), 129.3 (CAr), 126.5 (CAr), 123.9 (CAr), 121.2 (CAr), 120.8 (CAr), 120.8 
(CAr), 118.0 (CAr), 70.8 (CH2 PEG), 70.7 (CH2 PEG), 69.4 (CH2 PEG), 64.3 (CH2 PEG), 21.3 
(CH3), 17.6 (CH3). 
 
 
 
 
 
III. Experimental 
172 
 
III.4.3.11 PEG-bis(3-((3-(trifluoromethyl)phenyl)amino)benzoate) (III.20) 
 
 
1
H NMR (400 MHz, CDCl3) : 7.76 (s, ArH, 2H), 7.64 (d, J = 7.2 Hz, ArH, 2H), 7.39 – 
7.23 (m, ArH, 10H), 7.14 (d, J = 7.6 Hz, ArH, 2H), 6.52 (s, ArH, 2H), 4.51 – 4.42 (m, CH2 PEG, 
4H), 3.84 – 3.46 (m, CH2 PEG, 310 H). 
 
 
III.4.3.12 PEG-bis(4-(piperidin-1-yl)benzoate) (III.24) 
 
IR (KBr) νmax (cm
‐1
): 2873 (m), 1700 (s, C=O), 1603 (m), 1104 (m); 
1
H NMR (400 MHz, CDCl3) : 7.88 (d, J = 8.6 Hz, ArH, 4H), 6.82 (d, J = 8.6 Hz, ArH, 4H), 
4.40 – 4.38 (m, CH2 PEG, 4H), 3.78 – 3.62 (m, CH2 PEG, 205H), 3.30 (m, CH2, 8H), 1.63 (m, CH2, 
12H); 
13
C NMR (100 MHz, CDCl3) : 166.7 (C=O), 154.6 (CAr), 131.4 (CAr), 118.6 (CAr), 113.6 
(CAr), 70.7 (CH2 PEG), 70.6 (CH2 PEG), 69.5 (CH2 PEG), 63.6 (CH2 PEG), 48.8 (CH2), 25.4 
(CH2), 24.4 (CH2). 
 
 
III.4.3.13 PEG-bis(4-(benzylamino)benzoate) (III.25) 
 
IR (KBr) νmax (cm
‐1
): 2874 (m), 1698 (s, C=O), 1604 (m), 1104 (m); 
1
H NMR (400 MHz, CDCl3) : 7.85 (d, J = 8.7 Hz, ArH, 4H), 7.33 (m, ArH, 10H), 6.57 (d, J = 
8.7 Hz, ArH, 4H), 4.37 (m, CH2 benzylic, CH2 PEG, 8H), 3.79 – 3.62 (m, CH2 PEG, 282H); 
13
C NMR (100 MHz, CDCl3) : 166.7 (C=O), 152.0 (C-q), 138.5 (C-q), 131.7 (CAr), 128.8 
(CAr), 128.6 (CAr), 127.5 (CAr), 127.4 (CAr), 127.2 (C-q), 126.9 (CAr), 111.7 (CAr), 70.7 (CH2 
PEG), 70.6 (CH2 PEG), 70.4 (CH2 PEG), 69.4 (CH2 PEG), 63.5 (CH2 PEG), 47.6 (CH2). 
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III.4.3.14 PEG-bis(4-(pyrrolidin-1-yl)benzoate) (III.26) 
 
IR (KBr) νmax (cm
‐1
): 2871 (m), 1696 (s, C=O), 1605 (m), 1106 (m); 
1
H NMR (400 MHz, CDCl3) : 7.89 (d, J = 8.6 Hz, ArH, 4H), 6.49 (d, J = 8.6 Hz, ArH, 4H), 
4.40 (m, PEG CH2, 4H), 3.81 – 3.63 (m, PEG CH2, 240H), 3.34 (m, CH2, 8H), 2.02 (m, CH2, 8H); 
13
C NMR (100 MHz, CDCl3) : 167.2 (C=O), 151.0 (CAr), 131.6 (CAr), 116.2 (CAr), 110.7 
(CAr), 70.8 (CH2 PEG), 70.6 (CH2 PEG), 69.6 (CH2 PEG), 63.5 (CH2 PEG), 47.6 (CH2), 25.6 
(CH2). 
 
 
 
 
III.4.4 General procedure for cleavage of compounds from the polymer support:27 
The PEG bound compound (1 equiv) was dissolved in methanol and a 1 M solution of 
potassium cyanide (2 equiv) in methanol was added. The mixture was stirred at room temperature 
for 12 h. After completion of reaction, the inorganic material was removed by filtration and then 
filtrate was concentrated under reduced pressure. The polymer was precipitated out with excess of 
cold ether and removed by filtration. The filtrate was evaporated to dryness to obtain white 
products in good yields (70 - 90%). The spectral data is according to literature.
  
 
III.4.4.1 Methyl 4-(phenylamino)benzoate (III.21)49  
 
MP: 115-117ºC; 
IR (NaCl, cm
-1
): 3334 (m), 1695 (s, C=O), 1590 (m); 
1
H NMR (400 MHz, CDCl3) : 7.91 (d, J = 8.4 Hz, ArH, 2H), 7.34 (m, ArH, 2H), 7.17 (d, J = 
7.9 Hz, ArH, 2H), 7.06 (t, J = 7.3 Hz, ArH, 1H), 6.99 (d, J = 8.4 Hz, ArH, 2H), 6.04 (bs, NH, 1H), 
3.87 (s, CH3, 3H). 
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III.4.4.2 Methyl 4-(3-(trifluoromethyl)phenylamino)benzoate (III.22)50  
 
MP: 124-126 ºC; 
IR (NaCl, cm
-1
): 3344 (m), 1694 (s, C=O), 1593 (s), 1338 (m);  
1
H NMR (400 MHz, CDCl3) : 7.96 (d, J = 8.3 Hz, ArH, 2H), 7.47 – 7.22 (m, ArH, 4H), 7.03 
(d, J = 8.5 Hz, ArH, 2H), 6.21 (bs, NH, 1H), 3.89 (s, CH3, 3H). 
 
III.4.4.3 Methyl 4-(3-fluorophenylamino)benzoate (III.23)51  
 
MP: 129-131ºC; 
IR (NaCl, cm
-1
): 3337 (m), 1693 (s, C=O), 1597 (m); 
1
H NMR (400 MHz, CDCl3) : 7.94 (d, J = 8.5 Hz, ArH, 2H), 7.31 – 7.22 (m, ArH, 1H), 7.04 
(d, J = 8.5 Hz, ArH, 2H), 6.95 – 6.86 (m, ArH, 2H), 6.72 (t, J = 8.3 Hz, ArH, 1H), 3.88 (s, CH3, 
3H). 
 
III.4.5 Other synthesis 
III.4.5.1 PEG-bis(4-methylbenzenesulfonate) (III.28) 
 
To a PEG 2000 (2 g, 2 mmol) solution in DCM (20 mL) was added triethylamine (0.28 mL, 2 
mmol). The flask was placed in an ice bath and TsCl (382 mg, 2 mmol) and DMAP (25 mg, 0.2 
mmol) were added. The mixture was allowed to slowly rise to room temperature and stirred at this 
temperature overnight. The mixture was washed twice with saturated NH4Cl solution, water, dried 
over Na2SO4 and evaporated to dryness to obtain the compound as a white solid (quant.). 
IR (KBr) νmax (cm
‐1
): 3448 (m), 2885 (w), 1638 (s), 1467 (s), 1345 (m), 1115 (m); 
1
H NMR (400 MHz, CDCl3) : 7.76 (d, J = 7.9 Hz, ArH, 4H), 7.31 (d, J = 7.9 Hz, ArH, 4H), 
4.11 (t, J = 4.5 Hz, PEG CH2, 4H), 3.65 – 3.54 (m, PEG CH2, 210H), 2.41 (s, CH3, 6H). 
13
C NMR (100 MHz, CDCl3) : 144.8 (CAr), 133.0 (CAr), 129.8 (2xCAr), 128.0 (2xCAr), 
70.7 (CH2 PEG), 70.5 (CH2 PEG), 69.2 (CH2 PEG), 68.6 (CH2 PEG), 21.6 (CH3). 
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III.4.5.2 PEG-bis(2-amino-3-bromophenyl)-3,6,9,12-tetraoxatetradecane-1,14-dione 
(III.30) 
 
To a PEG tosyl (100 mg, 0.1 mmol) solution in DMF (0.5 mL) was added Cs2CO3 (35 mg, 0.1 
mmol) and II.39 (25 mg, 0.11 mmol). The mixture was stirred at room temperature overnight. The 
mixture was filtered over a celite pad and evaporated to dryness. Then it was dissolved in propanol 
and precipitated and washed with cold ether, to obtain the compound as a white solid (60 mg, %). 
IR (KBr) νmax (cm
‐1
): 3448 (m), 2887 (w), 1736 (s, C=O), 1467 (m), 1343 (m), 1148 (m), 1114 
(m), 1061 (m), 963 (w), 842 (w); 
1
H NMR (400 MHz, CDCl3) δ: 7.34 (d, J = 7.9 Hz, ArH, 2H), 7.03 (d, J = 7.5 Hz, ArH, 2H), 
6.57 (t, J = 7.7 Hz, ArH, 2H), 4.59 (s, CH2, 4H), 4.28 – 4.19 (m, PEG CH2, 4H), 3.84 – 3.42 (m, 
PEG CH2, 340H). 
13
C NMR (100 MHz, CDCl3) : 171.3 (C=O), 143.5 (C-6), 132.0 (C-4), 130.5 (C-2), 120.5 (C-
1), 119.2 (C-3), 111.0 (C-5), 72.74 (CH2 PEG), 70.7 (CH2 PEG), 70.4 (CH2 PEG), 68.9 (CH2 
PEG), 64.4 (CH2 PEG), 61.8 (CH2 PEG), 39.2 (C-7). 
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My contribution to the work was the synthesis of all the compounds reported on the 
experimental chapter and the methodology development. 
 
The work described in this chapter was developed in Maulide’s former lab at Max Planck 
Institute für Kohlenforshung from 1
st
 October 2012 until 20
th
 December 2012. 
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IV.1 Background 
IV.1.1 Claisen Rearrangement 
Claisen rearrangement is one of the most well known organic reactions, a [3,3] sigmatropic 
rearrangement early studied in the first years of organic chemistry classes.
1
 Firstly reported in 1912 
by Ludwig Claisen,
2
 this reaction can be defined as a suprafacial, concerted and nonsynchronous 
pericyclic process.
3
 The constant innovations turned it into an efficient and versatile procedure, 
proceeding with high degrees of chemo-, regio- and enantioselective control which allowed the 
construction of highly functionalized molecules applied in natural product and medicinal chemistry 
areas.
4
 
 
 
Figure IV.1. Cope and Claisen rearrangement and its variants. 
The Claisen rearrangement may be viewed as the oxy-variant of the Cope rearrangement.
5 
Systems displaying other heteroatoms in position 3 are known as hetero Claisen or hetero Cope 
rearrangements (Figure IV.1). When the heteroatom is nitrogen, these types of rearrangements are 
usually called as aza- or amino-Claisen or 3-aza-Cope rearrangement.  Moreover, one of the double 
bonds can be replaced by an aromatic ring (aromatic-Claisen rearrangement), an acetylenic group 
or other moieties. 
The majority of classical Claisen-type rearrangement reactions described to date are rough 
processes that require high temperatures (usually above 100 °C), usually leading to competitive 
side reactions and decomposition of the starting materials and/or products. In fact, during the last 
years, several efforts were made to transform this reaction into a synthetically versatile 
procedure.
[1] 
Substances such as transition-metal complexes, Lewis acids, and also the physical 
parameters have been changed or introduced to catalyze the Claisen rearrangement, accelerating 
the reaction rate.
6
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IV.1.1.1 Factors influencing the Claisen reaction 
An important feature is the effect of the substituents present in the skeleton of the substrate.
1
 
These effects have been extensively studied, and are currently recognized which groups accelerates 
or decelerates the Claisen reaction based on their electronic attributes (Table IV.1). 
 
Table IV.1. Influence of substituents on the Claisen reaction.1 
 
EWG acceleration  EDG acceleration 
Position Group Position Group 
2 -CN, -CO2, - CO2CH3, -CF3 1 -O, -NH2,-F, CH3 
4 -CN, -CF3 2 -OSi(CH3)3, - CH3, -F 
5 -CN 4 - COCH3, -CH3 
  6 - COCH3, -CH3 
EWG deceleration  EDG deceleration 
1 -CN, - CO2CF3 5 - OCH3, -CH3 
6 -CN   
 
Other factors include the use of polar solvents which increases the rearrangement rate, enabling 
the reaction to proceed under smooth conditions.
1
 Additionally it was also verified that microwave 
irradiation strongly accelerates the reaction,
 
reducing the thermal treatments imposed by the 
classical conditions.
7 
 In fact, the combined effect of microwave irradiation, temperature and 
solvent allows a considerable decrease in the reaction time.  
Positively charged intermediates have also been reported as valuable compounds that 
accelerates the rearrangement. This type of charge acceleration can be induced by an appropriate 
catalyst or a Lewis acid.
8
 
Besides the Lewis acid catalysis, transition metal catalysts such as Hg, Au, Cu or Pd salts are 
also employed in Claisen rearrangements.
9
 These reactions proceed by a “cyclization-induced 
rearrangement”, which explains the effect of the metal catalysts in the reaction. 
 
 
IV.1.1.2 Claisen rearrangement stereocontrol 
The stereochemical outcome of a Claisen reaction could be predicted since this [3,3]-
sigmatropic rearrangement follows highly ordered cyclic six membered transition states and obey 
to the orbital symmetry rules. 
The cyclic transition state of the Claisen rearrangement proceed via a chair- or a boat-like 
conformation, which leads to diastereomerically divergent products. These conformations can be 
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controlled by the structural features of the system, namely steric and electronic properties of the 
substrate or by the reaction conditions.  
In acyclic substrates the chair-like transition state is usually favored, a consequence of energetic 
minimization of torsional and transannular interactions (Scheme IV.1). On the other hand, this 
trend is not always verified when the allyl feature is incorporated in a cyclic system, and the 
Claisen rearrangement can also proceed through a boat-like transition state in order to minimize it 
energy.
10
 
 
Scheme IV.1. Claisen rearrangement transitions states for acyclic and cyclic substrates. 
Several approaches using external asymmetric promoters have been exploit in [3,3]-sigmatropic 
rearrangements,
11
 such the use of Lewis-acid based catalysts, or the asymmetric induction using a 
removable auxiliary to transfer the stereochemical information, like the work recently reported by 
Maulide et al. (Scheme IV.2).
12
 
  
Scheme IV.2. Traceless asymmetric -allylation described by Maulide et al. 
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IV.1.1.3 Claisen variants 
The synthetic potential of the procedure expanded the reaction to different substrates, creating a 
wide number of Claisen versions (Scheme IV.3). The Carroll rearrangement, described in 1940, is a 
thermal rearrangement of allylic β-ketoesters IV.1 to form the corresponding α-allyl-β-
ketocarboxylic acid (IV.3). This intermediate suffers a decarboxylation to yield γ,δ-unsaturated 
ketones IV.4.
13
  Years later, in 1964, Eschenmoser reports the [3,3] rearrangement of in situ formed 
N,O-ketene acetals IV.7 (from allylic alcohol) to yield γ,δ-unsaturated amides IV.8.
14 
The Johnson 
rearrangement consists of heating an allylic alcohol with an excess of ethyl orthoacetate IV.9 to 
yield a γ,δ-unsaturated ester IV.11.
15 
Few years later, Ireland and Mueller reports the rearrangement 
of allyl trimethylsilyl ketene acetals IV.12, prepared by reaction of allylic ester enolates with 
trimethylsilyl chloride, to yield γ,δ-unsaturated carboxylic acids IV.14.
16
 
 
 
Scheme IV.3. [3,3]-Sigmatropic rearrangements related to the Claisen rearrangement. 
 
Aza-Claisen rearrangement is other variant of Claisen reaction, giving access to attractive 
heterocyclic backbones.
17
 
 
 
 
Scheme IV.4. Example of chiral auxiliaries in an asymmetric approach.
18
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The oxygen replacement by the nitrogen atom can offer some advantages. For instance, while 
two valences of the nitrogen are occupied by allyl and vinyl substituents (involved in the 
rearrangement system), the third position can be used to anchor chiral auxiliaries in asymmetric 
approaches (Scheme IV.4).
18 
The first successful examples of the aza-Claisen rearrangement were reported in the 1960s 
initially by Marcinkiewicz and later by Hill and Gilman.
19
 These uncatalyzed systems were carried 
under harsh conditions, hindering the substrate scope and leading to undesired side products.
 
Thus, both aliphatic and aromatic aza-Claisen variants stood apart for a long period of time 
compared to the classic Claisen rearrangement. Gladly this trend has been changed, and in the last 
years, the introduction of Bronsted and Lewis-acids as well as transition-metals catalysis, allowed 
the aza-reaction to proceed under milder conditions. Moreover, as already seen for the oxygen 
substrates, a profusion of aza-Claisen variants were developed, making the aza-Claisen more 
attractive to construct complex compounds.
8a,17
 
Within these variants it can be found the ketene-aza Claisen rearrangement.
20
 The sigmatropic 
framework requires the addition of a tertiary allylamine to the carbonyl center of a ketene, 
generating an N-allyl ammonium enolate which can undergo the rearrangement. However, the key 
step is the formation of the ketene with a lifetime sufficient for the subsequent attack of the 
nucleophile, avoiding the competing [2+2] cycloadditions. Recently, Nubbemeyer and coworkers 
described a zwitterionic ketene aza-Claisen rearrangements of 4-arylbut-3-enoyl fluorides 7, were 
chiral pyrrolidines played an important role as asymmetric auxiliaries delivering the products with 
high diastereoselectivities (Scheme IV.5.a).
21
 
 
 
 
Scheme IV.5. Rearrangements involving heteroallenes: a) aza-ketene and b) Ficini-Claisen. 
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Other rearrangements involving heteroallenes can be pointed out (Scheme IV.5.b). An example, 
is the Ficini-Claisen rearrangement, an ynamine-Claisen rearrangement – where allylic alcohol 
reacts with an ynamine to form γ,δ-unsaturated amides.
22
 Due to the instability and synthetic 
inaccessibility of ynamines, ynamides have also emerged as alternatives in the Ficini–Claisen 
reaction.
23
 
 
IV.1.2 Amide Electrophilic Activation 
In 2010, Maulide et al. envisaged the use of keteniminium salts as key intermediates for the 
synthesis of natural products.
24
 In fact, keteniminium salts are powerful electrophilic heteroallenes 
well-known for their selectivity and stereocontrol in [2+2] cycloadditions to olefins, carbonyls and 
imine derivatives. Keteniminium salts can be prepared through different approaches (Scheme 
IV.6).
25
 
 
 
Scheme IV.6. Preparation of keteniminium salts.25 
In the synthetic plan, Maulide and his coworkers envisioned the direct preparation of 
bicyclobutanone IV.17 from amide IV.15 through a [2+2] cycloaddition of the keteniminium 
intermediate. However, treatment of -allyloxyamide IV.15 with triflic anhydride and 2,4,6-
collidine in dichloroethane did not lead to the desired product IV.17. Instead, it was observed an 
unprecedented Claisen rearrangement leading to allylated lactone IV.18 (Scheme IV.7). 
24
 
 
 
Scheme IV.7. Unexpected Claisen rearrangement observed by Maulide et al.24 
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Careful optimization of reaction conditions conducted to the use collidine as base, triflic 
anhydride as the most suitable amide activating agent and dichloromethane as solvent. The optimal 
protocol also required microwave irradiation of the reaction mixture for only 5 min, followed by 
hydrolytic workup with aqueous bicarbonate solution. 
Further investigation of substrate scope revealed a moderate to good functional-group tolerance 
and that lactones bearing branched allyl substitutents in the  position were generated with high 
diastereoselectivities (Scheme IV.8).
24
 
 
Scheme IV.8. Investigation of substrate scope.24 
Moreover, the substrate scope was also extended to propargyl ethers.  Fortunately, alkynes 
smoothly rearranged to -allenyl lactone in good yields (Scheme IV.9). Neither the isomeric 
propargylated butyrolactone nor [2+2] cycloadducts were detected in the reaction mixture. 
 
 
Scheme IV.9. Use of propargyl ethers to form the corresponding -allenyl lactones. 
The proposed reaction mechanism is shown in Scheme IV.10. The initial activation of the amide 
carbonyl group by the triflic anhydride would give the iminium triflate A that can be converted into 
enamine triflate B. Upon microwave or thermal activation, an elimination to form keteniminium 
ion C probably takes place. 
The enhanced electrophilicity of this intermediate then triggers an unusual nucleophilic attack 
of the ether, which may be reversible. This addition, however, generates a vinyl allyl oxonium 
intermediate D. Such a species should be ideally poised to undergo a “Claisen-like” [3,3]-
sigmatropic rearrangement, leading to the stabilized carbenium ion E. Finally, hydrolysis of E 
leads to the formation of lactone IV.18. 
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Scheme IV.10. Proposed mechanism for the unprecedented Claisen rearrangement. 
This unprecedent rearrangement of keteniminium salts – that allowed a direct and 
stereoselective access to challenging substituted lactones – was also extended to a “benzyl variant” 
procedure (Scheme IV.11).
26
 In this case, the -arylated lactones (IV.24a-i) were obtained, 
although in moderate yields. The rearrangement proved to be tolerant to the presence of several 
substituents on the aromatic ring. Additionally, some of the obtained products (IV.24f-i) contained 
two chemo-differentiated carboxylate moieties for further elaboration. 
 
 
Scheme IV.11. Benzyl Claisen rearrangement reported by Maulide group.26 
However, it was also verified along with the -arylated lactones, the presence of the 
corresponding -benzylated lactones as side products. Furthermore, substrates with R = OMe, CN 
and CF3 groups, exclusively afforded the benzylic transfer adducts as the products of the reaction.
26
 
The group also reported the smoothly rearrangement of the simple tetrahydrofuran and 
tetrahydropyran protected hydroxylamides IV.25a-e in the same reaction conditions, to the 
corresponding adducts IV.26a–e in moderate to good yields (Scheme IV.12). 
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Scheme IV.12. Tetrahydrofuran and tetrahydropiran protected hydroxylamides substrates. 
More recently, the same group reported structures incorporating a phenyl group within the alkyl 
tether, thereby restricting the conformational flexibility in the substrate (Scheme IV.13).
27
  The 
conditions for this type of substrates are remarkably mild proceeding at room temperature. The 
explanation could reside in the reduced conformational flexibility, resulting in significant pre-
organization for the cyclization/Claisen rearrangement events, perhaps combined with favorable 
formation of a conjugated keteniminium salt intermediate. Nucleophilic capture of the 
rearrangement product IV.28 gave rise to isochromanone IV.29 or the aromatic aminoalcohol 
IV.30 (Scheme IV.13. a). 
27
 
 
Scheme IV.13. Rearrangement of structures incorporating a phenyl group within the alkyl tether.27 
Surprisingly, for the O-benzyl analogue it was observed that the major product of this 
transformation was not the expected iminium ether IV.32 (or its rearomatized derivative), but the 
isomeric compound IV.33 (Scheme IV.13. b). The formation of IV.33 can be explained by the 
generation of iminium ether IV.32 that evolves through a Cope-type sigmatropic rearrangement.  
 
The unexpected skeletal reorganization observed in Maulide’s group that gave access to useful 
lactones, was the driving force that encouraged us to further explore this reaction for structures 
incorporating a phenyl group within the alkyl tether. 
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The development of this novel concept will allow the preparation of aromatic heterocycles with 
increased structural diversity and stereoselectivity, and could be the departure point to expand the 
methodology to different applications. 
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IV.2 Results and Discussion  
The relevance of the chromanones and coumaranones and its nitrogenated counterparts in 
natural products and as medicinal agents
28
 justify the synthetic efforts to create these heterocyclic 
structures with high levels of functionalization and sterocontrol. 
Based on these objectives and using the amide electrophilic activation/Claisen rearrangement 
methodology developed in Maulide’s group, it was proposed to perform additional studies on the 
substrates incorporating a phenyl ring within the alkyl tether and to expand the procedure to its aza 
analogs. 
 
IV.2.1 Six membered rings 
According to the preliminary studies performed in Maulide’s lab, α-arylated lactones generated 
from derivatives bearing a benzyl moiety were obtained in the racemic form, since basic hydrolysis 
conditions can cause racemization of the intermediate via a formal “iminium”-“enamine” 
equilibrium (Scheme IV.14). Moreover, the extended conjugation through the aromatic substituent 
can also promote epimerization at the chiral center under basic conditions.  
 
 
 
Scheme IV.14. Benzyl Claisen rearrangement of substrate IV.34. 
In order to achieve enantioenriched compounds, it was proposed to introduce a methyl group in 
the  position to the carbonyl to prevent the epimerization of the iminium ether intermediate. 
To test this hypothesis, substrate IV.39 was synthesized in three steps using 3-isochromanone 
IV.36 as starting material (Scheme IV.15). This compound was methylated by treatment of IV.36 
with LDA at -78ºC, followed by the addition of methyl iodide in THF. The ring opening product 
was achieved by treatment with potassium carbonate, followed by a simple O-allylation to yield 
compound IV.38. The corresponding amide was constructed through a carboxylic acid activation 
using the EDCI/HOBt system and pyrrolidine in CH2Cl2. Compound IV.39 was achieved with an 
overall yield of 25 %. 
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Scheme IV.15. Synthesis of compound IV.39 from 3-isochromanone. 
The initial experiments were performed using the previously established conditions for the 
Claisen rearrangement (treatment of a 0.2 M solution of IV.39 in CH2Cl2 with 1.20 equivalents of 
collidine and 1.05 equivalents of triflic anhydride, followed by microwave irradiation). NMR 
analysis of crude mixture showed the formation of IV.40 along with the deallylated product IV.41 
as the major product (entry1, Table IV.2). In order to prevent the deallylation reaction, the 
procedure was performed at room temperature overnight (entry 2). However, the reaction did not 
proceed (monitored by TLC) and it was further subjected to the irradiation conditions. In this case, 
the amount of the desired compound IV.40 increased, but compounds IV.39 and IV.41 were also 
identified (Figure IV.2.b).  
Table IV.2. Optimization of Claisen reaction to obtain the intermediate IV.40. 
 
 
 
Entry Tf2O (equiv) Collidine (equiv) Conditions 
Ratio 
IV.39:IV.40:IV.41 
1 1.05 1.2 W (120°C), 5 min 0:0.3:1 
2 1.05 1.2 
rt, overnight   
W (120°C), 5 min 
0.5:0.5:1 
3 1.05 1.2 
Addition at -78º C  
W (120°C), 15 min 
0:0:1 
4 1.5 1.2 
Addition at -78º C   
W (120°C), 15 min 
0:0.2:1 
5 1.1 3 W (120°C), 5 min 1:0.3:0.3 
6 1.1 1.5 W (80°C), 5 min 1:1:1 
 
The addition of collidine and Tf2O to IV.39 solution at -78ºC, did not give any improvement. 
Moreover, irradiating the mixture for 15 min. yielded IV.41 as the almost exclusive product (entry 
3). 
IV. Amide Electrophilic Activation and Aza-Claisen 
195 
 
 
Figure IV.2. a) Compound IV.39; b) entry 2; c) entry 3; d) entry 5. 
In fact, the formation of the deallylated lactone IV.44 was previously reported by Dr. I. 
Jurberg.
29a
 In his studies he confirmed the presence of the allyl triflate specie IV.43 in the crude 
reaction mixture that could be implicated in the formation of the deallylated byproduct (Scheme 
IV.16). 
 
Scheme IV.16. Studies described by Dr. I. Jurberg confirming the presence of the allyl triflate species. 
It was proposed that deallylation might occur by a mechanism where the cyclization takes place 
by nucleophilic attack of the oxygen atom directly on the iminium triflate 1A (before abstraction of 
the proton by the base), followed by loss of the allyl moiety by the triflate anion to form the 
iminium ether IV.42 (Scheme IV.16). Experiments performed by Dr. C. Madelaine and Dr. I. 
Jurberg, support this pathway. When allyloxy amide IV.15 was treated exclusively with triflic 
IV. Results and Discussion 
196 
 
anhydride, iminium ether IV.42 and allyl triflate IV.43 were identified as the only products in the 
crude reaction mixture.
29
 Additionally, Madeleine and Jurberg observed that an increased amount 
of collidine led to a decreased formation of deallylated lactone. Other mechanism that explains the 
loss of the allylic moiety was also recently proposed by the Maulide et al.
29b
 
Their results are also in accordance with the different ratios observed in our study upon 
modifying the relative quantities of reagents. Increasing the activating agent to 1.5 equivalents 
while maintaining the collidine, did not change the reaction output (Table IV.2, entry 4). On the 
other hand, using 3.0 equivalents of collidine conducted to a significant decrease of IV.41.  
However, a large amount of the unreacted starting material IV.39 was still observed (Table IV.2, 
entry 5). This could be explained by the presence of the methyl group that may increase the steric 
hindrance in the center, inhibiting the rearrangement reaction. 
Decreasing the reaction temperature to 80ºC, a mixture of IV.39, IV.40 and IV.41 was formed 
in an almost equal ratio (entry 6). 
 
Due to the failure of Claisen rearrangement for compound IV.39 we next explored the reaction 
methodology with compound IV.45, a 2-chromanone derivative.  In this case the phenyl ring 
within the tether is directly attached to the oxygen atom, which was expected to slightly change the 
electronic properties of the system and consequently the reactivity. 
 
Table IV.3. Optimization of Claisen reaction to obtain the intermediate IV.46. 
 
 
 
Entry Tf2O (equiv) Collidine (equiv) Conditions 
Ratio 
IV.45:IV.46:IV.47 
1 1,05 1,2 
RT overnight   
W (120°C), 5 min 
1:0:1 
2 1,05 1,2 W (120°C), 5 min 0:1:0 
3 1,05 2 W (120°C), 5 min 0:0:1 
 
In fact, while derivative IV.27 went through rearrangement at room temperature in 5 min. (see 
Scheme IV.13.a), reacting IV.45 at room temperature for 18 h yielded a mixture of starting 
material and the suggested activated specie IV.47 in a 1:1 ratio (Table IV.3, entry 1). The 
explanation could reside on the less available pair of electrons of the oxygen to undertake 
nucleophilic attack of the ketiminium intermediate. Moreover, this derivative does not have the 
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possibility of formation of a conjugated keteniminium salt intermediate, and the conformational 
flexibility is to some extent, higher than derivative IV.27. 
When the standard microwave conditions (120°C, 5 min.) were applied to IV.45, it was 
obtained IV.46 with full conversion (Table IV.3, entry 2). As seen before, raising the amount of 
collidine to 2 equivalents gave the activated product IV.47 (Table IV.3, entry 3). 
The water hydrolysis (room temperature, overnight) was achieved with full conversion of the 
IV.46 to afford the product IV.48 (45%) (Scheme IV.17). 
 
 
Scheme IV.17. Water hydrolysis of compound IV.46. 
Since the reaction proceeded in quite well manner for derivative IV.46 it was proposed to 
explore an asymmetric variant of this rearrangement.  
Encouraged by the previous literature that report a transfer of the stereochemical information by 
a removable auxiliary, Maulide’s group explored the use of chiral pyrrolidines as “traceless” chiral 
auxiliaries. These pyrrolidines would be present as the amine part of the starting amide, and 
cleaved (and possibly recovered) to give away the final product. 
Initial studies performed by Dr. C. Madelaine, showed that enantiomeric excesses can be 
obtained with alkoxyamide derived from the (S)-methoxymethylpyrrolidine IV.49 (61% e.e.), as 
well as with IV.50 incorporating a C2-symmetric chiral pyrrolidine (45% e.e.) (Scheme IV.18).
24
 
 
 
Scheme IV.18. Use of chiral pyrrolidines for asymmetric induction.
24
 
Thus, derivative IV.51 was prepared in order to perform the asymmetric studies. Unfortunately, 
when the standard microwave conditions were applied (120°C, 5 min.) to IV.51, the NMR of the 
crude mixture showed the presence of starting material along with other two minor products – the 
iminium ether IV.52 and the presumable activated intermediate IV.53. The mixture was then 
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subjected to microwave irradiation at 120°C for 15 min., in order to push it to full conversion, but 
without any improvement (Table IV.4, entry 1). 
 
Table IV.4. Optimization of Claisen reaction to obtain the intermediate IV.52. 
 
Entry Tf2O (equiv) Collidine (equiv) Conditions 
Ratio  
IV.51:IV.52:IV.53 
1 1,05 1,2 
W (120°C), 5 min   
W (120°C), 15 min 
1:0.5:0.5 
2 1,05 1,2 rt, overnight  50°C, 3 h 1:0.1:0.1 
3 1,05 1,2 W (80°C), 5 min 1:0.3:0.1 
 
Performing the reaction at room temperature (overnight) the rearrangement did not proceed, and 
only small amounts of compounds IV.52 and IV.53 were observed. The mixture was then heated to 
50°C for 3 h, but IV.52 was not formed in higher amounts (entry 2). 
The reaction was also performed under microwave conditions at 80ºC, but once more it was 
achieved a poor conversion of IV.51 to the desired compound IV.52 (entry 3). 
 
When the same standard conditions were applied to derivative IV.54 (at room temperature for 
~18 h), it was verified that the rearrangement did not proceed, and only the starting material was 
observed (Table IV.5, entry 1). When the microwave conditions (120°C, 5 min.) were employed 
(Table IV.5, entry 2), the NMR of the crude mixture showed a different profile. Analyzing the 
COSY spectrum it was verified that the structure did not correspond to the expected compound 
IV.55, being most likely the activated IV.56. The reaction was also performed under the same 
microwave conditions for 1 h, however without improved results (entry 3). 
It can be concluded that compound IV.54 is poorly reactive, fact that can be attributed to the 
bulkiness of the two phenyl rings present in the chiral auxiliary, which can impede the correct 
conformation for the rearrangement to take place. 
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Table IV.5. Optimization of Claisen reaction to obtain the intermediate IV.55. 
 
 
Entry Tf2O (equiv.) Collidine (equiv.) Conditions 
Ratio  
IV.54:IV.55:IV.56 
1 1,05 1,2 
rt, overnight  W (120°C), 
5 min.  W (120°C), 1 h 
1:0:0 
2 1,05 1,2 W (120°C), 5 min 0:0:1 
3 1,1 1,5 W (120°C), 1 h 0:0:1 
 
Having proved the unsuccessful trials of the asymmetric reaction we then further explored the 
five membered rings. 
 
 
IV.2.2 Five membered rings 
2-Coumaranones (or 3-H 2-benzofuranones) are prominent structural motifs of some natural 
products or in compounds with relevant properties, and many of them feature a chiral quaternary 
stereocenter at the C-3 position of the heterocyclic ring (Figure IV.3).
30
 Due to their relevance, the 
catalytic enantioselective functionalization at the C-3 position represents the most direct approach 
to chiral benzofuranones.
31
 
 
Figure IV.3. Natural products containing the coumaranone moiety. 
Initial studies using the five member substrate IV.57 showed that the rearrangement did not 
proceed at room temperature. On the other hand, applying the usual microwave conditions (120°C, 
5 min.) it was observed the full conversion of IV.57 to an intermediate that could be either the 
iminium IV.58 or the enamine IV.59. It was formulated that IV.59 could be formed due to the 
rearomatization of the aromatic system to form the most stable compound. 
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Scheme IV.19. Study of Claisen reaction with derivative IV.57. 
In order to clarify the intermediate structure, were performed 2D NMR experiments - HSQC 
and HMBC - of the crude mixture. The compound was identified as the structure IV.58 due to the 
observed correlation between proton in position C-3 and the CH2 of the allylic moiety. 
Hydrolysis attempts showed that IV.58 evolved to compound IV.59 under neutral or basic 
conditions, while washing the crude mixture with HCl 1M or saturated NH4Cl solutions furnished 
the ring open structure IV.60 as the major product (Scheme IV.20). Any other manipulation before 
column gave the benzofuran IV.59. 
 
Scheme IV.20. Different hydrolysis conditions used on IV.58 evolved to compound IV.59 or IV.60. 
 
The spectra of the compounds involved in these transformations are depicted in Figure IV.4. 
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Figure IV.4. a) – Compound IV.57; b) – Crude mixture after standard W conditions; c) – Compound 
IV.60. 
 
It was also made an attempt concerning the trapping of intermediate IV.58 with benzyl bromide 
with and without NaH (Scheme IV.21). Treatment with NaH led to IV.61 (10%) that after 
hydrolysis with a sat. NaHCO3 solution furnished the desired product IV.62 in low yield. However, 
without base it was also verified by NMR the presence of trace amounts of IV.61. 
 
 
Scheme IV.21. Trapping reaction with BnBr to obtain the intermediate IV.62. 
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IV.2.3 Aza-Claisen rearrangements 
Like the O-counterparts (chromanones and 2-coumaranones), indolinone and 
dihydroquinolinone frameworks possessing a C-3 quaternary stereocenter can be observed in some 
natural products and in therapeutic agents.
32
 
 
Figure IV.5. Natural products containing the oxindole moiety. 
The aza-Claisen rearrangements were already explored in Maulide’s group although with 
unsatisfactory results. The initial concern involved the substrate design, since the involvement of a 
nucleophilic and basic nitrogen atom implies an extra position to be protected. In addition, 
nitrogenated compounds could be hard to handle and sometimes difficult to purify.  
In the initial studies performed by D. Petkova, the protecting group was carefully chosen as it 
could influence the reactivity of the substrate under the electrophilic reaction conditions. It was 
anticipated that alkyl groups could be possible substituents, but would render the more basic 
nitrogen. On the other hand, acetyl or Boc groups would reduce the nucleophilicity of the nitrogen 
atom, and should compete with the amide moiety for the Tf2O. Thus, on the first efforts to 
construct the nitrogen analogues of the already reported lactones,
24
 tosyl group was chosen as N-
protecting group, given that it fulfilled all the desired requirements. 
 
 
Scheme IV.22. Preliminary studies on aza-Claisen rearrangements performed by Maulide’s group. 
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It was expected that the reaction proceed through a mechanism similar to the previously 
reported for the oxygen derivatives. However, in all the experiments performed by D. Petkova, it 
was verified an unexpected tosyl migration towards position 3 instead the desired Claisen 
rearrangement (Scheme IV.22).  
In the proposed mechanism the rearrangement proceed through the ketiminium formation 
followed by nucleophilic attack by the nitrogen atom. However, in this case, homolitic scission 
could take place to form a radical cation and a tosyl radical. This sulphur-based radical can attack 
the radical cation IV.63 C to yield the corresponding amidinium compound IV.64 (Scheme IV.23). 
 
 
Scheme IV.23. Proposed mechanism for tosyl migration. 
Based on the results obtained for oxygen containing structures incorporating a phenyl group 
within the alkyl tether and on the preliminary studies made for N-tosylated derivatives, we decided 
to adopt a combined strategy to explore aza-Claisen rearrangement for the construction of 
heterocyclic compounds. Despite the initial concerns, it was chosen to perform the dialkylation of 
nitrogen atom, with allyl, benzyl and propargyl groups. The obtained disubstituted anilines were 
then subjected to rearrangement conditions in order to obtain either fused five- or six-membered 
ring heterocycles. 
The corresponding derivatives IV.67-IV69 were synthesized according to Scheme IV.24. Using 
2-nitro phenyl acetic acid IV.65 as starting material, the corresponding amide derivative IV.66 was 
prepared using a standard carboxylic acid activation procedure. It was verified that the presence of 
the nitro group strongly influences this reaction, yielding the product in moderate yields (52 %). 
Then, it was performed a simple reduction of nitro group using 10% Pd/C in toluene and the 
resulting reaction mixture was filtered and evaporated, followed by the dialkylation to afford 
compounds IV.67-IV69 in good yields. 
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Scheme IV.24. Synthesis of allyl, benzyl and propargyl derivatives IV.67-IV.69. 
The initial studies were made using the diallylated derivative IV.67. Upon treatment of IV.67 
with Tf2O (1.05 equiv) and 2,4,6-collidine (1.2 equiv) in CH2Cl2 (0.2 M) under room temperature 
conditions, it was verified that the reaction was not complete being observed by NMR a mixture of 
an intermediate and starting material (Table IV.6). 
 
Table IV.6. Optimization of Claisen reaction with IV.67. 
Entry Tf2O (equiv) 
Collidine 
(equiv) 
Conditions 
Ratio 
IV.72:IV.71 
1 1.05 1.2 rt, overnight 1:0.5 
2 1.05 1.2 W (120°C), 5 min.  1:0 
3 1.05 1.2 W (150°C), 15 min.  1:0 
 
Appling microwave conditions (120°C, 5 min.), the NMR from the crude mixture indicated that 
IV.67 underwent the Claisen rearrangement leading to a mixture of two products, presumably the 
amidinium IV.70 and the activated specie IV.71 (Scheme IV.25). 
 
 
Scheme IV.25. Unexpected migration of allyl group under the usual conditions. 
However, attempts to isolate IV.70 revealed that the Claisen product was not the expected 
compound but the amidinium IV.72 that after column or acidic work up (stirring in HCl 1M 
solution) gave the product IV.73. 
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It was also attempted to increase the reaction time (15 min.) and temperature (to 150ºC, the 
maximum allowed for CH2Cl2 under microwave conditions) in order to examine if the reaction 
proceed towards the desired rearrangement. However, the same NMR profile was obtained (entry 
3). 
This aromatic Claisen rearrangement to position 7 of indole moiety could be anticipated since 
some examples describing this type of transformation have been described in the literature (Scheme 
IV.26).
33
 
 
Scheme IV.26. Aromatic Claisen rearrangement to position 7 of indole-like moieties.33 
This [3,3]-sigmatropic rearrangement of N-allyl-N-arylamines, usually requires very high 
temperatures, affording the corresponding anilines along undesired byproducts.
1,6
 Therefore, in the 
last years several developments were made to turn this transformation in a milder process, such as 
using Lewis-acid catalysts.  
Consequently, the rearrangement of IV.67 to the derivative IV.73 could be a step further in the 
development of a milder process since it evolves in a fast way under microwave conditions. 
 
It was also considered that derivative IV.73 could proceed via Claisen rearrangement to yield 
IV.74 if exposed to the regular Claisen conditions (Scheme IV.27). Thus, IV.73 was dissolved in 
toluene in order to reach higher temperatures under microwave conditions (in this case, 160ºC). 
However, it was verified by 
1
H NMR that IV.73 was highly stable under these reaction conditions, 
even when submitted to microwave conditions for 1 h. 
 
 
Scheme IV.27. Attempts of Claisen rearrangement. 
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As previously observed by Petkova in the preliminary experiments (unpublished results), 
hydrolysis of the amidinium product (IV.72) to the corresponding oxindole was not possible. 
Compound IV.72 couldn’t be hydrolysed either with water or under basic conditions (sat. solution 
NaHCO3). 
 
Expecting a similar rearrangement from the benzylated and propargylated derivatives, IV.68 
and IV.69, respectively, the standard electrophilic activation conditions were applied either at room 
temperature or under the usual microwave conditions.  
For compound IV.68, since the NMR spectra of crude mixture presented a complex profile – 
thus not providing the evidence (as for derivative IV.67) of the migration of benzilic moiety to the 
position 7 of aromatic ring – it was performed a simple aqueous work-up and a chromatographic 
column.  After a careful assignment of 
1
H NMR and COSY experiments, it was confirmed the 
presence of indoles IV.77 and IV.78, isolated in 17% and 7% yield (unoptimized yields) (Scheme 
IV.28). 
In fact, from the NMR of the crude mixture it could be anticipated the presence of the 
amidinium corresponding to IV.77, since a correlation between the CH2 of benzylic moiety and the 
hydrogen of position C-3 of indole was clearly verified. 
This result diverges from the result obtained for the allyllic derivative IV.67, where allyllic 
chain migrates to the aromatic moiety. 
 
Scheme IV.28. Products obtained for benzylated derivative IV.68 when submitted to the usual conditions. 
The same study was performed for propargylated derivative IV.69 (Scheme IV.29). Once more, 
the NMR from the crude mixture showed a complex pattern. After chromatographic isolation the 
corresponding indoles IV.81 and IV.82 were obtained in 23% and 7% yield respectively 
(unoptimized yields).  
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It could be said that IV.69 follows the same trend as the benzylated derivative IV.68, and that a 
migration of the benzyl and propargyl substituents is favored, while in the case of IV.67 it is 
difficult to understand whether a migration of allyl chain or a rearrangement took place. 
 
 
Scheme IV.29. Products obtained for propargylated derivative IV.69 when submitted to the usual conditions. 
In fact, as previously detected by V. Valerio et al. in the “benzyl-Claisen” studies, in addition to 
the expected rearranged products IV.84, in most cases the crude reaction mixture showed the 
presence of the corresponding -benzylated γ-butyrolactones IV.85 as side products (Scheme 
IV.30).
26
 
 
Scheme IV.30. Debenzylated γ-butyrolactones obtained from the benzyl containing derivatives. 
 
Besides the regular charge-accelerated “Claisen-like” [3,3] sigmatropic rearrangement, 
delivering the -arylated lactone products via dearomatized species B (Scheme IV.31, a), some 
other mechanistic hypothesis were proposed. 
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Scheme IV.31. Mechanistic hypothesis suggested by V.Valerio et al.26 
The observed formation of “benzyl-transfer” products IV.85 could be explained by the 
dissociation of the benzylic moiety from the oxonium intermediate A, generating two fragments C, 
that could combine to yield product IV.85a (Scheme IV.31, b).  An alternative scenario might 
explain the formation of such products IV.85b from electron-poor benzyl moieties as proceeding 
through an uncharged electrophile represented in D (Scheme IV.31, c).
26
 
 
In order to understand whether a migration or a rearrangement were favoured under these 
conditions, and its dependence on the nature of the substituent, one experiment was carried where 
both benzyl and allyl groups were installed at the nitrogen atom (Scheme IV.32). Therefore, 
compound IV.86 was submitted to regular rearrangement conditions being obtained a complex 
NMR mixture. After work-up and isolation, indolic compounds IV.87 and IV.88 were obtained in 
25% and 18% yields, respectively (unoptimized yields). 
 
 
Scheme IV.32. Products obtained for N-allyl-N-benzyl derivative IV.86 when submitted to the usual 
conditions. 
This result suggests that under these conditions, the migration of benzyl moiety is favored over 
the rearrangement (after cyclization to the indole unit), and that the benzyl group migrates 
preferentially to C-3. 
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The six-membered nitrogenated compound IV.93 was prepared from the 3-isochromanone 
(IV.89). The 3-isochromanone was hydrolysed in pyrrolidine/TEA affording the compound IV.90 
that upon treatment with diphenylphosphoryl azide (DPPA) in basic conditions afforded the 
corresponding IV.91 in excellent conversion, as confirmed by 
1
H NMR. This last compound was 
converted to the amine IV.92 under 10% Pd/C reductive conditions. Compound IV.92 when 
subjected to treatment with K2CO3/allyl bromide in THF afforded the corresponding IV.93 in 22% 
yield (4 steps) (Scheme IV.33). 
 
 
Scheme IV.33. Synthesis of compound IV.93. 
The diallylated derivative IV.93 was then subjected to the standard activation conditions either 
at room temperature (5 min.) and microwave (120°C, 5 min.) conditions (Scheme IV.34). 
Fortunately, in both cases the product was full converted to the corresponding amidinium 
intermediate IV.94.  
 
 
Scheme IV.34. Claisen reaction to obtain the six member amidinium compound IV.94. 
Like the O-allyl amide counterpart, IV.93 was quantitatively converted to iminium ether IV.94 
after five minutes at room temperature (see Scheme IV.13.a, page 191).
27
 As already reported by 
Peng et al. the mild conditions required for this transformation can be a result of the reduced 
conformational flexibility due to the phenyl ring within the alkyl tether, resulting in a pre-
organization for the cyclization/Claisen rearrangement events, perhaps combined with the 
favorable formation of a conjugated keteniminium salt intermediate. 
However, if the compound was the corresponding isomer 2-oxo-1,2,3,4-tetrahydroquinoline 
derivative, probably the result would be a similar rearrangement observed for derivative IV.67 
(Scheme IV.25, page 204). The rearrangement to position 8 was already reported for similar 
compounds (Scheme IV.35).
34
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Scheme IV.35. Claisen rearrangement to obtain 8-allyl-2-phenyl-1,2,3,4-tetrahydroquinoline.34 
It was further observed, that the amidinium derivative IV.94 could not be hydrolyzed under the 
mild conditions used for the oxygenated derivatives, such as water or NaHCO3 saturated solution at 
room temperature (Table IV.7, entries 1 and 2). Instead, strong basic were required, and although 
hydrolysis of IV.94 could be attained at room temperature using a 2 M NaOH solution, the NMR 
showed a mixture between IV.94 and the desired lactam IV.95 (entry 3). 
The hydrolysis with water under microwave conditions did not afford the desired product IV.95 
(entry 5). When a 1M NaHCO3 solution was used, the hydrolysis product was obtained as the 
major product. Using a saturated solution of NaHCO3, the amidinium was fully converted to IV.95 
(Table IV.7, entries 6 and 7). 
Table IV.7. Hydrolysis conditions used on amidinium IV.94 to obtain IV.95.a 
 
 
 
Entry Conditions Temp. 
NMR 
(IV.94:IV.95) 
Isolated yield 
1 H2O rt, overnight ---
b --- 
2 NaHCO3 sat. rt, overnight 1:0 --- 
3 NaOH 2M rt, 5 h 0.5:1 17% 
4 HCl 1M rt, 3 days 1:0 --- 
5 H2O 
W (120°C), 5 min 
 15 min. 
1:0 --- 
6 NaHCO3 1M W (120°C), 5 min 0.3:1 --- 
7 NaHCO3 sat. W (120°C), 15 min 0:1 90% 
a The crude mixture was evaporated to dryness and redissolved in THF (0,5 mL) and the corresponding 
aqueous solution (0,5 mL). b TLC indicated that no conversion occurred 
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IV.3 Conclusions 
The discovery of an unprecedented Claisen rearrangement through an amide electrophilic 
activation of allyl amides could be a valuable methodology to the enantioselective synthesis of 
heterocyclic structures. Consequently, several efforts were conducted to prepare coumaranones- 
and chromanones-based compounds with an enantioenriched center at position C-3 (Figure IV.6). 
Moreover the procedure was also attempted for the preparation of some nitrogenated analogues, the 
indolinones and dihydroquinolinones.  
 
 
Figure IV.6. Results obtained for the -allyloxyamides incorporating a phenyl group within the alkyl 
tether. 
It was verified that the conditions used for the previous reported lactones ( W 120ºC, 5 min.) 
were suitable for the - or -allyl amides comprising an arene within the alkyl tether (IV.45 and 
IV.57, respectively), to obtain the corresponding amidinium intermediates (Figure IV.6). The 
hydrolysis step to remove the pyrrolidine moiety was easily performed for compound IV.46 in 
order to attain IV.48; however, the amidinium IV.58 could not be hydrolyzed even using extreme 
basic conditions. The harsh hydrolysis conditions needed for these derivatives could be attributed 
to a stable conjugation of iminium with the aromatic ring. 
Due to the promising results obtained for the six membered derivative IV.46, it was also 
attempted a chiral approach using appropriate chiral auxiliaries. However, all the attempts were 
unsuccessful. 
 
In the aza-Claisen approach (Figure IV.7), the N,N-diallylated derivative IV.67 suffered a 
rearrangement towards the arene ring, yielding the 7-allylated indole IV.73. For the benzyl and 
propargyl derivatives, it was verified that a migration mechanism was favored over the 
rearrangement. Moreover, it was also verified that the hydrolysis step was an intricate task, 
requiring harsh hydrolysis conditions which could compromise the chiral center integrity. 
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Figure IV.7. Results obtained for the nitrogenated derivatives. 
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IV.4 Experimental 
IV.4.1 Materials 
All commercially obtained reagents were used without further purification unless specified. All 
the mentioned solvents used in the reactions were dried by usual methods.
130
 Column 
chromatography was carried out with silica gel 60 Å (220-440 mesh) using the described eluent for 
each case. Analytical TLC was performed with silica gel 60 F254 aluminum plates (Merck).TLCs 
were visualized by fluorescence quenching with UV light at 254 nm and/or by staining with 
potassium permanganate or phosphomolybdic acid stains.  
IR spectra were recorded using a Perkin‐Elmer Spectrum 1000 FT‐IR. The IR bands are 
classified as strong (s), medium (m), or weak (w). NMR spectra were recorded with a Brucker 
Avance 500 spectrometer using CDCl3 as solvent using the corresponding CHCl3 signal as 
reference. The spectra were recorded at room temperature (298 K) unless otherwise stated. 
Microwave experiments were performed using a CEM Discover Microwave SP-D (CEM). High 
resolution mass spectra were obtained on a Bruker APEX III FT-MS (7 T magnet). All masses are 
given in atomic units/elementary charge (m/z) and reported in percentage relative to the basic peak. 
 
 
IV.4.1.1 4-Methylisochroman-3-one (IV.37) 35 
 
In a two necked flask was prepared LDA (14.85 mmol, 1.1 equiv) in situ in THF (60 mL). To 
the cooled mixture at -78 °C was added 3-isochromanone (2 g, 13.5 mmol) in THF (30 mL). The 
resulting mixture was stirred for 1 h, and MeI (0.92 mL, 14.85 mmol) was added. The mixture was 
allowed to reach room temperature and then stirred for 2 h. The reaction was quenched with 
NH4Cl, extracted with EtOAc, dried and evaporated to dryness. Purification by flash column 
chromatography using hexane and ethyl acetate as eluent (gradient system from hexane to hexane: 
ethyl acetate 4:1) afforded the product as white solid (735 mg, 34 %). Rf = 0.5, hexane:EtOAc 4:1. 
Mp: 49-50 °C; 
1
H NMR (500 MHz, CDCl3) : 7.43 – 7.21 (m, ArH, 4H), 5.29 (m, CH2, 2H), 3.63 (q, J = 7.0 
Hz, CH, 1H), 1.63 (d, J = 7.0 Hz, CH3, 3H); 
13
C NMR (126 MHz, CDCl3) : 173.7 (C=O), 135.6 (CAr), 132.0 (CAr), 129.0 (CAr), 127.2 
(CAr), 124.8 (CAr), 124.7 (CAr), 69.3 (CH2), 39.5 (CH), 12.9 (CH3). 
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IV.4.1.2 2-(2-((Allyloxy)methyl)phenyl)propanoic acid (IV.38) 
 
The product (0.735 g, 4.56 mmol) was hydrolyzed in K2CO3 (375 mg, 2.72 mmol) in H2O (25 
mL), at reflux, overnight. The mixture was evaporated to dryness and the salt was kept under 
vacuum for 1 day. THF (9 mL, 0,5M) was added and the flask was placed in an ice bath. NaH (360 
mg, 9.06 mmol) was added portion wise and the mixture was allowed to reach room temperature 
and stirred for 1.5h. Then allyl bromide (0.8 mL, 9.06 mmol) was added and the mixture was 
stirred at room temperature overnight. The reaction was quenched with water, extracted with 
EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. Purification by 
flash column chromatography using hexane and ethyl acetate as eluent (gradient system from 
hexane to hexane: ethyl acetate 1:1) afforded the product as colourless oil (850 mg, 85 %). Rf = 0.4, 
hexane:EtOAc 4:1. 
IR (cm-1): 2982 (w), 2871 (w), 1703 (s, C=O);  
1
H NMR (500 MHz, CDCl3) δ: 7.45 – 7.24 (m, ArH, 4H), 5.95 (ddt, J = 11.7, 10.8, 8.1 Hz, -
CH2CHCH2,1H), 5.35 (ddd, J = 17.2, 2.9, 1.4 Hz, -CH2CHCH2, 1H), 5.29 – 5.25 (m, -CH2CHCH2, 
1H), 4.69 (d, J = 11.3 Hz, CH2, 1H), 4.60 (d, J = 11.3 Hz, CH2, 1H), 4.10 – 4.03 (m, -
CH2CHCH2,CH, 3H), 1.53 (d, J = 7.0 Hz, CH3, 3H); 
13
C NMR (126 MHz, CDCl3) δ: 139.7 (CAr), 135.0 (CAr), 133.7 (-CH2CHCH2), 130.4 (CAr), 
129.3 (CAr), 127.5 (CAr), 127.4 (CAr), 118.7 (-CH2CHCH2), 71.7 (-CH2CHCH2), 71.3 (CH2), 40.8 
(CH), 17.8 (CH3); 
HRMS: m/z Calculated for C17H23NO2 [M+Na]
+
: 243.0992, found: 243.0992. 
 
IV.4.1.3 2-(2-((Allyloxy)methyl)phenyl)-1-(pyrrolidin-1-yl)propan-1-one (IV.39) 
 
To 2-(2-((allyloxy)methyl)phenyl)propanoic acid (160 mg, 0.73 mmol) in DCM (5 mL), was 
added EDCI.HCl (139 mg, 0.73 mmol), HOBt (98 mg, 0.73 mmol), triethylamine (0.1 mL, 0.73 
mmol) and pyrrolidine (60 L, 0.73 mmol). The mixture was stirred at room temperature 
overnight. The mixture was evaporated to dryness and the crude product was purified by flash 
column chromatography using hexane and ethyl acetate as eluent (gradient system from hexane to 
hexane: ethyl acetate 1:1). The product was obtained as colourless oil (170 mg, 90 %). Rf = 0.4 
hexane:EtOAc (1:1). 
IV. Amide Electrophilic Activation and Aza-Claisen 
215 
 
IR (cm-1): 2973 (w), 2872 (w), 1637 (s, C=O), 1617 (s), 1422 (s), 1059 (s), 759 (s);  
1
H NMR (500 MHz, CDCl3) δ: 7.44 – 7.14 (m, ArH, 4H), 5.94 (ddt, J = 16.4, 10.8, 5.6 Hz, -
CH2CHCH2, 1H), 5.26 (ddd, J = 40.9, 13.8 Hz, -CH2CHCH2, 2H), 4.66 (d, J = 11.5 Hz, CH2, 1H), 
4.51 (d, J = 11.5 Hz, CH2, 1H), 4.15 – 4.00 (m, -CH2CHCH2, CH, 3H), 3.61 – 3.49 (m, CH2, 1H), 
3.49 – 3.35 (m, CH2, 2H), 3.01 – 2.89 (m, CH2, 1H), 1.88 – 1.65 (m, CH2, 4H), 1.42 (d, CH3, 2H);
 
13
C NMR (126 MHz, CDCl3) δ: 172.6 (C=O), 141.5 (CAr), 134.6 (CAr), 134.5 (-CH2CHCH2), 
130.2 (CAr), 129.2 (CAr), 127.3 (CAr), 126.7 (CAr), 117.5 (-CH2CHCH2), 71.4 (-CH2CHCH2), 
70.8 (CH2), 46.3 (CH2 pyrrolidine), 46.2 (CH2 pyrrolidine), 40.8 (CH), 26.2 (CH2 pyrrolidine), 24.3 
(CH2 pyrrolidine), 19.9 (CH3); 
HRMS: m/z Calculated for C17H23NO2 [M+Na]
+
: 296.1619, found: 296.1621. 
 
 
IV.4.1.4 3-(2-(Allyloxy)phenyl)propanoic acid 
 
Dihydrocoumarin (5 g, 33.75 mmol) was hydrolyzed by K2CO3 (3.73 g, mmol) in H2O (150 
mL) at reflux for 5 h. The mixture was evaporated to dryness and the salt was kept under vacuum 
overnight. Then, THF (100 mL) was added and the flask was placed in an ice bath. NaH (2.7 g, 
67.5 mmol) was added portion wise and the mixture was allowed to reach room temperature and 
stirred for 1.5h. Then allyl bromide (5.8 mL, 67.5 mmol) was added and the mixture was stirred at 
room temperature overnight. The reaction was quenched with water, extracted with EtOAc, washed 
with water and brine, dried over Na2SO4 and evaporated to dryness. The crude product was purified 
by flash column chromatography using a gradient system from hexane to hexane:EtOAc (1:1). The 
product was obtained as white solid (5.5 g, 79%). Rf = 0.2 hexane:EtOAc (4:1). 
Mp: 65-67°C; 
IR (cm-1): 3023 (w), 2923 (w), 1703 (s, C=O), 1493 (m), 1239 (m), 749 (s); 
1
H NMR (500 MHz, CDCl3) δ: 7.22 – 7.15 (m, ArH, 2H), 6.89 (td, J = 7.4, 0.7 Hz, ArH, 1H), 
6.84 (d, J = 8.0 Hz, ArH, 1H), 6.07 (ddt, J = 17.2, 10.3, 5.0 Hz, -CH2CHCH2, 1H), 5.46 – 5.38 (m, 
-CH2CHCH2, 1H), 5.28 (dd, J = 10.6, 1.4 Hz, -CH2CHCH2, 1H), 4.56 (dd, J = 4.8, 1.5 Hz, -
CH2CHCH2, 2H), 2.99 (t, J = 7.8 Hz, CH2, 2H), 2.78 – 2.61 (m, CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 156.6 (CAr), 133.5 (-CH2CHCH2), 130.3 (CAr), 128.9 (CAr), 
127.8 (CAr), 120.8 (CAr), 117.2 (-CH2CHCH2), 111.6 (CAr), 68.7 (-CH2CHCH2), 34.1 (CH2), 26.1 
(CH2); 
HRMS: m/z Calculated for C12H14NO3 [M+Na]
+
: 229.0837, found: 229.0835. 
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IV.4.1.5 3-(2-(Allyloxy)phenyl)-1-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)propan-1-one 
(IV.51) 
 
To the substrate (200 mg, 0.97 mmol) in DCM (5 mL), was added EDCI.HCl (186 mg, 0.97 
mmol), HOBt (131 mg, 0.97 mmol), triethylamine (0.27 mL, 0.97 mmol) and (2R,5R)-2,5-
dimethylpyrrolidine hydrochloride (132 mg, 0.97 mmol). The mixture was stirred at room 
temperature overnight. The mixture was evaporated to dryness and the crude product was purified 
by flash column chromatography using a gradient system from hexane to hexane:EtOAc (1:1). The 
product was obtained as colourless oil (225 mg, 81 %). Rf = 0.3, 2x (hexane:EtOAc, 4:1). 
IR (cm-1): 2966 (w), 1629 (s, C=O), 1409 (s), 1239 (m), 750 (s); 
1
H NMR (500 MHz, CDCl3) δ: 7.22 – 7.11 (m, ArH, 2H), 6.90 – 6.82 (m, ArH, 2H), 6.06 (ddt, 
J = 17.2, 10.4, 5.1 Hz, -CH2CHCH2, 1H), 5.46 – 5.37 (dd, -CH2CHCH2, 1H), 5.26 (dd, J = 10.5, 1.4 
Hz, -CH2CHCH2,1H), 4.56 (dt, J = 5.0, 1.4 Hz, , -CH2CHCH2, 2H), 4.21 (m, J = 6.4 Hz, CH, 1H), 
3.91 (m, J = 6.4 Hz, CH, 1H), 3.10 – 2.91 (m, CH2, 2H), 2.66 – 2.50 (m, CH2, 2H), 2.14 – 2.02 (m, 
CH2, 2H), 1.50 (m, J = 21.0, 6.0 Hz, CH2, 2H), 1.13 (d, J = 6.3 Hz, CH3, 3H), 1.09 (d, J = 6.4 Hz, 
CH3, 3H); 
13
C NMR (126 MHz, CDCl3) δ: 171.4 (C=O), 156.6 (CAr), 133.6 (-CH2CHCH2), 130.7 (CAr), 
130.1 (CAr), 127.4 (CAr), 120.8 (CAr), 117.2 (-CH2CHCH2), 111.5 (CAr), 68.8 (-CH2CHCH2), 
53.6 (CH), 53.0 (CH), 35.0 (CH2), 30.9 (CH2), 29.2 (CH2), 27.4 (CH2), 21.8 (CH3), 19.3 (CH3); 
HRMS: m/z Calculated for C18H25NO2 [M+Na]
+
: 310.1775, found: 310.1777. 
 
IV.4.1.6 2-(2-(Allyloxy)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.57) 
 
2-Coumaranone (1 g, 7.5 mmol) was refluxed in pyrrolidine (1.22 mL, 14.9 mmol) and 
triethylamine (3.12 mL, 22.4 mmol) overnight. The mixture was evaporated to dryness and THF 
(20 mL) was added. The flask was placed in an ice bath. NaH (597 mg, 14.9 mmol) was added 
portion wise and the mixture was allowed to reach room temperature and stirred for 1.5 h. Then 
allyl bromide (1.3 mL, 14.9 mmol) was added and the mixture was stirred at room temperature 
overnight. The reaction was quenched with water, extracted with EtOAc, washed with water and 
brine, dried over Na2SO4 and evaporated to dryness. The crude product was purified by flash 
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column chromatography a gradient system from hexane to hexane: EtOAc (1:1). The product was 
obtained as orange solid (1.55 g, 85 %). Rf = 0.2, hexane:EtOAc, 3:2. 
Mp: 68-69°C; 
IR (cm-1): 2970 (w), 2873 (w), 1635 (s, C=O), 1425 (m), 1242 (m), 745 (m); 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 7.16 (m, ArH, 2H), 6.92 (td, J = 7.5, 0.8 Hz, ArH, 1H), 
6.84 (d, J = 8.2 Hz, ArH, 1H), 6.03 (ddt, J = 17.2, 10.4, 5.2 Hz, -CH2CHCH2, 1H), 5.39 (dd, J = 
17.3, 1.6 Hz, -CH2CHCH2, 1H), 5.28 – 5.25 (m, -CH2CHCH2, 1H), 4.54 (dt, J = 5.1, 1.5 Hz, -
CH2CHCH2, 2H), 3.66 (s, CH2, 2H), 3.51 – 3.45 (m, CH2, 4H), 1.97 – 1.78 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 170.1 (C=O), 156.2 (CAr), 133.6 (-CH2CHCH2), 130.6 (CAr), 
128.0 (CAr), 124.4 (CAr), 121.0 (CAr), 117.3 (-CH2CHCH2), 111.7 (CAr), 69.0 (-CH2CHCH2), 
46.9 (CH2 pyrr), 45.9 (CH2 pyrr), 36.1 (CH2), 26.3 (CH2 pyrr), 24.6 (CH2 pyrr); 
HRMS: m/z Calculated for C15H19NO2 [M+Na]
+
: 268.1309 found:268.1308. 
 
 
IV.4.1.7 2-(2-Hydroxyphenyl)-1-(pyrrolidin-1-yl)pent-4-en-1-one (IV.60) 
 
1
H NMR (500 MHz, CDCl3) δ: 10.79 (s, -OH, 1H), 7.17 (dd, J = 7.9, 1.6 Hz, 1H), 6.98 – 6.90 
(m, 2H), 6.78 (dd, J = 7.4, 1.2 Hz, 1H), 5.68 (ddt, J = 17.1, 10.0 Hz, -CH2CHCH2, 1H), 5.14 – 4.95 
(m, -CH2CHCH2, 2H), 3.74 – 3.43 (m, -CH2, -CH, 5H), 2.99 – 2.90 (m, -CH2CHCH2, 1H), 2.66 – 
2.57 (m, -CH2CHCH2, 1H), 2.05 – 1.80 (m, -CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 173.85 (C=O), 157.27 (CAr-OH), 135.29 (-CH2CHCH2), 
131.14 (C-Ar), 129.34 (C-Ar), 123.36, 119.64 (C-Ar), 119.19 (C-Ar), 117.51 (-CH2CHCH2), 51.71 
(CH), 47.53 (CH2 pyrr), 46.46 (CH2 pyrr), 35.55 (-CH2CHCH2), 26.09 (CH2 pyrr), 24.46 (CH2 pyrr). 
 
 
IV.4.1.8 2-(2-Nitrophenyl)-1-(pyrrolidin-1-yl)ethanone (IV.66) 36 
 
To 2-nitrophenylacetic acid (1.5 g, 8.3 mmol) in DCM (27 mL) was added dropwise DIC (1.3 
mL, 9.1 mmol), and the solution turned from yellow to red. The mixture was stirred at room 
temperature for 30 min. Then, triethylamine (1.3 mL, 9.1 mmol) and freshly distilled pyrrolidine 
(0.75 mL, 9.1 mmol) were added. The mixture was stirred at room temperature overnight. The 
mixture was diluted with EtOAc and washed with HCl 1M solution, water and brine, dried over 
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Na2SO4 and evaporated. The crude was purified by flash column chromatography using a gradient 
system from hexane to hexane: EtOAc (1:1). The product was obtained as white solid (1.5 g, 77 
%). Rf = 0.2 hexane:EtOAc (1:1). 
To 2-nitrophenylacetic acid (1.5 g, 8.3 mmol) was added EDCI.HCl (1.6 g 8.3 mmol), HOBt 
(1.12 g, 8.3 mmol), triethylamine (1.2 mL, 8.3mmol) and pyrrolidine (0.7 mL, 8.3 mmol). The 
mixture was stirred at room temperature until total SM consumption (TLC) Rf = 0.3 hexane:EtOAc 
(1:1). The mixture was diluted with EtOAc and washed with water and brine, dried over Na2SO4 
and evaporated. The crude was purified by flash column chromatography using a gradient system 
from hexane to hexane:EtOAc (1:1). The product was obtained as white solid (1 g, 52 %). Rf = 0.2, 
hexane:EtOAc (1:1). 
IR (cm-1): 2971 (w), 2876 (w), 1645 (s, C=O), 1522 (s), 1433 (m) 1346 (m); 
1
H NMR (500 MHz, CDCl3) δ: 8.08 (d, J = 8.2, 1.1 Hz, ArH, 1H), 7.57 (dd, J = 7.5, 1.2 Hz, 
ArH, 1H), 7.50 – 7.41 (dd, ArH, 1H), 7.36 (d, J = 7.6 Hz, ArH, 1H), 3.99 (s, CH2, 2H), 3.57 (t, J = 
6.8 Hz, CH2, 2H), 3.49 (t, J = 6.9 Hz, CH2, 2H), 2.08 – 1.96 (m, CH2, 2H), 1.90 (m, CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 167.4 (C=O), 133.4 (CAr), 133.3 (CAr), 128.0 (CAr), 125.03 
(CAr), 46.7 (CH2 pyrr), 45.9 (CH2 pyrr), 39.9 (CH2), 26.1 (CH2 pyrr), 24.4 (CH2 pyrr). 
 
 
IV.4.1.9 2-(2-Aminophenyl)-1-(pyrrolidin-1-yl)ethanone  
 
2-(2-Nitrophenyl)-1-(pyrrolidin-1-yl)ethanone (250 mg, 1.07 mmol) was dissolved in toluene 
(10 mL) and Pd/C 10% (113 mg, 10 mol%) was added. The mixture was stirred under H2 
atmosphere until total consumption of starting material. The mixture was filtered through a celite 
pad and evaporated to dryness. The product was obtained as white solid (210 mg, quant.). Rf = 0.4, 
EtOAc. 
Mp: 85°C; 
IR (cm-1): 3373 (w), 3230 (w), 2972 (w), 2882 (w), 1604 (s), 1592 (s), 1443 (s);  
1
H NMR (500 MHz, CDCl3) δ: 7.11- 7.03 (m, ArH, 2H), 6.91 – 6.73 (m, ArH, 2H), 3.67 (s, 
CH2, 2H), 3.60 (t, J = 6.9 Hz, CH2, 2H), 3.45 (t, J = 6.9 Hz, CH2, 2H), 1.96 (m, CH2, 2H), 1.89 – 
1.81 (m, CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 169.91 (C=O), 131.2 (CAr), 128.4 (CAr), 119.7 (CAr), 117.7 
(CAr), 47.3 (CH2 pyrr), 46.2 (CH2 pyrr), 39.9 (CH2), 26.3 (CH2 pyrr), 24.4 (CH2 pyrr); 
HRMS: m/z Calculated for C12H16N2O [M+Na]
+
: 227.1155, found: 277.1155. 
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IV.4.1.10 2-(2-(Diallylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.67) 
 
2-(2-Aminophenyl)-1-(pyrrolidin-1-yl)ethanone (210 mg, 1.07 mmol) was dissolved in DMF 
(10 mL). Na2CO3 (171 mg , 3.2 mmol) and allyl bromide (0.37 mL, 3.2 mmol) were added and the 
mixture was stirred at 100°C overnight. The reaction was quenched with water, extracted with 
EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. Purification by 
flash column chromatography using a gradient system from hexane to hexane: ethyl acetate (2:3), 
afforded the product as colourless oil (170 mg, 65%). Rf = 0.3, hexane:EtOAc (3:2). 
IR (cm-1): 2974 (w), 2876 (w), 1623 (s), 1420 (s);  
1
H NMR (500 MHz, CDCl3) δ:  7.29 (d, ArH, 1H), 7.18 (dd, ArH, 1H), 7.08 – 7.03 (m, ArH, 
2H), 5.75 (ddt, J = 16.5, 10.2, 6.2 Hz, -CH2CHCH2, 2H), 5.17 – 5.08 (m, -CH2CHCH2, 4H), 3.75 
(s, CH2, 2H), 3.60 – 3.43 (m, -CH2CHCH2, CH2, 6H), 3.29 (t, J = 6.5 Hz, CH2, 2H), 1.84 (m, CH2, 
4H); 
13
C NMR (126 MHz, CDCl3) δ: 170.6 (C=O), 149.8 (CAr), 135.1 (-CH2CHCH2), 131.9 (CAr), 
130.1 (CAr), 127.1 (CAr), 124.2 (CAr), 122.8 (CAr), 117.5 (-CH2CHCH2), 56.5 (-CH2CHCH2), 
46.8 (CH2 pyrr), 45.9 (CH2 pyrr), 37.8 (CH2), 26.2 (CH2 pyrr), 24.5 (CH2 pyrr); 
HRMS: m/z Calculated for C18H24N2O [M+Na]
+
: 307.1778, found: 307.1781. 
 
 
IV.4.1.11 2-(2-(Allylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone 
 
Colourless oil (20 mg, 6 %). Rf = 0.35, hexane:EtOAc, 3:2. 
IR (cm-1): 3310 (w), 2972 (w), 2874 (w), 1692 (s), 1620 (s), 1589 (s), 1431 (s);   
1
H NMR (500 MHz, CDCl3) δ: 7.15 (td, J = 8.0, 1.5 Hz, ArH, 1H), 7.04 (dd, J = 7.6, 1.4 Hz, 
ArH, 1H), 6.70 – 6.60 (m, ArH, 2H), 5.99 (ddt, J = 17.2, 10.3, 5.1 Hz, -CH2CHCH2, 1H), 5.35 (dd, 
J = 17.2, 3.3, 1.7 Hz, -CH2CHCH2, 1H), 5.19 (dd, J = 10.4, 3.1, 1.5 Hz, -CH2CHCH2, 1H), 3.81 (d, 
J = 5.0, 1.5 Hz, -CH2CHCH2, 2H), 3.65 – 3.56 (m, CH2, CH2 pyrr, 4H), 3.44 (t, J = 6.9 Hz, CH2 pyrr, 
2H), 1.95 (m, J = 6.8 Hz, CH2 pyrr, 2H), 1.83 (m, J = 6.9 Hz, CH2 pyrr, 2H); 
HRMS: m/z Calculated for C15H20N2O [M+Na]
+
: 267.1465, found: 267.1468. 
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IV.4.1.12 2-(2-(Dibenzylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.68) 
 
2-(2-Aminophenyl)-1-(pyrrolidin-1-yl)ethanone (110 mg, 0.54 mmol) was dissolved in DMF 
(2.5 mL). K2CO3 (223 mg, 1.62 mmol) and benzyl bromide (0.19 mL, 1.62 mmol) were added and 
the mixture was stirred at 80°C overnight. The reaction was quenched with water, extracted with 
EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. Purification by 
flash column chromatography using a gradient system from hexane to hexane:ethyl acetate (1:4) 
afforded the product as colourless oil (170 mg, 83%). Rf = 0.35, hexane:EtOAc (3:2). 
Monobenzylated: (20 mg, 13%). Rf = 0.4, hexane:EtOAc, 3:2. 
IR (cm-1): 3060 (w), 2971 (w), 2872 (w), 1638 (s, C=O), 1421 (s), 697 (s); 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 7.03 (m, ArH, 14 H), 4.04 (s, CH2, 4H), 3.80 (s, CH2, 
2H), 3.46 (t, J = 6.7 Hz, CH2, 2H), 3.08 – 3.01 (m, CH2, 2H), 1.80 – 1.76 (m, CH2, 4H). 
13
C NMR (126 MHz, CDCl3) δ: 170.5 (C=O), 149.7 (CAr), 138.4 (CAr), 131.9 (CAr), 129.7 
(CAr), 129.1 (CAr), 128.2 (CAr), 127.2 (CAr), 127.1 (CAr), 124.6 (CAr), 123.4 (CAr), 57.8 (CH2), 
46.6 (CH2 pyrr), 45.9 (CH2 pyrr), 38.1 (CH2), 26.2 (CH2 pyrr), 24.5 (CH2 pyrr); 
HRMS: m/z Calculated for C26H28N2O [M+Na]
+
: 407.2092,found 407.2094. 
 
 
IV.4.1.13 2-(2-(Benzylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone  
 
2-(2-Aminophenyl)-1-(pyrrolidin-1-yl)ethanone (360 mg, 1.76 mmol) was dissolved in DMF (6 
mL). K2CO3 (487 mg, 3.52 mmol) and benzyl bromide (0.26 mL, 2.2 mmol) were added and the 
mixture was stirred at room temperature overnight. The reaction was quenched with water, 
extracted with EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. 
Purification by flash column chromatography using a gradient system from hexane to hexane:ethyl 
acetate (3:2) afforded the product as a white solid (370 mg, 71%). Rf = 0.4, hexane:EtOAc 3:2. 
Dibenzylated: (50 mg, 17%). Rf = 0.35, hexane:EtOAc 3:2. 
MP: 63-64ºC; 
IR (cm-1): 3313 (w), 2971 (w), 2874 (w), 1621 (s), 1445 (s),1428 (s); 
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1
H NMR (500 MHz, CDCl3) δ:  7.40 (d, J = 7.5 Hz, ArH, 2H), 7.32 (dd, J = 7.6 Hz, ArH, 
2H), 7.25 – 7.23 (m, ArH, 2H), 7.11 – 7.04 (m, ArH, 2H), 6.66 – 6.61 (m, ArH, 2H), 4.41 (s, CH2, 
2H), 3.65 (s, CH2, 2H), 3.61 (t, J = 6.8 Hz, CH2, 2H), 3.45 (t, J = 6.9 Hz, CH2, 2H), 1.95 (m, J = 
6.8 Hz, CH2, 2H), 1.84 (m, J = 6.9 Hz, CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 169.8 (C=O), 131.0 (CAr), 128.6 (CAr), 128.4 (CAr), 128.3 
(CAr), 127.4 (CAr), 126.9 (CAr), 116.8 (CAr), 111.9 (CAr), 47.3 (CH2 and CH2 pyrr), 46.28 (CH2 
pyrr), 40.57 (CH2), 26.31 (CH2 pyrr), 24.42 (CH2 pyrr); 
HRMS: m/z Calculated for C19H22N2O [M+Na]
+
: 307.1627, found 317.1624. 
 
 
IV.4.1.14 2-(2-(Di(but-2-yn-1-yl)amino)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.69) 
 
2-(2-Aminophenyl)-1-(pyrrolidin-1-yl)ethanone (150 mg, 0.73 mmol) was dissolved in DMF (3 
mL). K2CO3 (235 mg, 1.54 mmol) and 2-butynyl bromide (135 L, 1.54 mmol) were added and the 
mixture was stirred at 80°C overnight. The reaction was quenched with water, extracted with 
EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. Purification by 
flash column chromatography using a gradient system from hexane to hexane:ethyl acetate (2:3) 
afforded the product as colourless oil (210 mg, 93%). Rf = 0.4, EtOAc. 
IR (cm-1): 2970 (w), 2874 (w), 1634 (s, C=O), 1422 (s), 725 (m);  
1
H NMR (500 MHz, CDCl3) δ: 7.31 (m, ArH, 2H), 7.24 (dd, J = 7.6 Hz, ArH, 1H), 7.10 (dd, J 
= 7.4 Hz, ArH, 1H), 3.80 – 3.77 (m, J = 3.4 Hz, CH2, 6H), 3.54 – 3.40 (m, CH2, 4H), 1.91 – 1.75 
(m, CH2, CH3, 10H); 
13
C NMR (126 MHz, CDCl3) δ: 170.5 (C=O), 132.0 (CAr), 130.3 (CAr), 127.3 (CAr), 125.2 
(CAr), 122.7 (CAr), 46.9 (CH2 pyrr), 45.9 (CH2 pyrr), 43.0 (CH2), 37.6 (CH2), 26.3 (CH2 pyrr), 24.6 
(CH2 pyrr), 3.7 (CH3); 
HRMS: m/z Calculated for C20H24N2O [M+Na]
 +
: 331.1779, found: 331.1781. 
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IV.4.1.15 2-(2-(But-2-yn-1-ylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone 
 
Colourless oil (12 mg, 7%). Rf = 0.5, EtOAc. 
IR (cm-1): 3301 (w), 2971 (w), 2874 (w), 1620 (s, C=O), 1588 (m), 1429 (s), 725 (s);   
1
H NMR (500 MHz, CDCl3) δ: 7.19 (dd, J = 7.7 Hz, ArH, 1H), 7.04 (d, J = 7.3 Hz, ArH, 1H), 
6.79 (d, J = 8.1 Hz, ArH, 1H), 6.70 (dd, J = 7.3 Hz, ArH, 1H), 3.90 (s, CH2, 2H), 3.65 – 3.55 (m, 
CH2, 4H), 3.43 (t, J = 6.9 Hz, CH2, 2H), 2.02 – 1.93 (m, CH2, 2H) 1.84 – 1.72 (m, CH2, CH3, 5H); 
13
C NMR (126 MHz, CDCl3) δ: 169.83 (C=O), 147.3 (CAr), 130.9 (CAr), 128.4 (CAr), 120.5 
(CAr), 117.5 (CAr), 111.9 (CAr), 47.3 (CH2 pyrr), 46.2 (CH2 pyrr), 40.2 (CH2), 33.8 (CH2), 26.3 (CH2 
pyrr), 24.4 (CH2 pyrr), 3.8 (CH3); 
HRMS: m/z Calculated for C16H20N2O [M+Na]
+
: 279.1466, found: 279.1468. 
 
 
IV.4.1.16 2-(2-(Dibenzylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.73) 
 
2-(2-(benzylamino)phenyl)-1-(pyrrolidin-1-yl)ethanone (150 mg, 0.51 mmol) was dissolved in 
DMF (1.1 mL). Cs2CO3 (332 mg, 1.02 mmol) and allyl bromide (0.106 mL, 1.02 mmol) were 
added and the mixture was stirred at 80ºC overnight. The reaction was quenched with water, 
extracted with EtOAc, washed with water and brine, dried over Na2SO4 and evaporated to dryness. 
Purification by flash column chromatography using a gradient system from hexane to hexane: 
EtOAc (1:4) afforded the product as colourless oil (140 mg, %). Rf = 0.5, hexane:EtOAc, 4:1. 
IR (cm-1): 2972 (w), 2872 (w), 1641 (s, C=O), 1492 (s), 1421 (s); 
1
H NMR (500 MHz, CDCl3) δ: 7.23 (m, ArH, 7H), 7.15 – 7.03 (m, ArH, 2H), 5.82 (qd, J = 
12.0, 6.3 Hz, -CH2CHCH2, 1H), 5.16 (m, -CH2CHCH2, 2H), 4.11 (s, CH2, 2H), 3.79 (s, CH2, 2H), 
3.55 – 3.46 (m, CH2, 4H), 3.19 (s, CH2, 2H), 1.83 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 170.5 (C=O), 149.8 (CAr), 138.6 (C-q), 134.9 (C-allyl), 131.8 
(CAr), 130.0 (CAr), 129.0 (CAr), 128.2 (CAr), 127.1 (CAr), 127.04 (CAr), 124.4 (CAr), 123.0 
(CAr), 117.8 (C-Allyl), 57.6 (CH2Bn), 56.6 (C-Allyl), 46.7 (CH2 pyrr), 45.9 (CH2 pyrr), 37.9 (CH2), 
26.2 (CH2 pyrr), 24.5 (CH2 pyrr). 
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IV.4.1.17 2-(2-(Hydroxymethyl)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.90) 
 
3-Isochromanone (0.50 g, 3.37 mmol) was refluxed in pyrrolidine (0.55 mL, 6.75 mmol) and 
triethylamine (1.4 mL, 10.1 mmol) until total consumption of starting material, Rf = 0.3 EtOAc. 
The mixture was evaporated to dryness and the product was used without further purification. 
IR (cm-1): 3357 (m), 2971 (w), 2874 (w), 1614 (s, C=O,), 1440 (s), 1015 (m), 747 (s);
   
 
1
H NMR (500 MHz, CDCl3) δ: 7.41 (dd, Ar-H, 1H), 7.26 (m, Ar-H, 2H), 7.15 (dd, J = 6.8 Hz, 
Ar-H, 1H), 4.60 (s, CH2, 2H), 3.77 (s, CH2, 2H), 3.65 (t, J = 6.8 Hz, CH2, 2H), 3.47 (t, J = 6.9 Hz, 
CH2, 2H), 2.04 – 1.98 (m, CH2, 2H), 1.91 – 1.85 (m, CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 170.4 (C=O), 140.6 (CAr), 133.9 (CAr), 130.9 (CAr), 130.6 
(CAr), 128.3 (CAr), 127.8 (CAr), 63.8 (CH2), 47.5 (CH2 pyrr), 46.4 (CH2 pyrr), 39.0 (CH2), 26.3 (CH2 
pyrr), 24.4 (CH2 pyrr); 
HRMS: m/z Calculated for C13H17NO2 [M+Na]
+
: 242.1152, found: 242.1151. 
 
 
IV.4.1.18 2-(2-((Diallylamino)methyl)phenyl)-1-(pyrrolidin-1-yl)ethanone (IV.93) 
 
2-(2-(Hydroxymethyl)phenyl)-1-(pyrrolidin-1-yl)ethanone (200 mg, 0.92 mmol) was dissolved 
in THF (6 mL) and the flask was placed in an ice bath. Diphenyl phosphoryl azide (0.25 mL, 1.19 
mmol) was then added followed by DBU (0.18 mL, 1.19 mmol) and the mixture was allowed to 
reach room temperature and stirred overnight. The mixture was dissolved with EtOAc, washed 
with water and brine, dried over Na2SO4 and evaporated to dryness. The crude product was used 
without further purification. Rf = 0.5 EtOAc.  
1
H NMR (500 MHz, CDCl3) δ: 7.34 – 7.19 (m, Ar-H, 4H), 4.39 (s, CH2, 2H), 3.71 (s, CH2, 
2H), 3.47 (m, CH2, 4H), 1.95 (m, CH2, 2H), 1.85 (m, CH2, 2H). 
The crude product was dissolved in toluene (4.5 mL) and Pd/C 10% (97 mg, 10 mol%) was 
added. The mixture was stirred under H2 atmosphere for 5 h until total consumption of starting 
material, Rf = 0.1 EtOAc. The mixture was filtered through a celite pad and evaporated to dryness.  
The crude product was dissolved in THF (6 mL) and K2CO3 (633 mg, 4.58 mmol) and allyl 
bromide (0.2 mL, 2.29 mmol) were added and the mixture was stirred at 50°C overnight. The 
reaction was filtrated through a celite pad and evaporated to dryness. The crude product was 
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purified by flash column chromatography using a gradient system from hexane to hexane: ethyl 
acetate (1:5). The product was obtained as yellow oil (80 mg, 29 % over 4 steps). Rf = 0.2, 
hexane:EtOAc (1:1).  
IR (cm-1): 3372 (w), 2974 (w), 2874 (w), 1639 (s, C=O), 1417 (s), 915 (s), 748 (s);  
1
H NMR (300 MHz, CDCl3) δ: 7.21 – 7.16 (m, ArH, 4H), 5.83 (ddt, J = 6.7 Hz, -CH2CHCH2, 
2H), 5.14 (m, -CH2CHCH2, 4H), 3.85 (s, CH2, 2H), 3.55 – 3.49 (m, -CH2CHCH2, 4H), 3.38 (t, J = 
6.5 Hz, 2H), 3.03 (d, J = 5.8 Hz, CH2, 4H), 1.93-1.83 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 170.2 (C=O), 135.7 (-CH2CHCH2), 135.1 (CAr), 130.8 (CAr), 
129.4 (CAr), 127.5 (CAr), 126.5 (CAr), 126.3 (CAr), 117.7 (-CH2CHCH2), 56.6 (CH2 pyrr), 46.9 
(CH2 pyrr), 46.0 (-CH2CHCH2), 39.3 (CH2), 26.3 (CH2 pyrr), 24.6 (CH2 pyrr); 
HRMS: m/z Calculated for C19H26N2O [M+Na]
+
: 321,1939 found: 321,1937. 
 
 
 
 
IV.4.2 General procedure 
To a microwave vial charged with the allyl amide (1 equiv) in DCM (0.1 M) under argon at 
room temperature, was added 2,4,6-collidine (x equiv), followed by Tf2O (y equiv) (see Table). 
The reaction was allowed to stir at room temperature overnight or placed in the microwave (see 
Tables). The reaction was concentrated under reduced pressure and the presence of intermediate 
was verified by 
1
H NMR and COSY.  
For hydrolysis, the reaction was concentrated under reduced pressure, then diluted in THF (0,5 
mL) and in the adequate aqueous solution (0,5 mL). Then, the reaction was allowed to stir at room 
temperature of under microwave conditions (see Table).  
Purification by flash column chromatography afforded the corresponding products (except the 
indicated compounds which chemical shifts are taken from crude). 
 
IV.4.2.1 3-Allylchroman-2-one (IV.48) 37 
 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 7.23 (m, ArH, 1H), 7.17 (d, J = 7.3 Hz, ArH, 1H), 7.09 
(td, J = 7.4, 1.0 Hz, ArH, 1H), 7.04 (d, J = 8.1 Hz, ArH, 1H), 5.90 – 5.78 (m, -CH2CHCH2, 1H), 
5.13 (m, -CH2CHCH2, 2H), 2.99 (dd, J = 15.2, 5.4 Hz, CH2, 1H), 2.86 – 2.66 (m, CH2, -
CH2CHCH2, 3H), 2.35 (dt, J = 14.3, 7.8 Hz, CH,1H). 
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IV.4.2.2 3-Allyl-3-benzylbenzofuran-2(3H)-one (IV.62) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 6.80 (m, ArH, 9H), 5.39 (dq, J = 17.3, 1.6 Hz, -
CH2CHCH2, 1H), 5.00 – 4.91 (m, -CH2CHCH2, 2H), 3.13 (d, J = 13.3 Hz, CH2, 1H), 3.03 (d, J = 
13.3 Hz, CH2, 1H), 2.68 (dd, J = 13.6, 7.9 Hz, -CH2CHCH2, 1H), 2.61 (dd, J = 13.5, 6.8 Hz, -
CH2CHCH2, 1H). (acc. Peaks  taken from a mixture) 
 
 
IV.4.2.3 1,7-Diallyl-2-(pyrrolidin-1-yl)-1H-indole (IV.73) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 7.16 (m, ArH, 1H), 6.92 (dd, J = 7.5, 0.8 Hz, ArH, 1H), 
6.84 (d, J = 8.2 Hz, ArH, 1H), 6.03 (ddt, J = 17.2, 10.4, 5.2 Hz, -CH2CHCH2, 2H), 5.91 (s, CH, 
1H), 5.14 - 5.05 (m, -CH2CHCH2 , 2H), 4.91-4.78 (m, -CH2CHCH2, CH2CHCH2, 4H), 3.66 (m, -
CH2CHCH2, 2H), 3.54 – 3.42 (m, CH2, 4H), 1.97 – 1.78 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 150.4 (CAr), 138.8 (-CH2CHCH2), 136.7 (-CH2CHCH2), 
133.7 (CAr), 129.6 (CAr), 122.6 (CAr), 122.0 (CAr), 119.8 (CAr), 117.2 (CAr), 115.5 (-
CH2CHCH2), 115.1 (-CH2CHCH2), 86.4 (CH), 53.2 (CH2 pyrr), 46.5 (-CH2CHCH2), 36.2 (-
CH2CHCH2), 24.8 (CH2 pyrr); 
HRMS: m/z Calculated for C18H22N2 [M+Na]
+
: 266.1782, found: 266.1783. 
 
 
IV.4.2.4 1,3-Dibenzyl-2-(pyrrolidin-1-yl)-1H-indole (IV.77) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.35 – 6.95 (m, ArH, 14 H), 5.30 (s, CH2, 2H), 4.17 (s, CH2, 
2H), 3.14 (m, CH2, 4H), 1.89 – 1.78 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 141.9 (C-1), 139.2 (C-2), 134.0 (C-3), 128.7 (C-Ar
1
), 128.4 
(C-Ar
1
), 128.3 (C-Ar
2
), 127.0 (C-Ar
2
), 126.4 (C-Ar
2
), 125.8 (C-Ar
1
), 121.0 (C-Ar-indole), 119.2 
(C-Ar-indole), 118.5 (C-Ar-indole), 109.7 (C-Ar-indole), 104.3 (C-4), 52.8 (C-Pyrr), 45.9 (CH2), 
30.2 (CH2), 26.2 (C-Pyrr). 
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IV.4.2.5 1-Benzyl-2-(pyrrolidin-1-yl)-1H-indole (IV.78) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.32 – 7.00 (m, ArH, 9 H), 5.91 (s, CH, 1H), 5.32 (s, CH2, 2H), 
3.15 – 3.14 (m, CH2, 4H), 1.93 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 150.0 (CN), 138.5 (CAr), 135.8 (CAr), 129.1 (CAr), 128.7 
(CAr), 128.3 (CAr), 127.1 (CAr), 127.0 (CAr), 126.1 (CAr), 119.9 (CAr), 119.6 (CAr), 118.6 
(CAr), 109.3 (CAr), 85.0 (CH), 52.9 (CH2), 47.0 (CH2), 25.0 (CH2). 
 
 
IV.4.2.6 1,3-Di(but-2-ynyl)-2-(pyrrolidin-1-yl)-1H-indole (IV.81) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.60 (d, J = 7.7 Hz, ArH, 1H), 7.35 (d, J = 8.0 Hz, ArH, 1H), 
7.14 (m, ArH, 2H), 4.74 (s, CH2, 2H), 3.57 (s, CH2, 2H), 3.38 (s, CH2, 4H), 2.03 (s, CH2, 4H), 1.76 
(s, CH3, 6H); 
13
C NMR (126 MHz, CDCl3) δ: 133.0 (CAr), 127.2 (CAr), 121.1 (CAr), 119.4 (CAr), 118.1 
(CAr), 109.6 (CAr), 78.8 (C-prop), 74.8 (C-prop), 52.6 (CH2), 31.7 (CH2), 26.2 (CH2), 14.2 (CH2), 
3.8 (CH3), 3.7 (CH3). 
 
 
IV.4.2.7 1-(But-2-ynyl)-2-(pyrrolidin-1-yl)-1H-indole (IV.82) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.41 (d, J = 7.5 Hz, ArH, 1H), 7.32 (m, ArH, 1H), 7.08 (m, Ar-
H, 2H), 5.78 (s, H-3, 1H), 4.72 (s, CH2, 2H), 3.26 (s, CH2, 4H), 1.98 (s, CH2, 4H), 1.80 (s, CH3, 
3H); 
13
C NMR (126 MHz, CDCl3) δ: 149.0 (C-2), 135.0 (CAr), 128.5 (CAr), 120.0 (CAr), 119.6 
(CAr), 118.7 (CAr), 108.9 (CAr), 84.7 (CH), 79.5 (C-prop), 75.0 (C-prop), 52.8 (CH2), 33.4 (CH2), 
24.9 (CH2), 3.7 (CH3). 
 
 
 
IV. Amide Electrophilic Activation and Aza-Claisen 
227 
 
IV.4.2.8 1-Allyl-3-benzyl-2-(pyrrolidin-1-yl)-1H-indole (IV.87) 
 
1
H NMR (400 MHz, CDCl3) δ: 7.38 – 7.05 (m, ArH, 9H), 6.09 – 5.94 (m, -CH2CHCH2, 
1H), 5.18 (d, J = 10.2 Hz, -CH2CHCH2, 1H), 5.05 (d, J = 17.3 Hz, -CH2CHCH2, 1H), 4.75 – 4.74 
(m, -CH2CHCH2, 2H), 4.20 (s, CH2, 2H), 3.27 – 3.17 (m, CH2, 4H), 1.94 – 1.89 (m, CH2, 4H); 
13
C NMR (101 MHz, CDCl3) δ: 142.9 (-CH2CHCH2), 141.9 (CN), 134.6 (-CH2CHCH2), 
133.6 (CAr), 130.3 (CAr), 128.8 (CAr), 128.5 (CAr), 128.3 (CAr), 128.2 (CAr), 125.6 (CAr), 
120.7 (CAr), 118.9 (CAr), 118.2 (CAr), 115.7 (-CH2CHCH2), 109.4 (CAr), 103.7 (CAr), 52.6 
(CH2pyrr), 44.6 (-CH2CHCH2), 30.0 (PhCH2), 26.1 (CH2 pyrr). 
 
IV.4.2.9 1-(Allyl)-2-(pyrrolidin-1-yl)-1H-indole (IV.88) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.44 (m, ArH, 1H), 7.17 – 7.11 (m, ArH, 1H), 7.07 – 7.00 (m, 
ArH, 2H), 6.12 – 5.96 (m, -CH2CHCH2, 1H), 5.81 (s, CH, 1H), 5.14 (dd, J = 44.8, 13.7 Hz, -
CH2CHCH2, 2H), 4.66 (m, -CH2CHCH2, 2H), 3.20 (m, CH2, 4H), 1.96 (m, CH2, 4H); 
13
C NMR (126 MHz, CDCl3) δ: 149.8 (CN), 135.6 (-CH2CHCH2), 134.1 (CAr), 128.5 (CAr), 
119.8 (CAr), 119.4 (CAr), 118.5 (CAr), 116.2 (-CH2CHCH2), 109.1 (CAr), 84.6 (CH), 52.8 (CH2 
pyrr), 46.0 (-CH2CHCH2), 25.0 (CH2 pyrr). 
 
 
IV.4.2.10 1-(2,4-Diallyl-1,2-dihydroisoquinolin-3(4H)-ylidene)pyrrolidin-1-ium (IV.94) 
 
1
H NMR (500 MHz, CDCl3) δ: 7.28 – 7.16 (m, ArH, 1H), 6.92 (d, J = 7.5, 0.8 Hz, 1H), 6.84 
(d, J = 8.2 Hz, 1H), 6.03 (ddt, J = 17.2, 10.4, 5.2 Hz, 1H), 5.39 (dq, J = 17.3, 1.6 Hz, 1H), 5.31 – 
5.23 (m, 1H), 4.54 (dt, J = 5.1, 1.5 Hz, 1H), 3.66 (s, 1H), 3.54 – 3.42 (m, CH2, 2H), 1.97 – 1.78 (m, 
CH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 159.5 (C=N), 153.1, 132.5 (CAr), 131.7 (-CH2CHCH2), 130.1 
(CAr), 128.7 (CAr), 128.3 (CAr), 125.8 (CAr), 120.2 (-CH2CHCH2), 119.7 (-CH2CHCH2), 55.7 (-
CH2CHCH2), 53.3 (CH2), 45.9 (CH), 35.1 (-CH2CHCH2), 22.3 (CH2), 19.5 (CH2). (acc. Peaks  
taken from a mixture) 
IV. Experimental 
228 
 
IV.4.2.11 2,4-Diallyl-1,2-dihydroisoquinolin-3(4H)-one (IV.95) 
 
IR (cm-1): 2972 (w), 2921 (w), 1638 (s), 915 (m), 751 (m); 
1
H NMR (500 MHz, CDCl3) δ: 7.34 – 7.20 (m, ArH, 2H), 7.15 (d, J = 7.5 Hz, ArH, 2H), 5.81 
– 5.67 (m, -CH2CHCH2, 1H), 5.22 – 5.19 (m, -CH2CHCH2, 1H), 5.03 – 4.99 (m, -CH2CHCH2, 2H), 
4.59 (d, J = 15.8 Hz, CH2, 1H), 4.28 – 4.08 (m, CH2, -CH2CHCH2, 3H), 3.65 (t, J = 6.5 Hz, CH, 
1H), 2.63 (m, -CH2CHCH2, 2H); 
13
C NMR (126 MHz, CDCl3) δ: 171.1 (C=O), 135.9 (CAr), 134.4 (-CH2CHCH2), 132.8 (-
CH2CHCH2), 131.2 (CAr), 127.8 (CAr), 127.6 (CAr), 126.7 (CAr), 125.3 (CAr), 118.0 (-
CH2CHCH2), 117.9 (-CH2CHCH2), 49.9 (-CH2CHCH2), 49.5 (CH2), 47.4 (CH), 38.6 (-
CH2CHCH2); 
HRMS: m/z Calculated for C15H17NO [M+Na]
+
: 250.1203, found: 250.1202. 
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V.1 Background 
The sulfonamide moiety has a great importance in medicinal chemistry, being a pharmacophore 
present in a large number of pharmaceutical agents, such as antimicrobial, anti-inflammatory or 
anti-hypertensive drugs (Figure V.1).
1
 Its incorporation in therapeutically active molecules was 
first reported eighty years ago, when a German group discovered that red dye Prontosil was as an 
effective antibacterial agent.
2
 In fact, Prontosil acts as a pro-drug, which was converted in the body 
into its therapeutically active metabolite, sulfanilamide. 
 
 
Figure V.1. Pharmaceutical agents containing sulfonamide moiety. 
The most usual way to assemble sulfonamides is by treatment of sulfonyl chlorides with an 
amine or ammonia. However, the main difficulty associated with arylsulfonamides synthesis is the 
preparation of the corresponding arylsulfonyl chlorides. Furthermore, sulfonyl chlorides are not 
easily handled and are unstable when stored for long periods of time. These intermediates are 
usually prepared by electrophilic aromatic substitution with chlorosulfonic acid,
3
 or from the 
respective sulfonic acid or its sodium salt using chlorinating agents such as PCl5, N-
chlorosuccinimide (NCS) or SOCl2.
4
 Other methods include oxidative chlorination of organosulfur 
compounds.
5
 However, these approaches suffer from limitations. Sulfonamide synthesis from 
sulfonic acids is restricted to the commercially available starting materials. In electrophilic 
aromatic substitution the regioselectivity is driven by the arene substituents, limiting the desired 
substitution patterns. Moreover, some of these methods require acidic conditions, restricting the 
substrate scope. Other methods were developed, although requiring the use of toxic SO2 gas and 
sensitive organometallics (Scheme V.1).
6
 
 
Scheme V.1. Other methods to attain sulfonamides involving SO2 gas. 
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The reported issues regarding sulfonyl chlorides conducted to the development of numerous 
synthetic routes to prepare sulfonamides, such the use of sulfinic acids salts,
7
 although these 
methods are also limited to the commercially available sulfinic acid salts.  
 
More recently, some procedures were reported employing DABSO, a charge transfer complex 
generated from the combination of 1,4-diazabicyclo[2.2.2]octane and two equivalents of sulfur 
dioxide (DABCO·(SO2)2), as the source of SO2.
8
 In 2011, Willis group explored the one-pot 
preparation of sulfonamides from aryl Grignard reagents in the presence of this reagent, attaining 
the desired compounds in good yields (Scheme V.2).
9
 
 
 
Scheme V.2. One-Pot preparation of sulfonamides from Grignard reagents using DABSO.9 
More recently, Kopka et al. described the one-pot synthesis of aryl sulfonamides where the key 
step is a bromine-lithium exchange reaction followed by SO2 insertion using DABSO to attain the 
sulfonyl chlorides intermediates (Scheme V.3). It was also observed that the exact amount of t-
BuLi was sufficient for the exchange reaction in order to reach the desired sulfonamides.
10
 
 
 
Scheme V.3 Bromine-Lithium Exchange in arylsulfonamide synthesis. 10 
 
V.1.1 Pd-catalyzed aminosulfonylation 
The Pd-catalyzed aminosulfonylation processes, although scarcely developed, can solve the 
problems of classical sulfonamide synthesis allowing variation of both sulfonyl (R
1
−SO2−R
2
) 
substituents.
11
 
The first Pd-catalyzed aminosulfonylation process was reported by Willis group in 2010.
12
  
Inspired by his previous work on palladium-catalyzed aminocarbonylation reactions of aryl halides, 
Willis explored the catalytic process using SO2 in place of CO. In fact, it is documented that the 
coordination behavior between sulfur dioxide and metal centers is similar to carbon monoxide, 
suggesting that SO2 can perform viable insertions into metal-carbon bonds.
12
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Despite the unsuccessful trials using gaseous SO2, the reaction evolved using DABSO. 
Although the reaction was only possible using N,N-dialkylhydrazines as nucleophiles, aryl N-
aminosulfonamides were successfully prepared from aryl iodides in good to excellent yields 
(Scheme V.4).
12
 
 
 
Scheme V.4. Pd-Catalyzed aminosulfonylation of aryl halides.12 
In additional studies, Willis group investigated the scope of this aminosulfonylation reaction. 
Several aryl-, alkenyl- and heteroaryl iodides were tested employing different N,N-
dialkylhydrazines to provide N-aminosulfonamides in good to excellent yields in the presence of an 
excess of DABSO.
13
 One example using p-bromotoluene in the same conditions yielded the 
corresponding sulfonamide in 64% yield, while increasing the temperature from 70ºC to 90ºC rose 
the yield to 93%. 
This Pd-catalyzed aminosulfonylation method was also used by Willis as the key-step in a one-
pot, three-component sulfone synthesis.
14
 
In 2012, Wu et al. described an efficient palladium catalyzed three-component route to aryl N-
aminosulfonamides that relied on the utilization of DABSO and arylboronic acids instead of aryl 
iodides (Scheme V.5).
15
 As previously stated by Willis only hydrazines worked as efficient 
coupling partners in this procedure. 
 
 
Scheme V.5. Pd-catalyzed aminosulfonylation of arylboronic acids.15 
Interestingly, Wu group also described a successful Pd-catalyzed aminosulfonylation of aryl 
halides using potassium metabisulfite as the SO2 source (Scheme V.6).
16
 Despite the wide range of 
ligands tested, it was verified that P
t
Bu3HBF4 was the best ligand for this three-component reaction. 
Moreover, it was also verified that TBAB was fundamental since in its absence the reaction did not 
proceed. As previously observed by Willis, to ensure the same level of reactivity for the bromo 
containing substrates, the reaction temperature was raised from 80 °C to 100 °C using the same 
Pd/ligand conditions. 
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Scheme V.6. Pd-catalyzed aminosulfonylation of aryl halides using potassium metabisulfite.16 
Very recently, Wu et al. described a metal-free coupling of aryldiazonium tetrafluoroborates, 
hydrazines and DABSO to prepare aryl N-aminosulfonamides (Scheme V.7). The reaction 
proceeded in a very fast and smooth manner at room temperature also showing broad functional-
group tolerance. Several mechanistic studies were conducted suggesting that an aryl radical is 
involved as intermediate, which was presumably produced from the aryldiazonium salt.
17
 
 
 
Scheme V.7. Metal-free aminosulfonylation of aryldiazonium tetrafluoroborates.17 
In order to overcome the amine nucleophiles restrictions imposed by the previous described 
coupling methods, Buchwald envisaged the oxidative addition of LPd(0) to an electrophile of the 
type ArO−SO2−Cl, possessing two leaving groups of different reactivity. Subsequent coupling with 
arylboronic acids afforded the corresponding sulfonyl chlorides, which were further reacted with 
several primary and secondary amines to achieve the sulfonamide products (Scheme V.8).
18
 
 
 
Scheme V.8. Metal-free aminosulfonylation of aryldiazonium tetrafluoroborates.18 
Despite the efforts developed by several groups, a general, cheap and versatile method is not yet 
reported, to prepare sulfonamides (from alkyl and arylamines). The described methods still possess 
limited scope and require special ligands/additives. Thus a general method to prepare sulfonylated 
compounds is still essential. 
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V.2 Results and Discussion  
Following the previous studies developed in our group towards new methodologies for the 
synthesis of sulfonyl-containing compounds, it was proposed to develop a cheap, efficient and 
broad arylsulfonylation process using a safe and reliable SO2 surrogate. 
The preliminary studies, conducted in our group by Mónica Estevão,
19
 consisted on the 
investigation of a versatile intermediate to be used under mild conditions. Thus, several studies 
were conducted to attain a viable SO2 source, such as a Bt-SO2-Cl intermediate or a carbene·SO2 
adduct (result from SO2 capture by the NHC with the aim of developing a solid-phase catalytic 
system) for a subsequent transfer of this moiety to an aromatic unit. Unfortunately, the attempts to 
attain these intermediates failed (Figure V.2).
19
 
 
 
Figure V.2. Previous described sulfonylation methods and presented strategy. 
Inspired by Wu work,
16
 we firstly directed our efforts to the screening of several copper salts 
using sodium metabisulfite as SO2 source. Due to the high costs associated with palladium based 
catalyst systems, their substitution by copper catalysts appear as an attractive alternative. To date 
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several methods are described for copper-catalyzed coupling of sulfinic acid salts with aryl and 
alkyl halides in order to achieve a variety of alkyl−aryl, diaryl, and alkyl−heteroaryl sulfones.
20
 
However, the use of sulfinic acids is also limited to the commercial available ones (tolyl, methyl, 
phenyl). Moreover, a similar procedure was carried using silver salts, as well as a combination of 
Pd/Ag salts, in order to extend the reaction scope. 
In our subsequent studies it was envisaged the use of a versatile intermediate of general formula 
X-SO2-Y, to be used as SO2 surrogate. The different reactivity between X and Y could firstly aid 
the cross coupling reaction followed by the amine nucleophilic attack. During the course of this 
work, Buchwald reported a very similar work using an electrophile of the type ArO−SO2−Cl, using 
arylboronic acids as coupling partners.
18
 However, the reported work still present limitations, such 
as the reliance on exotic catalytic systems. 
 
V.2.1 Cu-catalyzed sulfonylation of iodo-toluene with potassium metabisulfite  
The examination of copper-catalyzed aminosulfonylation using sodium metabisulfite as SO2 
source is described in Table V.1. The initial experiments were performed using CuI. Generally, 
copper-catalyzed cross-coupling reactions are not too sensitive to the choice of the copper source 
[usually copper(I)], but can highly depend on other parameters, such as substrate, ligand, base or 
solvent.
21
 
As in Wu work, TBAB was employed as an additive. The role of TBAB is not quite clear and it 
is suggested to act as a base or to stabilize the catalyst.
16,22
 
 
Initially several ligands were tested, such as L-proline, neocuproine and DMEDA (entries 1-8). 
The system CuI/L-proline was described in the coupling reaction of aryl iodides with aliphatic and 
aromatic amines or hydrazines.
23
 However, for this type of reaction the system failed to give the 
desired product, being observed trace amounts of corresponding arylated compound V.4 (entry 1).  
The observation of V.4 is an indication that oxidative addition is taking place followed by 
coordination of amine to palladium, and that the insertion of sulfur dioxide is not occurring. 
1,10-Phenanthroline and its derivatives, such as neocuproine are already described as efficient 
ligands in copper catalyzed arylations.
24
 In our studies it failed to give any product either in the 
presence of TBAB or a strong base as Na
t
OBu (entries 2 and 3). 
The next ligand tested was N,N’-dimethylethylenediamine (DMEDA) a widely used copper 
ligand.
25
 Using an organic base, such as pyridine, in the presence of TBAB the reaction yielded an 
unidentified compound (entry 4). The NMR characterization can suggest the existence of an adduct 
or complex between hydrazine and SO2 or Cu, respectively, since only delocalized signals 
corresponding to hydrazine are observed. Using Cs2CO3, the arylated product V.4 was obtained 
(entry 5).  
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Table V.1. Studies on Cu-catalyzed sulfonylation.a 
 
Entry Catalytic system  Ligand  Additive  Observation 
1b CuI (10 mol%)  L-Proline Na salt (10mol%)  -- V.4 
2b CuI (10 mol%) Neocuproine (15 mol%) -- -- 
3b,d  CuI (10 mol%) Neocuproine (15 mol%) NatOBu (1.5 equiv) -- 
4  CuI (10 mol%)  DMEDA (20 mol%)  Pyridine (4 equiv) Unknown  
5d  CuI (10 mol%) DMEDA (20 mol%) Cs2CO3 (4 equiv) V.4  
6c,d  CuI (10 mol%)  DMEDA (20 mol%)  Cs2CO3 (4 equiv) Unknown  
7 
 
CuI (20 mol%)  DMEDA (40 mol%)  -- -- 
8  CuI (1 equiv.)  DMEDA (40 mol%)  -- -- 
9  CuCl (20 mol%)  DMEDA (40 mol%)  -- V.4  
10  Cu(OAc)2 (20 mol%)  DMEDA (40 mol%)  -- V.4 
11b Cu(OAc)2 (5 mol%)  -- -- V.4 
12  Cu(OAc)2 (1 equiv.)  DMEDA (40 mol%)  -- Mixture 
13 Pd2dba3 (5 mol%) XPhos (10 mol%) -- Mixture 
14 
Pd(OAc)2(5 mol%) 
/CuI(20 mol%) 
BINAP (10 mol%) -- Mixture 
a iodo-toluene (1 equiv), K2S2O5 (1 equiv), TBAB (1.5 equiv), DMF, 100 ºC, overnight; 
b dioxane, 100ºC, 
overnight; c 1) CuI, DMEDA and K2S2O3 at 100ºC overnight, 2) aminomorpholine and Cs2CO3; 
d without TBAB. 
 
However, pre-heating the CuI, ligand and potassium metabisulfite overnight with subsequent 
addition of aminomorpholine and Cs2CO3 gave the same unknown product (entry 6). Increasing the 
amount of CuI and DMEDA in the presence of TBAB, no products were obtained (entries 7 and 8).  
Other copper salts were also tested (entries 9-12). Using CuCl (20 mol %) in the presence of 
TBAB and DMEDA (40 mol %) gave V.4. Using a copper (II) salt such as Cu(OAc)2 (20 mol%) 
gave the same result. Increasing the amount of Cu(OAc)2 (1 equiv.) gave a complex mixture, while 
decreasing Cu(OAc)2 (5 mol%) in the absence of DMEDA gave the same arylated product V.4. 
Two trials using Pd(0) and a combination of Pd(II)/Cu were also conducted (entries 13 and 14). 
However, in both experiments complex mixtures of products were obtained. 
 
The current study using several copper salts under different several conditions, gave 
unsatisfactory results. Thus it was envisaged to explore silver salts or a combination of silver with 
Pd or Cu salts. 
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V.2.2  Ag-catalyzed sulfonylation of iodo-toluene with potassium metabisulfite  
Silver salts have been reported as efficient metal catalysts and co-catalysts in cross coupling 
reactions, despite the exact role of Ag salts is not clearly understood.
22,26
 Silver salts have been 
used to sequester the halides in direct arylation reactions or, when combined with Pd salts, used as 
an oxidizing agent to regenerate the Pd catalyst.
26-27
 Very recently, Chakaburty et al. reported the 
use of Ag(I) salts and DMEDA as ligand as efficient systems in C-N cross-coupling reactions.
28
 
Table V.2 Studies on Cu-catalyzed sulfonylation.a 
 
Entry Catalytic system  Ligand  Additive  Observation  
1 
CuI (20 mol%)/ 
AgNO3(20 mol%)  
DMEDA (40 mol%)  -- Unknown  
2 
CuI (1 equiv)/ 
AgBF4 (10 mol%)  
DMEDA (40 mol%)  -- V.4 
3  AgNO3 (20 mol%)  -- -- -- 
4  AgBF4 (50 mol%)  -- ---  Mixture  
5  
Pd(OAc)2 (5 mol%)/ 
AgBF4 (1 equiv)  
---  AcOH (1.5 equiv)  Mixture  
6b 
Pd(OAc)2 (5 mol%)/ 
AgBF4 (1 equiv)  
PtBu3 (10 mol%)  AcOH (1.5 equiv)   Mixture 
7 
Pd(OAc)2 (5 mol%)/ 
Ag2CO3 (1 equiv) 
 P
tBu3 (10 mol%)  --  Mixture  
8c  
Pd(OAc)2 (5 mol%)/ 
Ag2CO3 (1 equiv)
 P
tBu3 (10 mol%)  --  Mixture  
9 
Pd(OAc)2 (5 mol%)/ 
Ag2CO3 (1 equiv) 
PtBu3 (10 mol%)  Cs2CO3 (2 equiv)   Mixture  
10  
Pd(OAc)2 (5 mol%)/ 
Ag2O (1 equiv) 
P
t
Bu3 (10 mol%)  AcOH (1.5 equiv) Mixture  
a iodo toluene (1 equiv), amino morpholine (1.2 equiv), K2S2O5 (1 equiv), TBAB (1.5 equiv), dioxane, 100ºC, 
overnight; b addition order inverted;  c toluene, 100ºC, overnight;  
 
The same approach was attempted using silver salts in the presence of potassium metabisulfite 
and TBAB as reported in Table V.2. Further screening of the reaction conditions using Pd(OAc)2 
and several Ag salts were also made. 
The first trials comprised the use of CuI/Ag systems. Using AgNO3 (20 mol%) in the presence 
of DMEDA gave trace amounts of the previously observed unidentified compound, while using 
AgBF4 yielded the arylated specie V.4 (entries 1 and 2). Performing the same reactions with 
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AgNO3 and AgBF4 without using the copper source, as well as the corresponding ligand yielded no 
products or a product mixture, respectively (entries 3 and 4).  
 
The introduction of combined Pd/Ag systems could improve the reaction scope, since the 
reported procedure was only efficient for hydrazines. However, all the employed systems were 
unsuccessful. Pd(OAc)2 (5mol%)/Ag2BF4 (1 equiv) and Pd(OAc)2 (5mol%)/Ag2CO3 (1 equiv) 
systems revealed complex mixtures (entries 6-10) while using Pd(OAc)2 (5mol%)/Ag2O (1 equiv) 
did not improve the reaction outcome (entry 11). The poor results can be attributed to the lack of a 
specific ligand, since all the reported methodologies make use of uncommon metal/ligand systems. 
Other reason can be the use of stoichiometric amount of Ag salts. Despite the commonly use in Pd 
catalyzed reactions, is known that it can lead to the formation of side products. 
 
Since Wu does not report any mechanism involving the potassium metabisulfite,
16
 one can 
suggest that palladium might be a determinant mediator in the reaction.  
 
 
V.2.3  Synthesis of Aryl Sulfonamides via Palladium-Catalyzed Chlorosulfonylation 
Following the work developed on the group to attain a safe and efficient SO2 source, in 2013 it 
was decided to use the commercially available trimethylsilyl chlorosulfonate (TMSO−SO2−Cl), as 
a SO2 surrogate.  
In our strategy, Pd should suffer oxidative addition to this electrophile entity, which provides 
two different leaving groups of different reactivity. Additionally, it was envisioned the use aryl 
iodides (instead of the reported arylboronic acids) as coupling partners, to attain the corresponding 
sulfonyl chloride (V.6). Moreover, the optimizations studies were generally performed using 
Pd(OAc)2 as the Pd source and several Buchwald ligands. All the conditions and corresponding 
results are described on Table V.3. 
Cross-coupling reactions are usually conducted in toluene. In our case this solvent could not be 
used since trimethylsilyl chlorosulfonate can act as a sulfonating agent, performing electrophilic 
substitutions with arene moieties.
29
 Ether like solvents, such as THF or dioxane were also not 
suitable with this reagent due to its ability to form sulfur trioxide adducts.
30
 
Thus, the initial attempts were performed in chloroform at reflux (entries 1-4). Using 
Pd(OAc)2/BrettPhos system did not afford any product. The same outcome was obtained using 
other catalytic systems such as Pd(OAc)2/JohnPhos (entry 3) or BrettPhos precatalyst system (entry 
4).  
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Table V.3 Synthesis of Aryl Sulfonamides via Palladium-Catalyzed Chlorosulfonylation.a 
 
Entry [Pd] Ligand Solvent Additive Obs. 
1 Pd(OAc)2 BrettPhos CHCl3 Na2CO3 (50 mol%) - 
2 Pd(OAc)2 BrettPhos CHCl3 - - 
3 Pd(OAc)2 JohnPhos CHCl3 - - 
4 BrettPhosPd BrettPhos CHCl3 - - 
5 Pd(OAc)2 BrettPhos CH3CN Na2CO3 (50 mol%) - 
6 Pd(OAc)2 BrettPhos CH3CN - V.6 Trace 
7 Pd(OAc)2 BrettPhos DCM Na2CO3 (5 mol%) V.6 Trace 
8
 
Pd(OAc)2 BrettPhos DCM - V.6 Trace 
9 Pd(OAc)2 BrettPhos DCM TMSOTf (10 mol%) V.6 Trace  
10 Pd(OAc)2 JohnPhos DCM - V.6 Trace 
11 BrettPhosPd BrettPhos DCM - V.6 Trace 
12 Pd(OAc)2 XPhos DCM - V.6 Trace 
13 Pd(OAc)2 RuPhos DCM - V.6 Trace 
14b Pd(OAc)2 BINAP DCM - - 
15d Pd(OAc)2 BrettPhos DMSO - ? 
16c,d Pd(OAc)2/CuI BrettPhos DMSO - - 
17c Pd(OAc)2/CuI BrettPhos CH3CN - - 
18 Pd2dba3 BrettPhos DCM - - 
a [Pd] (4 mol%), ligand (8 mol%), trimethylsilylchlorosulfonate (1 equiv), 4-iodo toluene (1.5 equiv), reflux, 
overnight; b[Pd] (20 mol%), ligand (50 mol%); c [Pd] (15 mol%), CuI (1.5 equiv); d 80ºC 
 
The unsuccessful results of these initial tests could be attributed to the low temperature used. 
Consequently, acetonitrile was chosen due to its higher boiling point. Fortunately, when 
Pd(OAc)2/BrettPhos system was employed in the absence Na2CO3, trace amounts of the 
corresponding sulfonyl chloride (V.6) were obtained (entry 6). The reaction did not undergo using 
50 mol% of base (entry 5). This observation is according to the results previous reported by 
Buchwald.
18
 
Interestingly, when the reaction was carried in dichloromethane using Pd(OAc)2 and BrettPhos 
ligand, trace amounts of the corresponding sulfonyl chloride (V.6) were obtained (entries 7-9). 
Moreover, when the amount of Na2CO3 was decreased to 5 mol%, V.6 was also detected (entry 7). 
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Despite the trace amounts detected, these results compelled one to explore new catalytic 
systems in order to attain the optimal conditions to obtain V.6. Thus, several systems were 
employed such as Pd(OAc)2/JohnPhos (entry 10), BrettPhos precatalyst system (entry 11) 
Pd(OAc)2/XPhos (entry 12), Pd(OAc)2/RuPhos (entry 13). Unfortunately, all presented only trace 
amounts of V.6. On the other hand, V.6 was not detected when BINAP was employed as ligand 
(entry 14). 
When DMSO was used as solvent no reaction occurred (entry 15-16). In fact, other minor 
product was obtained. NMR interpretation suggests the presence of an adduct of DMSO with SO2. 
Combined systems like Pd(OAc)2/CuI were also not suitable (entries 16 and 17). 
Using a Pd(II) source, such as Pd2dba3, with BrettPhos in DCM did not give any product (entry 
18).  
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V.3 Conclusions 
The pursuit of an efficient arylsulfonylation process for a wide substrate scope has conducted 
several groups to the development of sulfonylation agents that could act as SO2 surrogates. 
However, to the best of our knowledge, this aim was not yet achieved since the majority of the 
developed processes are only functional for a small number of substrates. Unfortunately, our efforts 
to attain a cheap and versatile arylsulfonylation method also failed.  
The experiments performed with potassium metabisulfite in the presence of copper or silver 
salts were all unsuccessful. Since the mechanism by which the reaction proceeds in unknown, it is 
suggested that the reaction requires specific catalytic systems, mostly based on palladium metal. 
The addition of specific additives, such as TBAB, can also highly influence this approach. 
The experiments conducted with the commercially available trimethylsilyl chlorosulfonate as a 
SO2 surrogate, were also not effective. Despite the disappointing results obtained for the tested 
systems, the observation of trace amounts of V.6 can indicate that the reaction proceeds, although 
in poor way. Consequently, the optimal reaction conditions still need to be investigated. 
Simultaneously to our work, Buchwald group reported a palladium catalyzed sulfonylation.
18
 In his 
work, Buchwald included specific palladacycle precatalysts, which allowed the reaction to undergo 
at mild temperatures (in acetone). This fact can suggest that this type of reaction is highly 
dependent on the catalytic system, which can hinder a cheaper and broader methodology. 
 
 
 
 
 
 
 
 
 
 
 
 
V. Sulfonylation studies 
247 
 
V.4 Experimental 
V.4.1 Cu-catalyzed sulfonylation of iodo-toluene with potassium metabisulfite  
To a Schlenk-tube equipped with a magnetic stir bar, was added the Cu salt (5-100 mol %), 
K2S2O5 (1 equiv), ligand (10-40 mol %) and the iodo toluene (1 equiv) (see Table V.1, page 235). 
In the experiments having a solid additive, like TBAB (1.5 equiv) or a base it was added in this 
step. The tube was sealed with a suba-seal, evacuated and backfilled with argon. The solvent was 
added (0.25 M) and several cycles vacuum/argon were performed. Then amino morpholine (1.2 
equiv.) was then added via syringe. The reaction mixture was heated at 100ºC overnight. The 
solution was allowed to cool to room temperature, quenched by the addition of water and diluted 
with EtOAc and water. After extracting with 3 portions of EtOAc, the combined organic layers 
were washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo. 
 
 
V.4.2 Ag-catalyzed sulfonylation of iodo-toluene with potassium metabisulfite  
To a Schlenk-tube equipped with a magnetic stir bar, was added the Ag salt (10-100%), K2S2O5 
(1 equiv), TBAB (1.5 equiv) and the iodo toluene (1 equiv). In the experiments having an additive, 
like a Cu or Pd salt (5-100 mol%) and the corresponding ligands (10-40 mol %) it was added in this 
step. The tube was sealed with a suba-seal, evacuated and backfilled with argon. The solvent was 
added (0.25 M) and several cycles vacuum/argon were performed. Then amino morpholine (1.2 
equiv) was then added via syringe. The reaction mixture was heated at 100ºC overnight. The 
solution was allowed to cool to room temperature, quenched by the addition of water and diluted 
with EtOAc and water. After extracting with 3 portions of EtOAc, the combined organic layers 
were washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo. 
 
 
V.4.3 Synthesis of Aryl Sulfonamides via Palladium-Catalyzed Chlorosulfonylation 
To a Schlenk-tube equipped with a magnetic stir bar, was added the Pd salt (2 mol%), ligand (4 
mol%) the 4-iodo toluene (1.5 equiv). The tube was sealed with a suba-seal, evacuated and 
backfilled with argon. The solvent was added (0.5 M) and several cycles vacuum/argon were 
performed. Then trimethylsilyl chlorosulfonate (1 equiv) was then added via syringe. The reaction 
mixture was heated at desired temperature overnight. The solution was allowed to cool to room 
temperature, quenched by the addition of water and diluted with EtOAc and water. After extracting 
with 3 portions of EtOAc, the combined organic layers were washed with water, brine, dried over 
Na2SO4, filtered and concentrated in vacuo. 
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In the last years benzimidazole scaffold gained relevance in drug discovery. Present in a wide 
number of pharmaceutical compounds, until the date (to the best of our knowledge), was not 
reported the existence of a commercially available anti-inflammatory drug containing this motif. 
Thus, considering its unique properties, it was proposed to develop a novel anti-inflammatory drug 
devoid of adverse side effects. 
It was successfully demonstrated that the rational drug design strategy is an important method to 
attain promising drugs in a direct and efficient way. It was also verified that although presenting 
several limitations, the docking evaluation was a reasonable tool to predict the most promising 
compounds from a wide number of available structures. 
The proposed benzimidazole-based library was successfully synthesized from 7-bromo isatin, 
taking advantage of this heterocyclic structure to achieve the desired final substitution pattern. 
After a careful optimization of the synthetic strategy, the compounds were attained in seven to 
eight synthetic steps, in good yields. 
Eager to find potent and selective COX-2 inhibitors, all the compounds were biologically 
evaluated. It was verified that the acid derivatives were very poor COX inhibitors, while the ester 
demonstrated an elevated inhibitory activity towards COX-1 and COX-2, though showing a poor 
selectivity for COX-2. These results are in opposition to the docking predictions which anticipated 
an enhanced potency and COX-2 selectivity for all the synthesized compounds. However, the 
balanced COX-1/COX-2 inhibition observed for the ester derivatives can indicate that these 
compounds are excellent anti-inflammatory candidates with minimized adverse side effects. 
Compound II.77d was the most promising structure, showing 60 ± 8% of COX-2 inhibition at 
0.5 μM, almost similar to the inhibition percentage found for celecoxib at higher concentration (72 
± 10 %, at 5 M). Moreover, compound II.77d was found to inhibit COX-1 in 41 ± 13%, at 0.625 
μM. It was also observed that the compound containing the chlorine atom in meta was the most 
active, which is in accordance with the docking results. 
 
The STD-NMR experiments performed with the acid derivatives (II.78a-e) and with the ester 
II.77a showed that all the studied compounds interact with COX-2. Moreover, the competitive 
STD-NMR studies conducted with ibuprofen, naproxen and diclofenac, unveiled some of the 
binding mechanisms of these compounds within the protein. The results obtained for acid II.78a 
suggest that these type of compounds bind to a third binding site that do not contribute for COX 
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inhibition. This observation supports the biological evaluation results, which revealed that the acid 
derivatives do not possess relevant COX inhibitory activity. Moreover, the ester derivative II.77d 
seems to compete with naproxen for Eallo. This can indicate that the esters inhibit COX-2 similarly 
to naproxen. 
The studies conducted on Pd-catalyzed arylamination on PEG, demonstrated that PEG 2000 can 
efficiently act as a soluble polymeric support for aryl halides involved in C-N cross-coupling 
reactions with anilines. Moreover, it was also demonstrated that the cross-coupling reaction could 
be undertaken in solventless conditions, proving that PEG could as polymeric support and solvent. 
The reaction monitoring was performed by the usual 
1
H NMR without cleaving the compounds 
from the resin. It was proved that this methodology is highly valuable to prepare heterocyclic 
structures in a fast and efficient way, taking advantage of a solid-phase synthesis approach. 
The studies conducted on amide electrophilic activation/Claisen rearrangement methodology 
developed in Maulide’s group, demonstrated that despite the promising results achieved for the  or 
-allyl amides comprising an arene within the alkyl tether, the chiral approach using appropriate 
auxiliaries was not successful. Moreover, the hydrolysis of the pyrrolidine auxiliary was highly 
difficult, fact that could compromise the chiral centre. For the aza analogs, the N,N-diallylated five 
member derivative suffered a rearrangement towards the arene ring, yielding the 7-allylated indole. 
For the benzylated and propargylated derivatives was verified that a migration was favored over 
rearrangement. It was also verified that hydrolysis of the pyrrolidine moiety was an intricate task. 
All the attempts to attain a cheap, efficient and broad arylsulfonylation process using a safe and 
reliable SO2 surrogate, were unsuccessful. 
 
The results obtained in this thesis contributed to the development of novel anti-inflammatory 
drugs, which demonstrates a balanced inhibitory activity against COX-1/COX-2. These results 
indicate that the prepared benzimidazole library can potentially have reduced side effects. Thus, 
more studies would still be required in order to confirm this hypothesis. Moreover, despite the 
insights obtained with the NMR studies concerning the binding mechanism within COX-2, 
complementary x-ray crystallography studies can unravel the orientation of the molecules inside 
COX active site. 
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VII.1 STD-NMR spectra 
 
 
Figure VII.1 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of: a) 
80b (300 M) with b) ibuprofen (300 M) in the presence of oCOX-2 (3 M), at 600 MHz and 37 °C. 
 
 
Figure VII.2 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of: a) 
80c (300 M) with b) ibuprofen (300 M) in the presence of oCOX-2 (3 M), at 600 MHz and 37 °C. 
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Figure VII.3 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of: a) 
80d (300 M) and with ibuprofen: b) 150 M; c) 300 M; d) 600 M in the presence of oCOX-2 (3 M), at 
600 MHz and 37 °C. 
 
Figure VII.4 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of: a) 
80e (300 M) and with ibuprofen: b) 150 M; c) 300 M in the presence of oCOX-2 (3 M), at 600 MHz 
and 37 °C. 
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Figure VII.5 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of: 
80a at a) 32.6 M; b) 81.5 M; c) 163 M; d) 245 M; e) 326 M and f) 652 M in the presence of oCOX-2 
(3.26 M), at 600 MHz and 37 °C. 
 
Figure VII.6 Expansion of the aromatic region of the reference (black) and 1H STD-NMR (red) spectra of 
79a (163 M) with: b) diclofenac (163 M), c) diclofenac and naproxen (163 M) in the presence of oCOX-
2 (3.26 M), at 600 MHz and 37 °C. 
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